MX2007014866A - Pyrazole compound and therapeutic agent for diabetes comprising the same. - Google Patents

Abstract

A pyrazole compound represented by the general formula (I) or a salt thereof which has a hepatic glycogen phosphorylase inhibitory activity and therefore is useful as a therapeutic or prophylactic agent for diabetes or a pharmacologically salt thereof : wherein the ring Q represents an aryl group or an aromatic heterocyclic group; R¹ represents a hydrogen atom, a halogen atom, a C_1-6 alkyl group or a C_1-6 alkoxy group; R² represents a halogen atom, a C_1-6 alkyl group, a C_1-6 alkoxy group or an azide group; R³ represents a halogen atom, a hydroxyl group, a C_1-6 alkyl group, a halo-C_1-6 alkyl group, a C_1-6 alkoxy group, an azide group, an amino group, an acylamino group or a C_1-6 alkylsulfonylamino group; R⁴ and R⁵ independently represent a hydrogen atom, a C_1-6 alkyl group which may be substituted, a a C_3-8 cycloalkyl group, a saturated heterocyclic group which may be substituted, an aryl group which may be substituted, a C_7-14 aralkyl group, an aromatic heterocyclic group or the like.

Description

PIRAZOL COMPOUNDS AND ANTIDIABETES COMPRISING PIRAZOLE COMPOUNDS FIELD OF THE INVENTION The present invention relates to a pharmaceutical composition for the treatment or prevention of diabetes, comprising a pyrazole compound which has inhibitory activity of hepatic glycogen phosphorylase and a pharmaceutically acceptable carrier, a novel pyrazole compound, having said inhibitory activity of hepatic glycogen phosphorylase, and a pharmaceutical composition comprising a combination of the pharmaceutical composition for treating or preventing diabetes and another agent (eg, an antihyperlipidemic agent, a therapeutic or prophylactic agent for obesity, an agent therapeutic for glycosuria, a therapeutic agent for the complications of diabetes or an antihypertensive agent).

PREVIOUS TECHNIQUE Diabetes is a chronic disease caused by the abnormal metabolism of sugars, lipids and amino acids, due to insufficiency of the action of insulin. If left untreated, diabetes can lead to hyperglycemia and glycosuria.

Diabetes is classified as: diabetes mellitus type I (IDDM, Insulin Dependent Diabetes Mellitus, insulin-dependent diabetes mellitus), characterized by the hyposecretion of insulin, a consequence of the destruction of islet cells, caused by the production of autoantibodies mainly against the pancreatic islets; and type II diabetes mellitus, (NIDDM, non-insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus) that is derived from the dysfunctional insulin secretory function of the pancreas, and insulin resistance in peripheral tissues , such as muscle tissue, and in the liver. Insulin-dependent diabetes mellitus can lead to ketonemia and acidosis, due to the loss of the ability to secrete insulin and, if left untreated, can result in a diabetic coma. Neither dietary therapy nor treatment with an oral hypoglycemic agent are effective, and only insulin treatment is effective. On the other hand, non-insulin-dependent diabetes mellitus (NIDDM) presents only a small degree of ketonemia and acidosis, although the action of insulin is reduced compared to normal and insulin treatment is not always required. Between 90 and 95% of diabetics, approximately, suffer from non-insulin-dependent diabetes mellitus. Diabetes is a disease that can lead to complications, such as neuropathy, retinopathy and microvascular disorders in the kidney, as a result of long-term hyperglycemia. cli, ÜÁ term, and also lead to fatal complications, such as disease of the coronary artery and cerebrovascular accidents.

The hypoglycemic agents that are currently used to correcting hyperglycemia include preparations with insulin, sulfonylurea (for example, glibenclamide, toibutamide), biguanides (eg, metformin), agents for improving insulin resistance (e.g., pioglitazone) e, α-glucosidase inhibitors (e.g., acarbose).

Preparations with insulin, which are normally used for insulin-dependent diabetes, certainly serve to lower levels blood sugar, but must be given by injections and can lead to hypoglycemia.

Sulfonylurea stimulates pancreatic beta cells to promote endogenous insulin secretion from beta cells pancreatic, but the amount of insulin secreted and the time it produces the segregation depend on the dose and the time when administers the drug, independent of blood glucose levels. In consequently, the adverse effect of hypoglycemia can often be the > result of a prolonged action of the drug. On the other hand, they can present digestive symptoms, such as anorexia. It is contraindicated for patients with serious ketosis or renal or hepatic dysfunction. ' Biguanides do not stimulate pancreatic beta cells and do not induce hypoglycaemia in healthy persons or diabetics through a single administration. Possible modes of action include increased use | of sugar by anaerobic glycolysis, suppression of gluconeogenesis, and suppression of intestinal absorption of sugar. A probable adverse reaction is comparatively serious lactic acidosis. Thiazolidine derivatives, which are included among the agents that improve insulin resistance (insulin sensitizers), increase the action of insulin, instead of stimulating insulin secretion, and are capable of activating the receptor kinase. insulin, promoting the uptake of sugar by peripheral tissues, and improving the greater production of sugar in the liver. The known adverse reactions include: digestive symptoms and edema, and reductions in the red blood cell count, hematocrit and hemoglobin, as well as an increase in LDH. A-glucosidase inhibitors suppress the elevation of blood glucose levels after meals, delaying the digestion / absorption of sugars in the digestive tracts, but can cause problematic adverse reactions, such as bloating, borborygm and diarrhea (see , for example, document 1, which does not correspond to a patent). Therefore, these drugs have limited use due to the adverse reactions they produce and the lack of response in patients; In addition, there is a need to find a hypoglycemic agent with a new mechanism of action.

In recent times, it was reported that the release of sugar from the liver increased during fasting in patients with NIDDM, compared with normal people. The report suggests that the phenomenon of sugar being released from the liver may be an objective for drug therapy for NIDDM. According to recent findings in diabetic pathologies, the dysfunction of pancreatic beta cells and the greater release of sugar from the liver can participate in the onset and progression of diabetes to become a pathology of greater importance (see, for example, document 2, which does not correspond to a patent). The release of sugar from the liver is expressed as the sum of two pathways, that is, the breakdown of hepatic glycogen and gluconeogenesis. In diabetic pathologies, the hepatic glycogen decomposition system improves (see, for example, documents 3 and 4 that do not correspond to patents). On the other hand, by suppressing hepatic glycogen breakdown, blood glucose levels were reduced in diabetic animals or normal persons undergoing glucagon stimulation (see, for example, Document 5 which does not correspond to a patent). These findings suggest that the greater decomposition of liver glycogen has implications in diabetic pathologies. On the other hand, this glycogenolysis is catalyzed by hepatic glycogen phosphorylase, and glycogen decomposition is known i .., l (units of n glucose) by the perfosphoric acid results in glucose-1-phosphate (G-1-P) and glycogen (glucose units n-1). Therefore, an antidiabetic drug has been developed with a new mechanism, which has the effect of inhibiting hepatic glycogen phosphorylase, which is significantly involved in this glycogenolysis. However, an antidiabetic that has a satisfactory activity has not yet been found. On the other hand, it has been reported that the inhibitor of hepatic glycogen phosphorylase has various effects, in addition to being a therapeutic or prophylactic drug for diabetes. For example, a compound that has inhibitory activity of hepatic glycogen phosphorylase "is useful for the treatment of: diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataract, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinism, hyperlipidemia, atherosclerosis, tissue ischemia and myocardial ischemia. "(See, for example, patent document 1). has inhibitory activity of hepatic glycogen phosphorylase is effective as an appetite controlling agent and as a therapeutic agent for obesity, and is useful for the treatment or prevention of diseases for which the reduction of lipid levels is effective in blood, such as dyslipidemia, hypertriglyceridemia, hyperlipidemia, hyperlipoproteinemia, cardiovascular disease and hypertension (See, for example, patent document 2). liitil ..Üi In addition, an inhibitor of hepatic glycogen phosphorylase is effective in treating and preventing diseases related to glucose metabolism, such as diabetes and, especially, non-insulin-dependent diabetes mellitus (NIDDM), including the prolonged complications (for example, retinopathy, neuropathy, nephropathy and micro- and macro-vascular disease). (See, for example, patent document 3). In addition, three isoforms of glycogen phosphorylase have been identified in humans, ie, hepatic isoform, muscle isoform and brain isoform, and these isoforms are the products of three different genes, which have 80-83% amino acid identity. Glycogen phosphorylase is also present in bacteria, and a compound having inhibitory activity of hepatic glycogen phosphorylase provides a means for the treatment or prevention of infections, such as bacterial, fungal, parasitic or viral infections, and is effective to treat and prevent these infections. (See, for example, patent document 4). In addition to being useful for the treatment and prevention of diabetes, it is anticipated that a hepatic glycogen phosphorylase inhibitor will be useful as: a therapeutic agent to combat insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataract, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinism, hyperlipidemia, atherosclerosis, tissue ischemia and myocardial ischemia; a therapeutic agent for the control of appetite and obesity; and as a Lili ...,? U therapeutic agent for infections, such as bacterial, fungal, parasitic or viral infection. It is known that the compounds presented below are inhibitors of hepatic glycogen phosphorylase or compounds that may have a structure relatively similar to that of the compound of the present invention. The patent document with the number WO96 / 39384 (National Publication of the International Patent Application No. 1998-511687) describes indole compounds having inhibitory activity of glycogen phosphorylase (see patent document 5).

In the formula, R 4 is a phenylalkyl group or the like; R5 is a hydrogen atom or the like; R6 is an alkoxycarbonyl group or the like; R2 is a hydrogen atom; R-i, R-io and Rn are, independently, a hydrogen atom, a halogen atom or the like; R3 is a hydrogen atom or the like; A is -N = or similar.

For example, the following compound is described as a specific compound.

The patent document with the number WO01 / 94300A1 describes acylphenylurea derivatives, represented by the following general formula (I), which are effective for the treatment of type II diabetes, and a method of preparing them (see document of patent 6).

(In the formula: A represents a phenyl group or a naphthyl group, which may be substituted by various substituents: R 1 and R 2 represent a hydrogen atom, an alkyl group or the like; R 3, R 4, R 5 and R 6 represent a hydrogen atom; , a halogen atom or the like, X represents an oxygen atom or sulfur atom, and R7 represents an alkyl group or the like, substituted with a carboxy, phenyl or heterocyclic group.

The patent document with the number WO02 / 096864A1 describes phenylurea derivatives substituted with carboxamide, represented by the following general formula (I), which are effective for the treatment of type II diabetes, and a method of preparing them ( see patent document 7).

In the formula: A represents a phenyl group or a naphthyl group, which may be substituted with various substituents; R1 and R2 represent a hydrogen atom, a halogen atom or the like; R3, R4, R5 and R6 represent a hydrogen atom, a halogen atom or the like; R7 represents a hydrogen atom, an alkyl group or the like; R8 represents a hydrogen atom, a substituted or unsubstituted alkyl group or the like; and R9 represents a halogen atom. The patent document with the number WO03 / 015774A1 describes the use of the derivatives represented by the following general formula (I), for the treatment of diseases caused by glucokinase (GLK, glucokinase), such as type II diabetes (cf. the patent document 8).

In the formula: m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; n + m is > 0; R1 is, independently, OH, - (CH2)? OH, -CH3-aFa, halo, a C-1 alkyl group. 6, phenyl, a heterocyclic ring or the like, which may be substituted with a C-? 6 alkyl group; R2 is -X-Y, where X is a bond selected from -O-Z-, -O-Z-O-Z-, -C (O) O-Z-, -OC (O) Z-, -S-Z-, a direct bond or the like; Z is a direct union; a C2 ^ alkenylene group or the like; Y is aryl-Z1-, heteroaryl-Z1-, a C1-6 alkyl group, or the like; and R3 is a heterocyclic ring, which may be substituted with R7. The reference describes the compounds presented below in Example GG 2 and 5, as specific examples of the compounds having a pyrazole backbone for R3.

The reference also describes the compounds proposed in their descriptive memory, represented by the following general formula (Ib), as object of the invention.

Formula (Ib) In the formula: R1 is a hydroxyl group, a hydroxyalkyl group, a fluorinated alkyl group, a halogen atom, an alkoxy group, a group alkyl or the like; R2 is -X-Y, where X is -O-Z- or the like, Y is -Z1 -Aryl or Similary; and R2 does not include a halogen atom or an alkyl group, m is 0, 1 or Formula (Ib) 2; n is 1, 2 or 3; and m + n is 2 or 3. m is 2 at most, as is evident from the postulate above, and the phenyl group is never substituted with three atoms of halogen at the same time.

The patent document with the number WO03 / 084922A1 describes acyl-4-carboxyphenylurea derivatives, represented by the following general formula, which are useful as antidiabetics (see patent document 9).

In the formula: R7, R8, R9 and R10 are identical to each other or different from each other and represent a hydrogen atom, a halogen atom, an alkoxy group or the like; R1 and R2 represent a hydrogen atom, an alkyl group or the like; R3 represents a hydrogen atom, a halogen atom, a phenoxy group or the like; R4 represents a hydrogen atom, a halogen atom, a nitro group, a phenoxy group or the like; R5 represents a hydrogen atom, a halogen atom, a phenoxy group, an alkyl group, or the like; and R6 represents a hydrogen atom, a halogen atom, a phenoxy group, an alkyl group or the like. WO03 / 084923A1 describes acyl-3-carboxyphenylurea derivatives, represented by the following general formula (I), which are useful as antidiabetics (see patent document 10).

In the formula: R7, R8, R9 and R10 are identical to each other or different from each other, and represent a hydrogen atom, a halogen atom, an alkoxy group or the like; R1 and R2 represent a hydrogen atom, an alkyl group or the like; R3 represents a hydrogen atom, a halogen atom, a phenoxy group or the like; R4 represents a hydrogen atom, a halogen atom, a nitro group, a phenoxy group or the like; R5 represents a hydrogen atom, a halogen atom, a phenoxy group, an alkyl group or the like; and R6 represents a hydrogen atom, a halogen atom, a phenoxy group, an alkyl group or the like. The patent document with the number WO03 / 104188A1 describes N-benzoyl ureidocinnamate derivatives, represented by the following general formula (I), which are useful as antidiabetics (see patent document 11).

In the formula: R7, R8, R9 and R10 are identical to each other or different from each other and represent a hydrogen atom, a halogen atom, an alkoxy group or the like; R1 and R2 represent a hydrogen atom, an alkyl group or the like; R3, R4, R5 and R6 represent a hydrogen atom, a halogen atom, an alkyl group or the like; and R11 represents -OR12 or -N (R18) (R19). The patent document with the number WO2004 / 007455A1 describes benzoylurea derivatives substituted with heterocyclic aryl, represented by the following general formula (I), which are useful as therapeutic agents for type II diabetes (see patent document 12).

In the formula: R1 and R2 represent a hydrogen atom, an alkyl group, an amino group or the like; R3 and R4 represent a halogen atom, a hydroxyl group, an alkyl group, an alkoxy group or the like; R5 represents a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group or the like; A represents a hydrogen atom, a halogen atom, an alkyl group, an alkylcarbonyl group or the like, and Het represents a heterocyclic group, such as, for example, triazole, tetrazole or pyrazole. The patent document with the number WO2004 / 033416A2 discloses carboxyalkoxy-substituted acylcarboxiurea derivatives, represented by the following general formula (I), which are useful as therapeutic agents for type II diabetes (see patent document 13).

In the formula: R1 represents a hydrogen atom, an alkyl group, a phenyl group or the like; R 2 represents a hydrogen atom, an alkyl group, an alkoxy group or the like; R3 represents a hydrogen atom, a halogen atom, an alkoxy group or the like; and n represents an integer comprised between 1 and 8. The patent document with the number WO2004 / 065356A1 describes derivatives of acylphenylurea substituted with carbonylamino, represented by the following general formula (I), which are useful as therapeutic agents for diabetes of the type II (see the patent document R10 R11 In the formula: R8, R9, R10 and R11 represent a hydrogen atom, a halogen atom, a hydroxy group, a nitro group, an alkoxy group or the like; R1 and R2 represent a hydrogen atom, a substituted or unsubstituted alkyl group, an alkoxy group or the like; R3, R4, R5 and R6 represent a hydrogen atom, a halogen atom, a nitro group, a phenoxy group, a hydroxy group or the like; and R7 represents a hydrogen atom, an alkyl group, a cycloalkyl group or the like. Pyrazole compounds having an amide substituent have been reported.

For example, the patent document with the number WO2004 / 098589A1 describes derivatives of the pyrazole compound 4-bromo-5- (2-chloro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, represented by the following formulas general (I) or (II). However, these compounds are related to the bradykinin B1 receptor antagonists, for the treatment of inflammatory disease (see patent document 15).

(D (II) In the formulas: Z 'represents O, S or NH; Q represents N (R4) (R5), OH, an alkyl group or the like; R1 represents a hydrogen atom, an alkyl group, a substituted alkyl group, an aryl group, a substituted aryl group, a heterocyclic group, a substituted heterocyclic group or the like; R2 and R3 represent a hydrogen atom, an alkyl group, a substituted alkyl group, an aryl group or the like; R4 and R5 represent a hydrogen atom, an alkyl group, a substituted alkyl group, an alkoxy group, a cycloalkyl group, a substituted cycloalkyl group, a heterocyclic group, a substituted heterocyclic group or the like; and X represents a hydrogen atom, a halogen atom, an alkyl group or the like. In addition, on page 333 of the patent specification, many substituents, including 2-chlorophenyl, 2-fluorophenyl, 2-hydroxyphenyl, 2-nitrophenyl, etc. and, more specifically, 2,4-dichlorophenyl and 3,4,5-trifluorophenyl are described as specific examples of R1. However, according to the description on page 17 of the patent specification, a preferable R1 group is 2-chlorophenyl, 2-fluorophenyl, 2- (quinolin-8-yl) phenyl-1-yl, or - [(3-methylphenyl-1-yl-sulfanyl) methyl] phenyl-1-yl, and the 2-chloro-4,5-difluorophenyl group, the 4,5-difluoro-2-methylphenyl group and the group 2, 4-Dichloro-5-fluorophenyl is not specifically described or even suggested. In the document cited above, the following compounds are described as examples of derivatives. However, the specific compounds that include the examples described therein are characterized, mainly, by having a 2-chloro-phenyl group as R1 and a pyrazole ring having a substituent, which consists of a halogen atom or an alkyl group, as is evident from its title "acid amide derivatives" 4-Bromo-5- (2-chloro-benzoylamino) -1H-pyrazole-3-carboxylic acid ". In addition, its uses are related to the bradykinin B1 receptor, which is useful for treating inflammation that is different from diabetes.

DU ÜI EXAMPLE 2 EXAMPLE 6 15 EXAMPLE 7 EXAMPLE 11 EXAMPLE 11 EXAMPLE 16 10 EXAMPLE 20 twenty EXAMPLE 33 EXAMPLE 34 10 fifteen EXAMPLE 79 EXAMPLE 93 EXAMPLE 121 The patent document with the number WO2004 / 098590A1 describes pyrazole compounds represented by the following general formulas (I) or (II), which are useful as antagonists of the bradykinin B1 receptor for the treatment of inflammatory disease. (See patent document 16). These, however, are related in particular to specific pyrazole compounds, ie, 4-bromo-5- (2-chloro-benzoylamino) -1 H-pyrazole compounds, as evidenced in their title "Derivatives of (1) 4-bromo-5- (2-chloro-benzoylamino) -1H-pyrazole-3-carboxylic acid (aminocarbonyl) et-1-yl) amide.

O) (p) In the formulas, Z represents O, S or NH, and Q represents the following general formula.

R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group or the like; R2 and R4 represent a hydrogen atom, a substituted or unsubstituted alkyl group, R3 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group or the like; R5 and R6 represent a hydrogen atom, a side chain of amino acids or the like; and R7 represents -NRbRc, -ORb or the like. The following compounds are also described as examples of the derivatives described above.

EXAMPLE 1 The patent document with the number WO2004 / 099155A2 describes substituted pyrazole derivatives, represented by the following general formulas (I) or (II), which are useful as antagonists of the bradykinin B1 receptor to treat inflammatory disease (cf. of patent 17). (0 (D) where Z 'represents O, S or NH; R1 represents a hydrogen atom, an alkyl group, a substituted alkyl group, an aryl group, a substituted aryl group or the like; R 2 represents a hydrogen atom, an alkyl group, a substituted alkyl group or the like; R3 represents a hydrogen atom, an alkyl group, a substituted alkyl group, an aryl group, a substituted aryl group or the like; R 4 represents an aryl group, a substituted aryl group, a heteroaryl group or a substituted heteroaryl group; R5 represents a hydrogen atom, an alkyl group or a substituted alkyl group; and X represents a hydrogen atom, a substituted or unsubstituted alkyl group or the like. The following compounds are described as examples of the derivatives described above.

EXAMPLE 2 EXAMPLE 6 EXAMPLE 7 EXAMPLE 14 The patent document with the number WO2004 / 072060A1 discloses substituted 3- (benzoylureido) -thiophene derivatives, which are useful for treating and preventing type II diabetes (see patent document 18).

In the formula: R5 represents F, Cl or Br; R1 represents a hydrogen atom, F, Cl or Br; R 2 represents a hydrogen atom, F, Cl, Br, an alkyl group or the like; R3 represents a hydrogen atom, an alkyl group or the like; and R4 represents a hydrogen atom, an alkyl group or the like. The patent document with the number WO2004 / 078743A1 discloses substituted benzoylureidopyridyl-piperizin- and pyrrolidine-carboxylic acid derivatives, which are useful for treating and preventing type II diabetes (see patent document 19).

I In the formula: R1 and R2 represent a hydrogen atom, F or Cl; X represents OH, NH2, an alkoxy group or the like; A, B, D and E represent CH or N; and m represents 0, 1 or 2. [Document 1 that does not correspond to a patent] JOSLIN'S DIABETES MELLITUS 13th Edition, pp.521-522. [Document 2 that does not correspond to a patent] Coners DJ, Endocrinology 141; 1917-1921, 2000.

[Document 3 that does not correspond to a patent] Tayek JA, Am.

J. Physiol. 270; E709-E717, 1996.

[Document 4 that does not correspond to a patent] Diraison F, Diabetology 41; 212-220, 1998.

[Document 5 that does not correspond to a patent] William H.

Martin, Proc. Nati Acad. Sci. USA 95; 1776-1781, 1998, Judith L, Abstracts from the ADA 61 st Scientific Session [Abstracts of the 61st Scientific Session From ada].

[Patent Document 1] Japanese Patent Laid-Open No. 2004-002311.

[Patent Document 2] National Publication of the Application of International Patent No. 2002-536410. I i I [Patent Document 3] National Publication of International Patent Application No. 2002-515064. I [Patent Document 4] Open Japanese Patent No. 2001- j 247565. | [Patent Document 5] WO96 / 39384 (National Publication; I of International Patent Application No. 1998-511687). ! i [Patent Document 6] WO01 / 94300A1. ! [Patent Document 7] WO02 / 096864A1. I [Patent Document 8] WO03 / 015774A1. Í [Patent Document 9] WO03 / 084922A1. j [Patent Document 10] WO03 / 084923A1. iinJilái, J? í¿ [Patent Document 11 WO03 / 104188A1. [Patent document 12 WO2004 / 007455A1. [Patent document 13 WO2004 / 033416A2. [Patent document 14 WO2004 / 065356A1. [Patent document 15 WO2004 / 098589A1. [Patent document 16 WO2004 / 098590A1. [Patent document 17 WO2004 / 099155A2. [Patent document 18 WO2004 / 072060A1. [Patent document 19 WO2004 / 078743A1 DETAILED DESCRIPTION OF IMVEMCION Problems to be solved by the invention Many antidiabetics that are currently used are used for the pancreas (to promote insulin secretion), the periphery (to improve the resistance of insulin), the small intestine (to inhibit the absorption of sugar) and for insulin itself. However, in recent years, there has been a need to develop an antidiabetic drug based on a new mode of action, and attention has been drawn to the development of an antidiabetic drug that acts by inhibiting the hepatic glycogen phosphorylase. However, no drug has been developed that has a satisfactory activity. Nor has any drug been developed that meets the requirements for oral absorption and metabolic stability. Accordingly, there has been a need to develop a hepatic glycogen phosphorylase inhibitor, which has potent activity and fewer adverse reactions, and which is superior in oral absorption capacity and metabolic stability, compared to conventional antidiabetics. It is an object of the present invention to provide a hepatic glycogen phosphorylase inhibitor having potent activity and fewer adverse reactions, and which is superior in oral absorption capacity and metabolic stability, in comparison with antidiabetics conventional Another object of the invention is to provide a therapeutic agent to combat insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataract, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinism, hyperlipidemia, atherosclerosis, tissue ischemia and myocardial ischemia, a therapeutic agent for the control of appetite and obesity, and a therapeutic agent for infections, such as bacterial, fungal, parasitic or viral infection, where the therapeutic agent has an inhibitor of hepatic glycogen phosphorylase as an active ingredient. ÜÜ ^ üii Means to solve the problems In view of the problems described above, intensive studies have been carried out to discover a useful antidiabetic drug with inhibitory activity of hepatic glycogen phosphorylase and, as a result, it has been found that pyrazole compounds represented by the following general formula (I) possess a potent inhibitory activity of hepatic glycogen phosphorylase. The following items 1 to 57 describe the invention in a more specific manner. A pharmaceutical composition for treating or preventing diabetes, comprising a pyrazole compound or a pharmacologically acceptable salt thereof and a pharmaceutically acceptable carrier thereof, represented by the following general formula (I): wherein the Q ring represents an aryl group or a heteroaromatic group; R1 represents a hydrogen atom, a halogen atom, a C- | 6 alkyl group or a C-? 6 alkoxy group; R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group; R3 represents a halogen atom, a hydroxyl group, a C-? 6 alkyl group, a halo-C-? 6 alkyl group, a C? _6 alkoxy group, an azido group, an amino group, an acylamino group or a alkyl (C- | 6) sulfonylamino group; R4 and R5 are identical to each other or different from one another, and represent (1) a hydrogen atom; (2) a C-α-6 alkyl group, which may be substituted with a substituent selected from Group A, presented below: [Group A] A1. A hydroxyl group, A2. An alkoxy group C? _6, A3. -N (R41) (R41 ') wherein R41 and R41 are identical to each other or different from one another and represent a hydrogen atom or a C?-6¡ alkyl group and R41 and R41, together with the adjacent nitrogen atom , can form a heterocyclic ring, monocyclic 5 or 6 membered, saturated, A4. An aryl group, A5. A heteroaromatic group, A6. -CO-N (R411) (R411 ') wherein R411 and R411 are identical to each other or different from each other and represent a hydrogen atom or a C-i-β alkyl group; and R411 and R411, together with the adjacent nitrogen atom, can form a 5 or 6 membered monocyclic, saturated, heterocyclic ring, A7. A carboxy group, and. A8. An alkoxy group (C? 6) carbonyl (3) a C2.6 alkenyl group (4) a C2-6 alkynyl group; (5) a C3.8 cycloalkyl group; wherein the cycloalkyl group may be substituted with a hydroxyl group, a carboxy group or a (C -, 6) alkoxy group or may be fused with a pyridine ring, (6) a (C3.8) cycloalkyl group Ci-β alkyl; wherein the cycloalkyl group, of the (C3_8) cycloalkyl (C1-6) alkyl group, may be substituted with a hydroxyl group, a carboxy group or a (C6.6) alkoxycarbonyl group, or may be fused with a pyridine ring, ( 7) a saturated, monocyclic, 5- or 6-membered heterocyclic group, which may be substituted with a substituent selected from Group C presented below: [Group C] C1. A C? _6 alkyl group, C2. An acyl group, C3. An alkyl (C- | .6) sulfonyl group, C4. A carboxy group, C5. An alkoxy (C? .6) carbonyl group, and. C6 -CO- (Alk) n-COOR52, wherein R52 is a hydrogen atom or a C? _6 alkyl group; Alk is a C- alkylene group; and n is 0 or an integer comprised between 1 and 3, (8) an aryl group, which may be substituted with one or more substituents, selected from Group D, presented below: [Group D] D1. A hydroxyl group, D2. A C1-6 alkoxy group, D3. A cyano group, D4. A C - ?. alquilo alkyl group, wherein the C? .6 alkyl group may be substituted with a substituent selected from the group consisting of a hydroxyl group, a carboxy group and a (C? ^) Carbonyl alkoxy group, D5. -N (R53) (R53 '), wherein R53 and R53 are identical to each other or different from each other and represent a hydrogen atom, a C- | 6 alkyl group or an alkyl (C -? - 6) group sulfonyl, D6. -CO-N (R531) (R531 '), wherein R531 and R531 are identical to each other or different from each other and represent a hydrogen atom, a C-? 6 alkyl group or an alkyl group (C -? - 6) sulfonyl, D7. -COOR54, where R54 is a hydrogen atom, a C---6 alkyl group, a (C6-6) carbonyloxy-C---6 alkyl group or a cycloalkyloxy (C3.8) carbonyloxy-C-alkyl group -? - 6, D8. -C (NH (OH)) = N-R55, where R55 is a hydrogen atom or an alkyl (C6) sulfonyl group, D9. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, and. D10 A monocyclic 5 or 6 membered heteroaromatic group, which may be substituted with an oxo or thioxo group, (9) a heteroaromatic group fused with a benzene ring or a 5 or 6 membered monocyclic ring, which may be substituted with a substituent selected from a carboxy group and an alkoxy group (C? -6) carbonyl; (10) a C7 aralkyl group.; where the alkyl part of the C7-? 4 aralkyl group can be substituted with one or two substituents, selected from Group E presented below, and the aryl part can be substituted with one or more substituents selected from Group F, presented to continued: [Group E] E1. A C-i ^ alkyl group, which may be substituted with a hydroxyl group, E2. A cyano group, E3. A carboxy group, E4. An alkoxy (C? _6) carbonyl group, and. E5 A phenyl group, [Group F] F1. A C-i-β, F2 alkyl group. A halogen atom, F3. A cyano group, F4. A hydroxyl group, F5. A C-i-β alkoxy group, which may be substituted with a substituent selected from the group consisting of a carboxy group and an alkoxy group (C-α-6) carbonyl, F6. A haloalkyl group C? _6, F7. A carboxy group, F8. An alkoxy group (C? -6) carbonyl, F9. -CO-N (R56a) (R56a ') wherein R56a and R56a are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated group, having at least a nitrogen atom, or a C? _6 alkyl group, which may be substituted with a substituent selected from Group f presented below: [Group f] f1. An amino group, f2. A monoalkyl group (C -? _ 6) amino, f3. A dialkyl (C? -6) amino group, f4. A carboxy group, f5. An alkoxy group (C? -6) carbonyl, f6. A hydroxyl group, and. f7. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, having at least one nitrogen atom, F10. -N (R56) (R56b '), wherein R56b and R56b are identical to each other or different from one another and represent a hydrogen atom, a C1-6 alkyl group, which may be substituted with an imino group, an aralkyl group , which may be substituted with one or more identical or different substituents, selected from an imino group and a halogen atom, an arylsulfonyl group which may be substituted by a C? -6 alkyl group, an alkyl group (C? .6) sulfonyl, an acyl group, a carbamoyl group, a monoalkyl (C -? - 6) carbamoyl group or a dialkyl (C? ^) carbamoyl group, F11. -N = CR57 (-N (R58) (R58 ')), where R57 is a hydrogen atom or a C-? 6 alkyl group, R58 and R58 are identical to each other or different from each other and represent a hydrogen or a C? _6 alkyl group, F12. A heteroaromatic group, monocyclic, of 5 or 6 members, and. F13 A methylenedioxy group or an ethylenedioxy group, or, (11) a C-? 6 alkyl group, substituted with a heteroaromatic, monocyclic, 5- or 6-membered group, or a heteroaromatic group obtained by condensation of the heteroaromatic group with a ring of benzene; where the heteroaromatic group or the condensed heteroaromatic group may be substituted with one or more substituents selected from Group G presented below: [Group G] G1. A C-α-6 alkyl group, which may be substituted with a substituent selected from Group g, presented below: [Group g] g1. A halogen atom, g2. An amino group, g3. A monoalkyl (C? -6) amino group, g4. A dialkyl (C? .6) amino group, g5. An alkoxy (C? ^) Carbonylamino group, and > g6 A hydroxyimino group, G2. A halogen atom, G3. An alkoxy group C -? _ 6, which may be substituted with a halogen atom, G4. An aryloxy group, G5. A cyano group, G6. -N (R59a) (R59a '), wherein R59a and R59a are identical to each other or different from one another and represent a hydrogen atom or a C6-C6 alkyl group; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic, heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group (C ?) amino or a dialkyl (C? .6) amino group, G7. -CO-N (R59b) (R59b ') wherein R59b and R59b are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated or an alkyl C group ? _6, which may be substituted with the heterocyclic group, G8. An aryl group, and. G9 A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group, R4 and R5, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered heterocyclic ring, where a portion of the saturated heterocyclic ring can have a double bond and the saturated heterocyclic ring can be fused to a ring of benzene, to form a fused ring or the saturated heterocyclic ring that can be condensed with a benzene ring to form a fused ring can be substituted with a halogen atom, a C? _6 alkyl group, a C? > a carboxy group or a (C? -6) carbonyl alkoxy group. 2. The pharmaceutical composition for treating or preventing diabetes, according to item 1 described above, comprising a pyrazole compound or a pharmacologically acceptable salt thereof and a pharmaceutically acceptable carrier thereof, represented by the following formula general (I): iullic .lid where the Q ring represents an aryl group or a heteroaromatic group; R1 represents a hydrogen atom, a halogen atom, a C-α-6 alkyl group or a Ci ^ alkoxy group; R 2 represents a halogen atom, a C 6 alkyl group, a C 6 alkoxy group or an azido group; R3 represents a halogen atom, a hydroxyl group, a C1-4 alkyl group, a halo-C1-6 alkyl group, an alkoxy group, an azido group, an amino group, an acylamino group or an alkyl (C? 6) Sulfonylamino; R4 represents (1) a hydrogen atom; (2) a C-α-6 alkyl group, which may be substituted with a substituent selected from Group A, presented below: [Group A] A1. A hydroxyl group, A2. An alkoxy group C? _6, A3. -N (R41) (R41) wherein R41 and R41 are identical to each other or different from one another and represent a hydrogen atom or a Ci-β alkyl group; and R41 and R41, together with the adjacent nitrogen atom, can form a saturated, monocyclic 5 or 6 membered heterocyclic ring, A4. An aryl group, A5. A heteroaromatic group, A6. -CO-N (R411) (R411 ') wherein R4 1 and R411 are identical to each other or different from each other and represent a hydrogen atom or a C? -6 alkyl group; and R411 and R411, together with the adjacent nitrogen atom, can form a 5 or 6 membered monocyclic, saturated, heterocyclic ring, A7. A carboxy group, and. A8. An alkoxy (C? ^) Carbonyl group, (3) a C2.6 alkenyl group; (4) a C2.6 alkynyl group; (5) a C3.8 cycloalkyl group; (6) a (C3.8) alkylcycloalkyl group or, (7) an aryl group; and R5 represents (1) a C? 6 alkyl group, which may be substituted with a substituent selected from group B presented below: [Group B] B1. A hydroxyl group, B2. An alkoxy group C? _6, B3. -N (R51) (R5r) I wherein R51 and R51 are identical to each other or different from each other and represent a hydrogen atom or a C-? 6 alkyl group; and R51 and R51, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic heterocyclic ring, and, B4. -CO-N (R511) (R511 ') wherein R511 and R511 are identical to each other or different from each other and represent a hydrogen atom or a C6_6 alkyl group; and R511 and R511, together with the adjacent nitrogen atom, can form a 5 or 6 membered monocyclic, saturated, heterocyclic ring, (2) a C3.8 cycloalkyl; wherein the cycloalkyl group may be substituted with a hydroxyl group, a carboxy group or a (C6-6) alkoxycarbonyl group or may be fused with a pyridine ring, (3) a cycloalkyl (C3-8) alkyl group -C? .6; where the cycloalkyl group of the (C3.8) cycloalkyl group C-? 6 alkyl may be substituted with a hydroxyl group, a carboxy group or a (C-? 6) alkoxycarbonyl group, or it may be fused with a pyridine ring , (4) a saturated, monocyclic, 5- or 6-membered heterocyclic group, which may be substituted with a substituent selected from Group C presented below: [Group C] C1. An alkyl group C -? - 6, C2. An acyl group, C3. An alkyl (C? 6) sulfonyl group, C4. A carboxy group, C5. An alkoxy group (C? -6) carbonyl, and, C6. -CO- (Alk) n-COOR52, where R52 is a hydrogen atom or a C? _6 alkyl group; Alk is a C- alkylene group; and n is 0 or an integer comprised between 1 and 3, (5) an aryl group which may be substituted with one or more substituents selected from Group D presented below: [Group D] D1. A hydroxyl group, D2. An alkoxy group C? _6, D3. A cyano group, D4. A C? .6 alkyl group, wherein the C-i-β alkyl group may be substituted with a substituent selected from the group consisting of a hydroxyl group, a carboxy group and an alkoxy group (C? _6) carbonyl, D5. -N (R53) (R53 '), where R53 and R53 are identical to each other or different from each other and represent a hydrogen atom, a C? _6 alkyl group or an alkyl group (C -? - 6) sulfonyl, D6. -CO-N (R531) (R531 ') wherein R53 and R531 are identical to each other or different from each other and represent a hydrogen atom, a C-? 6 alkyl group or an alkyl (C? .6) group sulfonyl, D7. -COOR54, where R54 is a hydrogen atom, a C6_6 alkyl group, an alkylC ^ Jcarbonyloxy-C1-6alkyl group or a cycloalkyloxy (C3.8) carbonyloxy-C6_6, D8 alkyl group. -C (NH (OH)) = N-R55, where R55 is a hydrogen atom or an alkyl group (C. Β-sulfonyl, D9.) A heterocyclic group, monocyclic, 5- or 6-membered, saturated, and D10. heteroaromatic group, monocyclic, 5- or 6-membered, which may be substituted with an oxo or thioxo group, (6) a heteroaromatic group fused with a benzene ring or a 5- or 6-membered monocyclic ring, which may be substituted with a substituent selected from the group consisting of a carboxy group and a (C-? 6) carbonyl group; (7) a C 7 - aralkyl group wherein the alkyl part of the aralkyl group C 1 -? 4 may be substituted with one or two substituents selected from Group E, presented below, and the portion of the aryl group may be substituted with one or more substituents selected from Group F, presented below: [Group E] E1. C -? 6, which may be substituted with a hydroxyl group, E2 A cyano group, E3 A carboxy group, E4 An alkoxy (C? 6) carbonyl group, and, E5. A phenyl group, [Group F] F1. A C? _6 alkyl group, F2. A halogen atom, F3. A cyano group, F4. A hydroxyl group, F5. A C ^ alkoxy group, which may be substituted with a substituent selected from the group consisting of a carboxy group and a (C6-6) alkoxycarbonyl group, F6. A haloalkyl group d-6, F7. A carboxy group, F8. An alkoxy group (C? _6) carbonyl, F9. -CO-N (R56a) (R56a) wherein R56a and R56a are identical to each other or different from each other and represent a hydrogen atom, a saturated, monocyclic, 5- or 6-membered heterocyclic group having at least one atom of nitrogen, or a C? _6 alkyl group? which may be substituted with a substituent selected from Group f presented below: [Group f] f1. An amino group, f2. A monoalkyl group (C- | .6) amn, f3. A dialkyl (C? .6) amino group, f4. A carboxy group, f5. A group f6. A hydroxyl group, and. f7. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, having at least one nitrogen atom, F10. -N (R56) (R56b), wherein R56b and R56b are identical to each other or different from one another and represent a hydrogen atom, a C---6 alkyl group, which may be substituted with an imino group, a group aralkyl, which may be substituted with one or more identical or different substituents, selected from an imino group and a halogen atom, an arylsulfonyl group, which may be substituted with a C 1-6 alkyl group, an alkyl (C? 6) Sulfonyl, an acyl group, a carbamoyl group, a monoalkyl (C? .6) carbamoyl group or a dialkyl ^ C ^ carbamoyl group, F11. -N = CR57 (-N (R58) (R58 ')), where R57 is a hydrogen atom or a C-? 6 alkyl group; R58 and R58 are identical to each other or different from one another and represent a hydrogen atom or a C-_6 alkyl group, F12. A heteroaromatic group, monocyclic, of 5 or 6 members, and. F13 A methylenedioxy group or an ethylenedioxy group, or, (8) a C-? 6 alkyl group substituted with a heteroaromatic, monocyclic, 5- or 6-membered group or with a heteroaromatic group obtained by condensation of the heteroaromatic group with a benzene ring; wherein the heteroaromatic group may be substituted with one or more substituents selected from Group G, presented below: [Group G] G1. A C- | 6 alkyl group, which may be substituted with a substituent selected from Group g presented below: [Group g] g1. A halogen atom, g2. An amino group, g3. A monoalkyl (C? .6) amino group, g4. A dialkyl (C1.6) amino group, g5. An alkoxy group (C? -6) carbonylamino, and g6. A hydroxyimino group, G2. A halogen atom, G3. An alkoxy group C-i-β, which may be substituted with a halogen atom, G4. An aryloxy group, G5. A cyano group, G6. -N (R59a) (R59a '), wherein R59a and R59a are identical to each other or different from one another and represent a hydrogen atom or a C-_6 alkyl group; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic, heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group (C ? .6) amino or a dialkyl (C? -6) amino group, G7. -CO-N (R59b) (R59b) wherein R59b and R59b are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated or a C-alkyl group ? -6, which may be substituted with the heterocyclic group, G8. An aryl group, and.

G9 A heteroaromatic, monocyclic group of 5 or 6 members, which may be substituted with an oxo or thioxo group, or R4 and R5, together with the adjacent nitrogen atom, may form a saturated, 5- or 6-membered heterocyclic ring. where a portion of the saturated heterocyclic ring can have a double bond, and the saturated heterocyclic ring can be fused to a benzene ring to form a fused ring, or the saturated heterocyclic ring can be fused; to be condensed with a benzene ring to form a fused ring may be substituted with a halogen atom, a C6_6 alkyl group, a C1_6 alkoxy group, a carboxy group or an alkoxy group (C6_6) carbonyl. ' 3. - The pharmaceutical composition for treating or preventing diabetes, according to item 1 above, wherein the pyrazole compound is a pyrazole compound represented by the following general formula (II '): where R1, R2, R3, R4 and R5 are as defined in item 1 above. 4. - The pharmaceutical composition for treating or preventing diabetes, according to item 2 described above, wherein the pyrazole compound is a pyrazole compound represented by the following general formula (II): where R4 and R5 are as defined in item 1 above; R1a represents a halogen atom or a hydrogen atom; R2a, a halogen atom; and R3a, a halogen atom or a C ^ alkyl group. 5. The pharmaceutical composition for treating or preventing diabetes according to item 4 described above, wherein R a is a hydrogen or fluorine atom; R2a fluorine atom or chlorine, and R3a is a chlorine atom or a C ^ alkyl group. 6. The pharmaceutical composition for treating or preventing diabetes according to item 5 described above, wherein the pyrazole compound is a pyrazole compound represented by the following general formula (III): where R4 and R5 are as defined above. 7. The pharmaceutical composition for treating or preventing diabetes, according to any of the points 2 to 6 described above, wherein R4 is a group selected from the following groups: (1) a hydrogen atom; (2) a C1-6 alkyl group, which may be substituted with a substituent selected from Group A ', presented below: [Group A'] A'1. A hydroxyl group, A'2. An alkoxy group Ci ^, A'3. -N (R 1) (R41 ') wherein R41 and R41 are identical to each other or different from one another and represent a hydrogen atom or a C ^ alkyl group; and R41 and R41, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered heterocyclic ring, A'4. A phenyl group, A'5. A heteroaromatic group, monocyclic, of 5 or 6 members, A'6. -CO-N (R411) (R411 ') wherein R411 and R411 are identical to each other or different from each other and represent a hydrogen atom or an alkyl group and R411 and R411, together with the adjacent nitrogen atom, can form a heterocyclic ring, 5 or 6 membered monocyclic, saturated, A'7. A carboxy group, and A'8. An alkoxy (C?) Carbonyl group, (3) a C2-6 alkenyl group (4) a C2-6 alkynyl group (5) a C3.8 cycloalkyl; and, (6) a C3 M (C3.8) cycloalkyl group. 8. The pharmaceutical composition for treating or preventing diabetes, according to any of the points 2 to 7 described above, wherein R5 is an alkyl group 9.- The pharmaceutical composition for treating or preventing diabetes, according to any of points 2 to 7 described above, wherein R5 is a C3"8 cycloalkyl, which may be substituted with a hydroxyl group, a carboxy group or an alkoxy group (C? ^) carbonyl. 10. The pharmaceutical composition for treating or preventing diabetes, according to any of the points 2 to 7 described above, wherein R5 is a cycloalkyl (C3.8) C6-6 alkyl group. 11. The pharmaceutical composition for treating or preventing diabetes, according to any of the points 2 to 7 described above, wherein R5 is a saturated, saturated monocyclic, 5- or 6-membered heterocyclic group, which may be substituted with a substituent selected from an acyl group and -CO- (Alk) n-COOR52, where R52 is a hydrogen atom or a alkyl group and n is 0 or an integer between 1 and 3. 12. The pharmaceutical composition for treating or preventing diabetes, according to any of the points 2 to 7 described above, wherein R5 is a phenyl group, which can be substituted with one or more substituents selected from the following Group D ': [Group D'] D'1. A C-M alkyl group, which may be substituted with a carboxy group, D'2. -CO-N (R53) (R53 '), wherein R53 and R53 are identical to each other or different from one another and represent a hydrogen atom, a C-M alkyl group or a C-M-sulfonyl alkyl group, D'3. -COOR54, where R54 is a hydrogen atom, a C1-4 alkyl group, an alkyl (C? ^) Carbonyloxy-C-M alkyl group or a C3-8 cycloalkyloxy group, carbonyloxy-C-M alkyl, and. D'4 A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group. 13. - The pharmaceutical composition for treating or preventing diabetes, according to any of the points 2 to 7 described above, wherein R5 is an aralkyl group C? 4 and the aryl part of the aralkyl group C7 -? may be substituted with one or more substituents selected from the following Group F ': [Group F'] F'1. An alkyl group F'2. A halogen atom, F'3. A cyano group, F'4. A hydroxyl group, F'5. An alkoxy group C -? - 6, which may be substituted with a substituent selected from a carboxy group or a (C 6) alkoxycarbonyl group, F'6. A halo-C1-6 alkyl group, F'7. A carboxy group, F'8. An alkoxy group (C? ^) Carbonyl, F'9. -CO-N (R56a) (R56a '), wherein R56a and R56a are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated group having at least a nitrogen atom, or a C? _6 alkyl group, which may be substituted with a substituent selected from the following Group f: [Group f] f1. An amino group, f2. A monoalkyl (C? -6) amino group, f 3. A dialkyl (C? ^) Amino group, f4. A carboxy group, f5. An alkoxy group (C? _6) carbonyl, f6. A hydroxyl group, and. f7. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, having at least one nitrogen atom, F'10. -N (R56b) (R56b ') wherein R56b and R56b are identical to each other or different from each other and represent a hydrogen atom, a C-? 6 alkyl group, which may be substituted with a lower group, a Aralkyl group, which may be substituted with one or more identical or different substituents, selected from a lower group and a halogen atom, an arylsulfonyl group, which may be substituted by a C 1-6 alkyl group, an alkyl (C? .6) sulfonyl, an acyl group, a carbamoyl group, a monoalkyl (C [beta]) carbamoyl group or a dialkyl (C [beta] 6) carbamoyl group, F'11. -N = CR57 (-N (R58) (R58 ')), where R57 is a hydrogen atom or a C1-4 alkyl group, R58 and R58 are identical to each other or different from each other and represent a hydrogen atom or an alkyl group CM, F'12. A heteroaromatic, monocyclic group of 5 or 6 members, and- F'13. A methylenedioxy group or an ethylenedioxy group. 14. - The pharmaceutical composition to treat or prevent diabetes, according to any of the points 2 to 7 described above, where R5 is a C---6 alkyl group, substituted with a heteroaromatic group, > monocyclic, with 5 or 6 members and the heteroaromatic group can be substituted with one or more substituents selected from the following Group G ': [Group G '] G'1. A C -? - 6 alkyl group, which may be substituted with a substituent selected from Group g ', presented below: I [Group g'] g'1. A halogen atom, g'2. An amino group, g'3. A monoalkyl (C? ^) Amino group, g'4. A dialkyl (C? -6) amino group, g'5. An alkoxy (d_6) carbonyl group,, Y- . I g'6. A hydroxyimino group, G'2. A halogen atom, G'3. An alkoxy d-6 group, which may be substituted with a | halogen atom, i G'4. An aryloxy group, G'5. A cyano group, G'6. -N (R59a) (R59a '), wherein R59a and R59a are identical to each other or different from each other and represent a hydrogen atom or a d-β alkyl group; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic, heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group (C ? .6) amino or a dialkyl (C? ^) Amino group, G'7. -CO-N (R59b) (R59b) wherein R59b and R59b are identical to each other or different from one another and represent a hydrogen atom, a saturated, monocyclic, 5- or 6-membered heterocyclic group, or an alkyl group -6, which may be substituted with the heterocyclic group, G'8. An aryl group, and. G'9. A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group. 15. The pharmaceutical composition for treating or preventing diabetes according to any of the points 2 to 6 described above, where R5 and R4, together with the adjacent nitrogen atom, form a saturated, monocyclic, 5- or 6-membered heterocyclic group, where a portion of the saturated heterocyclic group may have a double bond, and the saturated heterocyclic group may be fused with a benzene ring, to form a fused ring, or the saturated heterocyclic group, which may be fused to a benzene ring to form a fused ring, may be substituted with a halogen atom, a C- ^ alkyl group, a alkoxy group d-6, a carboxy group or a alkoxy (d.6) carbonyl group. 16. The pharmaceutical composition for treating or preventing diabetes according to item 2 described above, wherein the pyrazole compound is a pyrazole compound represented by the following general formula (IV): where R4 is as described in point 2; RX1, RX2 and RX3 are identical to each other or different from one another and represent a hydrogen atom or a substituent selected from the following Group F "; and m is 0 or an integer between 1 and 2, [Group F"] F "1. An alkyl group C -? - 6, F" 2. A halogen atom, F "3. A cyano group, F" 4. A hydroxyl group, F "5. A C-M alkoxy group, which may be substituted by a carboxy group or an alkoxy group (C? ^) Carbonyl, F" 6. A haloalkyl group C-? 6, F "7. A carboxy group, F" 8. An alkoxy group (C? _6) carbonyl, F "9. -CO-N (R56a) (R56a ') wherein R56a and R56a are identical to each other or different from each other and represent a hydrogen atom, a group heterocyclic, monocyclic, 5- or 6-membered, saturated having at least one nitrogen atom, or a C 1-6 alkyl group, which may be substituted with a substituent selected from Group f ", presented below: [Group f '] f'1. An amino group, f '2. A monoalkyl group (C? -6) amino, f'3. A dialkyl group (C? -6) amino, f'4. A carboxy group, f "5. An alkoxy (d.6) carbonyl group, f'6 A hydroxyl group, and f7 A heterocyclic, monocyclic, 5- or 6-membered, saturated group having minus one nitrogen atom, F "10. -N (R56b) (R56b) wherein R56b and R56b are identical to each other or different from one another and represent a hydrogen atom, a C1-6 alkyl group, which may be substituted with an imino group, an aralkyl group, which may be substituted with one or more identical or different substituents, selected from an imino group and a halogen atom, an arylsulfonyl group which may be substituted by a C1-6 alkyl group, an alkyl (d.6) sulfonyl group, a group acyl, a carbamoyl group, a monoalkyl (C?) carbamoyl group or a dialkyl (d-6) carbamoyl group, F "11. -N = CR57 (-N (R58) (R58 ')), wherein R57 is a hydrogen atom or an alkyl group d_6; R58 and R58 are identical to each other or different from one another and represent a hydrogen atom or an alkyl group d-β, F "12. A heteroaromatic group, monocyclic, of 5 or 6 members, and. F "13. A methylenedioxy group or an ethylenedioxy group 17. The pharmaceutical composition for treating or preventing diabetes according to item 2 described above, wherein the pyrazole compound is a pyrazole compound represented by the following general formula ( V): where R4 is as defined in item 2 above, the Het ring represents a heteroaromatic group of a 5 or 6 membered monocyclic ring; RY1, RY2 and RY3 are identical to each other or different from one another and represent a hydrogen atom or a substituent selected from the following Group G '; and m 'is 0 or an integer between 1 and 2, [Group G'] G'1. A C? _6 alkyl group, which may be substituted with a substituent selected from Group g 'presented below: [Group g'] g'1. A halogen atom, g'2. An amino group, g'3. A monoalkyl (d.6) amino group, g'4. A dialkyl (C? ^) Amino group, g'5. An alkoxy (C6-6) carbonyl group, and, g6. A hydroxyimino group, G'2. A halogen atom, G'3. A C6-6 alkoxy group, which may be substituted with a halogen atom, G'4. An aryloxy group, G'5. A cyano group, G'6. -N (R59a) (R59a), wherein R59a and R59a are identical to each other or different from each other and represent a hydrogen atom or an alkyl group d.6; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic, heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group (C ? .6) amino or a dialkyl (C? 6) amino group, G'7. -CO-N (R59b) (R59b) wherein R59b and R59b are identical to each other or different from one another and represent a hydrogen atom, a saturated, monocyclic, 5- or 6-membered heterocyclic group, or an alkyl group -6, which may be substituted with the heterocyclic group, G'8. An aryl group, and. G'9. A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group. 18. The pharmaceutical composition for treating or preventing diabetes, according to item 17 described above, wherein the Het ring is a pyridine ring, a triazole ring or an oxazole ring. 19. The pharmaceutical composition for treating or preventing diabetes according to item 18 described above, wherein the pyrazole compound is a pyrazole compound represented by the following general formula (VI): where R 3J D RY1, D RY2, D RY3 and m 'are such as described above. 20. The pharmaceutical composition for treating or preventing diabetes according to item 2 above, wherein the pyrazole compound or a pharmacologically acceptable salt thereof is selected from the following group: (pyridin-3-ylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro) (pyridin-3-ylmethyl) -amide-dihydrochloride -benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide-hydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methyl-oxazol-5-ylmethyl) -amide, (4-Methyl-oxazol-5-ylmethyl) ) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (5-methyl-oxazol-5-ylmethyl) -amide-p-toluenesulfonate acid (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2- (2-) - (4- methyl-oxazol-5-ylmethyl) amide-L- (+) - tartrate) chloro-4,5-difluoro-benzoi lamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (2,4-dimethyl-oxazol-5-ylmethyl) -amide p-toluenesulfonate pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-oxazol-5-ylmethyl) -amide, (2 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-dimethyl-pyridin-3-ylmethyl acid, 5-chloro-4-diethylamide , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Ethyl- (pyridin-4-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- 3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-ethyl) -methyl-amide, Ethyl- (2-methoxy-ethyl) ) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-chloro-4,5-difluoro-benzoylamino) acid 2-fluoro-benzylamide ) -1 H-pyrazole-3-carboxylic acid, 3-Fluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 2-Di 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid methylamino-benzylamide, 5- (2-Chloro-3-chloro- (4-ethoxycarbonyl-cyclohexyl) -propyl-amide 4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1- (6-methoxy-pyridin-3-ylmethyl) -amide. H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,3-dimethoxy-benzylamide, 2,4-dimethoxy-benzylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,6-dimethoxy-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3,5-dimethoxy-benzylamide, 3,4-dimethoxy- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 2,3-difluoro-benzylamide of 5- (2-chloro-4,5-difluoro- benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,4-difluoro-benzylamide of 5- (2-chloro-4,5-difluor o-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,5-Difluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2, 6-Difluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3,4-difluoro-benzylamide of 5- (2-chloro-4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3,5-Difluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-lsopropoxy-pyridin-3-ylmethyl) -amide, (2-phenoxy-pyridin-3-ylmethyl) ) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, 5- (3-difluoro-pyridin-2-ylmethyl) -amide 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid trifluoromethyl-benzylamide, 5- (2-chloro-4,5-trifluoromethyl-benzylamide) -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-trifluoromethyl-benzylamide, 4-Terc 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl-benzylamide, 5- (2-chloro-pyridin-3-ylmethyl) -amide -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [2- (2,2,2-Trifluoro-ethoxy) -pyridin-3-ylmethyl] -amide of 5- (2 -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - 4- (2-Dimethylamino-ethylcarbamoyl) -benzylamide 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-ethyl-benzylamide, 5-hydroxy-4-lsopropyl-benzylamide 2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2-chloro-6-fluor 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid o-benzylamide, 5- (6-ethoxy-pyridin-3-ylmethyl) -amide-dihydrochloride 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -l (thiazol-4-ylmethyl) -amide H-pyrazole-3-carboxylic acid, [6- (2,2,2-trifluoro-ethoxy) -pyridin-3-ylmethyl] -amide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,6-Dimethyl-benzylamide, [2- (Pyridine- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-yl) -thiazol-4-ylmethyl] -amide-dihydrochloride, (1 H-Benzoimidazole-2- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid ylmethyl) -amide dihydrochloride [4- (. { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carbonyl] -amino} -methyl) -benzoylamino] -acetic acid, 3- [4- (. {[[5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carbonyl] -amino] methyl ester. -methyl) -benzoylamino] -propionic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (2-methyl-thiazol-4-ylmethyl) -amide-dihydrochloride carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,5-dimethyl-isoxazol-4-ylmethyl) -amide, 4- [2-Bis] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-acetoxyethyl) -amino-ethylcarbamoyl] -benzylamide, 4- (2-Hydroxy-ethylcarbamoyl) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 4-. { 2 - [(2-Acetoxyethyl) - (2-hydroxyethyl) -amino] -ethylcarbamoyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, (1-Methyl-1H-benzoimidazol-2-ylmethyl) -amide-hydrochloride acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro- (thiazol-2-ylmethyl) -amide-dihydrochloride) benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (Benzothiazol-2-ylmethyl) -amide-dihydrochloride, ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2,5-dimethyl-thiazol-4-ylmethyl) -amide dihydrochloride, [2- (Morpholin-4 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (1, 3,5-trimethylol) -amylamino-thiazol-4-ylmethyl] -amide dihydrochloride. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1H-pyrazol-4-ylmethyl) -amide, (2-Chloro-6-methyl-pyridin-3-ylmethyl) ) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dihydrochloride, 5-dimethylamino-thiazol-4-ylmethyl-amide-dihydrochloride - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (1-Methyl-1H-pyrrol-2-ylmethyl) -amide of 5- (2 -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-dimethyl-3-dimethoxy-pyridin-2-ylmethyl) -amide-dihydrochloride -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - (5-tert-butyl-thiazol-2-ylmethyl) -amide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) - 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro- 5-methyl-2-phenyl-2H- [1,2] triazol-4-ylmethyl) -amide benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) [4- (tert-butoxycarbonyl-amino) -methyl-pyridin-2-ylmethyl] -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro) - [4-Methyl-2- (morpholin-4-yl) -thiazol-5-ylmethyl] -amide-dihydrochloride] -benzoylamino) -1H-pyrazole-3-carboxylic acid, (pyridin-3-ylmethyl) -amide 3/2-hydrochloride-hemihydrate, of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-amino-benzylamide, 5- (2-methoxy-benzylamide) -c par-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-methoxy-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 -carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-methoxy-benzylamide, 5- (2-chloro-4-methyl-benzylamide) , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4- fluoro-benzylamide, 4- Chloro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -4-ethoxycarbonyl-benzylamide ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-carboxy-benzylamide, 5- (2-dibenzylamide) -chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, (cyano-phenyl-methyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H- pyrazole-3-carboxylic acid, cyclohexylmethyl-amide of 5- (2-Chloro-4,5-difluor o-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (2-hydroxy-ethyl) -phenyl-amide carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl-methyl-amide, 5- (2-chloro-4,5-difluoro-) cyclohexyl-amide benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl-ethyl acid, Allyl-cyclohexyl-acid amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Cyclohexyl- (pyridin-2-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro- benzoylamino) -1H-pyrazole-3-carboxylic acid, Methyl- (1-methyl-piperidin-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- 3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [(3,4-methylenedioxyphenyl) -methyl] -amide hydrochloride, Benzyl-butyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, Benzyl- ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-hydroxy-butyl) -amide-hydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl-ethyl-amide, 5- (2-chloro-4,5-cyclohexyl-propyl-amide) -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl-cyclohexyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Cyclohexyl- ( 2- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-methoxy-ethyl) -amide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-Chloro-4,5-difluoro-benzoylamino) -1 H-prazol-3-carboxylic acid, 2- (2-chloro-4-yl) -amino acid 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dibutylamide, Bis- (2-methoxy) ethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (2-methoxy-ethyl) -propyl-amide of 5- (2-chloro) -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluo) -Butyl- (tetrahydro-pyran-4-yl) -amide gold-benzoylamino) -1 H-pyrazole-3-carboxylic acid, (2-methoxy-ethyl) - (tetrahydro-pyran-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, Cyclopentyl- (2-methoxy-ethyl) -amide of 5- (2-chloro-4, 5-difluoro-benzoylamino) -! H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl- (3-methoxy-propyl) -amide, Cyclohexyl- (2 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, -cyclohexyl- (2-isopropoxy-ethyl) -amide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Cyclohexyl- (2-propoxy-ethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) - 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (2-methoxy-ethyl) -amide (1-Ethyl-propyl) - (2-methoxy-ethyl) -amide carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrrazol-3-carboxylic acid butyl- (1-tert-butoxycarbonyl-piperidin-4-yl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (tetrahydro-thiopyran-4-yl) -amide, (2-methoxy-ethyl) -amide 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-) butyl- (pyridin-3-ylmethyl) -amide difluoro-b enzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzyl- (2-methoxy-ethyl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (piperidin-4-yl-amide, (1-acetyl-piperidin-4-yl) -butyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-butyl- (1-methanesulfonyl-piperidin-4-yl) -amide) -amide -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro) butyl- (1-ethoxalyl-piperidin-4-yl) -amide. -benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl- (1-oxalo-piperidin-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 -amide -carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-butyl- (1,1-d-oxo-hexahydro-1,6-thiopyran-4-yl) -amide. -3-carboxylic acid, butyl- (1-oxo-hexahydro-1? thiopyran-4-yl) -amino acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, (6-methoxy-pyridin-3-ylmethyl) -propyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid amide, 5- (2-Chloro-4) propyl- (pyridin-3-methylmethyl) -amide , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-Diethylcarbamoyl-benzylamide, 3-Diethylcarbamoyl-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-Ethylcarbamoyl-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid; 3-Ethylcarbamoyl-benzylamide of 5- (2-chloro-4,5-difluoro-i! Benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-carbamoyl-benzylamide of 5- (2-chloro- 4,5-difluoro-yl, benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5) -I- (1-Oxalo-p-peridin-4-yl) -propyl-amide -, difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-1-carboxylacetyl-piperidin-4-yl) -propyl-amide 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [1- (2-Carboxypropionyl) -piperidin-4-yl] -propyl-amide of 5- (2- i) acid chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, Cyclopropyl- (6-methoxy-pyridin-3-ylmethyl) -amide of 5- (2-chloro-, i, 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, I cyclobutyl - (6-methoxy-pyridin-3-ylmethyl) -amide of 5- (2-chloro) -amide 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Cyclopropylmethyl- (6-methoxy-pyridin-3-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (6-Dimethylamino-pyridin-3) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-D-methylamino-pyridin-3-ylmethyl) -propyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-) benzyl- (2-carboxy-ethyl) -amide difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzyl- (2-ethoxycarbonyl-ethyl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-ylmethyl) -propyl-amide, 2,6-Dichloro-benzylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro) (3,5-Dichloro-pyridin-4-ylmethyl) -amide -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difl) (3,5-dichloro-pyridin-4-ylmethyl) -propyl-amide uoro-benzoylamino) -1H-pyrazole-3-carboxylic, [6- (1 H-pyrazol-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride of 5- (2-chloro-4,5- difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [6- (4-hydroxy-piperidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride of 5- (2-chloro-4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole (2-pyridin-2-yl-ethyl) -amide. -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-pyridin-3-yl-ethyl) -amide, i (2-pyridine- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid 4-yl-ethyl) -amide (4- [1,2,3] thiadiazol-4-yl) -benzyl) -amino acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (5-methyl-pyrazin-2-ylmethyl) -amide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole pyrazin-2-ylamide -3-carboxylic acid, quinolin-5-ylamide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, quinolin-8-ylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- 3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid lsoquinolin-5-ylamide, [3-ethoxy-5- (1-ethoxycarbonyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 1-methyl-ethyl) -pyridin-2-yl] -amide, [3-Ethoxy-5- ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [1-ethoxycarbonyl-1-hydroxy-ethyl) -pyridin-2-yl] -amide, [5- ( 1-Carboxy-1-methyl-ethyl) -3-ethoxy-pyridin-2-yl] -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid; co, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- [5- (1-Carboxy-1-hydroxy-ethyl) -3-ethoxy-pyridin-2-yl] -amide. pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyrazin-2-ylmethyl) -amide, [6- (Tiomorpholin-4-yl) 5- (2-Chloro-4-pyridin-3-ylmethyl) -amide), 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [6- (1, 1-Dioxo-1? 6-thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4, 4,5-dibromo-thiophen-2-methyl) -amide, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (5-chloro-thiophen-2-ylmethyl) -amide. pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-ethyl-2-methyl-oxazol-5-ylmethyl) -amide, ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-ethyl-4-methyl-oxazol-5-ylmethyl-amide dihydrochloride, ([2,2 '] Bitylophenyl-5-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (3-methoxy-thiophen-2-ylmethyl) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, 5- (2- (2-chloro-2-ylmethyl) -amide chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic or, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,5-dimethyl-oxazol-4-ylmethyl) -amide, (2-hexyl-4) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (methyl-oxazol-5-ylmethyl) -amide, (4-methoxy-thiophen-3-ylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-phenyl) -amide (4-Methyl-2-phenyl-oxazol-5-ylmethyl) -amide -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5- (2-methyl-4-phenyl-oxazol-5-ylmethyl) -amide) difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (4- (hexyl-2-methyl-oxazol-5-ylmethyl) -amide-dihydrochloride) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-ylmethyl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-ylmethyl) -amide-dihydrochloride, (4H- [1, 2, 4] Triazol-3-ylmethyl) -amide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro) (4 H- [1,4] triazol-3-ylmethyl) -amide-dihydrochloride -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (5-Fluoro-4H-quinazolin-3-yl) -amide. ) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- (5-Fluoro-4H-quinazolin-3-yl) -amide-dihydrochloride 3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4,6-dimethyl-pyridin-3-ylmethyl) -amide (4.6 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-dimethyl-pyridin-3-ylmethyl) -amide-dihydrochloride, (2-Methoxy-6-methyl-pyridine) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-methoxy-6-methyl-pyridin-3-ylmethyl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, (4-methoxy-6-methyl-pyridin-3-ylmethyl) -amide-dihydrochloride of acid 5- (2-chloro-4,5-dif luoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (2-methoxy-4,6-dimethyl-pyridin-3-ylmethyl) -amide. -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 (2-methoxy-4,6-dimethyl-pyridin-3-ylmethyl) -amide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-methyl-pyridin-2-ylmethyl) -amide, (5- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid methyl-pyridin-3-ylmethyl) -amide, (6-Methyl-pyridin-3-ylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4-methyl) (6-methyl-pyridin-2-ylmethyl) -amide , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole- (pyridin-3-ylmethyl) -amide-dihydrochloride] 3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-fluoro-pyridin-3-ylmethyl) -amide dihydrochloride (3-Ca) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid rboxi-phenyl) -methyl-amide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-methanesulfonylamino-benzylamide, 5- (2-chloro-4,5-acid) 4-methanesulfonylamino-benzylamide -difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 3-Acetylamino-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-Acetylamino 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-) 2-phenyl-thiazol-4-ylmethyl) -amide 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, ((R) -1-Phenylethyl) -amide of 5- (2-chloro-4,5-difluorobenzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ((S) -1-phenyl-ethyl) -amide, (6-) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid phenoxy-pyridin-3-ylmethyl) -amide-dihydrochloride, (6-Chloro-pyridin-3-) 5- (2-Methyl-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ylmethyl) -amide dihydrochloride (2-Clo) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ro-pyridin-3-ylmethyl) -amide dihydrochloride, sodium salt of (6-chloro-pyridine) 3-ylmethyl) -amide of 5- (2-methyl-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [1- (pyridin-3-yl) -ethyl] -amide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-pyridin-3-ylmethyl) -amide-dihydrochloride of 5- (2-chloro- 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (2- methyl-pyridin-3-ylmethyl) -amide-dihydrochloride) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (Biphenyl-3-ylmethyl) -amide, ((1 R, 2S) -2- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (-2S-2R) -2-hydroxy-indan-1-yl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (6-phenyl-pyridin-3-ylmethyl) -amide - (Hydroxy-indan-1-yl) -amide. amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (6-Methyl-2-pyridon-3-ylmethyl) -amide-5- (2-hydrochloride -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Benzyl-methyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1-phenylamide H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl-phenyl-amide, (Piperidin-1-yl) -amide acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-ethoxycarbonyl-piperidin-1-yl) -amide of 5- (2-chloro-4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole (4-Methyl-piperazin-1-yl) -amide. -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-carboxy-piperidin-1-yl) -amide, Fe 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid netilamide, 5- (2-Chloro-4,5-difluoro-benzoylamino) - methyl-phenethyl-amide 1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid ethylphenyl-amide, (1, 2,3,4-tetrahydroisoquinolin-2-yl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4) ((S) -a-Methoxycarbonyl-benzyl) -amide , 5- (2-chloro-4,5-difluoro-benzoylamino) -l- pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1, 2,3,4-tetrahydroquinolin-1-yl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid phenyl-propyl-amide, 5- (2-chloro-4,5-) -butyl-phenyl-amide difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid phenyl-phenyl-amide, Benzhydryl-amide acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (pyridin-2-ylmethyl) -amide-hydrochloride of 5- (2-cl) acid gold-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (Pyridin-4-ylmethyl) -amide-hydrochloride) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (2-) -hydroxy-1-phenyl-ethyl) -amide. carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ((S) -2-hydroxy-1-phenyl-ethyl) -amide, 4-dimethylamino- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-4,5-) (5- (2-chloro-4,5-) -amide (Furan-2-ylmethyl) -amide difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (Tiofen-2-ylmethyl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-phenyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) acid; (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-dimethylamino-benzylamide-5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-amino-benzylamide, 5- (2-) Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-Methyl-benzylamide , 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3-methyl-benzylamide, 5- (2-chloro-4,5-acid) 3-dimethylamino-benzylamide -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-dif-luoro-benzoylamino) - (2-methoxy-pyridin-3-ylmethyl) -amide; H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-chloro-benzylamide, 3-chloro-benzylamide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-methoxycarbonyl-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 -carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3-carboxy-benzylamide, (6-trifluoromethyl-pyridin-3-ylmethyl) -amide acid - (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-) 2- (2-ethoxy-pyridin-3-ylmethyl) -amide difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-dimethylamino-ethyl) -amide, Ethyl 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-dimethylamino-ethyl) -amide-dihydrochloride, Cyclohexyl- (2-dimethylamino-ethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, (4 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (methoxy-pyridin-2-ylmethyl) -amide, (2,6-dimethoxy-pyridin-3-ylmethyl) ) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-chloro-4,5-difluoro-) -2-methoxycarbonylmethoxy-benzylamide benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2-Carboxymethoxy-benzylamide, (6-methoxy-p, Ridin-3-ylmethyl) -amide of 5- (4, 5-Difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2,4-Dichloro-benzoylamino) - (6-methoxy-pyridin-3-ylmethyl) -amide pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,5-dimethoxy-pyridin-4-ylmethyl) -amide, (2 5- (4,5-Difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-dimethyl-oxazol-5-ylmethyl) -amide, (2,4-Dimethyl-oxazole-5-) 5- (2,4-dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxycarbonyl-phenyl) -methyl-amide methyl- (5- ( 2-Chloro-4,5-difluorobenzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (4- Carboxyphenyl) -methyl-amide pyrazole-3-carboxylic acid, 4- ({[[5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carbonyl] -methyl-aminoj-benzoate monosodium iso-propyl-phenyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-dif) acid (ethoxycarbonyl-methyl) -phenol-amide luoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (Carboxy-methyl) -phenyl-amide, 5- (2-Chloro-4-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2,4-Dichloro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-Chloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1-benzyl-phenyl-amide H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1-methyl-1-phenyl-ethyl) -amide, [2 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid -Oxo-2- (piperidin-1-yl) -ethyl] -phenyl-amide, acid benzylamide - (5-Fluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (5-Chloro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, Benzylamide 5- (4-Methoxy-2-methyl-benzoylamino) -1 H-pyrazole-3-carboxylic acid, Acyl benzylamide 5- (4-Chloro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (5-Fluoro-2-methoxy-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Chloro-2-methoxy-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-4,5-carboxylic acid (2-ethoxy-ethyl) -phenyl-amide difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Fluoro-5-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Chloro-2-acid) benzylamide -fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (3-Chloro-2,6-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-benzylamide -chloro-3-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ethylcarbamoylmethyl-phenyl-amide , 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (2-methoxycarbonyl-ethyl) -phenyl-amide -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-ethoxycarbonyl-propyl) -phenyl-amide, (2-Carboxy-ethyl) -phenyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-) -3- (carboxy-propyl) -phenyl-amide difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Hydroxy-4-methoxy-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-Hydroxy) acid benzylamide 5-methoxy-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (5-Fluoro-2-hydroxy-benzoylamino) -1 H -pyrrazole-3-carboxylic acid benzylamide, 5- (4-Fluoro acid) benzylamide -2-trifluoromethyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (5-Fluoro-2-trifluoromethyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide,. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-ethyl) -phenyl-amide, 5- (2,5-Dimethyl-) -benzylamide benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-5-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-pyridine-) benzylamide 3-carbonylamino) -1H-pyrazole-3-carboxylic acid, 5- (4-Chloro-pyridine-2-carbonylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2,6-) -benzylamide dichloro-pyridin-3-carbonylamino) -1H-pyrazole-3-carboxylic acid, butyl- (4-ethoxycarbonyl-phenyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (4-carboxy-phenyl) -amide, acid benzylamide 5- (2-Methyl-pyridine-3-carbonylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-6-methyl-pyridin-3-carbonylamino) -1H-pyrazole-3-benzylamide -carboxylic, 5- (3-chloro-pyridine-4-carbonylamino) acid benzylamide) -1H- pyrazole-3-carboxylic acid, butyl- (4-ethoxycarbonylmethyl-phenyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl- (4-carboxymethyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (4-methoxycarbonyl-phenyl) - (2-methoxy-ethyl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2- (2- (2-methoxy-ethyl) -amido) chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5- (6-methoxy-pyridin-3-ylmethyl) -amide-d-hydrochloride) difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-Methyl-4,5-difluoro-benzoylamino) -1H-pyrazole (6-methoxy-pyridin-3-ylmethyl) -amide-dihydrochloride -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (thiazol-4-ylmethyl) -amide-dihydrochloride, 4- [2- (Morpholine- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-yl) -ethylcarbamoyl] -benzylamide-dihydrochloride 4- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4- (morpholin-4-ylcarbamoyl) -benzylamide-dihydrochloride, sodium salt of acid [4- (. { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carbonyl] -amino} -methyl) -benzoylamino] -acetic acid, 3- [4- ( { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carbonyl] -amino acid sodium salt .}. -methyl) -benzoylamino] -propionic. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,5-dimethyl-isoxazol-4-ylmethyl) -amide hydrochloride, (1, 3,5- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid trimethyl-1H-pyrazol-4-ylmethyl) -amide dihydrochloride (3,5-Dimethyl-isoxazole 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-4-ylmethyl) -amide-sulfonate, 3- [2- (Morpholin-4-yl) -ethylcarbamoyl) ] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-benzylamide-dihydrochloride, 3- (Morpholin-4-ylcarbamoyl) -benzylamide-dihydrochloride - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid,. { 2- [2- (Morpholin-4-yl) -ethylcarbamoyl] -pyridin-4-ylmethyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide trichlorohydrate, [2- (Morpholin-4-ylcarbamoyl) -pyridin-4-ylmethyl] -amide- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid trichlorohydrate, 5- (2-methoxy-pyridin-3-ylmethyl) -amide methanesulfonate -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-) (6-methoxy-pyridin-3-ylmethyl) -amide-hemiside. benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1,5-dimethoxy-pyridin-4-ylmethyl) -amide-dihydrochloride H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (4-Aminomethyl-pyridin-2-ylmethyl) -amide trichlorhydrate carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-ylmethyl) -amide methanesulfonate, (6-Chloro-pyridin- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-car-3-ylmethyl) -amide dimethanesulfonate boxyl, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-pyridin-3-ylmethyl) -amide-hydrochloride, (Pyridin-3) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (methyl-ethyl) -amide-hydrochloride, (6-methoxy-pyridin-3-ylmethyl) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid propyl-amide-dihydrochloride, [6- (Piperidin-1-yl) -pyridin-3-ylmethyl] - amide-acid dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [6- (Morpholin-4-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride] - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4-chloro-3,5-dichloro-pyridin-4-ylmethyl) -amide-hydrochloride , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (6-dimethylamino-pyridin-3-ylmethyl) -amide-dichlorhydrate ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (6-dimethylaminopyridin-3-ylmethyl) -propyl-amide-dihydrochloride -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-diethylamino-pyridin-3-ylmethyl) -amide-dihydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-chloro-2-dimethylamino-pyridin-3-ylmethyl) -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4- [1,2,3] thiadiazol-4-yl-benzyl) -amide-hydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-Methyl-thiazol-5-ylmethyl) -amide hydrochloride, (2,4-Dimethyl-thiazole) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-5-ylmethyl) -amide hydrochloride, [6- (4-Hydroxy-piperidin-1-yl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid-5-methyl-pyrazin-2-ylamide-dihydrochloride-pyridin-3-ylmethyl] -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) quinoline-5-ylamide-dihydrochloride ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid quinoline-8-ylamide-dihydrochloride or, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid lsoquinolin-5-ylamide-dihydrochloride, [6- (4-Methylpiperazin-1-yl) -pyridin- 3-ylmethyl] -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [6- (4-Dimethylamino-piperidin-1-yl) -pyridin-3-ylmethyl] -amide- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dihydrochloride, [6- (Pyrrolidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro), (pyrazin-2-ylmethyl) -amide-dihydrochloride -benzoylamino) -1H-pyrazole-3-carboxylic acid [6- (thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [6- (1,1-Dioxo-1-l6-thiomorpholin-4-yl) -pyridin-3-ylmethyl] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid dihydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) -carbamoylmethyl-amide ) -1 H-pyrazole-3-carboxylic acid, (4-carbamoyl-phenyl) -methyl-amide, 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Methyl 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methylcarbamoyl-phenyl) -amide, (4-dimethylcarbamoyl-phenyl) -methyl-amide 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro- (4-methanesulfonylaminocarbonyl-phenyl) -methyl-amide benzoylamino) -1 H-pyrazole-3-carboxylic acid, Sodium salt of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole- (4-methanesulfonylaminocarbonyl-phenyl) -methyl-amide 3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (4-cyano-phenyl) -methyl-amide no) -1 H-pyrazole-3-carboxylic acid, Methyl- [4- (4H- [1, 2,4] triazol-3-yl) -phenyl] -amide-hydrochloride of 5- (2-chloro-4-acid) , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, j 5- (4-Azido-2-chloro-5-fluoro-) 4- (4-cyano-phenyl) -methyl-amide benzoylamino) -1H-pyrazole-3-carboxylic acid, methyl- [4- (1 H-tetrazol-5-yl) -phenyl] -amide of 5- (4-Azido-2- i) chloro-5-fluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid,! 5- (2-Chloro-I 4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid [4- (N-hydroxycarbamimidoyl) -phenyl] -methyl-amide; Methyl- [4- (5-oxo-2,5-dihydro- [1, 2,4] oxadiazol-3-yl) -phenyl] -amide of | i I 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid,. { 4 - [(2,2-Dimethyl-propionyloxy) -methoxycarbonyl] -phenyl} -methyl-amide. i 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, i 4- [N- (Methoxy-thiocarbonyloxy) -carbamimidoyl] -methyl-amide of acid i. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid,! Methyl- [4- (5-thioxo-4,5-dihydro- [1, 2,4] oxadiazol-3-yl) -phenyl] -amide of ' 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, j- Methyl- [4- (5-oxo-4,5-dihydro- [1, 2,4 ] thiadiazol-3-yl) -phenyl] -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, i. { 4- [1- (Cyclohexyloxycarbonyloxy) -ethoxycarbonyl] -phenyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl-amide I, | (4-Ethoxycarbonyl-thiazol-2-yl) -ethyl-amide of 5- (2-chloro-4,5-j) acid difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid,; I I I i: i 2-Methanesulfonylamino-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2-Acetylamino-benzylamide of acid, 5- (2-chloro-4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (Dimethylamino-methyleneamino) -benzylamide-acid hydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3- (2-chloro-4,5-difluoro) 3- (Dimethylamino-methyleneamino) -benzylamide-hydrochloride -benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4- (dimethylamino-methyleneamino) -benzylamide-hydrochloride, 2- [2- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid 3- [1- (Dimethylamino) ethylideneamino] 2- [1- (Dimethylamino) ethylideneamino] -benzylamide-dihydrochloride ] -benzylamide-5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid dihydrochloride, 4- [1- (dimethylamino) ethylideneamino] -benzylamide-acid dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro) 2- (diethylamino-methyleneamino) -benzylamide-dihydrochloride -benzoylamino) -1 H -pyrazole-3-carboxylic acid, 3- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3- (diethylamino-methyleneamino) -benzylamide-dihydrochloride or 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- acetylimidoamino-benzylamide-dihydrochloride of 5- (2-chloro-, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-, 5-difluoro-benzoylamino) -3-acetimidoylamino-benzylamide-dihydrochloride H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-acetimidoylamino-dihydrochloride, 4-cyano-benzylamide of acid, - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3 - [(2-Fluoro-benzimidoyl) -amino] -benzylamide-hydroiodide, 5- (2-chloro) -4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 4- (2-chloro-benzoimidoyl) -amino] -benzylamide-hydroxy acid 5- (2-chloro-4,5-difluoro) -benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3- (3,3-dimethyl-ureido) -benzylamide 4- (3,3-Dimethyl-ureido) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-4-carboxylic acid 2- (Toluene-4-sulfonylamino) -benzylamide) , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2-Amino-6-fluoro-benzylamide-5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole hydrochloride -3-carboxylic acid, 2-Amino-4,5-difluoro-benzylamide-5- (2-chloro-) hydrochloride 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, i I II II (lndan-l-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) - 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (lndan-2-yl) -amide, (4H-Quinazolin- 3-yl) -amino acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (4H-Quinazolin-3-yl) -amide-dihydrochloride of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4-chloro-4H-quinazolin-3-yl) -amide-dihydrochloride) , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4-chloro-4H-quinazolin-3-yl) -amide-hydrochloride, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro) -amide (2-Ethoxy-2-methyl-1,4-dihydro-2H-quinazolin-3-yl) -amide. -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - (2-cyano-pyridin-4-ylmethyl) -amide - 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole [2- (N-hydroxycarbamomidoyl) -pyridin-4-ylmethyl] -amide -3-carboxylic acid, 2- (5-Oxo-4,5-dihydro- [1, 2,4] oxadiazol-3-yl) -pyridin-4-ylmethyl] -amide of 5- (2-Chloro- 4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, Sodium salt of 4- acid. { [5- (4,5-difluoro-2-methyl-benzoylamino) -1 H-pyrrazol-3-carbonyl] -methyl-amino} Benzoic acid, 5- (4,5-Difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl- [4- (1 H-tetrazol-5-yl) -phenyl] -amide, ( 5- (2,4-Dichloro-benzoylamino) -1H-pyrazole-3-carboxylic acid pyridin-3-ylmethyl) -amide, 5- (2,4-Dichloro) -5-fluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2,6-Dichloro-5-fluoro-pyridine-3-carbonylamino) -1H- (Pyridin-3-ylmethyl) -amide. pyrazole-3-carboxylic acid, 5 - [(3-Chloro-benzo [b] thiophen-2-carbonyl) -amino] -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide, (Pir 5 - [(3-Chloro-thiophene-2-carbonyl) -amino] -1H-pyrazole-3-carboxylic acid din-3-ylmethyl) -amide, 5-pyridin-3-ylmethyl-amide -Benzoylamino-1 H-pyrazole-3-carboxylic acid, 5-phenylacetylamino-1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide, 5- (pyridin-3-ylmethyl) -amide-dihydrochloride (2-Methyl-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Amino-4,5-dif-luoro-ben) (pyridin-3-ylmethyl) -amide zoylamino) -1H-pyrazole-3-carboxylic acid, 5- (4,5-Difluoro-2-methanesulfonylamino-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide, (Pyridin- 5- (2-Acetylamino-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (3-ylmethyl) -amide of 5 - [(3, 4,5-trichloro-thiophene-2-carbonyl) -amino] -1H-pyrazole-3-carboxylic acid, 5- (4,5-difluoro-2-cyano-pyridin-4-ylmethyl) -amide -methyl-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (4,5-difluoro-2- (1 H-Tetrazol-5-yl) -pyridin-4-ylmethyl] -amide methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, and 3-Benzylamide of 5 - [(2,4-dichloro-phenyl) -amide] -1H-Pyrazole-3,5-dicarboxylic acid. 21. A medicine comprising a combination of a pharmaceutical composition for treating or preventing diabetes, according to any of the points 1 to 20 described above, and another therapeutic or prophylactic agent to combat diabetes. 22. The medicament according to item 21 described above, wherein the other therapeutic or prophylactic agent for combating diabetes is a preparation (injection) of insulin, an oral insulin agent, of low molecular weight, a receptor agonist of sulfonylurea (SU agent), an insulinotropic agent without sulfonylurea, a potassium-dependent ATP channel opening agent (KATP), an α-glucosidase inhibitor, an α-amylase inhibitor, an α-amylase inhibitor, insulin sensitivity, a low molecular weight tGLP receptor agonist, a peptide analogue tGLP-1, an inhibitor of dipeptidyl peptidase IV (DPP-IV), a glucagon receptor antagonist, a receptor antagonist of glucocorticoids, a biguanide, a SGLUT inhibitor, a fructose-1, 6-bisphosphatase inhibitor (FBPase), an inhibitor of glycogen synthase kinase 3 (GSK-3, glycogen synthase kinase 3), an inhibitor of the phospho enolpyruvate carboxykinase (PEPCK, phosphoenolpyruvate carboxikinase), an inhibitor of protein tyrosine 1B phosphatase (PTPasel B, protein tyrosine phosphatase 1B), an inhibitor of the SH2 domain containing inositol phosphatase (SHIP2, SH2 domain containing inositol phosphatase), glycogen phosphorylase inhibitor (GP, glycogen phosphorylase), a glucokinase activator, a GPR40 receptor agonist, an inhibitor of pyruvate dehydrogenase kinase (PDHK, pyruvate dehydrogenase kinase), a glutamine inhibitor: fructose-6-phosphate aminotransferase (GFAT), an antioxidant; a nitric oxide sequestrant, an inhibitor of carnitine O-palmitoyltransferase 1 (CPT-1), a growth hormone releasing factor (GHRF), a triacylglycerol lipase inhibitor (hormone-sensitive lipase) ), a PPARα receptor agonist, a PPARα receptor antagonist, a PPARα receptor agonist a / ?, an activator of the AMP activation protein kinase (AMPK, AMP activation protein kinase), a adiponectin receptor agonist or a β3-adrenoceptor agonist. 23.- The medication according to item 21 or 22 described above, where the other therapeutic or prophylactic agent for diabetes is insulin, toibutamide, gluclopyramide, acetohexamide, chlorpropamide, glibuzol, glibenclamide, gliclazide, Glimepiride, mitiglinide, repaglinide, nateglinide , voglibose, acarbose, miglitol, rosiglitazone maleate, metformin hydrochloride, pioglitazone hydrochloride or buformin hydrochloride. 24. A medicine comprising a combination of a pharmaceutical composition for treating or preventing diabetes, according to any of the points 1 to 20 described above, and another therapeutic or prophylactic agent to combat diabetic complications. 25.- The medication according to point 24 described above, where the other therapeutic or prophylactic agent to combat diabetic complications is an inhibitor of the protein kinase β (PKC β), an antagonist of the angiotensin II receptor, an inhibitor of aldose reductase, an inhibitor of angiotensin-converting enzyme (ACE), an inhibitor of advanced glycation end product (AGE) production, a therapeutic agent against neuropathy or a therapeutic agent against diabetic nephropathy. 26.- The medication according to point 24 or 25 described above, where the other therapeutic or prophylactic agent to combat diabetic complications is epalrestat, mexiletine hydrochloride or imidapril hydrochloride. 27. A medicine comprising a combination of a pharmaceutical composition for treating or preventing diabetes, according to any of the points 1 to 20 described above, and another therapeutic or prophylactic agent to combat hyperlipidemia. 28. The medication according to item 27 described above, wherein the other therapeutic or prophylactic agent to combat hyperlipidemia is a fibrate (PPARa receptor agonist), a PPAR receptor agonist, a transfer protein inhibitor of microsomal triglycerides (MTP), an inhibitor of cholesteryl ester transfer protein (CETP), a statin (HMG-CoA reductase inhibitor), an anion exchanger, probucol, a nicotinic drug, a plant sterol, an inducer of apolipoprotein-A1 (Apo-A1), a lipoprotein lipase activator (LPL), an inhibitor of endodermis lipase, ezetimibu, an inhibitor of IBAT, an inhibitor of the squalene synthesis enzyme, an ACAT inhibitor, an LXR receptor agonist, an FXR receptor agonist, an FXR receptor antagonist or an A1 adenosine agonist. 29.- The medication according to point 27 or 28 described above, where the other therapeutic or prophylactic agent to combat hyperlipidemia is clofibrate, bezafibrate, fenofibrate, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin, cerivastatin, cholestyramine, colestimide, nicotinate tocopherol, nicomol, niceritrol, soisterol or oryzanol range. 30. A medicine comprising a combination of a pharmaceutical composition for treating or preventing diabetes, according to any of the points 1 to 20 described above, and another therapeutic or prophylactic agent to combat obesity. 31- The medication according to point 30 described above, where the other therapeutic or prophylactic agent to combat obesity is a preparation of leptin, a pancreatic lipase inhibitor, a noradrenaline-serotonin reuptake inhibitor, a cannabinoid receptor antagonist, a reuptake inhibitor, monoamine, an inhibitor of diacylglycerol acyltransferase (DGAT), a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, a leptin receptor agonist, an agonist of subtype 3 of the bombesin receptors (BRS-3, bombesin receptor subtype 3), an inhibitor of perilipine, an inhibitor of acetyl-CoA carboxylase 1 (ACC1), an inhibitor of acetyl-CoA carboxylase 2 (ACC2), an inhibitor of fatty acid synthase, an inhibitor of sn-1-acyl-glycerol-3-phosphate-acyltransferase (AGPAT), an inhibitor of phospholipase A2 in the pancreas (pPLA2, pancreas phospholipase A2), an agonist melanocortin receptor (MC), a neuropeptide Y5 receptor antagonist (NPY5), an uncoupling protein (UCP) inducer or activator, an activator of carnitine O-palmitoyltransferase 1 (CPT-1), a CCK1 agonist (CCKA), a ciliary neurotrophic factor (CNTF, a ciliary neurotrophic factor), a CRF2 agonist, a neuropeptide Y2 receptor antagonist (NPY2), a neuropeptide Y4 receptor antagonist (NPY4), a receptor agonist H.H. of thyroid hormone, a growth hormone, an inhibitor of ATP citrate lyase, a 5-HT6 antagonist or a 5-HT2C agonist. 32.- The medication according to points 30 or 31 described above, where the other therapeutic or prophylactic agent to combat obesity is leptin, orlistat, sibutramine, rimonabant or mazindol. 33. A medicine comprising a combination of a pharmaceutical composition for treating or preventing diabetes, according to any of the points 1 to 20 described above, with another therapeutic or prophylactic agent against hypertension. 34.- The medication according to item 33 described above, where the other therapeutic or prophylactic agent against hypertension is a thiazide diuretic, a thiazide diuretic similar, a loop diuretic, a retention diuretic of K, a β a blocker, a a, b blocker, a blocker, a central sympathetic nervous system depressant, a peripheral sympathetic nervous system depressant (rauwolfia preparation), a Ca (benzothiazepine) antagonist, a Ca (dihydropyridine) antagonist, a vasodilator, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, a nitric acid preparation, an endothelin receptor antagonist ETA, an enzyme-converting enzyme inhibitor, endothelin; an inhibitor of neprilysin, a prostaglandin; an FP prostanoid agonist, a renin inhibitor, an enhancer of NOS3 expression; an analogue of prostacyclin, an inhibitor of phosphodiesterase V (PDE5A), an analogue of prostacyclin or an aldosterone antagonist. 35.- The medicament according to item 33 or 34 described above, wherein the other therapeutic or prophylactic agent for hypertension is hydrochlorothiazide, trichlormethiazide, bentilhidroclorotiazida, meticrane, indapamide, tripamide, chlorthalidone, mefruside, furosemide, spironolactone, triamterene, atenolol, bisoprolol fumarate, betaxolol hydrochloride, bevantolol hydrochloride, metoprolol tartrate, acebutolol hydrochloride, celiprolol hydrochloride, nipradilol, tilisolol hydrochloride, nadolol, propranolol hydrochloride, indenolol hydrochloride, carteolol hydrochloride, pindolol, sustained release pindolol hydrochloride, bunitrolol, penbutolol sulfate, malonate bopindolol, amosulalol hydrochloride, arotinolol, carvedilol hydrochloride, labetalol, urapidil, terazosin hydrochloride, doxazosin mesylate, bunazosin hydrochloride, prazosin hydrochloride, mesylate of phentolamine, clonidine hydrochloride, c guanfacine hydrochloride, guanabenzyl acetate, methyldopa, reserpine, rescinnamine, amlodipine besylate, aranidipine, efonidipine hydrochloride, cilnidipine, nicardipine hydrochloride, nisoldipine, nitrendipine, nifedipine, sustained-release nifedipine, nilvadipine, barnidipine hydrochloride, felodipine, hydrochloride of benidipine, manidipine hydrochloride, azelnidipine, diltiazem hydrochloride, hydrazine monohydrochloride, allralazine hydrochloride, budralazine, cadralazine, captopril, enalapril maleate, alacepril, delapril hydrochloride, cilazapril, lisinopril, benazepril hydrochloride, imidapril hydrochloride, hydrochloride of tamocapril, quinapril hydrochloride, trandolapril, perindopril erbumine, candesartan cilexetil, valsartan, telmisartan, olmesartan medoxomil, sodium nitroprusside or nitroglucerina. 36.- A pyrazole compound or a pharmacologically acceptable salt thereof, represented by the following general formula (I): I where, The Q ring represents an aryl group or a heteroaromatic group; R1 represents a hydrogen atom, a halogen atom, a d-β alkyl group or a C-i-β alkoxy group; R 2 represents a halogen atom, a C 1-6 alkyl group, a C 6 akoxy group or an azido group; R3 represents a halogen atom, a hydroxyl group, an alkyl group d_6, a haloalkyl group C -? - 6, a C -? --6 alkoxy group, an azido group, an amino group, an acylamino group or a group alkyl (C? 6) sulfonylamino; and R4 and R5 are identical to each other or different from one another, and represent: (1) a hydrogen atom; (2) a C? -6 alkyl group) which may be substituted with a substituent selected from Group A presented below: [Group A] Al A hydroxyl group, A2. An alkoxy d-e group, A3. -N (R41) (R41 ') wherein R41 and R41 are identical to each other or different from each other and represent a hydrogen atom or a d-β alkyl group; and R41 and R41, together with the adjacent nitrogen atom, can form a saturated, monocyclic 5 or 6 membered heterocyclic ring, A4. An aryl group, A5. A heteroaromatic group, A6. -CO-N (R411) (R411 ') wherein R411 and R411 are identical to each other or different from each other and represent a hydrogen atom or a d6 alkyl group; and R411 and R411, together with the adjacent nitrogen atom, can form a 5 or 6 membered monocyclic, saturated, heterocyclic ring, A7. A carboxy group, and. A8. An (C6-6) alkoxycarbonyl group, (3) a C2_6 alkenyl group; (4) a C2.6 alkynyl group (5) a C3_8 cycloalkyl group; wherein the cycloalkyl group may be substituted with a hydroxyl group, a carboxy group or an alkoxy (d-6) carbonyl group, or it may be fused with a pyridine ring, (6) a (C3.8) alkylcycloalkyl group C1-6; wherein the cycloalkyl group of the cycloalkyl (C3.8) alkyl d-β group may be substituted with a hydroxyl group, a carboxy group or a (C6-6) alkoxycarbonyl group, or may be fused to a ring of pyridine, (7) a saturated, monocyclic, 5- or 6-membered heterocyclic group which may be substituted with a substituent selected from Group C presented below: [Group C] Cl An alkyl group of, C2. An acyl group, C3. An alkyl (d-6) sulfonyl group, C4. A carboxy group, C5. An alkoxy (d.6) carbonyl group, and. C6 -CO- (Alk) n-COOR52, wherein R52 is a hydrogen atom or a d-e alkyl group; Alk is an alkylene C-M group; and n is 0 or an integer comprised between 1 and 3, (8) an aryl group which may be substituted with one or more substituents selected from Group D presented below: [Group D] DI A hydroxyl group, D2. An alkoxy group C? .6, D3. A cyano group, D4. A C1-6 alkyl group, wherein the d6 alkyl group may be substituted with a substituent selected from the group consisting of a hydroxyl group, a carboxy group and an alkoxy (d-6) carbonyl group, D5. -N (R53) (R53 '), where R53 and R53 are identical to each other or different from each other and represent a hydrogen atom, a d6 alkyl group or an alkyl (C2 ^) sulfonyl group, D6. -CO-N (R531) (R531 ') wherein R531 and R531 are identical to each other or different from one another and represent a hydrogen atom, a C---6 alkyl group or an alkyl (C--6) group sulfonyl, D7. -COOR54, where R54 is a hydrogen atom, a d-β alkyl group, an alkyl (C6-6) carbonyloxy-d-β alkyl group or a cycloalkyloxy (C3.8) carbonyloxy-d-β, D8 alkyl group . -C (NH (OH)) = N-R55, where R55 is a hydrogen atom or an alkyl (d.6) sulphonyl group, D9. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, and. D10 A heteroaromatic group, monocyclic, 5- or 6-membered, which may be substituted with an oxo or thioxo group, (9) a heteroaromatic group fused with a benzene ring or a 5- or 6-membered monocyclic ring, which may be substituted a substituent selected from the group consisting of a carboxy group and an alkoxy (d-6) carbonyl group; (10) a C7-4 aralkyl group; where the alkyl part of the aralkyl group C7_? may be substituted with one or two substituents, selected from Group E, presented below, and the aryl portion may be substituted with more than one to 3 substituent groups selected from Group F, presented below: [Group E] The Un alkyl group d-β. which may be substituted with a hydroxyl group, E2. A cyano group, E3. A carboxy group, E4. An alkoxy (d-6) carbonyl group, and. E5 A phenyl group, [Group F] Fl An alkyl group d.6, F2. A halogen atom, F3. A cyano group, F4. A hydroxyl group, F5. An alkoxy d-6 group, which may be substituted with a substituent selected from a carboxy group and a (C 6) alkoxycarbonyl group, F 6. A haloalkyl group d-6, F7. A carboxy group, F8. An alkoxy group (C? .6) carbonyl, F9. -CO-N (R56a) (R56a '), wherein R56a and R56a are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated group, having the minus one nitrogen atom, or a C---6 alkyl group, which may be substituted with a substituent selected from Group f presented below: [Group f] fl An amino group, f2. A monoalkyl (C? ^) Amino group, f3. A dialkyl (C -? _ 6) amino group, f4. A carboxy group, f5. An alkoxy group (C? .6) carbonyl, f6. A hydroxyl group, and. f7. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, having at least one nitrogen atom, F10. -N (R56b) (R56b) wherein R56b and R56b are identical to each other or different from each other and represent a hydrogen atom, a C? .6 alkyl group, which may be substituted with an imino group, an aralkyl group, which may be substituted with one or more identical or different substituents selected from an imino group and a halogen atom, an arylsulfonyl group which may be substituted with a C? _6 alkyl group, an alk¡ (C -? _) sulfon group It, an acyl group, a carbamoyl group, a monoalkyl (d.6) carbamoyl group or a dialkyl (C? 6) carbamoyl group, F11 -N = CR57 (-N (R58) (R58 ')) wherein R57 is a hydrogen atom or a C---6 alkyl group, R58 and R58 are identical to each other or different from one another and represent a hydrogen atom or a C1-6 alkyl group. F12. A heteroaromatic group, monocyclic, of 5 or 6 members, and. F13 A methylenedioxy group or an ethylenedioxy group, or, (11) a d.6 alkyl group substituted with a heteroaromatic, monocyclic, 5- or 6-membered group, or a heteroaromatic group obtained by condensation of the heteroaromatic group with a benzene ring; wherein the heteroaromatic group may be substituted with one or more substituents selected from Group G, presented below: [Group G] Gl An alkyl group d.6l which may be substituted with a substituent selected from Group g, presented below: [Group g] gl A halogen atom, g2. An amino group, g3. A monoalkyl (C? .6) amino group, g4. A dialkyl (C? .6) amino group, g5. An alkoxy group (C? -6) carbonylamino, and. g6 A hydroxyimino group, G2. A halogen atom, G3. A C6.6 alkoxy group which may be substituted with a halogen atom, G4. An aryloxy group, G5. A cyano group, G6. -N (R59a) (R59a '), wherein R59a and R59a are identical to each other or different from one another and represent a hydrogen atom or a d6 alkyl group; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic, heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group (C ? -6) amino or a dialkyl (d.6) amino group, G7. -CO-N (R59b) (R59b) wherein R59b and R59b are identical to each other or different from each other and represent a hydrogen atom, a saturated, monocyclic, 5- or 6-membered heterocyclic group, or a C1-alkyl group -6, which may be substituted with the heterocyclic group, G8. An aryl group, and >; G9 A heteroaromatic, monocyclic group of 5 or 6 members, which may be substituted with an oxo or thioxo group, R4 and R5, together with the adjacent nitrogen atom, may form a saturated, 5- or 6-membered heterocyclic ring, where a part of the saturated heterocyclic ring may have a double bond, and the saturated heterocyclic ring may be fused to a benzene ring to form a fused ring, or the saturated heterocyclic ring which may be fused to a benzene ring to form a fused ring it may be substituted with a halogen atom, a C? -6 alkyl group, a d6 alkoxy group, a carboxy group or a (C- | 6) alkoxycarbonyl group. 37. The pyrazole compound or a pharmacologically acceptable salt thereof, according to item 36 described above, represented by the following general formula (I): wherein the Q ring represents an aryl group or a heteroaromatic group; R1 represents a hydrogen atom, a halogen atom, an alkyl-β group or an alkoxy group d.6; R 2 represents a halogen atom, an alkyl-β group, an alkoxy group d 6 or an azido group; R3 represents a halogen atom, a hydroxyl group, a CM alkyl group, a haloalkyl group d.6) a C6.6 alkoxy group, an azido group, an amino group, an acylamino group or an alkyl group (C 6) Sulfonylamino; R4 represents (1) a hydrogen atom; (2) an alkyl d-e group, which may be substituted with a substituent selected from Group A presented below: [Group A] Al A hydroxyl group, A2. An alkoxy d-6 group, A3. -N (R41) (R41 '), wherein R41 and R41 are identical to each other or different from each other and represent a hydrogen atom or a C? 6 alkyl group and R41 and R41, together with the adjacent nitrogen atom , can form a heterocyclic ring, monocyclic 5 or 6 membered, saturated, A4. An aryl group, A5. A heteroaromatic group, A6. -CO-N (R411) (R411 '), wherein R411 and R411 are identical to each other or different from each other and represent a hydrogen atom or a d6 alkyl group; and R411 and R411, together with the adjacent nitrogen atom, can form a 5 or 6 membered monocyclic, saturated, heterocyclic ring, A7. A carboxy group, and, A8. An alkoxy group (C- | 6) carbonyl, (3) a C 2-6 alkenyl group; (4) a C2.6 alkynyl group; (5) a C3.8 cycloalkyl; (6) a (C3.8) C 1-6 alkylcycloalkyl group; or, (7) an aryl group; and R5 represents (1) an alkyl group d.6, which may be substituted with a substituent selected from group B presented below:, [Group B] B1 A hydroxyl group, B2. An alkoxy d-β, B3 group. -N (R51) (R51 '), wherein R51 and R51 are identical to each other or different from each other and represent a hydrogen atom or a C? _6 alkyl group; and R51 and R51, together with the adjacent nitrogen atom, can form a 5 or 6 membered heterocyclic, monocyclic, saturated ring, and > B4 -CO-N (R511) (R511 '), wherein R511 and R511 are identical to each other or different from each other and represent a hydrogen atom or an alkyl group d-β, and R511 and R511, together with the atom of adjacent nitrogen, can form a saturated, 5- or 6-membered heterocyclic ring, (2) a C3_8 cycloalkyl, where the cycloalkyl group may be substituted with a hydroxyl group, a carboxy group or an alkoxy group (d- 6) Carbonyl or can be | condensed with a pyridine ring, i (3) a (C3.8) cycloalkyl group, C? _6 alkyl; wherein the cycloalkyl group of the (C3.8) cycloalkyl alkyl group d-6 may be substituted with a hydroxyl group, a carboxy group or a (C6.6) alkoxycarbonyl group, or may be fused with a pyridine ring, (4) a saturated, monocyclic, 5- or 6-membered heterocyclic group which may be substituted with a substituent selected from Group C presented below: [Group C] Cl An alkyl group d.6, C2. An acyl group, C3. An alkyl group (C? _6) sulfonyl, C4. A carboxy group, C5. An alkoxy (C? ^) Carbonyl group, and. C6 -CO- (Alk) n-COOR52, where R52 is a hydrogen atom or an alkyl group d-β; Alk is an alkylene C-M group; and n is 0 or an integer comprised between 1 and 3, (5) an aryl group which may be substituted with one or more substituents selected from Group D, presented below: [Group D] DI A hydroxyl group, D2. An alkoxy group C? -6, D3. A cyano group, D4. A C -? 6 alkyl group, | wherein the d-6 alkyl group may be substituted with a 'substituent selected from the group consisting of a hydroxyl group, a carboxy group and a (C? ^) carbonyl alkoxy group, D5. -N (R53) (R53 '), wherein R53 and R53 are identical to each other or different from one another and represent a hydrogen atom, a C? _6 alkyl group or a (C -? - 6) sulfon alkyl group What, D6. -CO-N (R531) (R531 '), wherein R531 and R531 are identical to each other or different from each other and represent a hydrogen atom, a C1-6 alkyl group or an alkyl (C6.6) group sulfonyl, D7. -COOR54, where R54 is a hydrogen atom, an alkyl-β group, an alkyl (d-6) carbonylloxy-C6-6alkyl or a cycloalkyloxy (C3.8) carbonyloxy-C1.6alkyl group, D8 . -C (NH (OH)) = N-R55, where R55 is a hydrogen atom or an alkyl (d.6) sulphonyl group, D9. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, and.

I D10. A heteroaromatic group, monocyclic, 5- or 6-membered, which may be substituted with an oxo or thioxo group, (6) a heteroaromatic group fused with a benzene ring or a 5- or 6-membered monocyclic ring, which may be substituted a substituent selected from the group consisting of a carboxy group and an alkoxy (d_6) carbonyl group; (7) a C7.14 aralkyl group; where the alkyl part of the aralkyl group C. -i may be substituted with one or two substituents selected from Group E presented below, and the aryl part may be substituted with one or more substituents selected from Group F, presented below: [Group E] The A C6 alkyl group) which may be substituted with a hydroxyl group, E2. A cyano group, E3. A carboxy group, E4. An alkoxy group (C? -6) carbonyl, and. E5 A phenyl group, [Group F] Fl A C? -6 alkyl group, F2. A halogen atom, F3. A cyano group, F4. A hydroxyl group, F5. A C6.6 alkoxy group) which may be substituted with a substituent selected from the group consisting of a carboxy group and a (C6.6) alkoxycarbonyl group, F6. A haloalkyl group C -? - 6, F7. A carboxy group, F8. An alkoxy (d-6) carbonyl group, F9. -CO-N (R56a) (R56a), wherein R56a and R56a are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated group, having at least a nitrogen atom, or a C-? 6 alkyl group, which may be substituted with a substituent selected from Group f presented below: [Group f] fl An amino group, f2. A monoalkyl (C? ^) Amino group, f3. A dialkyl (C? -6) amino group, f4. A carboxy group, f5. An alkoxy (d-6) carbonyl group, f6. A hydroxyl group, and. f7. A saturated, monocyclic, 5- or 6-membered heterocyclic group having at least one nitrogen atom, wherein R56b and R56b are identical to each other or different from one of the others and represent a hydrogen atom, an alkyl group d-6, which can be substituted with an imino group, an aralkyl group, which can be replaced with one or more identical or different substituents selected of an imino group and a halogen atom, an aryisulfonyl group that can to be substituted with an alkyl group d_6, an alkyl (C? -6) sulfonyl group, a acyl group, a carbamoyl group, a monoalkyl (C -? - 6) carbamoyl group or an I dialkyl (C? -6) carbamoyl group, F11 -N = CR57 (-N (R58) (R58 ')), where R57 is a hydrogen atom or an alkyl group d-6, R58 and R58 are identical to each other or different from each other and represent a j hydrogen atom or a C1-6 alkyl group, | i F12. A heteroaromatic, monocyclic group of 5 or 6 members, and | F13 A methylenedioxy group or an ethylendioxy group, i ° -! i (8) a C-? 6 alkyl group substituted with a group heteroaromatic, monocyclic, 5- or 6-membered or a heteroaromatic group obtained by condensation of the heteroaromatic group with a 1-benzene ring; | wherein the heteroaromatic group may be substituted with one or more substituents selected from Group G, presented below: [Group G] Gl A C 1-6 alkyl group, which may be substituted with a substituent selected from Group g, presented below: [ Group g] gl A halogen atom, g2. An amino group, g3. A monoalkyl (d-6) amino group, g4. A dialkyl (C? _6) amino group, g5. An alkoxy (d-6) carbonyl group, and, g6. A hydroxyimino group, G2. A halogen atom, G3. A C6-6 alkoxy group which may be substituted with a halogen atom, G4. An aryloxy group, G5. A cyano group, G6. -N (R59a) (R59a '), where R59a and R59a are identical to each other or different from each other and represent a hydrogen atom or an alkyl group d.6; and R59a and R59a ', together with the adjacent nitrogen atom, can form a saturated, saturated 5 or 6 membered heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group ( C? _6) amino or a dalkyl (d_6) amino group, G7. -CO-N (R59b) (R59b ') wherein R59b and R59b are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated, or an alkyl group d_6, which may be substituted with the heterocyclic group, G8. An aryl group, and. G9 A heteroaromatic, monocyclic group of 5 or 6 members, which may be substituted with an oxo or thioxo group, R4 and R5, together with the adjacent nitrogen atom, may form a saturated, 5- or 6-membered heterocyclic ring, where a part of the saturated heterocyclic ring may have a double bond, and the saturated heterocyclic ring may be fused to a benzene ring to form a fused ring, or the saturated heterocyclic ring which may be fused to a benzene ring to form a fused ring it may be substituted with a halogen atom, a C-α-6 alkyl group, a C 1-6 alkoxy group, a carboxy group or a (C-α-6) alkoxycarbonyl group. 38.- The pyrazole compound or a pharmacologically acceptable salt thereof, according to item 36 described above, represented by the following general formula (II '): where R1, R2, R3, R4 and R5 are as defined in item 36 above. 39.- The pyrazole compound or a pharmacologically acceptable salt thereof, according to item 36 described above, represented by the following general formula (II): where R4 and R5 are such as defined in item 36 above described; R1a represents a halogen atom or a hydrogen atom; R2a, a halogen atom; and R3a, a halogen atom or a d6 alkyl group. 40.- The pyrazole compound or a pharmacologically acceptable salt thereof, according to item 39 described above, wherein R a is a hydrogen or fluorine atom; R2a, a fluorine or chlorine atom; and R is a chlorine atom or a C? _6 alkyl group. 41. The pyrazole compound or a pharmacologically acceptable salt thereof according to item 40 described above, wherein the pyrazole compound is a pyrazole compound represented by the following general formula (III): where R4 and R5 are as defined in item 37 above. The pyrazole compound or a pharmacologically acceptable salt thereof according to any of points 37 to 41 described above, wherein R 4 is a group selected from the following group: (1) a hydrogen atom; (2) an alkyl group d-6, which may be substituted with a substituent selected from Group A ', presented below: [Group A'] A'l A hydroxyl group, A'2. An alkoxy group C-M, A'3. -N (R41) (R41 '), wherein R41 and R41 are identical to each other or different from each other and represent a hydrogen atom or a CM alkyl group, and R41 and R41, together with the adjacent nitrogen atom, can form a 5 or 6 membered monocyclic heterocyclic ring, saturated, A'4. A phenyl group, A'5. A heteroaromatic group, monocyclic, of 5 or 6 members, A'6. -CO-N (R411) (R411 '), where R411 and R411 are identical to each other or different from each other and represent a hydrogen atom or a C grupo _ and R411 alkyl group and R411, together with the adjacent nitrogen, can form a saturated, monocyclic 5 or 6-membered heterocyclic ring, A'7. A carboxy group, and. A'8. An alkoxy (C? ^) Carbonyl group, (3) a C2.6 alkenyl group; (4) a C2.6 alkynyl group; (5) a C3.8 cycloalkyl; and, (6) a cycloalkyl (C3.8) alkyl group Ci ^. 43. The pyrazole compound or a pharmacologically acceptable salt thereof according to any of points 37 to 42 described above, wherein R5 is a C6_6 alkyl group. 44. - The pyrazole compound or a pharmacologically acceptable salt thereof, according to any of points 37 to 42 described above, wherein R5 is a C3.8 cycloalkyl, which may be substituted with a hydroxyl group, a carboxy group or a alkoxy (d_6) carbonyl group. 45. The pyrazole compound or a pharmacologically acceptable salt thereof according to any of points 37 to 42 described above, wherein R5 is a (C3.8) alkyl d6 alkylcycloalkyl group. 46. The pyrazole compound or a pharmacologically acceptable salt thereof according to any of points 37 to 42 described above, wherein R5 is a saturated, monocyclic, 5- or 6-membered heterocyclic group, which may be substituted with a substituent selected from an acyl group and -CO- (Alk) n-COOR52, where R52 is a hydrogen atom or an alkyl group d.6, Alk is an alkylene group CM, and n is 0 or an integer from 1 and 3. 47. The pyrazole compound or a pharmacologically acceptable salt thereof according to any one of items 37 to 42 described above, wherein R5 is a phenyl group, which may be substituted with one or more selected substituents. of the following Group D ': [Group D'] D'l A C1 alkyl group, which may be substituted with a carboxy group, D'2. -CO-N (R53) (R53 '), I wherein R53 and R53 are identical to each other or different from each other and represent a hydrogen atom, a C 0 alkyl group or a C-M-sulfonyl alkyl group, D'3. -COOR54, where R54 is a hydrogen atom, an alkyl group d-, an alkyl (C? -4) carbonyloxy-alkyl group, or a cycloalkyloxy group (C3. A) carbonyloxy-alkyl d-4, and, D'4 A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group. 48. The pyrazole compound or a pharmacologically acceptable salt thereof according to any of points 37 to 42 described above, wherein R5 is a C7-? 4 aralkyl group and the aryl part of the aralkyl group C. 14 may be substituted with one or more substituents selected from the following Group F ': [Group F'] F'l An alkyl group C? .6) F'2. A halogen atom, F'3. A cyano group, F'4. A hydroxyl group, F'5. An alkoxy d-6 group, which may be substituted with a carboxy group or an alkoxy group (C? 6) carbonyl, F'6. A haloalkyl group d-6, F'7. A carboxy group, F'8. An alkoxy (d.6) carbonyl group, F'9. -CO-N (R56a) (R56a) wherein R56a and R56a are identical to each other or different from each other and represent a hydrogen atom, a saturated, monocyclic, 5- or 6-membered heterocyclic group having at least one atom of nitrogen, or a C? 6 alkyl group, which may be substituted with a substituent selected from Group f, presented below: [Group f] fl An amino group, f2. A monoalkyl group (C -? - 6) amino, f3. A dialkyl (C? ^) Amino group, f4. A carboxy group, f5. An alkoxy (d.6) carbonyl group, f6. A hydroxyl group, y, f7. A heterocyclic, monocyclic, 5- or 6-membered, saturated group having at least one nitrogen atom, F'10. -N (R56b) (R56b '), wherein R56b and R56b are identical to each other or different from each other and represent a hydrogen atom, an alkyl group d.6, which may be substituted with an imino group, an aralkyl group , which may be substituted with one or more identical or different substituents selected from an imino group and a halogen atom, an arylsulfonyl group which may be substituted with a C1-6 alkyl group, an alkali (d.6) sulfon group It, an acyl group, a carbamoyl group, a monoalkyl (C? -6) carbamoyl group or a dialkyl (C? 6) carbamoyl group, F'11 -N = CR57 (-N (R58) (R58)) wherein R57 is a hydrogen atom or a C? _4 alkyl group, R58 and R58 are identical to each other or different from each other and represent a hydrogen atom or an alkyl group CM, F'12. A heteroaromatic group, monocyclic, of 5 or 6 members, Y. F'13. A methylenedioxy group or an ethylenedioxy group. 49. The pyrazole compound or a pharmacologically acceptable salt thereof according to any of points 37 to 42 described above, wherein R5 is a C6_6 alkyl group substituted with a heteroaromatic, monocyclic group of 5 or 6 members, and the heteroaromatic group may be substituted with one or more substituents selected from the following Group G ': [Group G'] G'1. An alkyl group d-6, which may be substituted with a substituent selected from Group g ', presented below: [Group g'] g'1. A halogen atom, g'2. An amino group, g'3. A monoalkyl (C? -6) amino group, g'4. A dialkyl (C? ^) Amino group, g'5. An alkoxy group (C? -6) carbonylamino, and, g'6. A hydroxyimino group, G'2. A halogen atom, G'3. An alkoxy d-6 group, which may be substituted with a halogen atom, G'4. An aryloxy group, G'5. A cyano group, G'6. -N (R59a) (R59a '), wherein R59a and R59a are identical to each other or different from each other and represent a hydrogen atom or a d-β alkyl group; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic, heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group. (C -? _ 6) amine or a dialkyl (C? _6) amino group, G'7. -CO-N (R59) (R59b ') wherein R59b and R59b' are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated or an alkyl group Ci-β, which may be substituted with the heterocyclic group, G'8. An aryl group, and, G'9. A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group. 50.- The pyrazole compound or a pharmacologically acceptable salt thereof according to any of the points 37 to 41 described above, wherein R5 and R4, together with the adjacent nitrogen atom, form a heterocyclic, monocyclic ring of 5. or 6 members, saturated, and the saturated heterocyclic group may have a double bond in one part, and may be fused to a benzene ring to form a fused ring, or the saturated heterocyclic group, which may be fused to a benzene ring to form a fused ring, it may be substituted with a halogen atom, a d-6 alkyl group, a C6-6 alkoxy group, a carboxy group or an alkoxy (d6) carbonyl group. 51. The pyrazole compound or a pharmacologically acceptable salt thereof according to item 37 described above, wherein the pyrazole compound is a pyrazole compound represented by the following general formula (IV): , where R > 44 is as described in 37; c R > X1, D RX2¿ and D RX? 3J are identical to each other or different from each other and represent an atom of hydrogen or a substituent selected from the following Group F "; and m is 0 or an integer between 1 and 2, [Group F "] F "1. A C1-6 alkyl group, F "2. A halogen atom, F "3. A cyan group, F "4. A hydroxyl group, F" 5. A C-M alkoxy group which may be substituted with a carboxy group or a (C-? _4) carbonyl group, F "6. A halo- C1-6 alkyl group, I F "7. A carboxy group, J F "8. An alkoxy group (C? -6) carbonyl,! F" 9. -CO-N (R56a) (R56a); where R56a and R56a are identical to each other or different from one of the j others and represent a hydrogen atom, a heterocyclic group, monocyclic, 5- or 6-membered, saturated having at least one atom of nitrogen, or a d-6 alkyl group, which may be substituted with a substituent selected from Group f "presented below: [Group f '] f'1. An amino group, f '2. A monoalkyl (C6-6) amino group, f "3. A dialkyl (C6-6) amino group, f '4. A carboxy group, f'5, An alkoxy (d-6) carbonyl group, f'6 A hydroxyl group, and, f'7 A heterocyclic, monocyclic group, 5 or 6 membered, saturated, having at least one nitrogen atom, F "10.N (R56b) (R56b '), where R56b and R56b are identical to each other or different from each other and represent an atom of hydrogen, an alkyl group d-6, which may be substituted with an imino group, an aralkyl group, which may be substituted with one or more identical or different substituents, selected from an imino group and a halogen atom, an aryisulfonyl group which may be substituted with an alkyl group d-6, a (C? -6) alkylsulfonyl group, an acyl group, a carbamoyl group, a monoalkyl (d-6) carbamoyl group or a dialkyl (C?) carbamoyl group , F "11 -N = CR57 (-N (R58) (R58 ')), where R57 is a hydrogen atom or an alkyl group d-6, R58 and R58 are identical to each other or different from each other and represent a hydrogen atom or a C-α-6 alkyl group, F "12. A heteroaromatic, monocyclic group, of 5 or 6 members, and, F" 13. A methylenedioxy group or an ethylenedioxy group. 53. The pyrazole compound or a pharmacologically acceptable salt thereof according to item 37 above, wherein the pyrazole compound is a pyrazole compound represented by the following general formula (V): where R4 is as defined above, the Het ring represents a heteroaromatic, monocyclic group, of 5 or 6 members; RY1, RY2 and RY3 are identical to each other or different from one another and represent a hydrogen atom or a substituent selected from the following Group G '; and m 'is 0 or an integer between 1 and 2, [Group G'] G'1. A C-α-6 alkyl group, which may be substituted with a substituent selected from Group g ', presented below: [Group g'] g'1. A halogen atom, g'2. An amino group, g'3. A monoalkyl (C? -6) amino group, g'4. A dialkyl group (C? _6) amino, g'5. An alkoxy group (C? -6) carbonylamino, and, g'6. A hydroxyimino group, G'2. A halogen atom, G'3. A C1-6 alkoxy group which may be substituted with a halogen atom, G'4. An aryloxy group, G'5. A cyano group, G'6. -N (R59a) (R59a '), wherein R59a and R59a are identical to each other or different from each other and represent a hydrogen atom or an alkyl group d.6; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic, heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group. (C? -6) amino or a dialkyl (C? -6) amino group, G'7. -CO-N (R59b) (R59b ') wherein R59b and R59b are identical to each other or different from one another and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated or an alkyl group -6, which may be substituted with the heterocyclic group, G'8. An aryl group, and.

I G'9. A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group. 53. The pyrazole compound or a pharmacologically acceptable salt thereof according to item 52 described above, wherein the Het ring is a pyridine ring, a triazole ring or an oxazole ring. 54.- The pyrazole compound or a pharmacologically acceptable salt thereof according to item 53 described above, wherein the pyrazole compound is a pyrazole compound, represented by the following general formula (VI), where R j4J D RY1, D RY2, D RY3 and m 'are as defined above. 55.- The pyrazole compound or a pharmacologically acceptable salt thereof, according to item 37 described above, wherein the pyrazole compound or a pharmacologically acceptable salt thereof is selected from the following group: (pyridin-3-ylmethyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-chloro-) -hydrochloride (5- pyridin-3-ylmethyl) -amide dihydrochloride 4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (pyridin-3-ylmethyl) -amide-hydrochloride pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methyl-oxazol-5-ylmethyl) -amide, (4-methyl) 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (4-methyl-oxazol-5-ylmethyl) amide-p-5-chloro-4,5-difluoro-benzoylamino) -amidozol-5-ylmethyl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid toluenesulfonate, (4-Methyl-oxazol-5-ylmethyl) amide-L - (+) - tartrate 5- (2-chloro-4,5-difl) acid uoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - (2,4-dimethyl-oxazol-5-ylmethyl) -amide p-toluenesulfonate of 5- (2-chloro-4,5-difluoro-benzoylamino) - 1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-oxazol-5-ylmethyl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-pyridin-3-ylmethyl) acid 5- (2-chloro) acid 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Ethyl- (pyridin-4-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-ethyl) -methyl-amide, Ethyl- (2 -methoxy-ethyl) -amide of 5- (2-Chloro-4) acid, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-fluoro-benzylamide, 3 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, fluoro-benzylamide, 5- (2-chloro-4,5-difluoro) acid, 2-dimethylamino-benzylamide -benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-ethoxycarbonyl-cyclohexyl) -propyl-amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-methoxy-pyridin-3-ylmethyl) -amide, 2,3-dimethoxy-benzylamide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,4-dimethoxy-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,6-dimethoxy-benzylamide, 3,5-dimethoxy-benzylamide - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic, I i 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid 3,4-dimethoxy-benzylamide of 5- (2-chloro-4,5-difluoro-benzylamide) acid chloro-4, 5-difluoro-benzoylamino) -! H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2,4-difluoro-benzylamide, 2,5-difluoro-benzylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 2,6-Difluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 3,4-Difluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3,5-Difluoro- 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-) 2-lsopropoxy-pyridin-3-ylmethyl) -amide 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (2-phenoxy-pyridin-3-ylmethyl) -amide. -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,5-difluoro-pyridin-2-ylmethyl) -amide; 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid trifluoromethyl-benzylamide, 3-Trifluoromet 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid il-benzylamide, 5- (2-chloro-4,5-difluoro- 4-trifluoromethyl-benzylamide benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-tert-butyl-benzylamide, (6-lsopropoxy) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-pyridin-3-ylmethyl) -amide, [2- (2,2,2-Trifluoro-ethoxy) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid pyridin-3-ylmethyl] -amide, 5- (2-Dimethylamino-ethylcarbamoyl) -benzylamide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-Ethyl-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- 3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-lsopropyl-benzylamide, 5- (2-chloro-6-fluoro-benzylamide 2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, (6-Ethoxy-pyridin-3-ylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid a-dihydrochloride, 5- (2-chloro-4, -thiazol-4-ylmethyl) -amide 5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro) -6- (2,2,2-trifluoro-ethoxy) -pyridin-3-ylmethyl] -amide-dihydrochloride -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,6-dimethyl-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 -carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [2- (pyridin-3-yl) -thiazol-4-ylmethyl] -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1 H-Benzoimidazol-2-ylmethyl) -amide-dihydrochloride, [4- (. { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] -amino} -methyl) -benzoylamino] -acetic acid, 3- [4- (. {[[5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] -amino methyl ester} -methyl) -benzoylamino] -propionic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 (2-Methyl-thiazol-4-ylmethyl) -amide-dihydrochloride -carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,5-dimethyl-isoxazol-4-ylmethyl) -amide, 4- [2-Bis] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-acetoxyethyl) -amino-ethylcarbamoyl] -benzylamide, 4- (2-Hydroxy-ethylcarbamoyl) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 4-. { 2 - [(2-Acetoxyethyl) - (2-hydroxyethyl) -amino] -ethylcarbamoyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, (1-Methyl-1H-benzoimidazol-2-ylmethyl) -amide-hydrochloride acid - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro- (thiazol-2-ylmethyl) -amide-dihydrochloride) benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4-benzothiazol-2-ylmethyl) -amide dihydrochloride, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-dimethyl-thiazol-4-ylmethyl) -amide-dihydrochloride -difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, l [2- (Morpholin-4-yl) -thiazol-4-ylmethyl] -amide-dihydrochloride of 5- (2-chloro-4,5- difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (1, 3,5-trimethyl-1H-pyrazol-4-ylmethyl) -amide ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (2-chloro-6-methyl-pyridin-3-ylmethyl) -amide-dihydrochloride -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-dimethylamino-thiazol-4-ylmethyl) -amide-dihydrochloride, ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1-methyl-1H-pyrrol-2-ylmethyl) -amide, (3,4 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dimethoxy-pyridin-2-ylmethyl) -amide-dihydrochloride (5-tert-butyl-thiazole-2) -ylmethyl) -amide-dichlorh 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid idrato, (5-Methyl-2-phenyl-2H- [1,2,3] triazole-4- 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (tert-butoxycarbonyl-amino) -methyl-pyridin-2-ylmethyl] -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, [4-Methyl-2- (morpholin-4-yl) -thiazol-5-ylmethyl] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid dihydrochloride, (pyridin-3-ylmethyl) -amide 3/2-hydrochloride hemihydrate, of acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2-Amino-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-methoxy-benzylamide of 5- (2- (2-methoxy-benzylamide chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- 4-methoxy-benzylamide 3-carboxylic acid, 4- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-methyl-benzylamide, 5- (2-chloro-) -fluoro-benzylamide 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-chloro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-ethoxycarbonyl-benzylamide, 5- (2-chloro-4,5-difluoro) -carboxy-benzylamide -benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dibenzylamide, (cyano-phenyl-methyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, cyclohexylmethyl-amide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-hydroxy-ethyl) -phenyl-amide, acid cyclohexyl-methyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carbox lithium, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl-amide, 5- (2-chloro-4,5-difluoro-) cyclohexyl-ethyl-amide benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, allyl-cyclohexyl-amide, Cyclohexyl- (p. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, ridin-2-ylmethyl) methyl ester (Methyl- (1-methyl-piperidin-4-yl) -amide) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro- [(3,4-methylenedioxyphenyl) -methyl] -amide-hydrochloride] -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzyl-butyl-amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzyl- (5- hydroxy-butyl) -amide hydrochloride, 5- (2-butyl-ethyl-amide) -chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, cyclohexyl-propyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl-cyclohexyl-5- (2-chloro-4-amide), 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-cyclohexyl- (2-methoxy-ethyl) -amide. -carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl- (pyridin-3-ylmethyl) -amide, [2- (Morpholin-4-yl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) acid dibutylamide) -1H- pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid bis- (2-methoxy-ethyl) -amide, (2- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methoxy-ethyl) -propyl-amide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, B-butyl- (tetrahydro-pyran-4-yl) -amide - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (2-methoxy-ethyl) - (tetrahydro-pyran-4-yl) -amide of 5- (2-chloro) -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) cyclopentyl- (2-methoxy-ethyl) -amide) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl- (3-methoxy-propyl) -amide, Cyclohexyl- ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-ethoxy-ethyl) -amide, Cyclohexyl- (2-isopropoxy-ethyl) -amide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Cyclohexyl- (2-propoxy-ethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) ) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- (1-Ethyl-propyl) - (2-methoxy-ethyl) -amide. 3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (1-tert-butoxycarbonyl-piperidin-4-yl) -amide , Butyl- (tetrahydro-thiopyran-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (2-methoxy-ethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-) butyl- (pyridin-3-ylmethyl) -amide difluoro-b enzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzyl- (2-methoxy-ethyl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (piperidin-4-yl-amide, (1-acetyl-piperidin-4-yl) -butyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-butyl- (1-methanesulfonyl-piperidin-4-yl) -amide) -amide -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro) butyl- (1-ethoxalyl-piperidin-4-yl) -amide. -benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl- (1-oxalo-piperidin-4-yl) -amide of 5- (2-chloro-4,5-i-difluoro-benzoylamino) -1H-pyrazole -3-carboxylic acid, butyl- (1,1-dioxo-hexahydro-1-6-thiopyran-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole -3-carboxylic acid, Butyl- (1-oxo-hexahydro-1? 4-thiopyran-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 -amide carboxylic, (6-methoxy-pyridine-3- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ylmethyl) -propyl-amide of 5- (2- (2-chloro-4,5-difluoro-benzoylamino) -1- pyrazole-3-carboxylic acid, 5- (2- (2- (2-yl) -propyl- (pyridin-3-ylmethyl) -amide) chloro-4, 5-difluoro-benzoylamino) -! H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-diethylcarbamoyl-benzylamide, 5- (5-ethylcarbamoyl-benzylamide 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-ethylcarbamoyl-benzylamide -carboxylic acid, 3- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3-ethylcarbamoyl-benzylamide, 5- (2-chloro-4-carbamoyl-benzylamide) , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H (1-Oxalo-piperidin-4-yl) -propyl-amide -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1-carboxylacetyl-piperidin-4-yl) -propyl-amide, [1 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-carboxypropionyl) -piperidin-4-yl] -propyl-amide, Cyclopropyl- (6-methoxy-pyridin-3-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, C-cyclobutyl- (6-methoxy) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid pyridin-3-ylmethyl) -amide, Cyclopropylmethyl- (6-methoxy-pyridin-3-ylmethyl) -amide 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4, 6-dimethylamino-pyridin-3-ylmethyl) -amide 5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (6-dimethylamino-pyridin-3-ylmethyl) -propyl-amide -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzyl- (2-carboxy-ethyl) -amide, Benzyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (2-ethoxycarbonyl-ethyl) -amide, (6-chloro-pyridin-3-ylmethyl) -propyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2- (2- (2- (2- (2-Dichloro-benzylamide Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro) - (3,5-Dichloro-pyridin-4-ylmethyl) -amide -benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (3,5-dichloro-pyridin-4-ylmethyl) -propyl-amide pyrazole-3-carboxylic acid, [6- (1H-pyrazol-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole -3-carboxylic acid 5- [2- (2-chloro-4,5-difluoro-benzoylamino) -1 H [3- (4-hydroxy-piperidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride] -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-pyridin-2-yl-ethyl) -amide, (2- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid pyridin-3-yl-ethyl) - (2-pyridin-4-yl-ethyl) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, (4- [1,2,3] thiadiazol-4-yl-benzyl) -amide acid , 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole- 3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-methyl-pyrazan-2-ylmethyl) -amide, pyrazin-2-ylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) - quinoline-5-ylamide 1 H-pyrazole-3-carboxylic acid, quinoline-8-ylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, lsoquinolin-5-ylamide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [3-ethoxy-5- (1-ethoxycarbonyl-1-methyl-ethyl) -pyridin-2-yl] -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [3-Ethoxy-5- (1-ethoxycarbonyl-1-hydroxy-ethyl) -pyridin-2-yl) ] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, [5- (1-Carboxy-1-methyl-ethyl) -3-ethoxy-pyridine] -2-yl] - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, [5- (1-Carboxy-1-hydroxy-ethyl) -3 -ethoxy-pyridin-2-yl] -amide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 (pyrazin-2-ylmethyl) -amide. H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- [6- (thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide 3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -6- (1, 1-Dioxo-1? 6-thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4,5-Dibromo-thiophen-2-ylmethyl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-chloro-thiophen-2-ylmethyl) -amide, (4-Ethyl-2-methyl-oxazole) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-ylmethyl) -amide (2-Ethyl-4-methyl-oxazol-5-ylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid dihydrochloride, ([2,2 '] Bithiophenyl-5-ylmethyl) -amide of 5- (2 -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carbo xyl, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-methoxy-thiophen-2-ylmethyl) -amide.5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4,5-dichloro-thiophen-2-ylmethyl) -amide, (2,5-dimethyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid oxazol-4-ylmethyl) -amide, (2-hexyl-4-methyl-oxazol-5-ylmethyl) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-chloro-) (4-methoxy-thiophene-3-ylmethyl) -amide 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-) 4- (methyl-2-phenyl-oxazol-5-ylmethyl) -amide. benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole (2-methyl-4-phenyl-oxazol-5-ylmethyl) -amide. -3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-hexyl-2-methyl-oxazol-5-ylmethyl) -amide-dihydrochloride; 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-ylmethyl) -amide, (6-chloro-pyridin-3-ylmethyl) -amide-dihydrochloride of 5- (2-c) acid par-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5- (1,4- [1,4] triazol-3-ylmethyl) -amide) -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (4- H- [1,4] triazol-3-ylmethyl) -amide-dihydrochloride ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3 (5-Fluoro-4H-quinazolin-3-yl) -amide. -carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-fluoro-4H-quinazolin-3-yl) -amide-dihydrochloride (4, 6-Dimethyl-pyridin-3-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (4,6-Dimethyl-pyridin-3-) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ylmethyl) -amide dihydrochloride, (2-Methoxy-6-methyl-pyridin-3-ylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2- (2- (2- (2-methoxy-6-methyl-pyridin-3-ylmethyl) -amide) chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxy-6-methyl-pyridin-3-ylmethyl) -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-4,6-dimethyl-pyridin-3-ylmethyl) -amide, (2-methoxy) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,6-dimethyl-pyridin-3-ylmethyl) -amide dihydrochloride, (3-Methyl-pyridine) 2- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-methyl-pyridin-3-ylmethyl) -amide; - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4, 1- (6-Methyl-pyridin-3-ylmethyl) -amide), 5-dif luoro- | benzoylamino) -1 H-pyrazole-3-carboxylic acid, (6-Methyl-pyridin-2-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-, benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2,4-Dichloro-5-pyridin-3-ylmethyl) -amide-dihydrochloride fluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-fluoro-pyridin-3-ylmethyl) -amide-dihydrochloride,! 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-carboxy-phenyl) -methyl-amide, 3-Methanesulfonylamino-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-Methanesulfonylamino-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 3-Acetylamino-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-acetylamino-benzylamide, 5- (2-phenyl-thiazol-4-ylmethyl) -amide. 2-chloro-4,5-difluoro-? benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ((R) -1-phenyl-ethyl) -amide. (5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid ((S) -1-phenyl-ethyl) -amide, (6-Phenoxy-pyridin-3-) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-ylmethyl) -amide-dihydrochloride of 5-chloro-pyridin-3-ylmethyl) -amide dihydrochloride - (2-Methyl-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4, 2-chloro-pyridin-3-ylmethyl) -amide-dihydrochloride, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Sodium salt of 5- (2-methyl-4,5-difluoro-benzoylamino) (6-chloro-pyridin-3-ylmethyl) -amide 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3 [1- (pyridin-3-yl) -ethyl] -amide-dihydrochloride -carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-fluoro-pyridin-3-ylmethyl) -amide dihydrochloride, (2-Met) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ylpyridin-3-ylmethyl) -amide dihydrochloride, (Biphenyl-3-ylmethyl) -amide of acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, ((1R, 2S) -2-Hydroxy-indan-1-yl) -amide of 5- (2 -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, ((1 S, 2R) -2-Hydroxy-indan-1-yl) -amide of 5- (2-chloro- 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - (6-phenyl-pyridin-3-ylmethyl) -amide-dihydrochloride - 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (6-Methyl-2-pyridon-3-ylmethyl) -amide-hydrochloride carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzyl-methyl-amide, 5- (2-chloro-4,5-difluoro-) acid benzylamide benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid phenylamide, Methyl-phenyl-acid-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5- (2-chloro-4,5-difluoro-) acid (Piperidin-1-yl) -amide benzoylamino) -1 H-pyrazole-3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-ethoxycarbonyl-piperidin-1-yl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methyl-piperazin-1-yl) -amide, (4-Carboxy-piperidin-1-) il) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-chloro-4,5-difluoro-benzoylamino) -phenethylamide 1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid methyl phenethyl-amide, 5-Chloro-4,5-difluoro-benzoylamino acid (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (1, 2,3,4-tetrahydroisoquinolin-2-yl) -amide of 5- (2-chloro-4) acid , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - ((S) -a-Methoxycarbonyl-benzyl) -amide -pirate l-3-carboxylic acid, ((R) -a-methoxycarbonyl-benzyl) -amide of 5- (2-chloro-4) acid, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (1, 2,3,4-tetrahydroquinolin-1-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid phenyl-propyl-amide, butyl-phenyl-amide acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) - 1 H phenyl-phenyl-amide -pyrazol-3-carboxylic acid, benzhydril-amide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, I (5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-2-ylmethyl) -amide-hydrochloride, (pyridin-4-methylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid hydrochloride, ((R) -2-Hydroxy-1-phenyl-ethyl) -amide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4) ((S) -2-hydroxy-1-phenyl-ethyl) -amide. , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-dimethylamino-benzylamide, ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid furan-2-ylmethyl) -amide of 5- (2-chloro-5-ylmethyl) -amide -chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (2-methoxy-phenyl) -amide -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-phenyl) -methyl-amide, 4-dimethylamino-benzylamide - 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid hydrochloride, 5- (2-chloro-4,5-difluoro-benzoylamino) -3-amino-benzylamide -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-amino-benzylamide, 5-methyl-benzylamide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-Methyl-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- 3-carboxylic acid, 3- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-pyridin-3-ylmethyl) -amide acid 3-dimethylamino-benzylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-2-chloro-benzylamide -pyrazol-3-carboxylic acid, 3- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3-chloro-benzylamide, 5- (2-methoxycarbonyl-benzylamide) -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-Carboxi 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2- (2-trifluoromethyl-pyridin-3-ylmethyl) -amide) chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-dif-luorobenzoylamino) (2-ethoxy-pyridin-3-ylmethyl) -amide. ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-dimethylamino-ethyl) -amide, Ethyl- ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-dimethylamino-ethyl) -amide-dihydrochloride, Cyclohexyl- (2-dimethylamino-ethyl) -amide of acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5) (4,5-chloro-4,5-methoxy-pyridin-2-ylmethyl) -amide -difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (2,6-dimethoxy-pyridin-3-ylmethyl) -amide -pyrazol-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-methoxycarbonylmethoxy-benzylamide Ixil, 2- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -3- (6-methoxy-pyridin-3-ylmethyl) -amide. (4,5-Difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2,4-Dichlorobenzoylamino) - (6-methoxy-pyridin-3-ylmethyl) -amide H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,5-dimethoxy-pyridin-4-ylmethyl) -amide, 5- (4,5-Difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-Dimethyl-oxazol-5-ylmethyl) -amide, (2,4-Dimethyl-oxazole) 5- (2,4-dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxycarbonyl-phenyl) -methyl-amide methyl- (5-ylmethyl) -amide. - (2-Chloro-4,5-difluorobenzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H (4-carboxyphenyl) -methyl-amide -pyrazole-3-carboxylic, 4-. { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] -methyl-amino} -monosodium benzoate 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid isopropyl-phenyl-amide5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-chloro-4,5-difluoro-benzoylamino) acid (5- (2-chloro-benzoylamino) acid (carboxymethyl) -phenyl-amide) ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, Benzylamide 5- (2,4-Dichloro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, Benzyl- 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid phenyl-amide, 5- (2- (2-methyl-1-phenyl-ethyl) -amide) chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, [2-Oxo-2- (piperidin-1-yl) -ethyl] -phenyl-amide of 5- (2-chloro- 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (5-Fluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-benzylamide 5-Chloro-2-methyl-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (4-Methoxy-2-) benzylamide methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (4-Chloro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Fluorocarbonyl) benzylamide 2-methoxy-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (5-Chloro-2-methoxy-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, (2-Ethoxy-ethyl) -phenyl 5- (2-Chloro-4,5-difluoro-benzoylamino) - acidamide! H-pyrazole-3-carboxylic acid, 5- (2-Fluoro-5-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Chloro-2-fluoro-benzoylamino) acid benzylamide -1 H- pyrazole-3-carboxylic acid, 5- (3-Chloro-2,6-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-3-fluoro acid) benzylamide benzoylamino) -1 H-pyrazole-3-carboxylic acid amide Etilcarbamoilmetil-phenyl-5- (2-chloro-4, 5-dif luoro-benzoylamino) acid - H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxycarbonyl-ethyl) -phenyl-amide, isobutyl-phenyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-acid) (3-ethoxycarbonyl-propyl) -phenyl-amide -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (2-carboxy-ethyl) -phenyl-amide carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-carboxy-propyl) -phenyl-amide, 5- (2-Hydroxy-4-benzylamide) -methoxy-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Hydroxy-5-methoxy-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Fluorocarbonyl) benzylamide 2-hydroxy-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (4-Fluoro-2-trifluoromethyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-) -benzylamide Fluoro-2-trifluoromethyl-benzoylamino) -1H-pyrazole-3-ca 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2,5-Dimethyl) acid benzylamide, 5- (2-Chloro-4,5-difluoro-benzoylamino) acid, 5- (2-methoxy-ethyl) -phenyl-amide -benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-5-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-pyridine-) benzylamide 3-carbonylamino) -! H-pyrazole-3-carboxylic acid, 5- (4-Chloro-pyridine-2-carbonylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2,6-dichloro-pyridin-3-benzylamide) carbonylamino) - H-pyrazole-3-carboxylic acid butyl- (4-ethoxycarbonyl-phenyl) -amide 5- (2-chloro-4,5-difluoro-benzoylamino) acid - H-pyrazole-3-carboxylic acid butyl- (4-carboxy-phenyl) -amide 5- (2-chloro-4,5-difluoro-benzoylamino) acid - H-pyrazole-3-carboxylic acid, 5- (2-Methyl-pyridine-3-carbonylamino) -! Benzylamide H-pyrazole-3-carboxylic acid, 5- (2-chloro-6-methyl-pyridine-3-carbonylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (3-Chloro-pyridin-) acid benzylamide 4-carbonylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (4-ethoxycarbonylmethyl-phenyl) -amide. , 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (4-carboxymethyl-phenyl) -amide.5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxycarbonyl-phenyl) - (2-methoxy-ethyl) -amide; phenyl) - 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (6-methoxy-pyridin-3-ylmethyl) - (2-methoxy-ethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid dihydrochloride, 5- (methoxy-pyridin-3-ylmethyl) -amide-dihydrochloride of 5- (2- Methyl-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (thiazol-4-ylmethyl) -amide-dihydrochloride) -1H-pyrazole-3-carboxylic acid, 4- [2- (Morpholin-4-yl) -ethylcarbamoyl] -benzylamide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4- (Morpholin-4-ylcarbamoyl) -benzylamide-dihydrochloride, sodium salt of acid [4] - ( { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] -amino.} - methyl) -benzoyl mino] -acetic acid sodium salt 3- [4- (. { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] -amino} -methyl) -benzoylamino] -propionic. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,5-dimethyl-isoxazol-4-ylmethyl) -amide hydrochloride, (1, 3.5 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid trimethyl-1H-pyrazol-4-ylmethyl-amide dihydrochloride, (3,5-dimethyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid isoxazol-4-ylmethyl) -amide-sulfonate, 3- [2- (Morpholin-4-yl) - ethylcarbamoyl] -benzylamide-5- (2-chloro-4,5-d -fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dihydrochloride, 3- (Morpholin-4-ylcarbamoyl) -benzylamide-dihydrochloride acid - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid,. { 2- [2- (Morpholin-4-yl) -ethylcarbamoyl] -pyridin-4-ylmethyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide trichlorohydrate, [2- (Morpholin-4-ylcarbamoyl) -pyridin-4-ylmethyl] -amide- 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid trichlorohydrate, 5- (2-chloro) methanesulfonate (6-methoxy-pyridin-3-ylmethyl) -amide methanesulfonate -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (6-methoxy-pyridin-3-ylmethyl) -amide hemisulfate) -1 H-pyrazole-3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole- (3,5-dimethoxy-pyridin-4-ylmethyl) -amide-dihydrochloride 3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-Aminomethyl-pyridin-2-ylmethyl) -amide-trichlorohydrate (6-carboxylic acid) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid chloro-pyridin-3-ylmethyl) -amide methanesulfonate, (6-Chloro-pyridin-3-ylmethyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carbo acid dimethanesulfonate xyl, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-pyridin-3-ylmethyl) -amide-hydrochloride, (Pyridin- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (3-ylmethyl) -amide-hydrochloride (6-methoxy-pyridin-3-ylmethyl) -propyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid dihydrochloride, [6- (Piperidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride of acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [6- (Morpholin-4-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4-chloro-4-dichloro-pyridin-4-ylmethyl) -amide-hydrochloride , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - (6-Dimethylamino-pyridin-3-ylmethyl) -amide-dihydrochloride - 1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-dimethylamino-pyridin-3-ylmethyl) -propyl-amide-dihydrochloride, (6-diethylamino-pyridine) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-ylmethyl) -amide-dihydrochloride (6-chloro-2-dimethylamino-pyridin-3-ylmethyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dihydrochloride, (4- [1,2,3] thiadiazol-4-yl-benzyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid hydrochloride, 5- (2-hydroxy acid (4-methyl-thiazol-5-ylmethyl) -amide-hydrochloride) -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-2,4-dimethyl-thiazol-5-ylmethyl) -amide-hydrochloride -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [5- (4-hydroxy-piperidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride, 5- (2-chloro- 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-d) 5-Methyl-pyrazin-2-ylamide-dihydrochloride ifluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid quinoline-5-ylamide-dihydrochloride, Quinolin-8 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid ylamide, 5-chloro-4,5-linoquinolin-5-ylamide-dihydrochloride -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, i i [6- (4-Methylpiperazin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, [6- (4-Dimethylamino-piperidin-1-yl) -pyridin-3-ylmethyl] -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dihydrochloride, [6- (Pyrrolidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride of acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro), (pyrazin-2-ylmethyl) -amide-dihydrochloride -benzoylamino) -1 H -pyrazole-3-carboxylic acid [6- (thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [6- (1, 1-Dioxo-1, 6-thiomorpholin-4-yl) -pyridin-3-ylmethyl] - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide-dihydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) carbamoylmethyl-amide -1 H-pyrazole-3-carboxylic acid, (4-carbamoyl-phenyl) -methyl-amide, 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Methyl- 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methylcarbamoyl-phenyl) -amide, 5-dimethylcarbamoyl-phenyl) -methyl-amide - (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (4-methanesulfonylaminocarbonyl-phenyl) -methyl-amide ) -1 H-pyrazole-3-carboxylic acid, Sodium salt of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3 (4-methanesulfonylaminocarbonyl-phenyl) -methyl-amide acid -carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) - (4-cyano-phenyl) -methyl-amide 1 H-pyrazole-3-carboxylic acid, Methyl- [4- (4H- [1, 2,4] triazol-3-yl) -phenyl] -amide-hydrochloride of 5- (2-chloro-4,5-) acid difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (4-azido-2-chloro-5-fluoro-benzoylamino) -1H-pyrazole- (4-cyano-phenyl) -methyl-amide 3-carboxylic acid, 5- (4-Azido-2-chloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl- [4- (1H-tetrazol-5-yl) -phenyl] -amide. , 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid [4- (N-hydroxycarbamimidoyl) -phenyl] -methyl-amide, Methyl- [4- (5 -oxo-2,5-dihydro- [1, 2,4] oxadiazol-3-yl) -phenyl] -amide of 5- (2-chloro-4) acid, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid,. { 4 - [(2,2-Dimethyl-propionyloxy) -methoxycarbonyl] -phenyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid methyl-4- (N- (methoxy-thiocarbonyloxy) -carbamimidoyl] -methyl-amide acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Methyl- [4- (5-thioxo-4,5-dihydro- [1,2,4] oxadiazole- 3-yl) -phenyl] -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Methyl- [4- (5-oxo-4,5-dihydro) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [1, 2,4] thiadiazol-3-yl) -phenyl] -amide ,. { 4- [1- (Cyclohexyloxycarbonyloxy) -ethoxycarbonyl] -phenyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl-amide, 5- (3-ethoxycarbonyl-thiazol-2-yl) -ethyl-amide (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole, 2-methanesulfonylamino-benzylamide -3-carboxylic acid, 2-Acetylamino-benzylamide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (Dimethylamino-methyleneamino) -benzylamide-hydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 3- (Dimethylamino-methyleneamino) -benzylamide-5- (2-chloro-4,5-) -hydrochloride difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 4- (Dimethylamino-methyleneamino) -benzylamide-acid hydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- [1- (Dimethylamino) ethylideneamino] -benzylamide-dihydrochloride of 5- (2-chloro-4,5-acid) -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3- (1- (dimethylamino) ethylidenamino] -benzylamide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4- (1- (dimethylamino) ethylidenamino] -benzylamide-dihydrochloride, 2- (Diethylamino 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3- (diethylamino-methyleneamino) -benzylamide-dihydrochloride -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (diethylamino-methyleneamino) -benzylamide-acid dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) - 2-Acetimidoylamino-benzylamide-dihydrochloride 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-acetylimidoamino-benzylamide-dihydrochloride, 4-Acetimidoylamino-benzylamide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 4-cyano-benzylamide acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3 - [(2-Fluoro-benzimidoyl) -amino] -benzylamide-acid hydride, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 -carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4- (2-fluoro-benzimidoyl) -amino] -benzylamide-hydroiodide, 3- ( 3,3-Dimethyl-ureido) -benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 4- (3,3-Dimethyl-ureido) -benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole acid l-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid 2- (Toluen-4-sulfonylamino) -benzylamide, 2-Amino-6- fluoro-benzylamide 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid hydrochloride, 2-Amino-4,5-difluoro-benzylamide-5- (2-hydrochloride) -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (lndan-l-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (lndan-2-yl) -amide (4H-Quinazolin-3-) il) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2- (2-chloro-3-yl) -amido-amide-dihydrochloride) Chloro-4,5-I-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, I 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (7-fluoro-4H-quinazolin-3-yl) -amide-dihydrochloride, (6-Fluoro-4H) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid -quinazolin-3-yl) -amide-hydrochloride, (2-Ethoxy-2-methyl-1, 4 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-dihydro-2H-quinazolin-3-yl) -amide, (2-Cyano-pyridin-4-ylmethyl) ) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, [2- (N-hydroxycarbamimidoyl) -pyridin-4-ylmethyl] -amide of 5 - (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, [2- (5-Oxo-4,5-dihydro- [1,2,4] oxadiazol-3-yl] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid pyridin-4-ylmethyl ester, sodium salt of 4- acid. { [5- (4,5-difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carbonyl] -methyl-amino} -benzoic acid, 5- (4,5-Difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid (4- (1H-tetrazol-5-yl) -phenyl] -amide, (Pyridine 5- (2,4-Dichloro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-ylmethyl) -amide, 5- (2,4-Dichloro-3-ylmethyl) -amide. 5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2,6-Dichloro-5-fluoro-pyridine-3-carbonylamino) -1H-pyrazole (Pyridin-3-ylmethyl) -amide. -3-carboxylic acid, 5 - [(3-Chloro-benzo [b] thiophen-2-carbonyl) -amino] -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide, (Pyridin- 3-ylmethyl) -amide of 5 - [(3-chloro-thiophene-2-carbonyl) -amino] -1 H -pyrazole-3-carboxylic acid, 5-benzoylamino- (pyridin-3-ylmethyl) -amide 1 H-pyrazole-3-carboxylic acid, 5-phenylacetylamino-1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide. 5- (2-Methyl-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide-dihydrochloride, 5-methyl-4,5-difluoro-benzoylamino) -hydrochloride, (Pyridin-3-ylmethyl) -amide - (2-Amino-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (4,5-Difluoro-2-methanesulfonylamino-benzoylamino) (pyridin-3-ylmethyl) -amide -1 H-pyrazole-3-carboxylic acid 5- (2-acetylamino-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide (Pyridin-3) 5 - [(3,4,5-trichloro-thiophene-2-carbonyl) -amino] -1H-pyrazole-3-carboxylic acid (2-cyano-pyridin-4-ylmethyl) -amide. 5- (4,5-difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, [2- (1 H-Tetrazol-5-yl) -pyridin-4-ylmethyl] -amide 5- (4,5-difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, and 3 - Benzylamide of 5 - [(2,4-dichloro-phenyl) -amide] 1 H- Pyrazole-3,5-dicarboxylic acid. 56.- A therapeutic or prophylactic agent to combat insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataract, glycemia, hypercholesterolemia, hypertension, hyperinsulinism, hyperlipidemia, atherosclerosis, tissue ischemia, myocardial ischemia, obesity, bacterial infection , fungal, parasitic or viral, comprising a pyrazole compound according to any of items 36 to 55 described above or a pharmacologically acceptable salt thereof, as an active ingredient. 57.- A drug comprising a combination of a therapeutic or prophylactic agent, according to point 56 described above, and another drug.

Advantages of the Invention The pyrazole compound of the present invention: has inhibitory activity of hepatic glycogen phosphorylase, with a potent activity and fewer adverse reactions, in addition to an oral absorption capacity and superior metabolic stability, in comparison with conventional antidiabetics; provides an extremely useful and novel pharmaceutical composition for treating or preventing diabetes; and has potential as: a useful therapeutic agent to combat insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataract, hypercholesterolemia, hypertension, hyperinsulinism, hyperlipidemia, atherosclerosis, tissue ischemia and myocardial ischemia; therapeutic agent for the control of appetite and obesity; and as a therapeutic agent to fight infections, such as bacterial, fungal, parasitic or viral infection.

BEST MODE FOR CARRYING OUT THE INVENTION The pyrazole skeleton of the pyrazole compound of the present invention has the following formula, presented below: I 1 and the following isomeric formula: Therefore, the pyrazole compounds of the present invention are not limited to the pyrazole compounds represented by the general formula (I) described above, but include the pyrazole compounds represented by the following general formula (I '). (i 1) The substituents and the parts used herein are defined herein in the following manner. A "halogen atom" is a fluorine, chlorine, bromine or iodine atom. A fluorine atom or a chlorine atom is preferred. A "d-β-alkyl group" represents a linear or branched alkyl group, having 1 to 6 carbon atoms and includes, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, an butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a 2-methylbutyl group, a neopentyl group, a 1-ethylpropyl group, a hexyl group, an isohexyl group , a 4-methylpentyl group, a 3-methylpentyl group, a 2-methylpentyl group, a 1-methylpentyl group, a 3,3-dimethylbutyl group, a 2,2-dimethylbutyl group, a 1, 1-dimethylbutyl group, a group 1, 2-dimethylbutyl, a 1,3-dimethylbutyl group, a 2,3-dimethylbutyl group, a 1-ethylbutyl group and a 2-ethylbutyl group. A C 1-4 alkyl group is preferred. A "CM alkyl group" represents a linear or branched alkyl group, having 1 to 4 carbon atoms, and includes, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group and a tert-butyl group. A methyl group is preferred. A "C2.6 alkenyl group" represents an optionally branched alkenyl group, having 2 to 6 carbon atoms with one or more double bonds and includes, for example, an ethenyl group (vinyl group), an iL vLiJiJ. 1-propenyl group, a 2-propenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a 2-methyl-1-propenyl group, a 1-pentenyl group, a 2-pentenyl group , a 3-pentenyl group, a 4-pentenyl group, a 3-methyl-2-butenyl group, a 1 -hexenyl group, a 3-hexenyl group, a 2,4-hexadienyl group and a 5-hexenyl group. Preferred are optionally branched C2_4 alkenyl groups, having 2 to 4 carbon atoms, such as an ethenyl group (vinyl group), a 1-propenyl group, a 2-propenyl group and a 1-butenyl group. A vinyl group and a propenyl group are more preferred. A "C2-6 alkynyl group" represents an optionally branched alkynyl group, having from 2 to 6 carbon atoms, with one or more triple bonds and includes, for example, an ethynyl group, a 1-propynyl group, a 2 group -propynyl, a 1-butynyl group, a 2-butynyl group, a 3-butynyl group, a 1-pentynyl group, a 2-pentynyl group, a 3-pentynyl group, a 4-pentynyl group, a 1-hexynyl group , a 2-hexinyl group, a 3-hexinyl group, a 4-hexinyl group and a 5-hexinyl group. Preferred are C2_4 alkynyl groups optionally branched, having from 2 to 4 carbon atoms, such as an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 1-butynyl group and a 2-butynyl group. An "alkylene d-β group" represents an optionally branched alkylene group, having 1 to 6 carbon atoms, and includes, for example, a methylene group, an ethylene group, a propylene group, a butylene group, a pentylene group , and a hexylene group and, preferably, groups Optionally branched C-M alkylene, having 1 to 4 carbon atoms, such as a methylene group, an ethylene group, a propylene group and a butylene group. A "haloalkyl group C? .6" represents a "C-? 6 alkyl group", as described above, substituted with one or more, preferably 1 to 6, especially preferably 1 to 3" halogen atoms "described above and includes, for example, a trifluoromethyl group, a trichloromethyl group, a difluoromethyl group, a dichloromethyl group, a dibromomethyl group, a fluoromethyl group, a 2,2,2-trifluoroethyl group, a group 2, 2,2-trichloroethyl, a 2-bromoethyl group, a 2-chloroethyl group, a 2-fluoroethyl group, a 2-iodoethyl group, a 3-chloropropyl group, a 4-fluorobutyl group, a 6-iodohexyl group and a group 2,2-dibromoethyl and, preferably, haloalkyl groups CM having from 1 to 4 carbon atoms. An "alkoxy d-β group" represents an alkoxy group having from 1 to 6 carbon atoms, wherein the alkyl part is an optionally branched "d-β alkyl group", as defined above and includes, for example, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a sec-butoxy group, a tert-butoxy group, a pentoxy group, an isopentoxy group, a group 2 -methylbutoxy, a 1-ethylpropoxy group, a 2-ethylpropoxy group, a neopentoxy group, a hexyloxy group, a 4-methylpentoxy group, a 3-methylpentoxy group, a 2-methylpentoxy group, a 3,3-dimethylbutoxy group, a 2,2-dimethylbutoxy group, a 1,1-dimethylbutoxy group, a 1,2-dimethylbutoxy group, a 1,3-dimethylbutoxy group and a 2,3-dimethylbutoxy group. Preferred are C-M alkoxy groups having from 1 to 4 carbon atoms, such as a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group and a butoxy group. A "C 1-6 alkyl group substituted with a C 1-6 alkoxy group" or a "Alkoxy group (C? -6) alkyl Ci-β" represents an "optionally branched C? _6" alkyl group, as described above, which is substituted with an optionally branched "alkoxy d.6 group", as described above and includes, for example, a methoxymethyl group, an ethoxymethyl group, a propoxymethyl group, an isopropoxymethyl group, a butoxymethyl group, an isobutoxymethyl group, a sec-butoxymethyl group, a tert-butoxymethyl group, a 2-methoxyethyl group, a 2-ethoxyethyl group, a 2-propoxyethyl group, a 2-isopropoxyethyl group, a 2-butoxyethyl group, a 2-isobutoxyethyl group, a 2- group (sec- butoxy) ethyl group, 2- (tert-butoxy) ethyl group, a 1 -metoxietilo group, a 1 -etoxietilo, a 1-propoxyethyl, 1-isopropoxyethyl group, a 1-butoxyethyl, 1-isobutoxyethyl group , a 1- (sec-butoxy) ethyl group, a 1- (tert-butoxy) ethyl group and a 3-isopropoxypropyl group. Preferred are the C.sub.4 alkoxy alkyl d-4 groups, wherein the alkoxy and alkyl portions have from 1 to 4 carbon atoms, such as a methoxymethyl group, an ethoxymethyl group, a 1-methoxyethyl group, a 2-methoxyethyl group and a 2-butoxyethyl group. An "alkoxy (d_6) carbonyl" group represents an optionally branched alkoxy group having from 1 to 6 carbon atoms, as described above, which is attached to a carbonyl group, and includes, for example, a group methoxycarbonyl, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, an isobutoxycarbonyl group, a sec-butoxycarbonyl group, a tert-butoxycarbonyl group, a pentyloxycarbonyl group, an isopentyloxycarbonyl group, a 2-methylbutoxycarbonyl, a group neopentyloxycarbonyl, 1-ethylpropoxycarbonyl group a hexyloxycarbonyl group, a 4-methylpentyloxycarbonyl, 3-methylpentyloxycarbonyl group, a 2-methylpentyloxycarbonyl, 1-methylpentyloxycarbonyl group, 3,3-dimethylbutoxycarbonyl group one, an 2,2- dimethylbutoxycarbonyl, a 1,1-dimethylbutoxycarbonyl group, a 1,2-dimethylbutoxycarbonyl group, a 1,3-dimethylbutoxycarbonyl group, a 2,3-dimethylbutoxycarbo group nyl and a 2-ethylbutoxycarbonyl group. Preferred are (C? -44) alkoxycarbonyl groups in which the alkoxy portion has from 1 to 4 carbon atoms, such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group and an isopropoxycarbonyl group. An "(C6-6) alkoxycarbonyloxy group" represents an optionally branched "C6-6 alkoxycarbonyl group", as described above, which is attached to an oxygen atom, and includes, for example, a methoxycarbonyloxy group, an ethoxycarbonyloxy group, a propoxycarbonyloxy group, an isopropoxycarbonyloxy group, a butoxycarbonyloxy group, an isobutoxycarbonyloxy group, a sec-butoxycarbonyloxy group, a tert-butoxycarbonyloxy group, pentyloxycarbonyloxy one group, isopentiloxicarboniloxi group, a 2-metilbutoxicarboniloxi a neopentiloxicarboniloxi group, a 1-etilpropoxicarboniloxi a hexyloxycarbonyloxy group, a 4-metilpentiloxicarboniloxi group, a 3-metilpentiloxicarboniloxi group, a 2-metilpentiloxicarboniloxi group, a 1-metilpentiloxicarboniloxi, 3,3-dimetilbutoxicarboniloxi group, a 2,2 - dimethylbutoxycarbonyloxy, a 1,1-dimethylbutoxycarbonyloxy group, a 1,2-dimethylbutoxycarbonyloxy group, a 1,3-dimethylbutoxycarbonyloxy group, a 2,3-dimethylbutoxycarbonyloxy group or a 2-ethylbutoxycarbonyloxy group. groups (d-4 alkoxy) carbonyloxy in which the alkoxy part has 1 to 4 carbon atoms such as a methoxycarbonyloxy group, an ethoxycarbonyloxy group, a propoxycarbonyloxy group, an isopropoxycarbonyloxy group and a butoxycarbonyloxy group are preferred. An "alkyl (d.6) carbonyloxy group" represents an optionally branched "d-6 alkyl group", as described above, which is attached to a carbonyloxy group and includes, for example, an acetyloxy group, a group propionyloxy, a butyryloxy group, an isobutyloxy group, a valeryloxy group, an isovaleryloxy group, a pivaloyloxy group and a hexanoyloxy group. An "alkyl (C6-6) carbonyloxy-alkyl group d-β" represents a group "d-β alkyl" substituted with the group "(C-? 6 alkyl) carbonyloxy", as described above and is preferably a d 4 alkyl group substituted with an alkyl (C 4 -4) carbonyloxy group. A "C 6 alkoxy group which may be substituted with an alkoxy (d 6) carbonyl group" represents an unsubstituted C 6 -6 alkoxy group;, or a C 1-6 alkoxy group substituted with a (C -? - 6) alkoxycarbonyl group, and a d-6 alkoxy group substituted with an alkoxy (d.sub.6) carbonyl group represents a "substituted d6-alkoxy group" with the "(C-? ^) carbonyl" alkoxy group, as described above. An unsubstituted alkoxy group d and a C-alkoxy group substituted with an alkoxy (d-4) carbonyl group are preferred. A "methylenedioxy group" and an "ethylenedioxy group" represent -O-CH2-O- and -O-C2H-O-, respectively. An "acyl group" represents an aliphatic, optionally branched C2.7 acyl group, or an aromatic acyl group, in which a saturated or unsaturated hydrocarbon group is attached to the carbonyl group. Aliphatic acyl groups include, for example, an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an isovaleryl group, a pivaloyl group, a hexanoyl group, an acryloyl group, a methacryloyl group and an crotonoyl group. The aromatic acyl groups include arylcarbonyl groups, such as the benzoyl group, the a-naphthoyl group and the b-naphthoyl group, the halogenated arylcarbonyl groups, such as a 2-bromobenzoyl group and a 4-chlorobenzoyl group, arylcarbonyl groups d.6 alkylated, such as a 2,4,6-trimethylbenzoyl group and a 4-toluoyl group, C 1 -C 6 alkoxylated arylcarbonyl groups, such as a 4-anisoyl group, nitro-arylcarbonyl groups, such as a 4-nitrobenzoyl group and a 2- group nitrobenzoyl, C 1 -C 6 alkoxycarbonyl arylcarbonyl groups, such as 2- (methoxycarbonyl) benzoyl group, and arylated arylcarbonyl groups, such as a 4-phenylbenzoyl group.

A "C6_6-amino-alkyl group" represents the following "monoalkyl (C-? - 6) amino" or "dialkyl (C? -6) amino" groups. Alkyl d-4-amino groups having 1 to 4 carbon atoms are preferred. A "monoalkyl (C? .6) amino group" represents an amino group substituted with the "d.6 alkyl group" defined above, and includes, for example, a methylamino group, an ethylamino group, a propylamino group, a isopropylamino group, a butylamino group, an isobutylamino group, a sec-butylamino group, a tert-butylamino group, a pentylamino group, an isopentylamino group, a 2-methylbutylamino group, a neopentylamino group, a 1-ethylpropylamino group, a hexylamino group , an isohexylamino group, a 4-methylpentylamino group, a 3-methylpentylamino group, a 2-methylpentylamino group, a 1-methylpentylamino group, a 3,3-dimethylbutylamino group, a 2,2-dimethylbutylamino group, a 1, 1 group dimethylbutylamino, a 1,2-dimethylbutylamino group, a 1,3-dimethylbutylamino group, a 2,3-dimethylbutylamino group and a 2-ethylbutylamino group. Preferred are C-M-amino monoalkyl groups substituted with a C-M alkyl group, such as a methylamino group, an ethylamino group, a propylamino group, an isopropylamino group, a butylamino group and an isobutylamino group. A "d6alkyl (C6-6) amino" group represents an amino group substituted with two identical or different "C6-6 alkyl" groups, as described above and includes, for example, a dimethylamino group, a diethylamino group, an N-ethyl-N-methylamino group, a dipropylamino group, a dibutylamino group, a dipentylamino group and a dihexylamino group. HE .I.J prefer dialkyl (d-4) amino groups substituted with two d.4 alkyl groups, such as a dimethylamino group and a diethylamino group. An "acylamino group" represents an amino group substituted with an "acyl group" described above and includes, for example, lower aliphatic, optionally branched acylamino groups, having from 2 to 7 carbon atoms, such as an acetylamino group, a group propionylamino, a butyrylamino group, an isobutyrylamino group, a valerylamino group, an isovalerylamino group, a pivaloylamino group, a hexanoylamino group, an acryloylamino group, a methacryloylamino group and a crotonylamino group, or aromatic acylamino groups, such as a benzoylamino group. An "alkoxy (C? -6) carbonylamino group" represents an amino group substituted with the "(C? ^) Carbonyl alkoxy group", which has been defined above and includes, for example, a methoxycarbonylamino group, an ethoxycarbonylamino group, a propoxycarbonylamino group and an isopropoxycarbonylamino group. Preferred are C-M-carbonylamino alkoxy groups, such as a methoxycarbonylamino group, an ethoxycarbonylamino group and a propoxycarbonylamino group. A "carbamoyl group" represents, in a limited sense, -CONH2, and, in a broad sense, -CONH2, a "monoalkyl (C? 6) carbamoyl" group, a "dialkyl (C- | .6) carbamoyl group" "or a" N-alkyl (C -? - 6) -N-arylcarbamoyl group ". A "monoalkyl (C-? - 6) carbamoyl group" represents a carbamoyl group that binds to a "C? -6 alkyl group", as described above and includes, for example, a methylcarbamoyl group, an ethylcarbamoyl group, a propylcarbamoyl group, an isopropylcarbamoyl group, a butylcarbamoyl group, an isobutylcarbamoyl group, a sec-butylcarbamoyl group, a tert-butylcarbamoyl group, a pentylcarbamoyl group, an isopentylcarbamoyl group, a 2-methylbutylcarbamoyl group, a neopentylcarbamoyl group, a group 1 ethylpropylcarbamoyl and a hexylcarbamoyl group, and preferably a C 4 -4 -carbamoyl monoalkyl group, wherein the alkyl group is an alkyl group having 1 to 4 carbon atoms, such as a methylcarbamoyl group, an ethylcarbamoyl group, a group propylcarbamoyl, an isopropylcarbamoyl group and a butylcarbamoyl group. A "dialkyl (d-6) carbamoyl group" represents a carbamoyl group that binds two identical or different "β-alkyl groups", as described above and includes, for example, a dimethylcarbamoyl group, a diethylcarbamoyl group, an N-ethyl-N-methylcarbamoyl group, a dipropylcarbamoyl group, a dibutylcarbamoyl group, a dipentylcarbamoyl group and a dihexylcarbamoyl group, and preferably dialkyl groups (C? .4) carbamoyl, wherein the alkyl group is an alkyl group having 1 to 4 carbon atoms, such as a dimethylcarbamoyl group and a diethylcarbamoyl group. An "N-alkyl (C6-6) -N-arylcarbamoyl group" represents a carbamoyl group which at a nitrogen atom is linked with an "aryl group" and the "d-β alkyl group" defined above and includes, for example , an N-methyl-N-phenylcarbamoyl group, an N-ethyl-N-phenylcarbamoyl group, an N-phenyl-N-propylcarbamoyl group, an N-isopropyl-N-phenylcarbamoyl group, an N-butyl-N-phenylcarbamoyl group , an N-pentyl-N-phenylcarbamoyl group, an N-hexyl-N-phenylcarbamoyl group, an N-methyl-N-naphthylcarbamoyl group, an N-ethyl-N-naphthylcarbamoyl group, an N-naphthyl-N-propylcarbamoyl group , an N-isopropyl-N-naphthylcarbamoyl group, a N-butyl-N-naphthylcarbamoyl group, a N-naphthyl-N-pentylcarbamoyl group and an N-hexyl-N-naphthylcarbamoyl group, and preferably N-alkyl (C? _4) -N-phenylcarbamoyl, wherein the alkyl group is an alkyl group having 1 to 4 carbon atoms and the aryl group is a phenyl group, such as an N-methyl-N-phenylcarbamoyl group and a N group -ethyl-N-phenylcarbamoyl. An "alkyl (d-6) sulfonyl group" represents a sulfonyl group that binds to the "Ci-β alkyl group" defined above and includes, for example, a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group , a butyisulfonyl group, an isobutylsulfonyl group, a sec-butylsulfonyl group, a tert-butylsulfonyl group, a pentylsulfonyl group, an isopentylsulfonyl group, a 2-methylbutylsulfonyl group, a neopentylsulfonyl group, a 1-ethylpropylsulfonyl group, a hexylsulfonyl group, a isohexylsulfonyl group, a 4-methylpentylsulfonyl group, a 3-methylpentylsulfonyl group, a 2-methylpentylsulfonyl group, a 1-methylpentylsulfonyl group, a 3,3-dimethylbutylsulfonyl group, a 2,2-dimethylbutylsulfonyl group, a 1, 1-dimethylbutylsulfonyl group , a 1,2-dimethylbutylsulfonyl group, a 1,3-dimethylbutylsulfonyl group, a 2,3-dimethylbutylsulfonyl group and a 2-ethylbutylsulfonyl group, and preferably, alkyl groups in which the alkyl part is an alkyl group having 1 to 4 carbon atoms, such as a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group and a butylsulfonyl group. The methylsulfonyl group is more preferred. An "alkyl (C? -6) sulfonylamino group" represents an amino group which is linked to the "(C?) Sulfonyl" alkyl group defined above and includes, for example, a methylsulfonylamino group, an ethylsulfonylamino group, a propylsulfonylamino group , an isopropylsulfonylamino group, a butylsulfonylamino group, an isobutylsulfonylamino group, a sec-butylsulfonylamino group, a tert-butylsulfonylamino group, a pentylsulfonylamino group, an isopentylsulfonylamino group, a 2-methylbutylsulfonylamino group, a neopentylsulfonylamino group, a 1-ethylpropylsulfonylamino group, an hexylsulfonylamino group, an isohexylsulfonylamino group, a 4-methylpentylsulfonylamino group, a 3-methylpentylsulfonylamino group, a 2-methylpentylsulfonylamino group, a 1-methylpentylsulfonylamino group, a 3,3-dimethylbutylsulfonylamino group, a 2,2-dimethylbutylsulfonylamino group, a group 1 , 1-dimethylbutylsulfonylamino, a 1,2-dimethylbutylsulfonylamino group, a 1,3-dimethylbutylsulfonylamino group, a 2,3-di group methylbutylsulfonylamino and a 2-ethylbutylsulfonylamino group and, preferably, alkyl (C 2) sulfonylamino groups, in which the alkyl group is an alkyl group having 1 to 4 carbon atoms, such as a methylsulfonylamino group, an ethylsulfonylamino group, a propylsulfonylamino group, an isopropylsulfonylamino group and a butylsulfonylamino group. A "C3.8 cycloalkyl" represents a saturated cycloalkyl group, having from 3 to 8, preferably, from 3 to 6 carbon atoms, or which may also represent a C3.8 cycloalkenyl group containing one or two double bonds within the ring. Examples of "saturated C3.8 cycloalkyl" include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group and a cyclooctyl group. In addition, a "C3-8 cycloalkenyl group" represents a cycloalkenyl group having from 3 to 8, preferably, from 5 to 7 carbon atoms, and containing at least one, preferably one or two, double bonds within the ring. Specific examples include a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, a cyclopentadienyl group, a cyclohexenyl group, a 2,4-cyclohexadien-1-yl group, a 2,5-cyclohexadien-1-yl group, a group cycloheptenyl and a cyclooctenyl group.

A "(C3.8) cycloalkyl-C6-6 alkyl" represents an "d.β alkyl group", as described above, substituted with the "C3.8 cycloalkyl group" described above, and includes, example, a cyclopropylmethyl group, a cyclopropylethyl group, a cyclopentylmethyl group, a cyclopentylethyl group, a cyclohexylmethyl group and a cyclohexylethyl group. Preferred are "(C3.8) cycloalkyl-CM alkyl" groups, wherein the alkyl is an alkyl group, having 1 to 4 carbon atoms, such as a cyclopropylmethyl group, a cyclopropylethyl group, a cyclopentylmethyl group, a cyclopentylethyl group and a cyclohexylmethyl group. A "C3.8 cycloalkyloxy group" represents a "C3.8 cycloalkyl group", as defined above, attached to an oxygen atom, and includes, for example, a cyclopropyloxy group, a cyclobutyloxy group, a cyclopentyloxy group, a cyclohexyloxy group, a cycloheptyloxy group and a cycloocyloxy group. Preferred are C3.6 cycloalkyloxy groups in which the cycloalkyl group is a cycloalkyl group, having from 3 to 6 carbon atoms, such as, a cyclopropyloxy group, a cyclobutyloxy group, a cyclopentyloxy group and a cyclohexyloxy group. A "(C3.8) cycloalkyloxycarbonyloxy group" or a "(C3.8) cycloalkyloxycarbonyloxy group" represents a "(C3.8) cycloalkyloxy group", as defined above, attached to a carbonyloxy group. , and includes, for example, a cyclopropyloxycarbonyloxy group, a cyclobutyloxycarbonyloxy group, a cyclopentyloxycarbonyloxy group, a cyclohexyloxycarbonyloxy group, a cycloheptyloxycarbonyloxy group and a cyclooctyloxycarbonyloxy group. Preferred are cycloalkyloxy (C3_6) -carbonylloxy groups in which the cycloalkyl group is a cycloalkyl group, having from 3 to 6 carbon atoms, such as a cyclopropyloxycarbonyloxy group, a cyclobutyloxycarbonyloxy group, a cyclopentyloxycarbonyloxy group, a cyclohexyloxycarbonyloxy group. A "(C3-8) cycloalkyloxycarbonyloxy-d-6 alkyl group" represents a "d-6 alkyl group", substituted with the "(C3.8) cycloalkyloxycarbonyloxy group" as described above and is preferably a group (C3.6) cycloalkyloxycarbonyloxy, wherein the cycloalkyl group is a cycloalkyl group, having 3 to 6 carbon atoms, and a cycloalkyloxycarbonyloxyalkyl group in which the alkyl group is an "alkyl CM group" An "aryl group" represents a group of aromatic hydrocarbons, having from 6 to 14 carbon atoms, and includes, for example, a phenyl group, a naphthyl group, an anthryl group, an indenyl group, a azulenyl group, an fluorenyl group and a phenanthryl group. The aryl group may be partially saturated, as the case may be. Examples of the partially saturated aryl groups include a dihydroindenyl group and a tetrahydronaphthyl group. C C-io aryl groups are preferred; more preferred is a phenyl or naphthyl group; and the most preferred of all is a phenyl group. A phenyl group is preferred as "Q" in the formula (I). An "aralkyl group" can be a "C- | 6 alkyl group", as defined above, that binds to one or two aryl groups having from 6 to 14 carbon atoms, such as a benzyl group, a naphthylmethyl group, an indenylmethyl group, a phenanthrenylmethyl group, an anthracenylmethyl group, a diphenylmethyl group, a phenethyl group, a naphthylethyl group, a phenylpropyl group, a naphthylpropyl group, a phenylbutyl group, a naphthylbutyl group, a phenylpentyl group, a naphthylpentyl group and a phenylhexyl group and, preferably, is an aralkyl group, wherein the aryl group is a phenyl group and the alkyl group is a Cμ alkyl group, such as, for example, a benzyl group, a naphthylmethyl group, a diphenylmethyl group and a phenethyl group and, more preferably, a benzyl or phenethyl group and, particularly preferably, a benzyl group. An "aryloxy group" is an "aryl group", as defined above, that binds to an oxygen atom and includes, for example, a phenoxy group and a naphthoxy group. A phenoxy group is preferred. An "arylsulfonyl group" represents a sulfonyl group that binds to the "aryl group", defined above, and includes, for example, aryl (C6-i4) sulfonyl groups, such as a phenylsulfonyl group, an indenylsulfonyl group, a naphthysulfonyl group , a phenanthrenylsulfonyl group, an anthracenylsulfonyl group and a fluorenylsulfonyl group, preferably, aryl (C6.? o) -sulfonyl groups in which the C6-? aryl or is attached to the sulfonyl group, more preferably, a phenylsulfonyl or naphthisulphonyl group, optimally , a phenylsulfonyl group. An "arylsulfonyl group which may be substituted with an alkyl group represents an" arylsulfonyl group ", as defined above, wherein the aryl group is substituted by one or more, preferably from 1 to 3," Ci-β alkyl groups. "as defined above, preferably," CM alkyl groups ", and includes, for example, a 4-methylphenylsulfonyl group An" arylsulfonylamino group "represents an" arylsulfonyl group ", as defined above, attached to an amino group , and includes, for example, aryl (C6-i4) -sulfonylamino groups, such as a phenylsulfonylamino group, an indenylsulfonylamino group, a naphthylsulfonylamino group, a phenanthrenylsulfonylamino group, an anthracenylsulfonylamino group and a fluorenylsulfonylamino group, preferably aryl (C6-? o) -sulfonylamino, more preferably, a phenylsulfonylamino group or a naphthylsulfonylamino group, optimally, a phenylsulfonylamino group A "phenyl group which may be substituted with a "halogen atom" represents a phenyl group, substituted with one or more, preferably, with 1 to 3 halogen atoms, identical or different, selected from a fluorine atom, a chlorine atom, a bromine atom and a hydrogen atom; iodo. A "phenyl group which may be substituted with a haloalkyl group Ci-β" represents a phenyl group substituted with one or more "halo-alkyl d-6", identical or different groups defined above. A "heterocyclic group" represents a saturated, partially unsaturated or aromatic ring, having, as ring-forming atoms, in addition to the carbon atoms, 1 to 4 identical or different heteroatoms, selected from an oxygen atom, a nitrogen atom and sulfur atom, and having from 3 to 14, preferably from 5 to 7, ring-forming atoms, and the ring may be a monocyclic or fused ring. A "monocyclic, heterocyclic, saturated group" represents a saturated or partially saturated, heterocyclic group and includes, for example, a pyrrolidinyl group, a tetrahydrofuryl group, a tetrahydrothienyl group, an imidazolidinyl group, a pyrazolidinyl group, a 1, 3 group -dioxolanil, a iiliyl group 1, 3-oxathiolanyl, an oxazolidinyl group, a thiazolidinyl group, a piperidyl group, a piperazinyl group, a tetrahydropyranyl group, a tetrahydrothiopyranyl group, a dioxanyl group, a morpholinyl group, a thiomorpholinyl group, a 2- group oxopyrrolidinyl, a 2-oxopiperidyl group, a 4-oxopiperidyl group and a 2,6-dioxopiperidyl group. Preferred are saturated, 5- or 6-membered heterocyclic groups, such as a pyrrolidinyl group, a piperidyl group and a morpholinyl group. A "monocyclic, heterocyclic, saturated, 5- or 6-membered group" represents the "monocyclic, heterocyclic, saturated group" defined above, having a ring of 5 or 6 members. Examples of heterocyclic rings constituting these heterocyclic groups, specifically monocyclic, heterocyclic, saturated, 5- or 6-membered rings, include 5-membered heterocyclic rings, such as tetrahydrofuran, 1,3-dioxolane, tetrahydrothiophene, pyrrolidine, pyrazolidine and the like. midazolidine and 6-membered heterocyclic rings, such as tetrahydropyran, 1,4-dioxane, thiano, 1,4-dithiane, piperidine, piperazine and morpholine. A part of the heterocyclic group can have a double bond. A "5 membered heterocyclic group, having from 1 to 4 heteroatoms selected from sulfur, oxygen and nitrogen atoms" represents, for example, 5-membered heteroaromatic groups, such as a furyl group, a thienyl group, a pyrrolyl group, a pyrazolyl group, an imidazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, an oxadiazolyl group, a triazolyl group, a tetrazolyl group and a thiadiazolyl group, and examples of monocyclic, heterocyclic, saturated groups or partially saturated include a tetrahydrofuran-2-yl group, a tetrahydrofuran-3-yl group, an imidazolidin-1-yl group, an imidazolidin-2-yl group, an imidazolidin-4-yl group, a pyrrolidin-1 group ilo, a pyrrolidin-2-yl group, a pyrrolidin-3-yl group, a 1,3-oxazolidin-3-yl group, an isothiazolidin-2-yl group, a 1,3-thiazolidin-3-yl group, a 1,2-pyrazolidin-2-yl group and a 1,2-pyrazolidin-1-yl group. A "monocyclic, heterocyclic, saturated, 5- or 6-membered group having at least one nitrogen atom" represents a saturated, 5- or 6-membered heterocyclic group having at least one nitrogen atom, and may have 1 to 3 heteroatoms selected from nitrogen, sulfur and oxygen atoms. Examples of heterocyclic rings that constitute 5-membered heterocyclic groups include, for example, pyrrolidine, pyrazolidin, imidazolidine, oxazolidine and thiazolidine, and examples of heterocyclic rings that constitute 6-membered heterocyclic groups include piperidine, piperazine, morpholine and oxadiazine. A part of the saturated heterocyclic ring can have a double bond. Examples of a "heteroaromatic monocyclic group" include a pyridyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a 1, 3,5-triazinyl group, a pyrrolyl group, a pyrazolyl group, an imidazolyl group, a group 1, 2,4-triazolyl, a tetrazolyl group, a thienyl group, a furyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group and a thiadiazolyl group. A 5- or 6-membered heteroaromatic group is preferred. The "saturated heterocyclic ring" - as used in "something may, together with the adjacent nitrogen atom, form a saturated heterocyclic ring" - represents, for example, nitrogen-containing heterocyclic rings, of a 5-7 membered ring which contains, as ring-forming atoms, in addition to the carbon atoms, at least one nitrogen atom, and may contain one or two heteroatoms selected from oxygen, sulfur and nitrogen atoms, including, for example, pyrrolidine, imidazolidine, pyrazolidine , piperidine, piperazine, morpholine and thiomorpholine. "The saturated heterocyclic group can be condensed with a benzene ring, to form a fused ring "means that the" monocyclic, heterocyclic, saturated group "can form a ring fused with a benzene ring, including, for example, indolinyl, isoindolinyl, 2,3-dihydrobenzofuranyl, benzothiazolinyl and chromanyl. "heteroaromatic group" represents a heteroaromatic group having, as ring-forming atoms, in addition to the carbon atoms, 1 to 4 identical or different heteroatoms, selected from oxygen, nitrogen and sulfur atoms, and having from 3 to 14, preferably from 5 to 7, more preferably, from 5 to 6 ring-forming atoms, or a condensed group thereof The heteroaromatic group may be substituted with one or more oxo or thioxo groups. tinea *, .ni heteroaromatic include, among others, a pyridyl group, a pyridazinyl group, an imidazolyl group, a pyrimidinyl group, a pyrazolyl group, a triazolyl group, a pyrazinyl group, a quinolyl group, an isoquinolyl group, a tetrazolyl group , a furyl group, a thienyl group, an isoxazolyl group, a thiazolyl group, an oxazolyl group, an isothiazolyl group, a pyrrolyl group, a quinolinyl group, an isoquinolinyl group, an indolyl group, a benzimidazolyl group, a benzofuranyl group, cinnolinyl group, an indazolyl group, an indolizinyl group, a phthalazinyl group, a pyridazinyl group, a triazinyl group, an isoindolyl group, a purinyl group, an oxadiazolyl group, a thiazolyl group, a thiadiazolyl group, a furazanyl group, benzofurazanyl group , a benzothiophenyl group, a benzotriazolyl group, a benzothiazolyl group, a benzoxazolyl group, a quinazolinyl group, a quinoxalinyl group, a naphthylizinyl group, a dihydroxy group uinolyl, a furopyridinyl group, a pyrrolopyrimidinyl group and an azaindolyl group. A "5- or 6-membered heteroaromatic group" represents a heteroaromatic group having, as ring-forming atoms, in addition to the carbon atoms, 1 to 4 identical or different heteroatoms, selected from oxygen, nitrogen and sulfur atoms, and having 5 to 6 ring-forming atoms, or a condensed group thereof. Examples include a pyrrolyl group, a furyl group, a thienyl group, an imidazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a 1, 2,4-triazolyl group, an Group 1, 2,3-triazolyl, a tetrazolyl group, a group 1, 3,4-oxadiazolyl, a group ÍÉMÍI rlÜl 1, 2,4-oxadiazolyl group, a 1, 3,4-thiadiazolyl group, 1, 2,4-thiadiazolyl, one furazanyl group, pyridyl group, pyrimidinyl group, pyridazinyl group, pyrazinyl group, a 1, 3,5-triazinyl group, an imidazolinyl group, a pyrazolinyl group, an oxazolinyl group (a 2-oxazolinyl group, a 3-oxazolinyl group, a 4-oxazolinyl group), an isooxazolinyl group, a thiazolinyl group, a isothiazolinyl group, a pyranyl group, a 2-oxopyranyl group and a 2-oxo-2,5-dihydrofuranyl group. Preferred are a pyrrolyl group, a furyl group, a thienyl group, an imidazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a pyridyl group and a 2-oxo-2 group, 5-dihydrofuranyl. A "5- or 6-membered heteroaromatic group, which may be substituted with an oxo or thioxo group" represents a 5- or 6-membered heteroaromatic group, as defined above, which is substituted with an oxo group (= O) or a thioxo group (= S). A "5 or 6 membered heteroaromatic group, which may be substituted with a carboxy group or a (C6-6) alkoxycarbonyl group" represents a "5- or 6-membered heteroaromatic group", as defined above , which can be substituted with one or more carboxy groups or "(C6-6) alkoxycarbonyl groups", as defined above. "The heteroaromatic group may be a monocyclic or condensed ring" means that the heteroaromatic group may be a monocyclic heteroaromatic group or a condensed group thereof, with one or More carbocyclic aromatic groups, such as benzene or other heterocyclic groups. A "monocyclic heteroaromatic group or a condensed heteroaromatic group with a benzene ring" represents a "monocyclic heteroaromatic", such as a thienyl group, a furyl group, a pyrrolyl group, an imidazolyl group, a pyrazolyl group, an isothiazolyl group , a group soxazolilo, a pyridyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group and an oxazolyl group or a condensed heteroaromatic group with a benzene ring, such as a benzofuranyl group, an isobenzofuranyl group, benzo [b] thienyl, an indolyl group, an isoindolyl group, a 1 H-indazolyl group, a benzimidazolyl group, a benzoxazolyl group, a benzothiazolyl group, a 1 H-benzotriazolyl group, a quinolyl group, an isoquinolyl group, a cinnolinyl group, a quinazolinyl group , a quinoxalinyl group and a phthalazinyl group. A "C?-6M alkyl group substituted with a monocyclic heteroaromatic group or a heteroaromatic group fused with a benzene ring" represents a "C?-6M alkyl group, substituted with the" monocyclic heteroaromatic group or a heteroaromatic group fused with a ring of benzene "as defined above.A" C- | 6 alkyl group "is preferred, substituted by a" monocyclic heteroaromatic group. "A" fused ring heterocyclic group "includes an indolyl group (e.g. -indolyl, a 7-indolyl group), an isoindolyl group, a 1,3-dihydro-1,3-dioxoisoindolyl group, a benzofuranyl group ki ii. (for example, a 4-benzofuranyl group, a 7-benzofuranyl group), an indazolyl group, an isobenzofuranyl group, a benzothiophenyl group (for example, a 4-benzothiophenyl group, a 7-benzothiophenyl group), a benzoxazolyl group (eg example, a 4-benzoxazolyl group, a 7-benzoxazolyl group), a benzimidazolyl group (e.g., a 4-benzimidazolyl group, a 7-benzimidazolyl group), a benzothiazolyl group (e.g., a 4-benzothiazolyl group, a group 7-benzothiazolyl), an indolizinyl group, a quinolyl group, an isoquinolyl group, a 1,2-dihydro-2-oxoquinolyl group, a quinazolinyl group, a quinoxalinyl group, a cinnolinyl group, a phthalazinyl group, a quinolizinyl group, a purinyl group, a pteridinyl group, an indolinyl group, an isoindolinyl group, a 5,6,7,8-tetrahydroquinolyl group, a 1, 2,3,4-tetrahydroquinolyl group, a 2-oxo-1, 2,3 group , 4-tetrahydroquinolyl, a benzo [1,3] dioxolyl group, a 3,4-methylenedioxypyridyl group, a 4,5-ethyl group nedioxypyrimidinyl, a chromenyl group, a chromanyl group and an isochromanyl group. "Something can be substituted with one or more substituents" means that something can be substituted with one or more, preferably with 1 to 6, in particular, preferably with 1 to 3 identical or different substituents. Furthermore, even if the amount of substituents is not specified, it means that substantially "something can be substituted with one or more substituents". The following describes the preferred groups in the general formula (I), which was described above, but the compounds of the present invention are not limited to these groups.

The "aryl group" in the Q ring is preferably a C6-10 aryl group, more preferably a phenyl or naphthyl group and, optimally, a phenyl group. The "heteroaromatic group" in the Q-ring is preferably a "5- or 6-membered heteroaromatic group, containing from 1 to 4 heteroatoms selected from sulfur, oxygen and nitrogen atoms" and, more preferably, a thienyl group or a pyridyl group. Ring Q, preferably, is a phenyl or pyridyl group and, in particular, preferably, a phenyl group. R1 is preferably a hydrogen atom, a halogen atom, an alkyl CM group or a CM alkoxy group, more preferably, a hydrogen atom or a halogen atom, in particular, preferably, a hydrogen atom, a fluorine atom or chloro, more preferably still, a hydrogen atom or a fluorine atom and, optimally, a fluorine atom. R 2 is preferably a halogen atom, a CM alkyl group, an alkoxy group, or an azido group, more preferably a halogen atom, particularly preferably a fluorine or chlorine atom, more preferably a fluorine atom. . R3 is preferably a halogen atom, a hydroxyl group, a C-, 6- alkyl group, a halo-C1-4 alkyl group, a C- alkoxy group, an azido group, an amino group, an acylamino group or an alkyl (C? _6) sulfonyllamine, more preferably a halogen atom or a CM alkyl group, in particular, ? i Preferably, a fluorine atom, a chlorine atom or a methyl group, more preferably, a chlorine atom or a methyl group. Preferred substituents (R1, R2 and R3) of the Q ring are: a hydrogen atom, a fluorine atom or a chlorine atom in the 5-position, for R1, more preferably, a fluorine atom or a hydrogen atom; a fluorine atom or a chlorine atom in the 4-position, for R2, more preferably, a fluorine atom; and a chlorine atom or a methyl group in the 2-position for R3, preferably, a chlorine atom. The Q ring substituted with the substituents R1, R2 and R3 is preferably as indicated below.

More preferred is the 2-chloro-4,5-difluorophenyl group shown below.

Preferably, R4 is a group selected from 1 to 7 ', presented below. 1'. a hydrogen atom; 2'. an alkyl group d.6 or a lower alkyl group?, substituted with a substituent selected from Group A ', presented below: [Group A'] A'l a hydroxyl group, A'2. a CM alkoxy group, such as, for example, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group and a butoxy group, in particular, preferably, a methoxy group, an ethoxy group, a propoxy group and an isopropoxy group, A'3. -N (R41) (R41 '), wherein R41 and R41' are, preferably, identical to each other or different from each other and represent a hydrogen atom or an alkyl group CM, O R41 and R41, together with the nitrogen atom adjacent, can form a 5 or 6 membered heterocyclic, monocyclic, saturated ring, and the most preferred examples of -N (R41) (R41) include an amino group, a methylamino group, an ethylamino group, a dimethylamino group, a diethylamino group, a piperidino group, a morpholino group, a pyrrolidino group and a piperazino group, more preferably still, an amino group, a methylamino group, an ethylamino group, a dimethylamino group, a diethylamino group, a piperidino group, a morpholino group , a pyrrolidino group and a piperazino group, A'4. a phenyl group or a naphthyl group (preferably a phenyl group), A'5. a heteroaromatic group of 5 or 6 members (preferably a pyridyl group), A'6. -CO-N (R 1) (R41 '), such as, for example, -CONH2, a monoalkyl group (C? _4) -carbamoyl, a d-alkyl group (d.4) -carbamoyl, a group N-alkyl (C 4 -4) -N-arylcarbamoyl, a dimethylcarbamoyl group, a diethylcarbamoyl group, a morpholinocarbonyl group, a pyrrolidinocarbonyl group and a piperazinocarbonyl group, preferably a methylcarbamoyl group, an ethylcarbamoyl group, a dimethylcarbamoyl group or a group diethylcarbamoyl, A'7. a carboxy group, and A'8. an alkoxy (CM) carbonyl group, such as, for example, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group and an isobutoxycarbonyl group, preferably, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group and an isopropoxycarbonyl group, 3 '. a C2_4 alkenyl group, such as, for example, an ethenyl group (vinyl), a 1-propenyl group, a 2-propenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group and a group 2-methyl-1-propenyl, preferably an ethenyl group (vinyl), a 1-propenyl group or a 2-propenyl group; 4'. a C2.4 alkynyl group, such as, for example, an ethynyl group, a 1-propynyl group, a 2-propynyl group and a 1-butynyl group, preferably an ethynyl group, a 1-propynyl group and a 2-propynyl group; 5'. a C3.6 cycloalkyl group, such as, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group and a cyclohexyl group; 6 '. a (C3.6) cycloalkyl-C-M alkyl group, preferably a cyclopropylmethyl group, a cyclopropylethyl group, a cyclobutylmethyl group, a cyclobutylethyl group, a cyclopentylmethyl group, a cyclopentylethyl group, a cyclohexylmethyl group and a cyclohexylethyl group; 7 '. an aryl group, for example, a phenyl group and a naphthyl group, preferably a phenyl group; Preferably R5 is a group selected from V and 8 'presented below. 1 '. a C? _6 alkyl group or a C? _6 alkyl group substituted with a substituent selected from group B 'presented below, preferably, a d-β-alkyl group; [Group B '] B'l a hydroxyl group, B'2. a C-M alkoxy group, such as, for example, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group and an isobutoxy, B'3. -N (R5) (R5r), where R51 and R51 ', preferably, are identical to each other or different from each other and represent a hydrogen atom or a C-M alkyl group; O R51 and R51, together with the adjacent nitrogen atom, can form a saturated heterocyclic ring, and examples include an amino group, a methylamino group, an ethylamino group, a dimethylamino group, a diethylamino group, an N-ethyl group, N-methylamino, a dipropylamino group, a piperidino group, a morpholino group, a pyrrolidino group and a piperazino group, preferably an amino group, a methylamino group, an ethylamino group, a dimethylamino group and a diethylamino group, and, B'4 . -CO-N (R51) (R51 '), wherein R51 and R51 are such as described above. Examples include a methylcarbamoyl group, an ethylcarbamoyl group, a dimethylcarbamoyl group, a diethylcarbamoyl group, a morpholinocarbonyl group, a pyrrolidinocarbonyl group and a piperazinocarbonyl group, preferably a methylcarbamoyl group, an ethylcarbamoyl group, a dimethylcarbamoyl group and a diethylcarbamoyl group, 2 ' . a C3.8 cycloalkyl group, such as, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group and a cyclooctyl group, preferably a C3-6 cycloalkyl group, selected from a cyclopropyl group , a cyclobutyl group, a cyclopentyl group and a cyclohexyl group, wherein the cycloalkyl group may be substituted with a hydroxyl group, a carboxy group or a (C 4) alkoxycarbonyl group (preferably a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group or an isopropoxycarbonyl group) and may also be fused with a pyridine ring, to form the next group; 3'. an alkyl group d-6, substituted with a C3.8 cycloalkyl group, preferably, a C1-alkyl group substituted with a C3.6 cycloalkyl group, in particular, preferably, a C? .2 alkyl group substituted with a C3 cycloalkyl group. 6, and specific examples include a cyclopropylmethyl group, a cyclopropylethyl group, a cyclobutylmethyl group, a cyclobutylethyl group, a cyclopentylmethyl group, a cyclopentylethyl group, a cyclohexylmethyl group and a cyclohexylethyl group, wherein the cycloalkyl group of the cycloalkyl group (C3.8 ) C6 alkyl may be substituted with a hydroxyl group, a carboxy group or a (C6.6) alkoxycarbonyl group, preferably a (C7C) alkoxycarbonyl group, such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group and an isopropoxycarbonyl group; 4'. a monocyclic, heterocyclic, saturated, 5- or 6-membered group which may be substituted with a substituent selected from group C, presented below, wherein preferred examples of the monocyclic, heterocyclic, saturated, 5- or 6-membered group include, for example , a pyrrolidinyl group, a tetrahydrofuryl group, a tetrahydrothienyl group, an imidazolidinyl group, a pyrazolidinyl group, a 1,3-dioxolanyl group, a 1,3-oxathiolanyl group, an oxazolidinyl group, a thiazolidinyl group, a piperidyl group, an piperazinyl group, a tetrahydropyranyl group, a tetrahydrothiopyranyl group, a dioxanyl group, a morpholinyl group, a thiomorpholinyl group, a 2-oxopyrrolidinyl group, a 2-oxopiperidyl group, a 4-oxopiperidyl group and a 2,6-dioxopiperidyl group, preferably a pyrrolidinyl group, a piperidyl group and a group ato morpholinyl, optimally a heterocyclic, 6-membered, saturated group presented below: [Group C] C'l an alkyl group d-6, preferably a C-M alkyl group, such as, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group and a butyl group, C'2. an acyl group, for example, an acetyl group, a propionyl group, a butyryl group and a benzoyl group, preferably an acetyl group, a propionyl group and a butyryl group, C'3. an alkyl (d, 6) sulfonyl group, for example, a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group and a butylsulfonyl group, preferably a methylsulfonyl group and an ethylsulfonyl group, C'4. a carboxy group, C'5. a (C-? - 6) alkoxycarbonyl group, preferably (d.) carbonyl alkoxy groups, such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group and an isobutoxycarbonyl group, and C ' 6 -CO- (Alk) n-COOR52, where R52 is preferably a hydrogen atom or an alkyl group d-4, Alk is an alkylene group CM, and n is 0 or an integer comprised between 1 and 2.5 '. . an aryl group, or an aryl group substituted with one or more, preferably, with 1 to 3 substituents selected from the group D1 presented below, wherein the aryl group is, for example, a phenyl or naphthyl group, preferably a phenyl group; [Group D '] D'l a hydroxyl group, D'2. alkoxy d-6 groups, preferably C-M alkoxy groups, such as a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group and an isobutoxy group, D3. a cyano group, D'4. an alkyl d-β group, preferably CM alkyl groups, such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group and a sec-butyl group, wherein the C alquilo alkyl group _6, may be substituted with a substituent selected from a hydroxyl group, a carboxy group and a (C?) Carbonyl alkoxy group (for example, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group and an isopropoxycarbonyl group), D ' 5. -N (R53) (R53), wherein R53 and R53 are preferably a hydrogen atom, a C-O alkyl group or an alkyl (CM) sulfonyl group, and specific examples may include an amino group, a methylamino group, an ethylamino group, a dimethylamino group, a diethylamino group, a methylsulfonylamino group and an ethylsulphonylamino group, D'6. -CO-N (R53) (R53 '), where R53 and R53' are, preferably, a hydrogen atom, a C-O alkyl group or an alkyl (C? ^) Sulfonyl group, and the specific examples may include a group carbamoyl, a dimethylcarbamoyl group and a diethylcarbamoyl group, preferably a methylcarbamoyl group, a Uj. t ethylcarbamoyl group, a dimethylcarbamoyl group, a diethylcarbamoyl group and a methylsulfonylcarbamoyl group, D'7. -COOR54, where R54 is preferably a hydrogen atom, an alkyl group (for example, a methyl group, an ethyl group, a propyl group, an isopropyl group and a butyl group), an alkyl group (C? -4 ) carbonyloxyalkyl (for example, a methylcarbonyloxymethyl group, an ethylcarbonyloxymethyl group and a propylcarbonyloxymethyl group) or a (C3.6) cycloalkyl) oxycarbonyloxy C1- alkyl group (for example, a cyclohexyloxycarbonyloxy group) methyl and a cyclohexyloxycarbonyloxy-ethyl group), optimally R54 is a hydrogen atom or an alkyl group d.4, D'8. -C (NH (OH)) = N-R55, where R55 is preferably a hydrogen atom or an alkyldisulfonyl group, for example, a methylsulfonyl group, D'9. a monocyclic, heterocyclic, saturated, 5- or 6-membered monocyclic group, for example, a pyrrolidinyl group, a tetrahydrofuryl group, a tetrahydrothienyl group, an imidazolidinyl group, a pyrazolidinyl group, a 1,3-dioxolanyl group, a 1, 3 group -oxatiolanyl, an oxazolidinyl group, a thiazolidinyl group, a piperidyl group, a piperazinyl group, a tetrahydropyranyl group, a tetrahydrothiopyranyl group, a dioxanyl group, a morpholinyl group, a thiomorpholinyl group, a 2-oxopyrrolidinyl group, a 2-oxopiperidyl group, a 4-oxopiperidyl group and a 2,6-dioxopiperidyl group, preferably a group 5 or 6 membered heterocyclic, saturated, having at least one nitrogen atom, such as, for example, a pyrrolidinyl group, a piperidyl group and a morpholinyl group, more preferably the 6-membered saturated heterocyclic groups, presented below: and, D'10. a monocyclic, heteroaromatic group of 5 or 6 members, which may be substituted with an oxo or thioxo group, for example, a pyrrolyl group, a furyl group, a thienyl group, an imidazolyl group, a pyrazolyl group, an oxazolyl group, an group: soxazolyl, a thiazolyl group, an isothiazolyl group, a 1-group, 2,4-triazolyl, a group 1, 2,3-triazolyl, a tetrazolyl group, a group 1, 3,4-oxadiazolyl, a group 1, 2,4-oxadiazolyl, a group 1, 3,4-thiadiazolyl, a group 1, 2,4-thiadiazolyl, a furazanyl group, a pyridyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a group 1, 3,5-triazinyl, an imidazolinyl group, a pyrazolinyl group, an oxazolinyl group (a 2-oxazolinyl group, a 3-oxazolinyl group, a 4-oxazolinyl group), an isooxazolinyl group, a thiazolinyl group, an isothiazolinyl group, an pyranyl group, a 2-oxopyranyl group and a 2-oxo-2,5-dihydrofuranyl group, preferably a pyrrolyl group, a furyl group, a t-group enyl, an imidazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a pyridyl group and a 2-oxo-2,5-dihydrofuranyl group, more preferably the 5-membered heterocyclic groups having at least two nitrogen atoms, presented below: more preferably still, the following 5-membered heterocyclic groups: wherein particularly preferred substituents among those comprised between D'1 and D'10 as described above are those selected from D'4, D'6, D'7 and D'10, and an unsubstituted phenyl group as R 5 is also preferred. , 6 '. a monocyclic, heteroaromatic group of 5 or 6 members or a ring fused with a benzene ring, which may be substituted with a carboxy group or an alkoxy group (C? 6) carbonyl, wherein the alkoxy group (C? -6) The carbonyl is preferably an alkoxy (4 -4) carbonyl group, for example a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group and a butoxycarbonyl group, and the heteroaromatic group is, for example, a group pyrrolyl, a furyl group, a thienyl group, an imidazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a group 1, 2,4-triazolyl, a group 1, 2, 3-triazolyl, a tetrazolyl group, a group 1, 3,4-oxadiazolyl, a group 1, 2,4-oxadiazolyl, a group 1, 3,4-thiadiazolyl, a group 1, 2,4-thiadiazolyl, a group furazanil, a pyridyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a group 1, 3,5-triazinyl, a upo imidazolinyl, a pyrazolinyl group, an oxazolinyl group (a 2-oxazolinyl group, a 3-oxazolinyl group, a 4-oxazolinyl group), an isooxazolinyl group, a thiazolinyl group, an isothiazolinyl group, a pyranyl group, a 2- group oxopyranyl and a 2-oxo-2,5-dihydrofuranyl group, preferably, a pyrrolyl group, a furyl group, a thienyl group, an imidazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, a group isothiazolyl, a pyridyl group and a 2-oxo-2,5-dihydrofuranyl group, preferably a pyrrolyl group, a furyl group, a thienyl group, an imidazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, a group thiazolyl, an isothiazolyl group, a 1,2-triazolyl group, a pyridyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a thiazolinyl group, an isothiazolinyl group and a pyranyl group; Particularly preferred heteroaromatic groups of 5 or 6 members are those presented below: 7 '. a C7-4 aralkyl group, for example, a CM alkyl group substituted with a group of aromatic hydrocarbons of a benzyl group or a phenethyl group, such as, for example, a benzyl group, a naphthylmethyl group, an indenylmethyl group, a phenanthrenylmethyl group , an anthracenylmethyl group, a diphenylmethyl group, a phenethyl group, a naphthylethyl group, a phenylpropyl group, a naphthylpropyl group, a phenylbutyl group and a naphthylbutyl group, preferably, a benzyl group, a naphthylmethyl group, a diphenylmethyl group and a phenethyl group , more preferably a benzyl group or a phenethyl group, wherein the alkyl part of the aralkyl group C-? 4 may be unsubstituted or substituted with one or two substituents, selected from the following Group E '; preferably, the alkyl portion is unsubstituted, or the aryl portion of the C7-? 4 aralkyl group can be substituted with one or more, preferably, with 1 to 3 substituents selected from the following Group F ', [Group E'] E A CM alkyl group, which may be substituted with a hydroxyl group, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a hydroxymethyl group and a hydroxyethyl group , E'2. a cyano group, E'3. a carboxy group, E'4. a (C-? 6) alkoxycarbonyl group, preferably, (alkoxy d-4) carbonyl groups, such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, an isobutoxycarbonyl group, an sec-butoxycarbonyl group and a tert-butoxycarbonyl group, and, E'5. a phenyl group, Hll ^ Jl [Group F '] F'l a C-? 6 alkyl group, preferably C? _4 alkyl groups, such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group and a sec-butyl group, F'2. a halogen atom, for example, a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, preferably a fluorine or chlorine atom, F'3. a cyano group, F'4. a hydroxyl group, F'5. an alkoxy d-6 group, an alkoxy group with a carboxy group or a d-β-substituted alkoxy group with a (C6-6) alkoxycarbonyl group, wherein the d6 alkoxy group is preferably represented by alkoxy groups as a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group and an isobutoxy group, and the alkoxy (d-6) carbonyl group in the C6_6 alkoxy group substituted with an alkoxy group (d 6) -carbonyl is preferably represented by alkoxy (d.sub.4) carbonyl groups, such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group and a butoxycarbonyl group, F'6. a haloalkyl group C-? 6, for example, a trifluoromethyl group, a fluoromethyl group and a 2,2,2-trifluoroethyl group, preferably halo-C-M alkyl groups, such as a trifluoromethyl group, F'7. a carboxy group, üiái F'8. a (C6-6) alkoxycarbonyl group, preferably, (C4.4) alkoxycarbonyl groups, such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, an isobutoxycarbonyl group and a sec-butoxycarbonyl group, F'9. -CO-N (R56a) (R56a), wherein R56a and R56a 'are identical to each other or different from each other, and represent a hydrogen atom, a monocyclic, heterocyclic, saturated, 5- or 6-membered group, having the minus one nitrogen atom, such as a piperidino group, a morpholino group, a pyrrolidino group and a piperazino group, or a C? 6 alkyl group; which may be substituted with a substituent selected from group f presented below, preferably, the saturated heterocyclic group are the saturated, 6-membered heterocyclic groups, presented below: and, the C ?_6 alkyl group is preferably represented by CM alkyl groups, such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group and a sec-butyl group, [Group f] fl an amino group, f2. a "monoalkyl (d.6) -amino" group, such as, for example, a methylamino group, an ethylamino group, a propylamino group, an isopropylamino group, a butylamino group, an isobutylamino group, a sec-butylamino group , a tert-butylamino group, a pentylamino group, an isopentylamino group, a 2-methylbutylamino group, a neopentylamino group, a 1-ethylpropylamino group, a hexylamino group, an isohexylamino group, a 4-methylpentylamino group, a 3-methylpentylamino group , a 2-methylpentylamino group, a 1-methylpentylamino group, a 3,3-dimethylbutylamino group, a 2,2-dimethylbutylamino group, a 1,1-dimethylbutylamino group, a 1,2-dimethylbutylamino group, a 1, 3 group -dimethylbutylamino, a 2,3-dimethylbutylamino group and a 2-ethylbutylamino group, preferably a monoalkyl (d-4) amino, f3 group. a dyalkyl (C-? 6) amino group, such as, for example, a dimethylamino group, a diethylamino group, a N-ethyl-N-methylamino group, a dipropylamino group, a dibutylamino group, a dipentylamino group and a dihexylamino group, preferably a dialkyl (C?) amino group, f4. a carboxy group, f5. a (C-? - 6) alkoxycarbonyl group, preferably a (C? -4) alkoxycarbonyl group, such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group and an isobutoxycarbonyl group, f6. a hydroxyl group, and, f7. a monocyclic, heterocyclic, saturated, 5- or 6-membered group having at least one nitrogen atom, such as a piperidino group, a morpholino group, a pyrrolidino group and a piperazino group, áüik, ... ¡i4 F'10. -N (R56b) (R56b), wherein R56b and R56b 'are identical to each other or different from each other and represent a hydrogen atom, a C1.6 alkyl group, which may be substituted with an imino group, an aralkyl group, which may be substituted with one or more identical or different substituents, selected from a lower group and a halogen atom, an arylsulfonyl group, which may be substituted by a C-? 6 alkyl group, an alkylene group (d) -6) sulfonyl, an acyl group, a carbamoyl group, a monoalkyl (C6-6) carbamoyl group or a dialkyl (C-? 6) carbamoyl group, the C-? 6 alkyl group it is preferably represented by alkyl groups d. > such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group and a tert-butyl group, the aralkyl group, which may be substituted with one or more identical or different substituents, selected from an imino group and a halogen atom, is, for example, a (imino) (halogenated phenyl) -methyl group, the arylsulfonyl group, which may be substituted with an alkyl group d-6 is, for example, a tolylsulfonyl group, and the d-6 alkyl group in the monoalkyl (C-? - 6) carbamoyl group or the d (C? -6) carbamoyl group is, preferably, an alkyl group CM, F ' 1 l -N = CR57 (-N (R58) (R58 ')), where R57 is preferably a hydrogen atom or a C, R58 and R58 alkyl group are preferably identical to each other or different from each other and represent a hydrogen atom or an alkyl group CM, ütt4 ¡F'12. a monocyclic, heteroaromatic group of 5 or 6 members, preferably the group represented by the following formula presented below: and, F'13. a methylenedioxy group attached to the two adjacent carbon atoms, of the phenyl ring constituting a C. 14 aralkyl group, such as a benzyl or phenethyl group, and, 8 '. a C6-6 alkyl group, substituted with a monocyclic, heteroaromatic, 5- or 6-membered group or a d-β alkyl group substituted with a heteroaromatic group obtained by the condensation of the heteroaromatic group with a benzene ring, wherein the monocyclic group , heteroaromatic, of 5 or 6 members is, for example, a pyrrolyl group, a furyl group, a thienyl group, an imidazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, an group 1, 2,4-triazolyl, a group 1, 2,3-triazolyl, a tetrazolyl group, a group 1, 3,4-oxadiazolyl, a group 1, 2,4-oxadiazolyl, a group 1, 3,4 -thiadiazolyl, a 1, 2,4-thiadiazolyl group, a furazanyl group, a pyridyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a 1-triazinyl group, an imidazolinyl group, a pyrazolinyl group , an oxazolinyl group (a 2-oxazolinyl group, a 3-oxazolinyl group, a 4-oxazolinyl group), an isoo group xazolinyl, a thiazolinyl group, an isothiazolinyl group, a pyranyl group, a 2-oxopyranyl group and a 2-oxo-2,5-dihydrofuranyl group, preferably, a pyrrolyl group, a furyl group, a thienyl group, an imidazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a pyridyl group and a 2-oxo-2,5-dihydrofuranyl group, wherein the heteroaromatic group obtained by condensation of the heteroaromatic group with a ring of benzene is, for example, a benzofuranyl group, an isobenzofuranyl group, a benzo [b] thienyl group, an indolyl group, an isoindolyl group, a 1 H-indazolyl group, a benzimidazolyl group, a benzoxazolyl group, a benzothiazolyl group, a group 1 H-benzotriazolyl, a quinolyl group, an isoquinolyl group, a cinnolyl group, a quinazolyl group, a quinoxalinyl group and a phthalazinyl group, more preferably, the C 6 alkyl part is a d 4 alkyl group, for example a gru methyl, an ethyl group and a propyl group, and the heteroaromatic group is a heterocyclic group, such as the one presented below: These heteroaromatic groups are, in particular, preferably, but in a non-limiting manner, a pyridyl group, an oxazolyl group and a triazolyl group, The lithium heteroaromatic group or the condensed heteroaromatic group can be substituted with one or more, preferably, with 1 to 3 substituents selected from the group G ', presented below: [Group G'] G'1. a C? -6 alkyl group, which may be substituted with a substituent selected from the group g 'presented below, preferably a C1-4 alkyl group; [Group g '] g'1. a halogen atom, for example, a fluorine atom or chlorine atom, preferably, a fluorine atom, g'2. an amino group, g'3. a monoalkyl (d_6) amino group, preferably a monoalkyl (C?) amino group, such as a methylamino group, an ethylamino group and a propylamino group, g'4. a dialkyl (C- | .6) amino group, preferably, a dialkyl (C?) amino group, such as, for example, a dimethylamino group and a diethylamino group, g'5. an alkoxy (d.6) carbonylammonium group, for example, a methoxycarbonylamino group, an ethoxycarbonylamino group, a propoxycarbonylamino group and an isopropoxycarbonylamino group, preferably a (C?) carbonylamino, and, g'6 alkoxy group. a hydroxyimino group, G'2. a halogen atom, for example, a fluorine atom or chlorine atom, preferably, a fluorine atom, G'3. an alkoxy group C -? - 6, which may be substituted with a halogen atom, preferably, for example, an alkoxy C-M group substituted with one or more fluorine or chlorine atoms, such as a trifluoroethoxy group, G'4. an aryloxy group, preferably a phenoxy group, G'5. a cyan group, G'6. -N (R59a) (R59a '), where R59a and R59a are identical to each other or different from one another and they represent a hydrogen atom or a C-M alkyl group, and R59a and R59a, together with the adjacent nitrogen atom, they can form a monocyclic, heterocyclic, saturated, 5- or 6-membered group, which is preferably pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, morpholinyl or thiomorpholinyl and the saturated heterocyclic group may be substituted with a hydroxyl group, an amino group, a monoalkyl group (C? _ 'I 4) amino or a dialkyl (CM) amino group, j I G'7. -CO-N (R59b) (R59b) 'I where R59b and R59b are identical to each other or different from each other, and represent a hydrogen atom, a 5 or 6 membered saturated monocyclic, heterocyclic, I I group, prepared together with the nitrogen atom adjacent, such as pyrrolidino, imidazolidino, pyrazolidin, piperidino, piperazino, morpholino and thiomorpholino, or a C-M alkyl group, which may be substituted with the heterocyclic group, G'8. an aryl group, for example, preferably, a phenyl group, i and,! G'9. a monocyclic, heteroaromatic group of 5 or 6 members which may be substituted with an oxo or thioxo group, for example, a pyridinyl group, a pyridazinyl group, an imidazolyl group, a pyrimidinyl group, a pyrazolyl group, a triazolyl group, a group pyrazinyl, a quinolyl group, an isoquinolyl group, a tetrazolyl group, a furyl group, a thienyl group, an isoxazolyl group, a thiazolyl group, an oxazolyl group, an isothiazolyl group, a pyrrolyl group, a quinolinyl group, an isoquinolinyl group, an indolyl group, a benzimidazolyl group, a benzofuranyl group, a cinnolinyl group, an indazolyl group, an indolizinyl group, a phthalazinyl group, a pyridazinyl group, a triazinyl group, an isoindolyl group, a purinyl group, an oxadiazolyl group, a group thiazolyl, a thiadiazolyl group, a furazanyl group, a benzofurazanyl group, a benzothiophenyl group, a benzotriazolyl group, a benzothiazolyl group, a benzoxazolyl group, a quinazo group linilo, a quinoxalinyl group, a naphthylizinyl group, a dihydroquinolyl group, a benzofuryl group, a furopyridinyl group, a pyrrolopyrimidinyl heteroaromatics group R4 and R5, together with the adjacent nitrogen atom, they can form a saturated, 5- or 6-membered heterocyclic ring, where the "saturated heterocyclic group" can have a double bond in part, and can be fused to a benzene ring to form a fused ring, for example, heterocyclic groups saturated, such as pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, morpholino and thiomorpholino, or a 4H-quinazolinyl group, prepared by condensation of the heterocyclic group saturated with a benzene ring, preferably, the groups represented by the following formulas: or the saturated heterocyclic group may be substituted with a halogen atom, a C-M alkyl group, a C-M alkoxy group, a carboxy group or a (C? -4) carbonyl group. Preferred specific examples of the compounds (I) of the present invention are described later in the examples. Particularly preferred pyrazole compounds include, but are not limited to, the following. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide-dihydrochloride - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-) pyridin-3-ylmethyl-amide-hydrochloride benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methyl-oxazol-5-ylmethyl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-Methyl-oxazol-5-ylmethyl) -amide, (4-Methyl-oxazole-5-) 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (4-Methyl-oxazol-5-ylmethyl) amide-L- (5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid +) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid tartrate, (2,4-Dimethyl-oxazol-5-ylmethyl) -amide p-toluenesulfonate 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-) -2- (2,4-Dimethyl-oxazol-5-ylmethyl) -amide 4.5 -difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (2,4-dimethyl-pyridin-3-ylmethyl) amide pyrazole-3-carboxylic,! 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid diethylamide, 5- (2-chloro-4-ethyl- (pyridin-4-ylmethyl) -amide 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- (2-methoxy-ethyl) -methyl-amide 3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ethyl- (2-methoxy-ethyl) -amide, 2-Fluoro-benzylamide of 5-carboxylic acid - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-Fluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-dimethylamino-benzylamide), (4-ethoxycarbonyl-cyclohexyl) -propyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4, 6-methoxy-pyridin-3-ylmethyl) -amide, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,3-dimethoxy-benzylamide of 5- (2-chloro-4,5-difluoro-benz) oleylamino) -1H-pyrazole-3-carboxylic acid, 2,4-dimethoxy-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,6- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dimethoxy-benzylamide, 5- (2-chloro-4,5-difluoro) -3,5-dimethoxy-benzylamide -benzoylamino) -1H-pyrazole-3-carboxylic acid, 3,4-dimethoxy-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,3 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid trifluoro-benzylamide, 5- (2-chloro-4,5-2,4-difluoro-benzylamide) -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,5-Difluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2 , 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 6-difluoro-benzylamide, 5- (2-chloro-4-acid) 3,4-difluoro-benzylamide , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3,5-Difluoro-benzylamide of 5- (2-chloro) o-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (2-lsopropoxy-pyridin-3-ylmethyl) -amide -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-phenoxy-pyridin-3-ylmethyl) -amide, ( 3,5-Difluoro-pyridin-2-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 2-trifluoromethyl-benzylamide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid trifluoromethyl-benzylamide, 5- (2-chloro-4,5-trifluoromethyl-benzylamide) -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-tert-butyl-benzylamide, ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid 6-lsopropoxy-pyridin-3-ylmethyl) -amide, [2- (2,2,2-Trifluoro) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-dimethylamino-ethylcarbamoyl) -amino] -pyridin-3-ylmethyl] -amide. 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-4,5-difluoro-benzoylamino) -4-ethyl-benzylamide ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 4-lsopropyl-benzylamide, 2-Chloro-6-fluoro 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, (6-Ethoxy-pyro) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid idin-3-ylmethyl) -amide-dihydrochloride, 5- (2-chloro-4,5-difluoro-benzoylamino) acid (thiazol-4-ylmethyl) -amide (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [6- (2,2,2-trifluoro-ethoxy) -pyridin-3-ylmethyl] -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,6-dimethyl-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) - 1 H-pyrazole-3-carboxylic acid, [2- (pyridin-3-yl) -thiazol-4-ylmethyl] -amide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pirazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1 H-benzoimidazol-2-ylmethyl) -amide dihydrochloride, Methyl ester of acid [4- (. { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] -amino} -methyl) -benzoylamino] -acetic acid, 3- [4- (. {[[5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] -amino methyl ester} -methyl) -benzoylamino] -propionic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole (2-methyl-thiazol-4-ylmethyl) -amide-dihydrochloride -3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,5-dimethyl-isoxazol-4-ylmethyl) -amide, 4- [2 -Bis- (2-acetoxyethyl) -amino-ethylcarbamoyl] -benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-Hydroxy-ethylcarbamoyl) ) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid benzylamide, 4-. { 2 - [(2-Acetoxyethyl) - (2-hydroxyethyl) -amino] -ethylcarbamoyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, (1-Methyl-1H-benzoimidazol-2-ylmethyl) -amide-hydrochloride acid - (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, ; L. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (thiazol-2-ylmethyl) -amide-dihydrochloride, (Benzothiazol-2-ylmethyl) -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-dimethyl-thiazol-4-ylmethyl) -amide-dihydrochloride -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [2- (Morpholin-4-yl) -thiazol-4-ylmethyl] -amide-dihydrochloride of 5- (2-chloro- 4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-trifluoryl-1H-pyrazol-4-ylmethyl) -amide -difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) 2- (2-chloro-4,5-difluoro-benzoylamino) (2-chloro-6-methyl-pyridin-3-ylmethyl) -amide-dihydrochloride ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 (2-dimethylamino-thiazol-4-ylmethyl) -amide-dihydrochloride -carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1-methyl-1 H-pyrrol-2-ylmethyl) -amide. or, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,4-dimethoxy-pyridin-2-ylmethyl) -amide-dihydrochloride, (5- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid tert-butyl-2-ylmethyl) -amide-dihydrochloride, (5-Methyl-2-phenyl- 2 H- [1, 2,3] triazol-4-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, [4- (Ter- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [4-Methyl-2- (5-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, butoxycarbonyl-amino) -methyl-pyridin-2-ylmethyl] -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid morpholin-4-ylmethyl] -amide dihydrochloride (pyridin-3-ylmethyl) -amide 3/2-hydrochloride-hemihydrate, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro) -amino-benzylamide -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-methoxy-benzylamide , 3-Methoxy-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-methoxy-benzylamide of 5- (2-chloro-4,5-) acid difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-methyl-benzylamide, 4-fluoro- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-4,5-difluoro-benzoylamino) -4-chloro-benzylamide -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-ethoxycarbonyl-benzylamide, 4-carboxy-benzylamide of 5-carboxylic acid - (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-dibenzylamide carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyano-phenyl-methyl-amide, 5- (2-chloro-4-cyclohexylmethyl) -amide , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (2-Hydroxy-ethyl) l) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid phenyl-amide, 5- (2-chloro-4,5-cyclohexyl-methyl-amide -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl-amide, acid cyclohexyl-ethyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-Allyl-cyclohexyl-amide -pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl- (pyridin-2-ylmethyl) -amide, Methyl- (1-) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl-piperidin-4-yl) -amide, [(3,4-methylenedioxyphenyl) -methyl] -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid hydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) acid benzyl-butyl-amide ) -1 H-pyrazole-3-carboxylic acid, Benzyl- (4-hydroxy-butyl) -amide-hydrochloride of 5- (2-chloro-4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl ethyl-amide of 5- (2-chloro-4), 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Cyclohexyl-propyl-amide, Butyl 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl-amide, 5- (2-chloro) -cyclohexyl- (2-methoxy-ethyl) -amide -4, 5-dif luoro-benzoylamino) -! H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl- (pyridin-3-ylmethyl) -amide, [2- (Morpholine 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-dibutylamide) -amide. -difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, Bis- (2-methoxy-ethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -! H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - (2-methoxy-ethyl) -propyl-amide H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -butyl- (tetrahydro-pyran-4-yl) -amide -! H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- (2-methoxy-ethyl) - (tetrahydro-pyran-4-yl) -amide. 3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid cyclopentyl- (2-methoxy-ethyl) -amide, Cyclohexyl- (3-methoxy-propyl) ) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-chloro-) cyclohexyl- (2-ethoxy-ethyl) -amide 4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H- Cyclohexyl- (2-isopropoxy-ethyl) -amide pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl- (2-propoxy-ethyl) -amide, (1-Ethyl-propyl) ) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-ethyl) -amide, butyl- (1-tert-butoxycarbonyl-piperidin-4) -yl) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, butyl- (tetrahydro-thiopyran-4-yl) -amide acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (2-methoxy-ethyl) -amide ) -1 H-pyrazole-3-carboxylic acid, Butyl- (pyridin-3-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Benzyl 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-ethyl) -amide, butyl- (piperidin-4-yl-amide) - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4, 1-acetyl-piperidin-4-yl) -butyl-amide 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl- (1-methanesulfonyl-piperidin-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (1-ethoxalyl-piperidin-4-yl) -amide, Butyl- (1-oxalo-piperidin-4-yl) -amide of .5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl- (1, 1-) dioxo-hexahydro-1? 6-thiopyran-4 -yl) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, butyl- (1-oxo-hexahydro-1? thiopyran-4-yl) -amino acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, (6-methoxy-pyridin-3-ylmethyl) -propyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, ii ii ii Propyl- (pyridin-3-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-Diethylcarbamoyl-benzylamide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-Diethylcarbamoyl-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole -3-carboxylic acid, 4- (2-chloro-4,5-difluoro-benzoylamino) - 4-ethylcarbamoyl-benzylamide H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3-ethylcarbamoyl-benzylamide, 4- (Carbamoyl-benzylamide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-) -l- (1-Oxalo-piperidin-4-yl) -propyl-amide difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (1-Carboxylacetyl-piperidin-4-yl) -propyl-amide pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1- H-1- (2-Carboxypropyl) -piperidin-4-yl] -propyl-amide pyrazole-3-carboxylic acid, cyclopropyl- (6-methoxy-pyridin-3-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, C-cyclobutyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-methoxy-pyridin-3-ylmethyl) -amide, l Cyclopropylmethyl- (6-methoxy-pyridin-3-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (6-Dimethylamino-pyridine- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3-ylmethyl) -amide, (6-dimethylamino-pyridin-3-ylmethyl) -propyl-acid amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Benzyl- (2-carboxy-ethyl) -amide of 5- (2-chloro-4,5-difluoro- benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzyl- (2-ethoxycarbonyl-ethyl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-ylmethyl) -propyl-amide, 2,6-dichloro-benzylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-) -3- (3-dichloro-pyridin-4-ylmethyl) -amide 4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5- (3,5-dichloro-pyridin-4-ylmethyl) -propyl-amide) difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5) -6- (1 H-pyrazol-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4-hydroxy-5- (4-hydroxy-piperidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride] , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-d? -fluoro-benzoylamino) - (2-pyridin-2-yl-ethyl) -amide - 1H-p-razol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-pyridin-3-yl-ethyl) -amide; 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-pyridin-4-yl-ethyl) -amide, (4- [1, 2, 3] thiadiazol-4-yl-benzyl) -amide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (5-Methyl-pyrazin-2-ylmethyl) ) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-chloro-4,5-difluoro-) pyrazin-2-ylamide benzoylamino) -1H-pyrazole-3-carboxylic acid quinoline-5-ylamide or 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) - 1-quinoline-8-ylamide H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid lsoquinolin-5-ylamide, [3-ethoxy-5- ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid 1-ethoxycarbonyl-1-methyl-ethyl) -pyridin-2-yl] -amide, [3-Ethoxy] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (1-ethoxycarbonyl-1-hydroxy-ethyl) -p-ridin-2-yl] -amide. carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- [5- (1-Carboxy-1-methyl-ethyl) -3-ethoxy-pyridin-2-yl] -amide. pyrazole-3-carboxylic acid, [5- (1-Carboxy-1-hydroxy-ethyl) -3-ethoxy-pyridin-2-yl] -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyrazin-2-ylmethyl) -amide, [6- (Tiomorphol-4-yl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid pyridin-3-ylmethyl] -amide, [6- (1,1-Dioxo-1α-6-) thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (4,5-Dibromo-thiophene) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (5-chloro-thiophen-2-ylmethyl) -amide - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-) 4-ethyl-2-methyl-oxazol-5-ylmethyl) -amide 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5- (2-ethyl-4-methyl-oxazol-5-ylmethyl) -amide-dihydrochloride] difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- ([2,2 '] Bithiophenyl-5-ylmethyl) -amide. pyrazole-3-carboxylic acid (3-methoxy-thiophen-2-ylmethyl) -amide - (2-chloro-4, 5-difluoro-benzoylamino) -! H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - (4,5-dichloro-thiophen-2-ylmethyl) -amide. H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - (2,5-dimethyl-oxazol-4-ylmethyl) -amide. H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (2-hexyl-4-methyl-oxazol-5-ylmethyl) -amide. carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxy-thiophen-3-ylmethyl) -amide, (4-methyl-2-phenyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid oxazol-5-ylmethyl) -amide, (2-Methyl-4-phenyl-oxazol-5-ylmethyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, (4-hexyl-2-methyl-oxazol-5-ylmethyl) -amide-dihydrochloride of acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-chloro-pyridin-3-ylmethyl) -amide -difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (6-chloro-pyridin-3-ylmethyl) -amide-dihydrochloride -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (2- (2H-Chloro-4,5-difluoro-benzoylamino) - (4H- [1,4] triazol-3-ylmethyl) -amide. carboxylic, (4H- [12,4] Triazol-3-ylmethyl ) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide dihydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-Fluoro-4H-quinazolin-3-yl) -amide, (5-Fluoro- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4H-quinazolin-3-yl) -amide-dihydrochloride, (4,6-Dimethyl-pyridine- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-ylmethyl) -amide, (4,6-Dimethyl-pyridin-3-ylmethyl) -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2- (2- (2-methoxy-6-methyl-pyridin-3-ylmethyl) -amide) chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5- (4-methoxy-6-methyl-pyridin-3-ylmethyl) -amide) difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (4- (3-methoxy-6-methyl-pyridin-3-ylmethyl) -amide-dihydrochloride) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole (2-methoxy-4,6-dimethyl-pyridin-3-ylmethyl) -amide. -3-carboxylic, (2-Meto) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid xi-4,6-dimethyl-pyridin-3-ylmethyl-amide dihydrochloride, (3-methyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid pyridin-2-ylmethyl) -amide, (5-Methyl-pyridin-3-methyl) ) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2- (2- (2-methyl-pyridin-3-ylmethyl) -amide) Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (6-Methyl-pyridin-2-ylmethyl) -amide) -1 H-pyrazole-3-carboxylic acid 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide dihydrochloride (6-) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid fluoro-pyridin-3-ylmethyl) -amide-dihydrochloride, (3-Carboxy-phenyl) -methyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-methanesulfonylamino-benzylamide of 5- (2-chloro-4,5-difluoro-benzoi acid lamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-methanesulfonylamino-benzylamide, 3-Acetylamino-benzylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -H-4-Acetylamino-benzylamide -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-phenyl-thiazol-4-ylmethyl) -amide, ((R 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (-1) -phenyl-ethyl) -amide, ((S) -1-Phenyl-ethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro) acid (6-phenoxy-pyridin-3-ylmethyl) -amide-dihydrochloride -4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-Methyl-4,5-difluoro-benzoylamino) (6-chloro-pyridin-3-ylmethyl) -amide-dihydrochloride ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro- (2-chloro-pyridin-3-ylmethyl) -amide-dihydrochloride) benzoylamino) -1 H -pyrazole-3-carboxylic acid, Sodium salt of 5- (2-methyl-4,5-difluoro-benzoylamino) -1H-pyrazole (6-chloro-pyridin-3-ylmethyl) -amide -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [1- (pyridin-3-yl) -ethyl] -amide-dihydrochloride, ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-fluoro-pyridin-3-ylmethyl) -amide dihydrochloride, (2-Methyl-pyridin-3-) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ylmethyl) -amide dihydrochloride, 5- (2-chloro) -amide -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, ((1R, 2S) -2-Hydroxy-indan-1-yl) -amide of 5- (2-chloro-4,5-acid) -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, ((1S, 2R) -2-Hydroxy-indan-1-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) ) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-phenyl-pyridin-3-ylmethyl) -amide-dihydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-Methyl-2-pyridon-3-ylmethyl) -amide-hydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzyl-methyl acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid phenylamide, 5- (2-Chloro-4,5-difluoro-benzoylamino) methyl-phenyl-amide - 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (Piperidin-1-yl) -amide. (4-Ethoxycarbonyl-piperidin-1-yl) -amide of 5- (2-chloro-4,5-) acid difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methyl-piperazin-1-yl) -amide, ii (4-Carboxy-piperidin-1) -yl) 5- (2-chloro-4,5-difluoro-I and benzoylamino) -1H-pyrazole-3-carboxylic acid amide; 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-! Phenethylamide pyrazole-3-carboxylic acid, and 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid methyl phenyl-5-ethyl-5-phenyl-amide -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (1, 2,3,4-tetrahydroisoquinolin-2-yl) -amide of 5- (2-chloro-4,5-acid) -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole ((S) -a-methoxycarbonyl-benzyl) -amide. -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ((R) -a-methoxycarbonyl-benzyl) -amide, (1, 2, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3,4-tetrahydroquinolin-1-yl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -amide. -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole -3-carboxylic acid, butyl-phenyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 -carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid phenyl-phenyl-amide, Benzhydryl-acid amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro) (pyridin-2-ylmethyl) -amide-hydrochloride -benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-4-ylmethyl) -amide-hydrochloride (5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid ((R) -2-hydroxy-1-phenyl-ethyl) -amide, ((S) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid-2-hydroxy-1-phenylethyl) -amide, 5- (2-chloro-4,5-difluoro-benzoylamino) acid, 4-dimethylamino-benzylamide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (Furan-2-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-phenyl) (2,5-methoxy-phenyl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, 5- (2-chloro-4-methyl) (2-methoxy-phenyl) -methyl-amide , 5-difluoro-benzoyl amino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-dimethylamino-benzylamide, 3-Amino-benzylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - 4-amino-benzylamide 1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-methyl-benzylamide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 3-Dimethylamino-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole- 3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-pyridin-3-ylmethyl) -amide, 2-chloro-benzylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-chloro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 3-methoxycarbonyl-benzylamide of 5- (2-chloro-4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-Carboxy-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (6 5- (2-Chloro-4-trifluoromethyl-pyridin-3-ylmethyl) -amide, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (2-Ethoxy-pyridin-3-ylmethyl) -amide. pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-dimethylamino-ethyl) -amide, Ethyl- (2-dimethylamino-ethyl) ) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dihydrochloride, 5- (2- (2- (2- (2- (2-dimethylamino-ethyl) -amide) chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (4-methoxy-pyridin-2-ylmethyl) -amide. -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3- (2,6-dimethoxy-pyridin-3-ylmethyl) -amide. carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-methoxycarbonylmethoxy-benzylamide, 5- (2-chloro-4-carboxylic acid) benzylamide 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-methoxy-pyridin-3-ylmethyl) -amide - (4,5-Difluoro-2-methyl-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2,4-Dichloro-benzoylamino) (6-methoxy-pyridin-3-ylmethyl) -amide. -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (3,5-dimethoxy-pyridin-4-ylmethyl) -amide. carboxylic acid 5- (4,5-Difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-Dimethyl-oxazol-5-ylmethyl) -amide (2,4-Dimethyl) 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxycarbonyl-phenyl) -methyl-amide-methyl-5-oxazolyl) -amide. - (5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (4-carboxyphenyl) -methyl-amide ) -1 H-pyrazole-3-carboxylic acid, 4-. { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] -methyl-amino} monosodium benzoate 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (5- (2-chloro-4,5-difluoro-benzoylamino), (ethoxycarbonyl-methyl) -phenyl-amide 5- (2-yl) acid ester -chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, (Carboxy-methyl) -phenyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazol-3-carboxylic acid, 5- (2-chloro-4-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2,4-Dichloro-benzoylamino) -1H-pyrazole acid benzylamide -3-carboxylic acid, 5- (2-chloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-4,5-difluoro) -benzyl-phenyl-amide -benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3 (1-methyl-1-phenyl-ethyl) -amide. -carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [2-oxo-2- (piperidin-1-yl) -ethyl] -phenyl-amide , 5- (5-Fluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, Benc 5- (5-Chloro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid ilamide, 5- (4-Methoxy-2-methyl-benzoylamino) -1H-pyrazole-3-benzylamide carboxylic acid, 5- (4-Chloro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Fluoro-2-methoxy-benzoylamino) -1H-pyrazole-3-benzylamide -carboxylic acid, 5- (5-chloro-2-methoxy-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-4-acid) (2-ethoxy-ethyl) -phenyl-amide , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Fluoro-5-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-benzylamide -Chloro-2-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (3-Chloro-2,6-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, acid benzylamide 5- (2-Chloro-3-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole, Ethylcarbamoylmethyl-phenyl-amide -3-carboxylic, isobutyl-phenyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-) 2- (methoxycarbonyl-ethyl) -phenyl-amide difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (3-ethoxycarbonyl-propyl) -phenyl-amide carboxylic(2- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (2-carboxyethyl) -phenyl-amide, (3-Carboxy-propyl) -phenyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, 5- (2-Hydroxy-4-methoxy-benzoylamino) -1H-pyrazole acid benzylamide -3-carboxylic acid, 5- (2-Hydroxy-5-methoxy-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Fluoro-2-hydroxy-benzoylamino) -1H- acid benzylamide pyrazole-3-carboxylic acid, 5- (4-Fluoro-2-trifluoromethyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Fluoro-2-trifluoromethyl-benzoylamino) -1-benzylamide H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-ethyl) -phenyl-amide, acid benzylamide - (2,5-Dimethyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-5-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5-Benzylamide (2-chloro-pyridine-3-carbonylamino) -1 H-pir azole-3-carboxylic acid, 5- (4-Chloro-pyridine-2-carbonylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2,6-dichloro-pyridine-3-carbonylamino) acid benzylamide -1 H-pyrazole-3-carboxylic acid, butyl- (4-ethoxycarbonyl-phenyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-carboxy-phenyl) -amide, 5- (2-Methyl-pyridin-3-) acid benzylamide carbonylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-6-methyl-pyridine-3-carbonylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (3-) -benzylamide Chloro-pyridin-4-carbonylamino) -1H-pyrazole-3-carboxylic acid, Butyl- (4-ethoxycarbonylmethyl-phenyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (4-carboxymethyl-phenyl) -amide, (4-methoxycarbonyl-phenyl) - 5- (2-Chloro-4,5-difluoro-be (2-methoxy-ethyl) -amide) n-oylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (4-Carboxy-phenyl) - (2-methoxy-ethyl) -amide. pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-methoxy-pyridin-3-ylmethyl) -amide-dihydrochloride, 5- (2-Methyl-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-methoxy-pyridin-3-ylmethyl) -amide-dihydrochloride, (thiazol-4-ylmethyl) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide dihydrochloride, 4- [2- (Morpholin-4-yl) -ethylcarbamoyl] -benzylamide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-chloro-4-morpholin-4-ylcarbamoyl) -benzylamide-dihydrochloride, 5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, Sodium salt of acid [4- (. { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] -amino} -methyl) -benzoylamino] -acetic, Ul ^ Sodium salt of 3- [4- ( { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] -amino} -methyl) - benzoylamino] -propionic. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,5-dimethyl-isoxazol-4-ylmethyl) -amide hydrochloride, (1, 3.5 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid trimethyl-1H-pyrazol-4-ylmethyl-amide dihydrochloride, (3,5-dimethyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid isoxazol-4-ylmethyl) -amide-sulfonate, 3- [2- (Morpholin-4-yl) - ethylcarbamoyl] -benzylamide-5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid dihydrochloride, 3- (Morpholin-4-ylcarbamoyl) -benzylamide-dihydrochloride acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid,. { 2- [2- (Morpholin-4-yl) -ethylcarbamoyl] -pyridin-4-ylmethyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide trichlorohydrate, [2- (Morpholin-4-ylcarbamoyl) -pyridin-4-ylmethyl] -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid hydrochloride, 5- (2- (2-methoxy-pyridin-3-ylmethyl) -amide methanesulfonate) chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (6-methoxy-pyridin-3-ylmethyl) -amide hemisulfate ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole (3,5-dimethoxy-pyridin-4-ylmethyl) -amide-dihydrochloride -3-carboxylic, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-Aminomethyl-pyridin-2-ylmethyl) -amide-trichlorohydrate, (6-Chloro-pyridine) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-ylmethyl) -amide methanesulfonate, acid (6-chloro-pyridin-3-ylmethyl) -amide dimethanesulfonate 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, of (2,4-dimethyl-pyridin-3-ylmethyl) -amide-hydrochloride, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 (pyridin-3-ylmethyl) -amide-hydrochloride H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (6-methoxy-pyridin-3-ylmethyl) -propyl-amide-dihydrochloride carboxylic acid [6- (piperidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [6- (Morpholin-4-yl) -pyridin-3-methylmethyl] -amide dihydrochloride 5- acid (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4-dichloro-pyridin-4-ylmethyl) -amide-hydrochloride , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - (6-Dimethylamino-pyridin-3-ylmethyl) -amide-dihydrochloride - 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 (6-dimethylamino-pyridin-3-ylmethyl) -propyl-amide-dihydrochloride -carboxylic, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-dimethylamino-pyridin-3-ylmethyl) -amide-dichlorhydrate. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid chloro-2-dimethylamino-pyridin-3-ylmethyl-amide dihydrochloride, (4- [1, 2,3] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid thiadiazol-4-yl-benzyl) -amide hydrochloride, (4-Methyl-thiazole- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-ylmethyl) -amide-hydrochloride, (2,4-Dimethyl-thiazol-5-ylmethyl) -amide- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid hydrochloride, [6- (4-Hydroxy-piperidin-1-yl) -pyridin-3-ylmethyl] - amide-acid dihydrochloride, 5- (2-chloro-4,5-d -fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5-Methyl-pyrazin-2-ylamide-dihydrochloride of 5- (2- chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, quinoline-5-ylamide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoyl) no) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid quinoline-8-ylamide-dihydrochloride, lsoquinolin-5- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid ilamide-dihydrochloride, [6- (4-Methylpiperazin-1-yl) -pyridin-3-ylmethyl] - amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, iiUi ^ aj [5- (4-Dimethylamino-piperidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole -3-carboxylic acid [6- (pyrrolidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro), (pyrazin-2-ylmethyl) -amide-dihydrochloride -benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro- [6- (thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride] -benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro) -6- (1, 1-Dioxo-1, 6-thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Carbamoylmethyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, ( 4-Carbamoyl-phenyl) -methyl-acid amide, 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Methyl- (4-methylcarbamoyl-phenyl) -amide 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2,4-Dichloro-5-fluoro) (4-dimethylcarbamoyl-phenyl) -methyl-amide -benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benz) (4-methanesulfonylaminocarbonyl-phenyl) -methyl-amide oylamino) -1 H-pyrazole-3-carboxylic acid, Sodium salt of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole- (4-methanesulfonylaminocarbonyl-phenyl) -methyl-amide 3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (4-cyano-phenyl) -methyl-amide, Methyl- [4- (4H- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [1, 2,4] triazol-3-yl) -phenyl] -amide-hydrochloride, (4- 5- (4-Azido-2-chloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyano-phenyl) -methyl-4- (1H-tetrazole-5-) 5- (4-Azido-2-chloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid yl) -phenyl] -amide, [4- (N-hydroxycarbamimidoyl) -phenyl] -methyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, Methyl- [4- (5-oxo-2,5-dihydro- [1, 2,4 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid] oxadiazol-3-yl) -phenyl] -amide. { 4 - [(2,2-Dimethyl-propionyloxy) -methoxycarbonyl] -phenyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid methyl-4- (N- (methoxy-thiocarbonyloxy) -carbamimidoyl] -methyl-amide acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Methyl- [4- (5-thioxo-4,5-dihydro- [1,2,4] oxadiazole- 3-yl) -phenyl] -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, Methyl- [4- (5-oxo-4,5- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [1, 2,4] thiadiazol-3-yl) -phenyl] -amide. ,. { 4- [1- (Cyclohexyloxycarbonyloxy) -ethoxycarbonyl] -phenyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl-amide, 5- (4-ethoxycarbonyl-thiazol-2-yl) -ethyl-amide (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole, 2-methanesulfonylamino-benzylamide -3-carboxylic acid, 2-Acetylamino-benzylamide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (Dimethylamino-methyleneamino) -benzylamide-acid hydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3- (2-chloro-4,5-difluoro- 3- (dimethylamino-methyleneamino) -benzylamide-hydrochloride) benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4- (dimethylamino-methyleneamino) -benzylamide-hydrochloride, 2- (2-Chloro-4,5-d-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3- [1 - (Dimethylamino) 2- [1- (Dimethylamino) ethylideneamino] -benzylamide-dihydrochloride ethylidenamino] -benzylamide-di 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid hydrochloride, 4- [1- (Dimethylamino) ethylideneamino] -benzylamide-dihydrochloride of 5- (2-chloro) acid -4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 2- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2- (diethylamino-methyleneamino) -benzylamide-dihydrochloride, 5- (2-chloro-4,5-difluoro-benzoylamino), 3- (diethylamino-methyleneamino) -benzylamide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-diethylamino-methyleneamino) -benzylamide-dihydrochloride -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-Acetimidoylamino-benzylamide-dihydrochloride, 3 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid-acetylimidoamino-benzylamide-5- (2-chloro-4,5-difluoro-benzoylamino) acid, 5-chloro-4-acetylimidoamino-benzylamide-dihydrochloride , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-cyano-benzylamide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, - [(2-Fluoro-benzimidoyl) -amino] -benzylamide-acid hydride, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- [(2-Fluoro-benzimidoyl) -amino] -benzylamide-5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3- (3,3-Dimethyl) -ureido)-5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 4- (3,3-dimethyl-ureido) -benzylamide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) 2- (Toluene-4-sulfonylamino) -benzylamide) -1 H-pyrazole-3-carboxylic acid, I 2-Amino-6-fluoro-benzylamide-5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid hydrochloride, 2-Amino-4,5-difluoro-benzylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid hydrochloride, (lndan-l-yl) -amide of 5- (2-chloro-4,5-) acid difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (lndan-2-yl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4H-Quinazolin-3-yl) -amide, (4H-Quinazolin-3-yl) -amide 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dihydrochloride, (7-Fluoro-4H-quinazolin-3-yl) -amide-dihydrochloride of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4-chloro-4H-quinazolin-3-yl) -amide-hydrochloride , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro) - (2-Ethoxy-2-methyl-1,4-dihydro-2H-quinazolin-3-yl) -amide. -4,5-difluoro- benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-cyano-pyridin-4-ylmethyl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [2- (NH-dicarboxymimidyl) -pyridin-4-ylmethyl] -amide, [2- (5 -Oxo-4,5-dihydro- [1, 2,4] oxadiazol-3-yl) -pyridin-4-ylmethyl] -amide: 5- (2-Chloro-4,5-difluoro-benzoylamino) - 1 H-pyrazole-3-carboxylic,; I Sodium salt of acid 4-. { [5- (4,5-difluoro-2-methyl-benzoylamino) -1 H- I-pyrazole-3-carbonyl] -methyl-amino} -benzoic,; I-5- (4,5-Difluoro-2-! I-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl- [4- (1 H-tetrazol-5-yl) -phenyl] -amide, I! 5- (2,4-Dichloro-benzoylamino) - (Pyridin-3-ylmethyl) -amide - | 1 H-pyrazole-3-carboxylic acid, 5- (2,4-Dichloro-5-f luoro-! I benzoylamino) -1H-pyrazole-3-carboxylic acid li (pyridin-3-ylmethyl) -amide, ( 5- (2,6-Dichloro-5-fluoro-pyridin-3-ylcarbonylamino) -1H-pyrazole-3-carboxylic acid pyridin-3-ylmethyl, i (pyridin-3-ylmethyl) 5 - [(3-Chloro-benzo [b] thiophen-2-carbonyl) -amino] -1H-pyrazole-3-carboxylic acid amide, 5 - [(3-Chloro-thiophene-2-carbonyl) -amino] -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide; (Pyridin-3-ylmethyl) -amide of 5-Benzoylamino-1 H-pyrazole-3-acid; carboxylic, 5-Phenylacetylamino-1 H -pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide, 5- (2-Methyl-4,5-α-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (py-din-3-ylmethyl) -amide dihydrochloride,! 5- (2-Amino-4,5-difluoro-benzoylamino) -! (Pyridin-3-ylmethyl) -amide. H-pyrazole-3-carboxylic acid, 5- (4,5-Difluoro-2-methanesulfonylamino-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide, (Pyridin-3-ylmethyl) ) 5- (2-Acetylamino-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, 5 - [(3,4,5 -trichloro-thiophene-2'-carbonyl) -amino] -1H-pyrazole-3-carboxylic acid, 5- (4,5-difluoro-2-methyl) (2- (cyano-pyridin-4-ylmethyl) -amide) -benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (4,5-difluoro-2-methyl- [2- (1 H-Tetrazol-5-yl) -pyridin-4-ylmethyl] -amide benzoylamino) -1H-pyrazole-3-carboxylic acid, and 3-Benzylamide of 5 - [(2,4-dichloro-phenyl) -amide] -1H-Pyrazole-3,5-dicarboxylic acid. A "pharmacologically acceptable salt thereof" can be any salt with the pyrazole compound of the present invention, having the general formula (I). Examples thereof include: acid halide salts, such as hydrofluoric salts, hydrochloric salts, hydrobromic salts and hydroiodic salts; salts of inorganic acids, such as nitrate, perchlorate, sulfate and phosphate; lower alkanesulfonates, such as methanesulfonate, trifluoromethanesulfonate and ethanesulfonate, arylsulfonates, such as benzenesulfonate and p-toluenesulfonate; salts of organic acids, such as acetate, malate, fumarate, succinate, citrate, ascorbate, tartrate, oxalate and maleate; and salts of amino acids, such as glycine, lysine, arginine, ornithine, glutamate and aspartate. Other examples thereof include alkali metal salts, such as the sodium, potassium and lithium salts; alkaline earth metal salts, such as calcium and magnesium salts, metal salts, such as aluminum and iron salts; inorganic salts, such as, ammonium salt, amine salts of organic salts or the like, such as tert-octylamine, dibenzylamine, morpholine, glucosamine, phenylglycine alkyl ester, ethylenediamine, N-methylglucamine, guanidine, diethylamine, triethylamine, dicyclohexylamine , N, N'-dibenzylethylenediamine, chloroprocaine, procaine, diethanolamine, N-benzylphenethylamine, piperazine, tetramethylammonium and salts of tris (hydroxymethyl) aminomethane; and salts of amino acids, such as glycine, lysine, arginine, ornithine, glutamate and aspartate, optimally, alkali metal salts. The compounds of the present invention represented by the general formula (I) can be present in the form of various isomers, for example, optical isomers, geometric isomers and tautomers. All these isomers and mixtures thereof are within the scope of the present invention. From the pyrazole derivatives having the general formula (I) of the present invention, esters or other derivatives thereof, prodrugs and metabolites thereof can be obtained.

On the other hand, the compounds of the invention and pharmacologically acceptable salts thereof may be present in the form of various solvates (eg, hydrates). These solvates are within the scope of the present invention. A "prodrug", as used in the present invention, is a derivative of a compound (I) of the present invention, which has a chemically or metabolically degradable group and may exhibit pharmaceutical activity by hydrolysis and solvolysis, or by degradation in physiological conditions. Examples include compounds in which the hydroxyl group is substituted with -CO-alkyl, -COO-alkyl, -CONH-alkyl, -CO-alkenyl, -COO-alkenyl, -CONH-alkenyl, -CO-aryl, - COO-aryl, -CONH-1 aryl, -CO-heterocycle, -COO-heterocycle, -CONH-heterocycle (the alkyl, alkenyl, aryl ring and the heterocyclic ring may be substituted with a halogen atom, an alkyl group, a hydroxyl group, an alkoxy group, a carboxy group, an amino group, an amino acid residue, -PO3H2, -S03H, -OPO3H2, -OSO3H, etc.), a residue of -CO-polyethylene glycol, a residue of -COO polyethylene glycol, a monoalkyl ether residue of -CO-polyethylene glycol, a residue of monoalkyl ether -COO-polyethylene glycol, -PO3H2, etc., those compounds in which the amino group is substituted with -CO-alkyl, -COO-alkyl , -CO-alkenyl, -COO-alkenyl, -COO-aryl, -CO-aryl, -CO-heterocycle, -COO-heterocycle (the alkyl, alkenyl, aryl ring and the heterocyclic ring can if it is substituted with a halogen atom, an alkyl group, a hydroxyl group, an alkoxy group, a carboxy group, an amino group, an amino acid residue, -PO3H2, -SO3H, -OPO3H2, -OSO3H, etc.), a residue of -CO-polyethylene glycol, a residue of -COO-polyethylene glycol, a residue of mono-alkyl ether of -CO-polyethylene glycol, a residue of monoalkyl ether of -COO-polyethylene glycol, -PO3H2, etc., or those compounds in which the carboxy group is substituted with an alkoxy group, an aryloxy group (the alkoxy and aryloxy groups may be substituted with a halogen atom, an alkyl group, a hydroxyl group, an alkoxy group, a carboxy group, an amino group, a residue of amino acids, -PO3H2, -SO3H, -OPO3H2, -OSO3H, etc.), a polyethylene glycol residue, a monoalkyl residue of polyethylene glycol, etc. The obtained pyrazole compound can be isolated and purified, as required, using conventional methods in the appropriate combination, for example, recrystallization, reprecipitation or methods commonly used to isolate / purify organic compounds, for example, methods employing a synthetic adsorbent, such as column chromatography by adsorption and column chromatography by partition, ion exchange chromatography, or normal or reverse phase column chromatography, using silica gel or alkylated silica gel, and eluting with an appropriate eluent. The pyrazole compounds of the present invention or the salts thereof, the esters or other derivatives thereof, the prodrugs and metabolites thereof, or the hydrates and solvates thereof, may be combined with a pharmaceutically acceptable carrier and administered orally or parenterally in solid form, such as, for example, in tablets, capsules, granules and powder, or in liquid form, such as, for example, by syrup or injection. A "pharmaceutical composition", as used herein, refers to a homogeneous mixture of a pyrazole compound or a pharmacologically acceptable salt thereof, an ester or other derivative thereof, a prodrug or metabolite thereof or a hydrate or solvate thereof, as an active ingredient, with an excipient, lubricant and binder used to prepare solid formulations, or a third ingredient, such as, for example, a solvent, solubilizer, suspending agent, an isotonizing agent and a buffer used for the preparation of liquid formulations. The administration can be carried out by oral administration with tablets, pills, capsules, granules, powder or liquid form, or by parenteral administration with injections, such as intravenous and intramuscular administration, suppositories or transdermal formulations. Parenteral administration includes intravenous, intramuscular, subcutaneous, interstitial, nasal, intracutaneous, drip infusion, intracerebral, rectal, intravaginal and intraperitoneal administration. "Solid compositions for oral administration" according to the present invention include tablets, powders and granules. In these solid compositions, one or more active substances are mixed with at least one inactive excipient, such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone and There is magnesium aluminometasilicate. The composition, according to the conventional method, may also contain additives in addition to the inactive excipient, such as, for example, a lubricant, a disintegrating agent, a stabilizer, such as, for example, an antioxidant and a solubilizer. The tablets or pills may be coated, as required, with a sugar film or film that can be dissolved in the gastrointestinal tract, such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose phthalate, macrogol, titanium dioxide and talcum. "Liquid compositions for oral administration" include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs, and contain a commonly used inert solvent, such as purified water and ethanol. The composition may contain an auxiliary agent in addition to the inert solvent, such as, for example, a solubilizer, a wetting agent and a suspending agent, a sweetening agent, a flavoring substance, an aromatic agent and a preservative. An "injection for parenteral administration" can be prepared by dissolving, suspending or emulsifying a given amount of an active ingredient in an aqueous solvent (eg, distilled water for injection, physiological saline, Ringer's solution, etc.) or a solvent of oily base (for example, vegetable oils, such as olive oil, sesame oil, cottonseed oil and corn oil, and U propylene glycol, etc.) together with a dispersing agent (eg, polysorbate 80, polyoxyethylene 60 hydrogenated castor oil, polyethylene glycol, carboxymethylcellulose, sodium alginate, etc.), a preservative (eg, methylparaben, propylparaben, benzyl alcohol, chlorobutanol, phenol, etc.), an isotonizing agent (eg, sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose, etc.), etc. During this process, additives, such as a solubilizer (e.g., sodium salicylate and sodium acetate), a stabilizing agent (e.g., human serum albumin) and a softening agent (e.g., benzyl alcohol), may be used, as is desired If necessary, you can also add an antioxidant, a coloring agent and other additives. "Pharmaceutically acceptable carriers" include various organic or inorganic carrier materials, commonly used as raw materials for the formulation; for example, excipients, lubricants, binders and disintegrating agents are used as appropriate for the solid formulation, and solvents, solubilizers, suspending agents, isotonizing agents, buffers and softening agents for the liquid formulation. If necessary, additives may also be employed in the formulation, according to conventional methods, such as a preservative, an antioxidant, a coloring agent, a sweetener, an adsorbent and a gelling agent. Preferred examples of the "excipients" may include lactose, corn starch, sucrose, D-mannitol, D-sorbitol, starch, dextrin, Use crystalline cellulose, hydroxypropylcellulose with low substitution, sodium carboxymethylcellulose, gum arabic, glucose and silicon dioxide. Preferred examples of "antioxidants" may include sulfite and ascorbic acid. Suitable "disintegrating agents" for use include carboxymethylcellulose, calcium carboxymethylcellulose, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, low substituted hydroxypropylcellulose, and hydroxypropyl starch. The "binders" include, for example, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, crystalline cellulose, sucrose and acacia powder. The binder is preferably hydroxypropylcellulose or polyvinylpyrrolidone. Preferred examples of "lubricants" may include magnesium stearate, calcium stearate, talc and colloidal silica. Preferred examples of "isotonizing agents" include glucose, D-sorbitol, sodium chloride, glycerin and D-mannitol. "PH adjusters" include citrate, phosphate, carbonate, tartrate, fumarate, acetate and amino acid salts. Preferred examples of "solubilizers" include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzaic acid, ethanol, tris-aminomethane, cholesterol, triethanolamine, sodium carbonate and sodium citrate.

Preferred examples of "solvents" include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil and olive oil. Preferred examples of "suspending agents" include hydrophilic macromolecules, such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose and hydroxypropylcellulose. Preferred examples of "surfactants" may include sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate. Preferred examples of "softening agents" may include benzyl alcohol. Preferred examples of "buffers" include phosphate, acetate, carbonate and citrate buffers. Preferred examples of "preservatives" include paraoxybenzoic acid ester, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid and sorbic acid. When the present invention is used as an antidiabetic, it is administered systemically or locally by the oral or parenteral routes. The dosage may vary according to age, body weight, symptoms and therapeutic effect, and may be administered, generally one to several times per day, at a dose of 10 mg to 1 g for an adult.

The compound (I) of the present invention can be mixed with an appropriate diluent, a dispersant, an adsorbent, a solubilizing agent, etc., to prepare solid and liquid compositions intended for oral administration, or formulations for parenteral administration, such as an injection. The compound (I) of the present invention can also be used for the treatment and prevention of diabetes in animals other than humans, such as mammals. The compound (I) of the present invention can be used in combination with one or more other agents, in a manner common in the practice of medicine. The compound (I) of the present invention can be combined with various drugs, including, preferably, antilipidemic and antidiabetic drugs. "Combination use", in this context, refers to the use of an agent containing the compound of the present invention (I) in combination with one or more other agents, and is not particularly limited. The other agents may have an efficacy and mechanism of action equal or different from those of the agent containing the compound of the present invention (I). These agents can be administered as individual formulations or as a mixture. These formulations can be combined to prepare a team. On the other hand, the administration time is not particularly limited. Both formulations can be administered at the same time, or each formulation can be administered at different times.

The compound, pharmaceutical composition or drug of the present invention can be combined with other pharmaceutical compositions or drugs (hereinafter, also referred to herein as concomitant drugs). The dosing schedule of the pharmaceutical composition or drug of the present invention and its concomitant drug has no limitation, and may be administered to an object concurrently or with an interval in the medium. The dosing of the concomitant drug may be in accordance with the clinical standard, and may be selected as appropriate, according to the subject, the age and body weight of the object, the symptom, the administration schedule, the dosage form, the method of administration and combination. The concomitant drug administration form is not limited, as long as the concomitant drug is combined in some way with the pharmaceutical composition or with the drug of the present invention. Concomitant drugs include: (1) therapeutic or prophylactic agents for hyperlipidemia, (2) therapeutic or prophylactic agents for obesity, (3) therapeutic or prophylactic agents for diabetes, (4) therapeutic or prophylactic agents for diabetic complications, and (5) therapeutic or prophylactic agents for hypertension, One and 1 to 3 of these agents can be combined with the compound of the present invention. "Therapeutic or prophylactic agents for hyperlipidemia" include, for example: (1) fibrates (PPARa receptor agonist), (2) PPARd receptor agonist, (3) inhibitor of microsomal triglyceride transfer protein (MTP, microsome triglyceride transfer protein), (4) inhibitor of cholesteryl ester transfer protein (CETP, cholesteryl ester transfer protein), (5) statins (HMG-CoA reductase inhibitor), (6) anion exchange resin , (7) probucol, (8) nicotinic acid, (9) plant sterol, (10) inducer of apolipoprotein-A1 (Apo-A1), (11) lipoprotein lipase activator (LPL), (12) inhibitor of endothelial lipase, (13) ezetimibu, (14) inhibitor of IBAT, (15) inhibitor of squalene synthase, (16) ACAT inhibitor, (17) LXR receptor agonist, (18) FXR receptor agonist , (19) FXR receptor antagonist, and (20) adenosine A1 agonist, and specific examples include: clofibrate, bezafibrate, fenofibrate, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin, cerivastatin, cholestyramine, colestimide, tocopherol nicotinate, nicomol, niceritrol, soy sterols and oryzanol range. The "therapeutic or prophylactic agents for obesity" include, for example, (1) leptin formulation, (2) pancreatic lipase inhibitor, (3) noradrenaline serotonin reuptake inhibitor, (4) antagonist of the cannabinoid receptor, (5) monoamine reuptake inhibitor, (6) diacylglycerol acyltransferase inhibitor (DGAT), (7) glucose dependent insulinotropic polypeptide receptor (GIP) antagonist, (8) leptin receptor agonist, (9) agonist of bombesin receptor subtype 3 (BRS-3, subtype 3 receptor), (10) perilipine inhibitor, (11) acetyl-CoA carboxylase 1 inhibitor (ACC) 1), (12) acetyl-CoA carboxylase 2 inhibitor (ACC 2), (13) fatty acid synthase inhibitor, (14) sn-1-acyl-glycerol-3-phosphate acyltransferase inhibitor ( AGPAT), (15) pancreatic phospholipase A2 inhibitor (pPLA2), (16) melanocortin receptor (MC) agonist, (17) neuropeptide receptor antagonist Y5 (NPY5), (18) inducer or activator of the uncoupling protein (UCP), (19) carnitine activator O-palmitoyltransferase 1 (CPT-1), (20) CCK1 agonist (CCKA), (21) ciliary neurotrophic factor (CNTF, ciliary neurotrophic factor), ( 22) CRF2 agonist, (23) neuropeptide Y2 receptor antagonist (NPY2), (24) neuropeptide receptor Y4 (NPY4) antagonist, (25) thyroid hormone receptor β agonist dea, (26) growth hormone, I (27) inhibitor of ATP citrate lyase, I (28) 5-HT6 antagonist, and (29) 5-HT2C agonist, and specific examples include leptin, oriistat , sibutramine, rimonabant and mazindol. tiU "Therapeutic or prophylactic agents for diabetes" include, for example, (1) insulin preparation (injection), (2) low molecular weight oral insulin agent, (3) sulfonylurea receptor agonist (SU agent) ), (4) insulinotropic agent without sulfonylurea, (5) potassium-dependent ATP channel opening agent (KATP, potassium-dependent ATP), (6) glucosidase inhibitor, (7) amylase inhibitor, (8) insulin sensitivity enhancer, (9) low molecular weight tGLP-1 receptor agonist, (10) tGLP-1 peptide analog, (11) dipeptidyl-peptidase IV inhibitor (DPP-IV), (12) glucagon receptor antagonist, (13) glucocorticoid receptor antagonist, (14) biguanide, (15) SGLUT inhibitor, (16) fructose-1, 6-bisphosphatase inhibitor (FBPase), (17) inhibitor of glycogen synthase kinase 3 (GSK-3), glycogen synthase kinase 3), (18) inhibitor of phosphoenolpyruvate carboxy kinase (PEPCK, phosphoenolpiruvate carboxikinase), (19) protein tyrosine phosphatase 1 B inhibitor (PTPasel B, protein tyrosine phosphatase 1 B), ( 20) inhibitor of inositol phosphatase containing the SH2 domain (SHIP2, SH2 domain containing inositol phosphatase), (21) glycogen phosphorylase inhibitor (GP, glycogen phosphorilase), (22) glucokinase activator, (23) GPR40 receptor agonist, (24) inhibitor of pyruvate dehydrogenase kinase (PDHK, pyruvate dehydrogenase kinase), (25) glutamine inhibitor: fructose-6-phosphate-aminotransferase (GFAT), (26) antioxidant; nitric oxide scrubber, (27) carnitine inhibitor O-palmitoyltransferase 1 (CPT-1), (28) growth hormone releasing factor (GHRF), (29) triacylglycerol lipase inhibitor (hormone-sensitive lipase), (30) PPARα receptor agonist, (31) PPARα receptor antagonist, (32) PPARα receptor agonist a / ?, (33) protein kinase activator of AMP activation (AMPK, AMP activation protein kinase), (34) adiponectin receptor agonist, and (35) β3-adrenoceptor agonist, and specific examples include insulin, toibutamide, glyclopyramide, acetohexamide, chlorpropamide, glibuzole, glibenclamide, gliclazide, glimepiride, mitiglinide, repaglinide, nateglinide, voglibose, acarbose, miglitol, rosiglitazone maleate, metformin hydrochloride, pioglitazone hydrochloride and buformin hydrochloride. "Therapeutic or prophylactic agents for diabetic complications" include, for example, (1) inhibitor of the protein β-kinase (PKCβ, protein kinase β), (2) angiotensin II receptor antagonist, (3) inhibitor of aldose reductase, (4) angiotensin-converting enzyme (ACE) inhibitor, (5) inhibitor of advanced glycation end product (AGE) production, (6) therapeutic agent for neuropathy, and (7) therapeutic agent for diabetic nephropathy, and specific examples include epalrestat (Kinedak), mexiletine hydrochloride and imidapril hydrochloride. "Therapeutic or prophylactic agents for hypertension" include, for example: (1) thiazide diuretic, (2) thiazide-type diuretic, (3) loop diuretic, (4) diuretic with retention of K, (5) β blocker, (6) a, ß blocker, (7) a blocker, (8) central sympathetic nerve depressant, (9) peripheral sympathetic nerve depressant (rauwolfia preparation), (10) Ca (benzothiazepine) antagonist, ( 11) Ca (dihydropyridine) antagonist, (12) vasodilator, (13) angiotensin converting enzyme inhibitor (ACE, angiotensin converting enzyme), (14) angiotensin II receptor antagonist, (15) nitric acid, (16) endothelin receptor antagonist ETA, (17) inhibitor of the endothelin-converting enzyme; neprilysin inhibitor, (18) prostaglandin; FP prostanoid agonist, (19) renin inhibitor, (20) enhancer of NOS3 expression; prostacyclin analog, (21) phosphodiesterase V (PDE5A) inhibitor, (22) prostacyclin analog, and (23) aldosterone antagonist, and specific examples include hydrochlorothiazide, trichlormethiazide, benzylchlororthiazide, meticrane, indapamide, tripamide , chlorthalidone, mefruside, furosemide, spironolactone, triamterene, atenolol, bisoprolol fumarate, betaxolol hydrochloride, bevantolol hydrochloride, metoprolol tartrate, acebutolol hydrochloride, celiprolol hydrochloride, nipradilol, tilisolol hydrochloride, nadolol, propranolol hydrochloride, hydrochloride of indenolol, carteolol hydrochloride, pindolol, sustained release pindolol tablet, bunitrolol hydrochloride, penbutolol sulfate, bopindolol malonate, amosulalol hydrochloride, arotinolol hydrochloride, carvedilol, labetalol hydrochloride, urapidil, terazosin hydrochloride, mesylate doxazosin, bunazosin hydrochloride, prazosin hydrochloride, mesylate of faith ntolamine, clonidine hydrochloride, guanfacine hydrochloride, guanabenz acetate, methyldopa, reserpine, rescinnamine, amlodipine besylate, aranidipine, efonidipine hydrochloride, cilnidipine, nicardipine hydrochloride, nisoldipine, nitrendipine, nifedipine, sustained-release nifedipine, nilvadipine, hydrochloride of barnidipine, felodipine, benidipine hydrochloride, manidipine hydrochloride, azelnidipine, diltiazem hydrochloride, hydrazine hydrochloride, allralazine hydrochloride, budralazine, cadralazine, captopril, enalapril maleate, alacepril, delapril hydrochloride, cilazapril, lisinopril, benazepril hydrochloride, imidapril hydrochloride, tamocapril hydrochloride, quinapril hydrochloride, trandolapril, perindopril erbumine, candesartan cilexetil, valsartan , telmisartan, olmesartan medoxomil, sodium nitroprusside and nitroglycerin. The following describes an example of a method for preparing the pyrazole compound represented by the compound (I), but the method of preparation of the present invention is not limited thereto. During the reaction, as required, functional groups other than the one in the site of interest can be protected in advance and they can be deprotected at the appropriate stage. The amount of solvent used in each step is not limited, as long as the reaction mixture can be stirred well. On the other hand, the reagents used in each step can be hydrates or salts thereof, unless they inhibit the reaction in question. On the other hand, in each step, the reaction can be carried out in a conventional manner and the isolation / purification can be carried out using any of the routine methods or by combining them, such as crystallization, recrystallization, column chromatography and preparative HPLC. The following describes in detail methods for the preparation of the compounds represented by the general formula, according to the invention, but the present invention should not be construed as being limited thereto. Therefore, the compounds of the present invention can I I LUj.y "? L synthesized through the following Preparation Method A (A-1 to A-3), method B or method C (C-1 to C-6), or according to later examples, or by reference to these methods. In preparing the compounds of the present invention, the order of reaction can be changed as appropriate. The reaction may begin with the stage or place of substitution that is considered rational. A reactive functional group can be protected and then unprotected, as appropriate. Other reagents than those exemplified may be used, as appropriate to promote the reaction. The flow of the preparation process presented below is an example of a representative method of preparation, but the preparation of the compounds of the present invention should not be construed as limited thereto. Any compound from each step can be isolated and purified by conventional methods, or the isolation / purification step can be ignored, optionally.

Preparation Method A (Preparation Methods A-1 to A-3) Preparation Method A is shown as follows. Each reference symbol in the reaction formulas is defined in the same manner as described above. This applies to the following description. stage 1 f (A5) stage3 Step 1: Preparation of the compound (A2) The compound (A2) can be obtained by hydrogenation of the nitro group of the compound (A1) to the amino group, in a solvent in the presence of a catalyst.

(A 1) (A 2) Examples of the solvent used in the reaction include solvents with alcohol, such as methanol, ethanol and the like; ether solvents, such as dioxane, tetrahydrofuran and the like; ester solvents, such as ethyl acetate and the like; polar solvents, such as N, N-dimethylformamide and the like; and water or similar. They can be used alone or in combination. Examples of the catalyst used in the reaction include palladium catalysts, such as palladium black, palladium / carbon and the like; nickel catalysts, such as Raney nickel; and catalysts of platinum and the like (Reference: M. Hudiicky, Reductions in Organic Chemistry, Wiley-lnterscience, New York, 1984).

The reaction temperature varies between approximately 0 ° C and 100 ° C and, is preferably, about 0 ° C at the temperature ambient. The reaction time varies between about 10 minutes and 48 hours and is preferably about 30 minutes to 24 hours.

Other hydrogen donors, in addition to hydrogen, such as formic acid, ammonium formate, cyclohexene, hydrazine, and the like can also be used (Reference: M. Hudiicky, Reductions in Organic Chemistry, Wiley-lnterscience, New York, 1984). ). In addition, other methods of reducing the nitro group include a method where zinc / hydrochloric acid, tin chloride (1), sodium hidosulfite, titanium chloride (III) or the like are used (Reference: M. Hudiicky, Reductions in Organic Chemistry, Wiley-lnterscience, New York, 1984).

Step 2: Preparation of the compound (A5) The compound (A4) can be prepared from the compound (A3) by a conventional method of synthesis of the acid chloride. The compound (A5) can be obtained by acylation of the amino group in the compound (A2), using the compound (A4) in a solvent, in the presence of a base.

(A 2) (A 5) Examples of reagents used in the formation of acid chloride include: oxalyl chloride, thionyl chloride, phosphorus pentachloride and the like.

N, N-dimethylformamide can be used to promote the reaction, as necessary. On the other hand, examples of the solvent used in the reaction include ether solvents, such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like; hydrocarbon solvents, such as benzene, toluene, hexane, xylene and the like; halogenated hydrocarbon solvents, such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; ester solvents, such as ethyl acetate, methyl acetate, butyl acetate and the like; and they can be used alone or in combination. The reaction temperature varies between about -20 ° C and 120 ° C, and is preferably between about 0 ° C and 80 ° C. The reaction time varies between about 10 minutes and 48 hours and, preferably, is about 30 minutes to 24 hours. Examples of the solvent that can be used in the acylation reaction include ether solvents, such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like; hydrocarbon solvents, such as benzene, toluene, hexane, xylene and the like; halogenated hydrocarbon solvents, such as methylene chloride, chloroform, carbon tetrachloride, 1,2-d-chloroethane and the like; ester solvents, such as ethyl acetate, methyl acetate, butyl acetate and the like; polar solvents, such as acetone, N, N-dimethylacetamide, 'MÍkM. dimethyl sulfoxide and the like; and water or similar. They can used alone or in combination Examples of the base used in this reaction include bases i organic, such as triethylamine, pyridine, 4-dimethylaminopyridine, N-methylmorpholine and the like; inorganic bases, such as lithium hydroxide, j sodium hydroxide, potassium hydroxide, sodium carbonate, carbonate of i potassium, sodium bicarbonate, potassium bicarbonate and the like. I The reaction temperature is about 0 ° C to! i 120 ° C and, preferably, is from about 0 ° C to 95 ° C. , | i The reaction time is approximately 10 minutes to 48! i hours and, preferably, is from about 30 minutes to 24 hours. I The compound (A5) can also be obtained by direct bonding. of the compound (A3) and the compound (A2), using a forming reaction of amide bonds other than the one described here.

Examples of methods that can be used include method of synthesis of phases in solution, by means of an anhydride method acid in mixture, an acid azide method, a DCC method, a method of EDC, a method of EDC-HOBt, an EDC-HOSu method, another method of: active ester, a CDI method, as well as a method of synthesis of ¡ solid peptide phases. I (DCC; 1,3-dicyclohexylcarbodiimide) (EDC; 1-ethyl-3- (3'-dimethylaminopropyl) carbodiimide) '! (HOBt: 1-hydroxybenzotriazole) I i (HOSu; 1 -hydroxysuccinimide) (CDl; 1-1 '-carbonyldiimidazole) Step 3: Preparation of compound (A6) Compound (A6) can be obtained from a reaction of hydrolysis of the compound (A5), in a solvent with an alkali metal hydroxide. stage3 (A 5) (A 6) Examples of the solvent used in the reaction include alcohol solvents, such as methanol, ethanol and the like; ether solvents, such as dioxane, tetrahydrofuran and the like; ketone solvents, such as acetone and the like; polar solvents, such as N, N-dimethylformamide, dimethyl sulfoxide and the like; and water or similar. They can be used alone or in combination. Examples of the base used in this reaction include the alkali metal hydroxides, such as sodium hydroxide, potassium hydroxide; alkaline earth metals, such as barium hydroxide and the like. The reaction temperature is from about 0 ° C to 100 ° C and, preferably, it is from about 0 ° C to room temperature. The reaction time is from about 10 minutes to 48 hours and, preferably, is from about 30 minutes to 24 hours. m * a Step 4 to Step 8: Preparation of compound (I) A summary will now be described from Step 4 to Step 8. The compound represented by the general formula (I) can be synthesized by isolating a compound prepared by activating the group carboxyl of compound (A6), for example, active amide, such as imidazolide (compound (A7); Steps 4 and 5 of Preparation method A-1), or active ester, such as HOBt ester (compound (A8); Steps 6 and 7 of Preparation Method A-2) or HOSu ester; and forming an amide linkage with the compound (A9) as an amine. The compound represented by the general formula (I) can also be synthesized directly from the compound (A6), by a conventional amide linker forming reaction, for example, a method of synthesis of liquid phases, such as an anhydride method acid in admixture, an acid azide method, a DCC method, an EDC method, an EDC-HOBt method, an EDC-HOSu method, other active ester methods or a CDI method; or a method of synthesizing solid peptide phases to form an amide linkage with compound (A9) as an amine, without isolating the active carbonyl compound described above (Step 8 of Preparation Method A-3, presented below). (Reference: E. Gross., The Peptides, Academic Press, 1981) Method of preparation A-l method of preparation of compound (I) by Compound (A7) Step 4: Preparation of the compound (A7) The compound (A7) can be obtained by reacting the compound (A6) in a solvent with CDl (carbonyldiimidazole).

Examples of the solvent used in the reaction include ether solvents, such as tetrahydrofuran and the like; halogenated hydrocarbon solvents, such as chloroform and the like; solvents | aromatic compounds, such as toluene and the like; and polar solvents, | such as N, N-dimethylformamide and the like. They can be used alone or in combination. 'I I The reaction temperature is from about 0 ° C to I 100 ° C and, preferably, it varies between the ambient temperature and approximately 80 ° C. The reaction time is from about 10 minutes to 48 hours and, preferably, is from about 30 minutes to 24 hours. When an analogous compound of the same is used instead of CDl, for example 1, 1'-carbonylbis (2-methylimidazole), a corresponding active amide can be obtained. The compound (A7) - or a corresponding active amide - can be obtained by using another active amide synthesis reaction.

Step 5: Preparation of the compound (I) from the compound (AZI The compound represented by the general formula (I) can be obtained by reacting the compound (A7) in a solvent with the amine-type compound (A9).

I) Examples of the solvent used in the reaction include ether solvents, such as tetrahydrofuran and the like; ester solvents, such as ethyl acetate and the like; halogenated hydrocarbon solvents, such as chloroform and the like; hydrocarbon solvents, such as toluene and the like; and polar solvents, such as N, N-dimethylformamide and the like. They can be used alone or in combination.

The reaction temperature is from about 0 ° C to 100 ° C and, preferably, it is from about 0 ° C to room temperature. The reaction time is from about 10 minutes to 48 hours and, preferably, is from about 30 minutes to 24 hours. Preparation method A-2: method of preparation of compound (I) through Compound (A8) Step 6: Preparation of compound (A8) from Compound tm. The active ester compound (A8) can be obtained by condensation of the compound (A6), in a solvent with HOBt, in the presence of a condensing reagent.

Examples of the condensing reagent include carbodiimides, such as EDC, DCC and the like; and haloformate, such as ethyl chloroformate and the like. Examples of the solvent used in the reaction include ether solvents, such as tetrahydrofuran and the like; ester solvents, such as ethyl acetate and the like; halogenated hydrocarbon solvents, such as chloroform and the like; hydrocarbon solvents, such as toluene and the like; and polar solvents, such as N, N-dimethylformamide and the like. They can be used alone or in combination. The reaction temperature is from about 0 ° C to 100 ° C and, preferably, it is from about 0 ° C to room temperature. The reaction time is from about 10 minutes to 48 hours and, preferably, is from about 30 minutes to 24 hours. When N-hydroxyimides, such as HOSu or the like, are used instead of HOBt, the corresponding active esters can be obtained.

Step 7: Preparation of Compound I from Compound Í8) The compound represented by the general formula (I) can be obtained by reacting the compound (A8) in a solvent with amine compound (A9).

Examples of the solvent used in the reaction include ether solvents, such as tetrahydrofuran and the like; ester solvents, such as ethyl acetate and the like; halogenated hydrocarbon solvents, such as chloroform and the like; hydrocarbon solvents, such as toluene and the like; polar solvents, such as N, N-dimethylformamide and the like; and water or similar. They can be used alone or in combination. The reaction temperature is about 0 ° C to 100 ° C and, preferably, is about 0 ° C at room temperature. The reaction time is from about 10 minutes to 48 hours and, preferably, is from about 30 minutes to 24 hours. Preparation method A-3: Method for directly preparing Compound (I) from Compound (A6) Step 8: Preparation of Compound (I) from Compound I 6) The compound represented by the general formula (I) is synthesized from Compound (A6), by a conventional amide linker forming reaction, for example, a method of synthesis of phases in solution, such as, for example, an acid anhydride method in admixture, an acid azide method, a DCC method, an EDC method, an EDC-HOB method, another active ester method or a CDI method; or a method of synthesis of solid peptide phases.

N-N ¿'JJR. step ß (Aß) (A,) Examples of the solvent used in the reaction include ether solvents, such as tetrahydrofuran and the like; ester solvents, such as ethyl acetate and the like; hydrocarbon solvents halogenated, such as chloroform and the like; hydrocarbon solvents, such as toluene and the like; polar solvents, such as N, N-dimethylformamide and the like; and water or similar. They can be used alone or in combination.

The reaction temperature is about 0 ° C to 100 ° C and, preferably, it is approximately 0 ° C at temperature ambient. The reaction time is from about 10 minutes to 48 hours and, preferably, is from about 30 minutes to 3 hours.

Preparation method B: Preparation method B is presented as follows. Each reference symbol in the formulas is defined in the same way as described above. This also applies to the following description.

(A4) (") Step!: Preparation of compound (B2) Compound (B2) can be obtained from Compound (Bl), in the same manner as in the acid chloride formation of Step 2, from Preparation method A .

(B 1) (B 2) Step 2: Preparation of compound (B4) Compound (B4) can be obtained by reacting compound (B2), in a solvent, with compound (B3), in the presence of a base as necessary.

Examples of the solvent used in the reaction include ether solvents, such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like; hydrocarbon solvents, such as benzene, toluene, hexane, xylene and the like; halogenated hydrocarbon solvents, such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; ester solvents, such as ethyl acetate, methyl acetate, butyl acetate and the like; polar solvents, such as acetone, N, N-dimethylformamide and the like; and water and the like. They can be used alone or in combination. Examples of the base used include organic bases, such as triethylamine, pyridine, 4-dimethylaminopyridine, N-methylmorpholine and the like; inorganic bases, such as lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate and the like. The reaction temperature is from about 0 ° C to 120 ° C and, preferably, it is from about 0 ° C to 60 ° C. The reaction time is from about 10 minutes to 48 hours and, preferably, is from about 30 minutes to 2 hours.

Step 3: Preparation of compound (B6) Compound (B6) can be obtained by hydrogenation of the nitro group of compound (B4), in a solvent, in the presence of a catalyst, in the same manner as in Step 1 of the Preparation method TO.

(B 4) (B 6 Step 4: Preparation of compound (I) from Compound IB61 The compound represented by the general formula (I) can be obtained in the same manner as in Step 2 of Preparation Method A, by acylating the amino group of Compound (B6) using Compound (A4) in a solvent, in the presence from a base.

Preparation method C: method of preparing the salt of a pyrazole compound Preparation method C-1 The compound represented by the general formula (I) is dissolved in a solvent A, and the resulting solution is charged with an acid or a base (as is or in solution). This resulting solution is allowed to stand, and the solid formed is filtered, whereby a salt of the compound represented by the general formula (I) can be obtained.

Preparation method C-2 The compound represented by the general formula (I) is dissolved in a solvent A, and the resulting solution is charged with an acid or a base (as is or in solution). The resulting solution is concentrated and allowed to stand. The solid formed is filtered, whereby a salt of the compound represented by the general formula (I) can be obtained.

Preparation method C-3 The compound represented by the general formula (I) is dissolved in a solvent A, and the resulting solution is charged with an acid or a base (as it is or in solution). The resulting solution is charged with a solvent B, and then allowed to stand. The solid formed is filtered, whereby a salt of the compound represented by the general formula can be obtained (- Preparation method C-4 The compound represented by the general formula (I) is suspended in a solvent A, and the resulting solution is charged with an acid or a base (as is or in solution) to form a solution. This solution is allowed to stand, and the solid formed is filtered, whereby a salt of the compound represented by the general formula (I) can be obtained.

Preparation method C-5 The compound represented by the general formula (I) is suspended in a solvent A, and the resulting solution is charged with an acid or a base (as is or in solution) to form a solution. This solution is concentrated and allowed to stand, and the solid formed is filtered, whereby a salt of the compound represented by the general formula (I) can be obtained.

Preparation method C-6 The compound represented by the general formula (I) is suspended in a solvent A, and the resulting solution is charged with an acid or a base (as is or in solution) to form a solution. This solution is charged with a solvent B and left. The solid formed is filtered, whereby a salt of the compound represented by the general formula (I) can be obtained. In addition, a monoacid addition salt can be obtained, by dissolving or suspending, a diacid addition salt produced according to the Preparation method C described above (C-1 to C-6) in the solvent A described above, and then letting rest. Examples of the diacid addition salt include dihydrochloride, dimethanesulfonate and the like. Examples of the addition salt of a monoacid include monohydrochloride and monomethanesulfonate.

Examples of "solvent A" which is used in Production Method C-1 to C-6 include alcohol solvents, such as methanol, ethanol, propanol and the like; ether solvents, such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like; hydrocarbon solvents, such as benzene, toluene, hexane, xylene and the like; halogenated hydrocarbon solvents, such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; ester solvents, such as ethyl acetate, methyl acetate, butyl acetate and the like; and polar solvents, such as acetone, N, N-dimethylformamide, dimethyl sulfoxide; water and the like. An alcohol or tetrahydrofuran solvent, or a combined solvent thereof, are preferred. More preferable are ethanol, propanol and a combined solvent of tetrahydrofuran with ethanol or propanol. Examples of "solvent B" that is used include ethers, such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme and the like; hydrocarbon solvents, such as benzene, toluene, hexane, xylene and the like; halogenated hydrocarbon solvents, such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; and ester solvents, such as ethyl acetate, methyl acetate, butyl acetate and the like. Ethers and ethyl acetate are preferable. Examples of the "acid" that is used include inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid and the like; l? i., JJ carboxylic acids, such as malic acid, citric acid, oxalic acid and the like; and sulfonic acids, such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like. Hydrochloric acid and p-toluenesulfonic acid are preferable. Examples of the "base" that is used include inorganic bases and aqueous solution of sodium hydroxide, sodium hydride, potassium hydroxide, calcium carbonate and the like; and organic amines, such as ethanol amine, triethylamine and the like. Aqueous sodium hydroxide is preferable EXAMPLES The present invention will now be explained in more detail, with reference to the examples, although the present invention is not limited thereto.

REFERENCE EXAMPLE 1 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid imidazolide and (benzotriazole-1-iQ-acid ester 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid Stage 1 Preparation of 2-chloro-4,5-difluorobenzoyl chloride To a solution of 2-chloro-4,5-difluorobenzoic acid (508.20 g) in toluene (250 mL) was added N, N-dimethylformamide (0.2 mL), and the resulting solution was heated to 65 ° C. Then thionyl chloride (230 mL) was added dropwise. The reaction solution was stirred for 3 hours at 120 ° C and then concentrated under reduced pressure. The obtained residue was distilled under reduced pressure (bp of 51 to 64 ° C (130 to 140 Pa)), to obtain the title compound (534.45 g) as an oil.

Step 2: Preparation of ethyl 5-nitro-3-pyrazolecarboxylate To a solution of 5-nitro-3-pyrazolecarboxylic acid (310.24 g) in ethanol (3 L), methanesulfonic acid (143 mL) was added, and the resulting solution was stirred overnight at 94 ° C. The resulting reaction solution was concentrated under reduced pressure, and water (1.5 L) was added to the obtained residue. By cooling in an ice bath, aqueous potassium carbonate (prepared by dissolving 153.07 g of potassium carboxylate in 750 mL of water) was added. The solid formed was filtered to obtain the title compound (343.09 g) as white crystals.

Step 3: Preparation of ethyl 5-amino-3-pyrazolecarboxylate To a solution of ethyl 5-nitro-3-pyrazolecarboxylate (331.48 g) in tetrahydrofuran (1.5 L) and ethyl acetate (1.5 L) was added 7.5% palladium-carbon (30.036 g), and this solution was stirred for overnight at room temperature, under a nitrogen atmosphere. The catalyst was removed by filtration, and the resulting filtrate was concentrated under reduced pressure. The solid obtained was recrystallized from ethyl acetate-hexane, to obtain the title compound (265.38 g) as white crystals.

Step 4: Preparation of ethyl 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylate To a solution of ethyl 5-amino-3-pyrazolecarboxylate (265.38 g) in tetrahydrofuran (133 L) was added pyridine (153 mL), and 2-chloro-4,5-difluorobenzyl chloride (362.00 g) obtained in Step 1 of Reference Example 1 was added dropwise to the resulting solution, by cooling in an ice bath. This solution was stirred for 2 hours at room temperature. The resulting reaction mixture was concentrated under reduced pressure, and then recrystallized from 2-propanol-water, to obtain the title compound (538.85 g) as white crystals.

Step 5: Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid To a suspension of ethyl 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylate (568.22 g) in ethanol (1 L), water (1 L) was added. Then, 4 N aqueous sodium hydroxide (500 mL) was added dropwise to the resulting solution by cooling in an ice bath. This resulting solution was stirred for 3 days at room temperature. 3 N Hydrochloric acid (1.2 L) was added dropwise to the resulting reaction mixture, by cooling in an ice bath. Water (2 L) was added to the resulting suspension, and the reaction mixture was stirred at room temperature. The crystals formed were filtered under reduced pressure, and were removed at 110 ° C, to obtain the title compound (504.71 g) as white crystals.

Step 6: Preparation of benzotriazol-1-yl-5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylate To a solution of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4.88 g) in N, N-dimethylformamide (70 mL) were added 1-hydroxybenzotriazole monohydrate. (2.73 g) and EDC hydrochloride (3.42 g). The resulting solution was stirred at room temperature, for 24 hours. 120 mL of water was added to the reaction solution in several portions for approximately 2 hours. The solid formed was filtered to obtain the title compound (5.84 g) as a yellow solid. NMR (s value, 400 MHz, DMSO-d6) d: 13.52 (3H, br s); 1125 (2H, s); 8.01-7.82 (4H, m), 7.75-7.71 (1 H, m); 7.60-7.54 (1 H, m); 7.45-7.41 (! H, m); 7.04 (1H, s).

Step 7: Preparation of 5 (2-chloro-4,5-difluoro-benzoylamino-1 H-pyrazole-3-carboxylic acid imidazolide To a suspension of 1,1 '-carbonyldiimidazole (64.65 g) in tetrahydrofuran (1.3 L) was added dropwise a solution of 5- (2-chloro-4,5-difluorobenzoylamino) -1 H -pyrazole-3-carboxylic acid. (100.05 g) in tetrahydrofuran (700 mL) at 55 ° C. The resulting reaction solution was stirred at 73 ° C for 1 hour. Then, ethyl acetate (500 mL) was added to this reaction mixture. The resulting solution was concentrated under reduced pressure. Ethyl acetate (1 L) and hexane (2 L) were added to the residue to prepare a suspension. Ice water (1 L) was added to the suspension, and then stirred for 10 minutes, under cooling with ice. The solid formed was filtered to obtain the title compound (110.42 g) as white crystals. 1 H NMR (400MHz, DMSO-d 6) d: 13.97 (1 H, br s); 1166 (1 H, br s); 8.76 (1 H, s); 8.05-7.87 (3H, m); 7.18 (1 H, s); 6.90 (1 H, s).

REFERENCE EXAMPLE 2 Preparation of 3-aminomethyl-2-isopropoxy-pyridine Stage 1: Preparation of 2-isopropoxy-nicotinamide To a solution of 2-chloronicotinamide (150 g) in 2-propanol (45 m), 60% sodium hydroxide (640 mg) was added, and the resulting solution was stirred for 2 days at 100 ° C. The resulting reaction solution was added to an amount of water (50 mL), and extracted with ethyl acetate (80 mL). The organic layer was washed with 1 N hydrochloric acid. The washed solution was dried over anhydrous sodium sulfate, and the dehydrated solution was then concentrated. The residue obtained was purified by column chromatography with silica gel (n-hexane-ethyl acetate, 5: 1 -> 2: 1) to obtain the title compound (1.64 g) as colorless crystals.

Stage 2: Preparation of 2-isopropoxy-nicotinonitrile To a solution of 2-isopropoxy-nicotinamide (164 g) in chloroform (16 mL), triethylamine (2.8 mL), and then trichloroacetyl chloride (1.1 mL), were added dropwise by cooling in an ice bath. The resulting solution was stirred overnight at room temperature. Saturated, aqueous sodium hydrogen carbonate was added to the resulting reaction solution and stirred for 30 minutes. The organic layer was washed with saturated brine. The washed layer was dried in anhydrous sodium sulfate, and the dehydrated layer was then concentrated under reduced pressure, to obtain the title compound (1.37 g) as a brown oil.

Stage 3: Preparation of 3-aminomethyl-2-isopropoxy-pyridine To a solution of 2-α-propoxy-nicotinonitrile (1.37 g) in methanol (25 mL) were added concentrated hydrochloric acid (2.1 mL) and 7.5% palladium-carbon (780 mg), and this resulting solution was stirred under an atmosphere of nitrogen, for 18 hours at room temperature. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The obtained oil was dissolved in water, and the resulting solution was washed with ethyl acetate. The aqueous layer was made alkaline, and extracted with chloroform. The residue obtained by concentration of the organic layer was purified by column chromatography with silica gel (chloroform-methanol, 8: 1) to obtain the title compound (545 mg), as a brown oil. Then, the following compounds were prepared according to the Preparation method described above A-1, EXAMPLE 1-1 Preparation of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide To a suspension of imidazolide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6.00 g), obtained in Step 7 of the Reference Example 1, in N, N-dimethylformamide (50 mL) was added 3-picolylamine (1.72 mL) by cooling in an ice bath, and the resulting solution was stirred overnight at room temperature. Water (25 mL) and saturated aqueous sodium hydrogen carbonate (50 mL) were added to the resulting reaction mixture. The solid formed was filtered, to obtain the title compound (4.49 g) as a white solid.

EXAMPLE 1-1-1 Preparation of (pyridin-3-ylmethyl) -amide dihydrochloride, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid To a suspension of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide (1.05 g), obtained in Example 1-1, in methanol (10 mL), 4N hydrochloric acid / ethyl acetate (1.8 mL) was added. The resulting reaction mixture was concentrated under reduced pressure, until the remaining residue reached about 5 mL. The solid formed was then filtered to obtain the title compound (1.13 g) as white crystals.

EXAMPLE 1-1-2 Preparation of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide hydrochloride.

To a suspension of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide (700 mg), obtained in Example 1- 1 in methanol (15 mL), 4N hydrochloric acid / ethyl acetate (1.5 mL) was added. This reaction mixture was concentrated under reduced pressure, and methanol (7.5 mL) was added to the resulting residue. The resulting solution was stirred for 8 hours at 80 ° C. The solution was allowed to cool to room temperature. The solid formed was filtered to obtain the title compound (638 mg), as white crystals.

EXAMPLE 1-2 Preparation of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methyl-oxazol-5-ylmethyl) -amide Stage 1: Preparation of 5-chloromethyl-4-methyl-oxazole To a solution of 4-methyloxazole-5-methanol (1.01 g) in chloroform (10 mL) was added triethylamine (1.4 mL). Methanesulfonyl chloride (0.83 mL) was added to the resulting solution, by cooling in an ice bath. This solution was stirred overnight at room temperature. Sodium hydrogen carbonate, saturated aqueous, was added to the resulting reaction mixture. This resulting solution was stirred for 30 minutes, after which, the organic layer was separated. The organic layer was washed with saturated brine, and the washed layer was dried over anhydrous sodium sulfate. The dehydrated solution was concentrated under reduced pressure, to obtain the title compound (955 mg) as a brown solid.

Stage 2: Preparation of 5-aminomethyl-4-methyl-oxazole To a solution of 5-chloromethyl-4-methyl-oxazole (955 mg) in dioxane (20 mL) was added 28% aqueous ammonia (100 mL), and the resulting solution was stirred overnight at room temperature. The resulting reaction mixture was concentrated under reduced pressure, and 8 N potassium hydroxide (20 mL) was added to the concentrated product. The organic matter was extracted using tetrahydrofuran (20 mL). The organic layer was dried in anhydrous sodium sulfate, and then the dehydrated layer was concentrated under reduced pressure, to obtain the title compound (502 mg) as a brown oil. Reference: Synth. Commun. 22 (13), 1939-1948, 1992 Step 3: Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methyl-oxazol-5-ylmethyl) -amide To a suspension of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid imidazolide (2.00 g), obtained in Step 7 of Reference Example 1, in N, N-dimethylformamide (6 mL) was added 5-aminomethyl-4-methyl-oxazole (502 mg), and the resulting solution was stirred overnight, at room temperature. Sodium carbonate, aqueous, saturated (30 mL) and then water (30 mL) were added to the resulting reaction mixture. The solid formed was filtered to obtain the title compound (1.11 g), as a white solid.

EXAMPLE 1-2-1 A Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methyl-oxazol-5-ylmethyl) -amide sesquihydrochloride To a suspension of (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methyl-oxazol-5-ylmethyl) -amide (200 mg) obtained in Example 1-2, in methanol (2 mL), 4 N hydrochloric acid / ethyl acetate (0.15 mL) was added. The resulting mixture was charged with ethyl acetate. The solids that formed were filtered to obtain the title compound (53 mg) as a white solid.

EXAMPLE 1 -2-1 B Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3 (4-methyl-oxazol-5-ylmethyl) -amide p-toluenesulfonate - carboxylic 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (4-methyl-oxazol-5-ylmethyl) -amide (828 mg) was dissolved in acetone (8 mL), was heated to 55 ° C in oil and stirred. To this solution was added dropwise, over 5 minutes, p-toluenesulfonate-chloride hydrate (p-toluenesulfonate hydrochloride) (380 mg) in ethanol (1.9 ml). After stirring this resulting reaction mixture at 55 ° C temperature for 2 hours, it was stirred for a further 2 hours at room temperature. The solid formed was filtered, to obtain the title compound (1052 g), as a white solid.

EXAMPLE 1-2-1C Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methyl-oxazol-5-ylmethyl) -amide tartrate 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methyl-oxazol-5-ylmethyl) -amide (100 mg) was dissolved in acetone (1.1). mL). It was heated to 55 ° C in oil and stirred. To this solution was added L - (+) - tartaric acid (45 mg), and this resulting reaction mixture was stirred for one day, at room temperature. The solid formed was filtered to obtain the title compound (70 mg), as a white solid.

EXAMPLE 1-2-2 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole- (2,4-dimethyl-oxazol-5-ylmethyl) -amide p-toluenesulfonate 3-carboxylic Stage 1: Preparation of ethyl 2,4-dimethyloxazole-5-carboxylate Acetoamide (17.01 g) was added to ethyl 2-chloroacetoacetate (22.91 g), and stirred for 28 hours at 120 ° C. Water (75 mL) and ethanol (7.5 mL) were added to the resulting reaction mixture. The resulting solution was cooled with an ice bath, after which the solid formed was filtered, to obtain the title compound (10.82 g) as a brown solid.

Stage 2: Preparation of 2,4-dimethyl-5-hydroxymethyl-oxazole To a suspension of lithium aluminum hydride (1.82 g) in tetrahydrofuran (30 mL) was added ethyl 2,4-dimethyl-oxazole-5-carboxylate (7,845 g) in tetrahydrofuran (30 mL) by drip, and the solution of The resulting reaction was stirred for 1 hour 30 minutes. Water (1.8 mL), 15% aqueous sodium hydroxide (1.8 mL) and water (5.4 mL) were added, in order, to the resulting reaction mixture, and the resulting solution was stirred at room temperature. The solution was dried over anhydrous sodium sulfate, and the dehydrated solution was concentrated under reduced pressure, to obtain the title compound (5.539 g) as a yellow oil.

Stage 3: Preparation of 5-chloromethyl-2,4-dimethyl-oxazole hydrochloride To a solution of 2,4-dimethyl-5-hydroxymethyl-oxazole (5.539 g) in chloroform (50 mL), thionyl chloride (4.2 mL) was added dropwise, by cooling in an ice bath, and then this solution was added. stirred for 3 hours at room temperature. The resulting reaction mixture was concentrated under reduced pressure, to obtain the title compound (6.626 g) as a brown solid.

Stage 4: Preparation of 5-azidomethyl-2,4-dimethyl-oxazole To a solution of 5-chloromethyl-2,4-dimethyl-oxazole hydrochloride (6.626 g) in N, N-dimethylformamide (18 mL) was added triethylamine (6 mL) and then 20% aqueous lithium azide (10 mL). ). The resulting solution was stirred for 6 hours at 60 ° C. Ethyl acetate (100 mL) was added to the resulting reaction mixture, and the resulting solution was washed, in order, with water and saturated brine. The washed product was dried in anhydrous sodium sulfate. The dehydrated product was concentrated under reduced pressure, to obtain the title compound (4.31 g) as a brown oil.

Step 5: Preparation of 5-aminomethyl-2,4-dimethyl-oxazole dihydrochloride To a solution of 5-azidomethyl-2,4-dimethyl-oxazole (4.31 g) in tetrahydrofuran (45 mL), a solution of triphenylphosphine (8.27 g) in tetrahydrofuran (25 mL) was added at 50 ° C. Water (1.2 mL) was added to the resulting solution, and this solution was stirred overnight. The resulting reaction mixture was concentrated under reduced pressure, after which diethyl ether (50 mL) was added to the resulting residue. The solid formed was filtered, and the filtrate was concentrated under reduced pressure. The concentrated product was dissolved in ethyl acetate (20 mL) and 4N hydrochloric acid / ethyl acetate (15 mL) was added to the solution. The solid formed was filtered to obtain the title compound (5.30 g) as a yellow solid.

Step 6: Preparation of (2,4-dimethyl-oxazol-5-ylmethyl) -amide 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid To a solution of 5-aminomethyl-2,4-dithomethyl-oxazole dihydrochloride (772 mg) in N, N-dimethylformamide (3 mL) were added triethylamine (114 mL) and 5- (2-imidazolide). -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1.37 g), and the resulting solution was stirred overnight at room temperature. Water (24 mL) was added to the resulting reaction mixture. The solid formed was filtered to obtain the title compound (1.47 g) as a white solid.

Step 7: Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-oxazol-5-ylmethyl) -p-toluenesulfonate 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-oxazol-5-ylmethyl) -amide (1.00 g) was added. Propanol (6 mL), and the resulting solution was heated to reflux. To this solution was added a solution of p-toluenesulfonic acid (466 mg) in 1-propanol (0.5 mL), and the resulting solution was stirred under reflux for 30 minutes, and then cooled to room temperature and stirred throughout. night. The crystals formed were filtered to obtain the title compound (1.36 g), as colorless crystals.

EXAMPLE 1-3 Preparation of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (2,4-dithmethyloxazol-5-ylmethyl) -amide Stage 1: Preparation of 3-hydroxymethyl-2,4-dimethylpyridine To a solution of ethyl 2,4-dimethylpyridine-3-carboxylate (3.00 g) in tetrahydrofuran (30 mL), lithium aluminum hydride (1.21 g) was added, gradually, by cooling in an ice bath. The resulting reaction mixture was stirred for 2 hours and water (1.2 mL), 15% aqueous sodium hydroxide (1.2 mL) and water (3.6 mL) were added in order. The resulting solution was stirred at room temperature. The organic layer was obtained and dried over anhydrous sodium sulfate, and the dehydrated solution was concentrated under reduced pressure, to obtain the title compound (2.26 g) as white crystals.

Stage 2: Preparation of 3-chloromethyl-2,4-dimethylpyridine To a solution of 3-hydroxymethyl-2,4-dimethylpyridine (3.00 g) in chloroform (30 mL), thionyl chloride (2.8 mL) was added dropwise, by cooling in an ice bath, and then the resulting solution it was stirred for 1 hour and 30 minutes. Saturated aqueous sodium hydrogen carbonate (60 mL) was added to the resulting reaction mixture by cooling in an ice bath. The organic layer was washed with brine, and the washed layer was dried in anhydrous sodium sulfate. The dehydrated product was then concentrated under reduced pressure, to obtain the title compound (3.45 g) as a brown oil.

Stage 3: Preparation of 3-azidomethyl-2,4-dimethylpyridine To a solution of 3-chloromethyl-2,4-dimethylpyridine (3.45 g) in N, N-dimethylformamide (15 mL) was added 20% aqueous lithium azide (5.5 mL). The resulting solution was stirred overnight at 60 ° C. Ethyl acetate (100 mL) was added to the resulting reaction mixture, and the resulting solution was washed, in order, with water and saturated brine. The washed product was dried in anhydrous sodium sulfate. This dehydrated solution was concentrated under reduced pressure, to obtain the title compound (3.18 g) as a brown oil.

Stage 4: Preparation of 3-aminomethyl-2,4-dimethylpyridine To a solution of 3-azidomethyl-2,4-dimethylpyridine (3.18 g) in ethanol (45 mL) was added platinum-carbon oxide (613 mg). After stirring at a hydrogen atmosphere of 4 atm, the solution was stirred for 30 minutes at room temperature. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure, to obtain the title compound (2.53 g) as a brown oil.

Step 5: Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-pyridin-3-ylmethyl) -amide To a solution of 3-aminomethyl-2,4-dimethylpyridine (2.53 g), in N, N-dimethylformamide (15 mL), 5- (2-chloro-4,5-difluorobenzoylamino) -1 H imidazolide was added. 3-carboxylic acid (6.21 g), obtained in Step 7 of Reference Example 1, and the resulting solution was stirred overnight at room temperature. Water (50 mL) and then 10% aqueous potassium hydroxide (15 mL) were added to the resulting reaction mixture. The solid formed was filtered to obtain the title compound (7.02 g) as a white solid.

EXAMPLE 1-3-1 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-pyridin-3-ylmethyl) -amide hydrochloride To a solution of the 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-pyridin-3-ylmethyl) -amide obtained in the Example 1-3 (120 mg), in methanol (1 mL) was added 4 N hydrochloric acid / ethyl acetate (0.2 mL). Ethyl acetate was added to the resulting reaction mixture. The formed solid was filtered to obtain the title compound (135 mg) as a white solid. The compounds of Example 1-4 to Example 1-167 were prepared in the same manner as in Example 1-1 to Example 1 -3-1 above. The following tables 1 to 24 show the constitutive form and NMR data for these compounds.

TABLE 1 TABLE 2 TABLE 3 TABLE 4 TABLE 5 TABLE 6 TABLE 7 TABLE 8 TABLE 9 TABLE 10 TABLE 11 TABLE 12 TABLE 13 TABLE 14 TABLE 15 TABLE 16 TABLE 17 TABLE 18 TABLE 19 TABLE 20 TABLE 21 TABLE 22 TABLE 23 TABLE 24 Then, the following compounds were prepared according to Preparation A-2, described above.

EXAMPLE 2-1 Preparation of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-ylmethyl) -amide.

To a solution of the benzotriazol-1-yl 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylate (2.15 g), obtained in Step 6 of Reference Example 1, in N, N-dimethylformamide (11 mL), which was being stirred, was added 3-aminomethyl-6-chloro-pyridine (0.77 g), commercially available. This resulting solution was stirred for 3 hours at room temperature; then, 10 mL of water in several portions were added there by dripping. The white solid formed was filtered and the resulting product washed, in order, with water, saturated aqueous sodium bicarbonate and water. The washed solid was dried under reduced pressure, to obtain the title compound (2.10 g).

EXAMPLE 2-1-1 Preparation of (6-chloro-pyridin-3-ylmethyl) -amide acid dihydrochloride 5- (2-Chloro-415-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid To a solution of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-methylmethane) -amide (1.16 g) , obtained in Example 2-1, in a solution of methanol (10 mL) -tetrahydrofuran (10 mL), 1.7 mL of a solution of 4 N-hydrochloric acid-ethyl acetate was added, and the resulting solution was allowed to stand. The solid formed was filtered, to obtain the title compound (1.07 g).

EXAMPLE 2-2 Preparation of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4H- [1, 2,4] triazol-3-ylmethyl) -amide.

In the same manner as in Example 2-1, the title compound (50 mg) was obtained from benzotriazol-1-yl-5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylate (160 mg) and (4 H- [1, 2,4] triazol-3-ylmethyl) -amine) (42 mg), prepared according to Bioorganic Med. Chem. Lett., 4, 2441, 1994, EXAMPLE 2-2-1 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- (4H- [1,2,4] triazol-3-ylmethyl) -amide dihydrochloride 3-carboxylic In the same manner as in Example 2-1-1, the title compound (30 mg) was obtained from (4H- [1, 2,4] triazol-3-ylmethyl) -amide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid (37 mg).

EXAMPLE 2-3 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-fluoro-4H-quinazolin-3-yl) -amide.

In the same manner as in Example 2-1, the title compound (155 mg) was obtained from benzotriazol-1-yl-5- (2-chloro-4,5-difluorobenzoylamine) -1 Hp. razol-3-carboxylate (210 mg) and 5-fluoro-3,4-dihydro-quinazoline (150 mg), which was prepared according to J. Heterocyclic Chem., 12, 883 1975.

EXAMPLE 2-3-1 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-fluoro-4H-quinazolin-3-yl) -amide dihydrochloride In the same manner as in Example 2-1-1, the title compound (23 mg) was obtained from 5- (2-chloro-5-fluoro-4H-quinazolin-3-yl) -amide of 5-chloro acid -4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (48 mg).

EXAMPLE 2-4 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4,6-dimethyl-pyridin-3-ylmethyl) -amide Step 1: Preparation of 3-aminomethyl-4,6-dimethyl-pyridine 3-Cyano-4,6-dimethylpyridine (1.23 g) was prepared from 2-chloro-3-cyano-4,6-dimethylpyridine (2.00 g) according to Tetrahedron, 22, 3417, 1996. The title compound (436 mg) was prepared from 3-cyano-4,6-dimethylpyridine, with reference to J. Heterocyclic Chem., 30, 473, 1993.

Step 2: Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (4,6-dimethyl-pyridin-3-methylmethyl) -amide of acid carboxylic In the same manner as in Example 2-1, the title compound (110 mg) was obtained from benzotriazol-1-yl-5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylate (140 mg) and 3-aminomethyl-4,6-d-methy1-pyridine (70 mg).

EXAMPLE 2-4-1 Preparation of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-dimethyl-pyridin-3-ylmethyl-amino acid dihydrochloride -carboxylic To a suspension of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid (4,6-dimethyl-pyridin-3-ylmethyl) -amide (430 mg), in a solution of methanol (0.5 mL) -tetrahydrofuran (25 mL), a solution of 4 N hydrochloric acid / ethyl acetate (0.64 mL) was added. The resulting solution was concentrated to about 1/6, under reduced pressure. This solution was allowed to stand. The solid formed was filtered to obtain the title compound (444) mg.

EXAMPLE 2-5 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-6-methyl-pyridin-3-ylmethyl) -amide.

Step 1: Preparation of 3-aminomethyl-2-methoxy-6-methyl-pyridine 3-Cyano-2-methoxy-6-methylpyridine (2.74 g) was prepared from 2-chloro-3-cyano-6-methylpyridine (3.00 g), according to J. Heterocyclic Chem., 36, 653, 1999. The title compound (608 mg) was further prepared, from 3-cyano-2-methoxy-6-methylpyridine (739 mg), with reference to J. Heterocyclic Chem., 30, 473, 1993.

Step 2: Preparation of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-6-methyl-pyridin-3-ylmethyl) -amide.

In the same manner as in Example 2-1, the title compound (501 mg) was obtained from benzotriazol-1-yl-5- (2-chloro-4,5-difluorobenzoylamino) -1 H- pyrazole-3-carboxylate (1.66 g) and 3-aminomethyl-2-methoxy-6-methyl-pyridine (603 mg).

EXAMPLE 2-6 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxy-6-methyl-pyridin-3-ylmethyl) -amide.

Stage 1: Preparation of ethyl 4-methoxy-6-methylnicotinate Ethyl 2-chloro-4-methoxy-6-methyl-ethyl (387 mg) was prepared from ethyl 2,4-dichloro-6-methylnicotinate (1.00 g), according to Synthesis, 6, 479, 1988 The title compound (217 mg) was also prepared, according to the same document.

Step 2: Preparation of 3-hydroxymethyl-4-methoxy-6-methylpyridine The title compound (61 mg) was prepared from 4-methoxy-6-methoxy nicotinate (212 mg), with reference to Synthesis, 26, 2257, 1996.

Step 3: Preparation of 3-aminomethyl-4-methoxy-6-methyl-pyridine 3-Chloromethyl-4-methoxy-6-methylpyridine was prepared from 3-hydroxy-methyl-4-methoxy-6-methylpyridine (553 mg), with reference to J. Med. Chem., 46, 453, 2003. Without being purified, this product was reacted with sodium azide, to prepare 3-azidomethyl-4-methoxy-6-methylpyridine (403 mg). The title compound (331 mg) was further prepared according to the same document.

Step 4: Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxy-6-methyl-pyridin-3-ylmethyl) -amide.

In the same manner as in Example 2-1, the title compound (368 mg) was obtained from benzotriazol-1-yl-5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole 3-carboxylate (413 mg) and 3-aminomethyl-4-methoxy-6-methyl-pyridine (150 mg).

EXAMPLE 2-6-1 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole- (4-methoxy-6-methyl-pyridin-3-ylmethyl) -amide dihydrochloride 3-carboxylic In the same manner as in Example 2-4-1, the title compound (124 mg) was prepared from 5- (2-methoxy-6-methyl-pyridin-3-ylmethyl) -amide. -chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (363 mg).

EXAMPLE 2-7 Preparation of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-4,6-dimethyl-pyridin-3-ylmethyl) -amide.

Stage 1: Preparation of 3-aminomethyl-2-methoxy-4,6-dimethyl-pyridine 3-Cyano-2-methoxy-4,6-dimethylpyridine (1.31 g) was prepared from 3-cyano-2-chloro-4,6-dimethylpridine (1.50 g), according to J. Heterocyclic Chem. , 36, 653, 1999. The title compound (826 mg) was further prepared from 3-cyano-2-methoxy-4,6-dimethylpyridine (809 mg) with reference to J. Heterocyclic Chem. , 30, 473, 1993.

Step 2: Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 (2-methoxy-4,6-dimethyl-pyridin-3-ylmethyl) -amide. -carboxylic In the same manner as in Example 2-1, the title compound (1.23 g) was obtained from benzotriazol-1-yl-5- (2-chloro-4,5-difluorobenzoylamino) -1 H-pyrazole- 3-carboxylate (1.26 g) and 3-aminomethyl 2-methoxy-4,6-dimethyl-pyridine (500 mg), obtained in Step 1.

EXAMPLE 2-7-1 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole (2-methoxy-4,6-dimethyl-pyridin-3-ylmethyl) -amide hydrochloride -3- carboxylic In the same manner as in Example 2-1-1, the title compound (288 mg) was prepared from (2-methoxy-4,6-dimethyl-pyridin-3-ylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (261 mg). Then, the compounds according to Example 2-8 were prepared to Example 2-33, presented below, which are illustrated in the following tables, in the same manner as in Example 2-1 to Example 2-7- 1, described above.

TABLE 25 TABLE 26 TABLE 27 TABLE 28 TABLE 29 TABLE 30 The following compounds were prepared according to the preparation method A-3 described above.

EXAMPLE 3-1 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzyl-methyl-amide To a solution of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (70 mg), prepared according to Step 5 of Reference Example 1, N-methylbenzylamine (33 μM) and 1-hydroxybenzotriazole hydrate (43 mg), in N, N-dimethylformamide (1 mL), EDC hydrochloride (50 mg) was added; This resulting solution was stirred overnight, at room temperature. Saturated aqueous sodium bicarbonate (2 mL) and water (5 mL) were added to the resulting reaction mixture. The solid formed was filtered, to obtain the title compound (76 mg), as a white solid.

EXAMPLE 3-2 Preparation of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide To a solution of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (70 mg), obtained according to Step 5 of Reference Example 1, benzylamine (28 μM ) and 1-hydroxybenzotriazole hydrate (45 mg) in N, N-dimethylformamide (1 mL), EDC hydrochloride (50 mg) was added; This resulting solution was stirred overnight, at room temperature. 0.1 N aqueous sodium hydroxide (1 mL) and then water (3 mL) were added to the resulting reaction mixture. The solid formed was filtered to obtain the title compound (66 mg), as a white solid. The compounds according to Example 3-3 to Example 3-53 presented below were prepared in the same manner as in Example] 3-1 and Example 3-2, described above.

TABLE 31 TABLE 32 TABLE 33 TABLE 34 TABLE 35 TABLE 36 TABLE 37 The following compounds were prepared, according to Preparation Method B described above.

EXAMPLE 4-1 Preparation of methyl 5- (2-chloro-4,5-difluorobenzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxycarbonyl-phenyl) -methyl-amide Step 1: Preparation of methyl 4- (methyl- (5-nitro-1 H-pyrazole-3-carbonyl) -aminol-benzoate To a solution of 5-nitro-3-pyrazolecarboxylic acid (400 mg), in chloroform (10 mL), oxalyl chloride (0.27 mL) and N, N-dimethylformamide (1 drop) were added, with cooling in a water bath. ice. This resulting solution was stirred overnight, at room temperature, and the resulting reaction mixture was then concentrated under reduced pressure, to obtain 5-nitro-3-pyrazolecarbonyl chloride. Then, to a suspension of 5-nitro-3-pyrazolcarbonyl chloride and methyl 4-methylaminobenzoate (410 mg) in chloroform (25 mL), triethylamine (1.2 mL) was added, and the resulting solution was stirred overnight at room temperature. The resulting reaction mixture was washed, in order, with saturated aqueous sodium bicarbonate, 1 N hydrochloric acid and brine.

I, The washed mixture was dried over anhydrous sodium sulfate and the dried mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography with silica gel (chloroform-ethyl acetate, 5: 1 → 3: 1 → 2: 1), to obtain the title compound (394 mg) as white crystals.

Step 2: Preparation of methyl 4 - [(5-amino-1 H -pyrazole-3-carbonyl) -methyl-amino] -benzoate To a solution of methyl 4- (methyl- (5-nitro-1 H-pyrazole-3-carbonyl) -amino] -benzoate (394 mg), in tetrahydrofuran (10 mL) -ethyl acetate (10 mL), 7.5% palladium-carbon (60 mg) was added. The resulting solution was stirred overnight, at room temperature, in a hydrogen atmosphere. The catalyst was removed by filtration and the resulting product was concentrated under reduced pressure, to obtain the title compound (244 mg) as a white solid.

Step 3: Preparation of methyl 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxycarbonyl-phenyl) -methyl-amide To a solution of methyl 4 - [(5-amino-1 H-pyrazole-3-carbonyl) -methyl-amino-benzoate (244 mg), in tetrahydrofuran (5 mL), pyridine (0.1 mL) was added. 2-Chloro-4,5-difluorobenzoyl chloride (0.135 mL) was added dropwise to the resulting solution. The resulting solution was stirred overnight, at room temperature. The resulting reaction mixture was concentrated under reduced pressure. The resulting residue was purified using column chromatography with silica gel (chloroform-ethyl acetate, 5: 1 → 1: 1), to obtain the title compound (228 mg) as white crystals.

EXAMPLE 4-2 Preparation of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-carboxyphenyl) -methyl-amide To a solution of methyl 5- (2-chloro-4,5-difluorobenzoylamino) -1 H-pyrazole-3-carboxylic acid (4-methoxycarbonyl-phenyl) -methyl-amide (100 mg), obtained in accordance with Example 4-1, in methanol (2 mL), 1N aqueous sodium hydroxide (0.7 mL) was added, and this solution was stirred overnight, at room temperature. The resulting reaction mixture was charged with 1 N hydrochloric acid (1.5 mL). The solid formed was filtered to obtain the title compound (78 mg), as white crystals.

EXAMPLE 4-2-1 Preparation of 4-. { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carbonyl-methyl-aminol-monosodium benzoate To a suspension of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic (4-carboxyphenyl) -methyl-amide (49.4 mg), obtained according to Example 4- 2, in ethanol (0.81 mL), an aqueous solution of 4 N sodium hydroxide (0.025 mL) was added. This solution was allowed to stand at room temperature, and the solids that formed were filtered to obtain the title compound (36 mg). The compounds according to Example 4-3 to Example 4-48 presented below, which are illustrated in the following tables, were produced in the same manner as in Example 4-1 and in Example 4-2-1, • previously described TABLE 38 TABLE 39 : 13.19 (1H, br s), 7.72 (1H, br s). d, J = 7.7 Hz), J = 5.9 Hz). : 13.20 (1H, br J = 5.7 Hz), 7.58 J = 8.6, 3.1 Hz), J = 5.9 Hz). 13. 35 (1H, br s), 7.42-7.17 (10H.s). 13. 00 (1H. Br s), 7.86-7.79 (2H, m). m), 7.33-7.23 (2H, (6H, s). 13. 30 (1H, br s), 7.71 (1H, m), 7.47- (2H. S), 3.45- 13. 16 (1H, br s), 7.39-7.17 (9H, m), s).

TABLE 40 TABLE 41 TABLE 42 TABLE 43 TABLE 44 TABLE 45 The compounds according to Example 5-1 to Example 5-44 illustrated in the following Tables were prepared in the same manner as in the Preparation Methods A, B, C described above or the respective Examples described above.

TABLE 46 TABLE 47 TABLE 48 TABLE 49 TABLE 50 TABLE 51 TABLE 52 TABLE 53 In addition, the compounds of Example 6-1 to Example 6-50 and the compounds of Example 7-1 to Example 7-17, illustrated in the following Tables, were prepared in the same manner.

TABLE 54 TABLE 56 TABLE 57 TABLE 58 i ' TABLE 59 TABLE 60 TABLE 61 TABLE 62 TABLE 63 TABLE 64 (Pharmacological test) 1. Exemplary test (1): method to measure the activity of hepatic glycogen phosphorylase. The measurement of glycogen phosphorylase activity was carried out by a method using the direct reaction system. The measurement of glycogen phosphorylase activity using the direct reaction system was carried out as explained below. Glucose-1-phosphate prepared from glycogen, by glycogen phosphorylase, was converted to glucono-d-lactone 6-phosphate, through transphosphorylation and dehydrogenation, using phosphoglucomutase and glucose-6-phosphate dehydrogenase (G6PDH ). NADPH, prepared from NADP, was detected during dehydrogenation by G6PDH. A homogenate of Sf9 cells expressing human liver glycogen phosphorylase, exogenously recombinant, was diluted with 100 mmol / L of BES buffer solution (pH 6.8, containing 2 mmol / L EDTA) and the dilution was used as the enzymatic solution of human hepatic glycogen phosphorylase. As the substrate, a phosphate buffer (containing 16 mmol / L KH2PO4, 24 mmol / L Na2HPO) was used. A mixture of 8U / mL of phosphoglucomutase and 60U / mL of G6PDH was prepared in BES buffer solution. The buffer solution (containing 1.4 mmol / L NADP, 30 mmol / L MgCl 2, 8 μmol / L glucose-1,6-diphosphate, 8 mg / mL glycogen, 40 mmol / L) was prepared individually. BES, 0.8 mmol / L EDTA) for the reaction and a glucose solution (containing 75 mmol / L glucose, 100 mmol / L BES, 2 mmol / L EDTA). The test product was dissolved in aqueous solution of 1% DMSO. The enzymatic reaction was initiated by adding 20 μL of the recombinant human liver glycogen phosphorylase solution and 20 μL of the phosphoglucomutase and G6PDH mixture to the mixture of 20 μL of the glucose solution, 20 μL of the substrate, 100 μL of the solution of buffer for the reaction and 20 μL of the solution with the test product. As a control, aqueous solution of 1% DMSO was added in place of the test product. The mixture devoid of the substrate was used as a control. The absorbance at 340 nm was measured immediately after the reaction started. Absorbance to M.Ji 340 nm was re-measured after the reaction, at room temperature, for 75 minutes. The enzymatic activity is a value obtained by subtracting the variation of the control in absorbance during 75 minutes of the variation in absorbance during 75 minutes. The inhibition rate (%) of the test product was calculated by the expression of "(1 - enzymatic activity of the test product / control enzymatic activity) x 100". A linear equation was determined from the concentration points before and after the 50% inhibition rate, and the IC50 value was calculated from the concentration at the intersection of the line, with the inhibition rate of 50% . The results of the exemplary test described above are shown in the above table. As described above, the activity to inhibit hepatic glycogen phosphorylase was represented as ++, when the value IC50 (nmol / L) was less than 100 nmol / L, as +, when the IC50 value was between 100 nmol / L and 300 nmol / L, and without any sign, when the IC50 value was equal to 300 nmol / L or higher. 2. Exemplary Test (2): Method for Measuring Glucose Concentration in Blood Plasma Db / db mice representing a type of obesity of the diabetic model were used to examine the effect of the compound (1) of the present invention on the concentrations of glucose in the blood plasma. The plasma glucose concentrations of the db / db mice (10-18 weeks of age) were measured, and these were divided into groups of 5 mice each, so that there was no difference in the mean value of the plasma concentrations of the mice. glucose. After a four-hour fast, the example compound or the solvent (0.5% methylcellulose) was orally administered to the db / db mice, and the plasma glucose concentrations were measured 1 and 3 hours after the administration. The analysis of the hypoglycaemic effect of the compound of the example was carried out by means of a significant test of the groups receiving the solvent or the compound of the example, which was carried out every hour (Dunnett test). The results of the exemplary test described above are represented in the above table. As described above, compounds exhibiting a statistically significant hypoglycemic effect, at a dose of 10 mg / kg or less, are indicated by the symbol "++", and compounds that do not indicate a significant hypoglycemic effect, but Obviously, at a dose of 10 mg / kg, they are indicated by the "+" symbol.

TABLE 65 TABLE 66 TABLE 67 TABLE 68 I TABLE 69 TABLE 70 TABLE 71 TABLE 72 TABLE 73 TABLE 74 TABLE 75 TABLE 76 TABLE 77 TABLE 78 TABLE 79 Industrial Applicability As evident from the results of the test described above, the compounds of the present invention and the pharmacologically acceptable salts thereof have potent inhibitory effects on the phosphorylase of human liver glycogen. Therefore, the compounds of the present invention are useful as a novel antidiabetic, by the new mode of action of the inhibitory effect of GP [glycogen phosphorylase, glycogen phosphorylase]. In addition to having potential as a combination therapy with other antidiabetic or antilipidemic drugs, the compound of the present invention has potential as a therapeutic agent to combat insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataract, hypercholesterolemia, hypertension , hyperinsulinism, hyperlipidemia, atherosclerosis, tissue ischemia and myocardial ischemia; as a therapeutic agent to control appetite and obesity; and as a therapeutic agent against infections such as a bacterial, fungal, parasitic or viral infection.

Claims (13)

1. NOVELTY OF THE INVENTION CLAIMS 1. - A pharmaceutical composition for treating or preventing diabetes, comprising a pyrazole compound or a pharmacologically acceptable salt thereof and a pharmaceutically acceptable carrier thereof, represented by the following general formula (I): wherein the Q ring represents an aryl group or a heteroaromatic group; R1 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group or a C-? 6 alkoxy group; R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group; R3 represents a halogen atom, a hydroxyl group, a C-? 6 alkyl group, a C6-C6 haloalkyl group, a C-? 6 alkoxy group, an azido group, an amino group, an acylamino group or an alkyl (C-? 6) sulfonylamino group; R4 and R5 are identical to each other or different from one another, and represent (1) a hydrogen atom; (2) a C-1 alkyl group. 6, which may be substituted with a substituent selected from Group A, presented below: [Group A] A1. A hydroxyl group, A2. An alkoxy group C? .6, A3. -N (R41) (R4r) wherein R41 and R41 are identical to each other or different from one another and represent a hydrogen atom or a C-i-e alkyl group; and R41 and R41, together with the adjacent nitrogen atom, can form a saturated, monocyclic 5 or 6 membered heterocyclic ring, A4. An aryl group, A5. A heteroaromatic group, A6. -CO-N (R 11) (R 411 ') wherein R 411 and R 41' are identical to each other or different from each other and represent a hydrogen atom or a C-α_6 alkyl group; and R411 and R411, together with the adjacent nitrogen atom, can form a saturated, 5 or 6 membered monocyclic heterocyclic ring, A7. A carboxy group, and, A8. An alkoxy group (C-). 6) carbonyl (3) a C2.6 alkenyl group; (4) a C2.6 alkynyl group; (5) a C3.8 cycloalkyl group; wherein the cycloalkyl group may be substituted with a hydroxyl group, a carboxy group or a (C? -6) carbonyl alkoxy group or it may be fused with a pyridine ring, (6) a (C3.8) alkyl cycloalkyl group d- H.H; wherein the cycloalkyl group, of the C3_8 cycloalkyl group, C_2_6 alkyl, may be substituted with a hydroxyl group, a carboxy group or a (C_6_) alkoxycarbonyl group, or may be fused with a pyridine ring, (7) a saturated, monocyclic, 5- or 6-membered heterocyclic group, which may be substituted with a substituent selected from Group C presented below: [Group C] C1. A C? .6 alkyl group, C2. An acyl group, C3. An alkylsulfonyl group, C4. A carboxy group, C5. An alkoxy (C-? 6) carbonyl group, and, C6. -CO- (Alk) n-COOR52, wherein R52 is a hydrogen atom or a C-i-β alkyl group; Alk is a C- alkylene group; and n is 0 or an integer comprised between 1 and 3, (8) an aryl group, which may be substituted with one or more substituents, selected from Group D, presented below: [Group D] D1. A hydroxyl group, D2. An alkoxy group C? _6, D3. A cyano group, D4. A C? -6 alkyl group, wherein the C-uß alkyl group may be substituted with a substituent selected from the group consisting of a hydroxyl group, a carboxy group and a C-carbonyl alkoxy group, D5. -N (R53) (R53), wherein R53 and R53 are identical to each other or different from one another and represent a hydrogen atom, a C- | 6 alkyl group or an alkyl (C? 6) sulfonyl group, D6. -CO-N (R531) (R53r), wherein R531 and R53r are identical to each other or different from each other and represent a hydrogen atom, a C? _6 alkyl group or an alkyl (C? -6) sulfonyl group, D7. -COOR54, where R54 is a hydrogen atom, a C6_6 alkyl group, a (C6_6) carbonyloxy-C6_6 alkyl group or a (C3.8) cycloalkyloxycarbonyloxy-C_6 alkyl group , D8. -C (NH (OH)) = N-R55, where R55 is a hydrogen atom or an alkyl (C-α-6) sulfonyl group, D9. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, and, D10. A monocyclic 5 or 6 membered heteroaromatic group, which may be substituted with an oxo or thioxo group, (9) a heteroaromatic group fused with a benzene ring or a 5 or 6 membered monocyclic ring, which may be substituted with a substituent selected from a carboxy group and an alkoxy group (C? -6) carbonyl; (10) an aralkyl group C7.-?; where the alkyl part of the C 7 aralkyl group can be substituted with one or two substituents, selected from Group E presented below, and the aryl part can be substituted with one or more substituents selected from Group F, presented below : [Group E] E1. A C -? 6 alkyl group, which may be substituted with a hydroxyl group, E2. A cyano group, E3. A carboxy group, E4. An alkoxy (C-? 6) carbonyl group, and, E5. A phenyl group, [Group F] F1. An alkyl group C- | .6, F2. A halogen atom, F3. A cyano group, F4. A hydroxyl group, F5. An Icoxy C-α-6 group, which may be substituted with a substituent selected from the group consisting of a carboxy group and a (C ?6) alkoxycarbonyl group, F6. A halo-C1-6 alkyl group, F7. A carboxy group, F8. An alkoxy group (C-? 6) carbonyl, F9. -CO-N (R56a) (R56a) wherein R56a and R56a 'are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated group, having at least a nitrogen atom, or a Ci-β alkyl group, which may be substituted with a substituent selected from Group f presented below: [Group f] f1. An amino group, f2. A monoalkyl (C? .6) amino group, f3. A dialkyl (C? .6) amino group, f4. A carboxy group, f5. An alkoxycarbonyl group, f6. A hydroxyl group, y, f7. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, having at least one nitrogen atom, F10. - (R56b) (R56), where R56b and R56b 'are identical to each other or different from each other and represent a hydrogen atom, a C -? 6 alkyl group, which may be substituted with an imino group, an aralkyl group , which may be substituted with one or more identical or different substituents, selected from an imino group and a halogen atom, an arylsulfonyl group which may be substituted by a C -? 6 alkyl group, an (C? --6) alkyl group sulfonyl, an acyl group, a carbamoyl group, a monoalkyl (C? 6) carbamoyl group or a dialkyl (C? .6) carbamoyl group, F11. -N = CR57 (-N (R58) (R58 ')), where R57 is a hydrogen atom or a C1.6 alkyl group, R58 and R58 are identical to each other or different from each other and represent a hydrogen atom or a C1-6 alkyl group, F12. A heteroaromatic group, monocyclic, of 5 or 6 members, and, F13. A methylenedioxy group or an ethylenedioxy group, or, (1 1) a Ci-β alkyl group, substituted with a heteroaromatic, monocyclic, 5- or 6-membered group, or a heteroaromatic group obtained by condensation of the heteroaromatic group with a benzene ring; wherein the heteroaromatic group may be substituted with one or more substituents selected from Group G presented below: [Group G] G1. A C? .6 alkyl group which may be substituted with a substituent selected from Group g, presented below: [Group g] g1. A halogen atom, g2. An amino group, g3. A monoalkyl (C? -6) amino group, g4. A dialkyl group (C -? - 6) amine, g5. An alkoxy group (C? -6) carbonylamino, and, g6. A hydroxyimino group, G2. A halogen atom, G3. A C6.6 alkoxy group, which may be substituted with a halogen atom, G4. An aryloxy group, G5. A cyano group, G6. -N (R59a) (R59a '), where R59a and R59a' are identical to each other or different from one another and represent a hydrogen atom or a C- | 6 alkyl group; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic, heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group (C ? 6) amine or a group dalkyl (C? -6) amine, G7. -CO-N (R59b) (R59b) where R59b and R59b 'are identical to each other or different from each other and represent a hydrogen atom, a group It is heterocyclic, monocyclic, 5- or 6-membered, saturated or a C?-6 alkyl group, which may be substituted with the heterocyclic group, G8. An aryl group, and, G9. A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group, or R4 and R5, together with the I-atom adjacent nitrogen, can form a saturated, 5- or 6-membered heterocyclic ring, where a portion of the saturated heterocyclic ring can have a double bond and the saturated heterocyclic ring can be fused to a benzene ring, to form a fused ring or the Saturated heterocyclic ring which can be condensed with a benzene ring to form a fused ring can be substituted with a halogen atom, a Ci-β alkyl group, a C-? 6 alkoxy group, a carboxy group or an alkoxy group ( C? _6) carbonyl. 2 - The pharmaceutical composition for treating or preventing diabetes according to claim 1, further characterized in that it comprises a pyrazole compound or a pharmacologically acceptable salt thereof and a pharmaceutically acceptable carrier thereof, represented by the following general formula ( I): wherein the Q ring represents an aryl group or a heteroaromatic group; R1 represents a hydrogen atom, a halogen atom, a C? 6 alkyl group or a C-i-β alkoxy group; R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group; R3 represents a halogen atom, a hydroxyl group, a C1-alkyl group, a halo-C1-6 alkyl group, an alkoxy d-6 group, an azido group, an amino group, an acylamino group or an alkyl group ( C? .6) sulfonylamino; R4 represents (1) a hydrogen atom; (2) a C-? 6 alkyl group, which may be substituted with a substituent selected from Group A, presented below: [Group A] A1. A hydroxyl group, A2. An alkoxy group d_6, A3. -N (R41) (R4r) wherein R41 and R4r are identical to each other or different from one another and represent a hydrogen atom or a C1.5 alkyl group; and R41 and R41, together with the adjacent nitrogen atom, can form a saturated, monocyclic 5 or 6 membered heterocyclic ring, A4. An aryl group, A5. A heteroaromatic group, A6. -CO-N (R411) (R411 ') wherein R411 and R411' are identical to each other or different from each other and represent a hydrogen atom or a C1.6 alkyl group; and R411 and R411, together with the adjacent nitrogen atom, can form a 5 or 6 membered monocyclic, saturated, heterocyclic ring, A7. A carboxy group, and, A8. An alkoxy group (C? .6) carbonyl, (3) a C2.T. alkenyl group; (4) a C2.6 alkynyl group; (5) a C3.8 cycloalkyl group; (6) a (C3.8) C 1-6 alkylcycloalkyl group; or, (7) an aryl group; and R5 represents (1) a C1-6 alkyl group, which may be substituted with a substituent selected from group B presented below: [Group B] B1. A hydroxyl group, B2. An alkoxy group C -? 6, B3. -N (R51) (R51 ') wherein R51 and R51 are identical to each other or different from each other and represent a hydrogen atom or a Ci-β alkyl group; and R51 and The R51, together with the adjacent nitrogen atom, can form a 5 or 6 membered monocyclic, saturated, and, B4 heterocyclic ring. -CO- N (R511) (R511) wherein R511 and R511 are identical to each other or different from each other and represent a hydrogen atom or an alkyl group d.6; and R511 and R511, together with the adjacent nitrogen atom, can form a 5 or 6 membered monocyclic, saturated, heterocyclic ring, (2) a C3 cycloalkyl. 8; wherein the cycloalkyl group may be substituted with a hydroxyl group, a carboxy group or a (C6-6) alkoxycarbonyl group or may be fused with a pyridine ring, (3) a (C3.8) cycloalkyl-C-alkyl group ? .6; wherein the cycloalkyl group of the (C3.8) cycloalkyl group d6 alkyl may be substituted with a hydroxyl group, a carboxy group or a (C6-6) alkoxycarbonyl group, or may be fused with a pyridine ring, (4) a saturated, monocyclic, 5- or 6-membered heterocyclic group, which may be substituted with a substituent selected from Group C presented below: [Group C] C1. An alkyl group d.6, C2. An acyl group, C3. An alkyl (C6-6) sulfonyl group, C4. A carboxy group, C5. An alkoxy group (C6-6) carbonyl, and, C6. - CO- (Alk) n-COOR52, where R52 is a hydrogen atom or an alkyl group d.6; Alk is an alkylene C-M group; and n is 0 or an integer comprised between 1 and 3, (5) an aryl group which may be substituted with one or more substituents selected from Group D presented below: [Group D] D1. A hydroxyl group, D2. An alkoxy group d.6, D3. A cyano group, D4. A C-? 6 alkyl group, wherein the C? _6 alkyl group may be substituted with a substituent selected from the group consisting of a hydroxyl group, a carboxy group and an alkoxy (d_6) carbonyl group, D5. -N (R53) (R53 '), where R53 and R53 are identical to each other or different from each other and represent a hydrogen atom, a C? _6 alkyl group or an alkyl group (C -? - 6) sulfonyl, D6. -CO-N (R531) (R531 ') wherein R531 and R531' are identical to each other or different from one another and represent a hydrogen atom, an alkyl group d.6 or a (C_6) alkylsulphonyl group, D7 . -COOR54, where R54 is a hydrogen atom, a C1-6 alkyl group, an alkyl (C6.6) carbonyloxy-alkyl d6 group or a cycloalkyloxy (C3.8) carbonyloxy-alkyl d.6, D8 group. -C (NH (OH)) = N-R55, where R55 is a hydrogen atom or an alkyl (C? -6) sulfonyl group, D9. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, and D10. A heteroaromatic group, monocyclic, 5- or 6-membered, which may be substituted with an oxo or thioxo group, (6) a heteroaromatic group fused with a benzene ring or a 5- or 6-membered monocyclic ring, which may be substituted a substituent selected from the group consisting of a carboxy group and a (C6.6) alkoxycarbonyl group; (7) an aralkyl group C7.-?; where the alkyl part of the C. 4 aralkyl group can be substituted with one or two substituents selected from Group E, presented below, and the aryl part can be substituted with one or more substituents selected from Group F, presented below : [Group E] E1. A C? _6 alkyl group, which may be substituted with a hydroxyl group, E2. A cyano group, E3. A carboxy group, E4. An alkoxy (d-6) carbonyl group, and, E5. A phenyl group, [Group F] F1. A C -? 6 alkyl group, F2. A halogen atom, F3. A cyano group, F4. A hydroxyl group, F5. An alkoxy group d. ÍÉÍUA ?? and, F13. A methylenedioxy group or an ethylenedioxy group, or, (8) an alkyl group Ci. 6 substituted with a heteroaromatic, monocyclic, 5- or 6-membered group or with a heteroaromatic group obtained by condensation of the heteroaromatic group with a benzene ring; wherein the heteroaromatic group may be substituted with one or more substituents selected from Group G, presented below: [Group G] G1. A C1-6 alkyl group, which may be substituted with a substituent selected from Group g presented below: [Group g] g1 a halogen atom, g2. An amino group, g3. A monoalkyl (C? -6) amino group, g4. A dialkyl (C? -6) amino group, g5. An alkoxy group (C- | 6) carbonylamino, and g6. A hydroxyimino group, G2. A halogen atom, G3. An alkoxy group C -? - 6, which may be substituted with a halogen atom, G4. An aryloxy group, G5. A cyano group, G6. -N (R59a) (R59a), wherein R59a and R59a are identical to each other or different from each other and represent a hydrogen atom or an alkyl group d.6; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic, heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group (C ? .6) amino or a dialkyl (d.6) amino group, G7. -CO-N (R59b) (R59b) wherein R59b and R59b 'are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated or a C1-alkyl group -6, which may be substituted with the heterocyclic group, G8. An aryl group, and, G9. A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted Ill., L with an oxo or thioxo group, or R4 and R5, together with the nitrogen atom adjacent, can form a heterocyclic ring, of 5 or 6 members, saturated, where a part of the saturated heterocyclic ring can have a double bond, and the saturated heterocyclic ring can be condensed with a benzene ring to form a fused ring, or the heterocyclic ring > saturated that can be condensed with a benzene ring to form a condensed ring may be substituted with a halogen atom, a Ci ^ alkyl group, an alkoxy d-6 group, a carboxy group or an alkoxy group (C? 6) carbonyl. 3. The pharmaceutical composition for treating or preventing diabetes in accordance with claim 1, further characterized in that I t the pyrazole compound is a pyrazole compound represented by the following general formula (II1): where R1, R2, R3, R4 and R5 are as defined in the claim 1. A.- The pharmaceutical composition for treating or preventing diabetes according to claim 1, further characterized in that the pyrazole compound is a pyrazole compound represented by the following general formula (II): wherein R4 and R5 are such as defined in claim 1; R1a represents a halogen atom or a hydrogen atom; R2a, a halogen atom; and R3a, a halogen atom or a C? 6 alkyl group. 5. The pharmaceutical composition for treating or preventing diabetes according to claim 4, further characterized in that R1a is a hydrogen or fluorine atom, R2a fluorine or chlorine atom, and R3a is a chlorine atom or an alkyl group C ? _6. 6. The pharmaceutical composition for treating or preventing diabetes according to claim 5, further characterized in that the pyrazole compound is a pyrazole compound represented by the following form. (ffl) where R4 and R5 are as defined above. 7. The pharmaceutical composition for treating or preventing diabetes according to any of claims 2 to 6, further characterized in that R4 is a group selected from the following groups: (1) a hydrogen atom; (2) an alkyl group d-6, which may be substituted with a substituent selected from Group A ', presented below: [Group A'] A'1. A hydroxyl group, A'2. An alkoxy group d.4, A'3. -N (R41) (R41) wherein R41 and R41 'are identical to each other or different from one another and represent a hydrogen atom or a C- alkyl group; and R41 and R41, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered heterocyclic ring, A'4. A phenyl group, A'5. A heteroaromatic group, monocyclic, of 5 or 6 members, A6. -CO-N (R411) (R411 ') wherein R411 and R411' are identical to each other or different from each other and represent a hydrogen atom or an alkyl group Ci ^; and R411 and R411, together with the adjacent nitrogen atom, can form a 5 or 6 membered monocyclic, saturated, heterocyclic ring, A7. A carboxy group, and A'8. An alkoxy (C?) Carbonyl group, (3) a C2-6 alkenyl group (4) a C2.6 alkynyl group; (5) a C3.8 cycloalkyl; and, (6) a cycloalkyl (C3-8) alkyl d-4 group. 8. The pharmaceutical composition for treating or preventing diabetes according to any of claims 2 to 7, further characterized in that R5 is a C1-6 alkyl group. Ui ^ i 9. - The pharmaceutical composition for treating or preventing diabetes according to any of claims 2 to 7, further characterized in that R5 is a C3.8 cycloalkyl group, which may be substituted with a hydroxyl group, a carboxy group or an alkoxy group ( C. 6) carbonyl. 10. The pharmaceutical composition for treating or preventing diabetes according to any of claims 2 to 7, further characterized in that R5 is a cycloalkyl (C3.8) alkyl d.6 group. 11. The pharmaceutical composition for treating or preventing diabetes according to any of claims 2 to 7, further characterized in that R5 is a heterocyclic, monocyclic, 5- or 6-membered, saturated group, which may be substituted with a selected substituent between an acyl group and -CO- (Alk) n-COOR52, where R52 is a hydrogen atom or an alkyl group of; Alk is an alkylene group C-, and n is 0 or an integer between 1 and 3. 12. The pharmaceutical composition for treating or preventing diabetes according to any of claims 2 to 7, further characterized in that R5 is a phenyl group, which may be substituted with one or more substituents selected from the following Group D ': [Group D'] D'1. A C-M alkyl group, which may be substituted with a carboxy group, D'2. -CO-N (R53) (R53 '), wherein R53 and R53' are identical to each other or different from one another and represent a hydrogen atom, a C1-4 alkyl group or an alkyl (C? ^) Group sulfonyl, D'3. -COOR54, where R54 is a hydrogen atom, a C-M alkyl group, a C 1 -4 alkylcarbonyloxy-C-M alkyl group or a C 3-8 cycloalkyloxy group, carbonyloxy-C 1 alkyl, and, D'4. A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group. 13. The pharmaceutical composition for treating or preventing diabetes according to any of claims 2 to 7, further characterized in that R5 is an aralkyl group C7_-? and the aryl portion of the C7-4 aralkyl group may be substituted with one or more substituents selected from the following F 'Group: [Group F'] F'1. An alkyl group d-6, F'2. A halogen atom, F'3. A cyano group, F'4. A hydroxyl group, F'5. An alkoxy d.6 group, which may be substituted with a substituent selected from a carboxy group or a (C? ^) Carbonyl alkoxy group, F'6. A haloalkyl group d-6, F7. A carboxy group, F'8. An alkoxy (C 6) carbonyl group, F'9. -CO-N (R56a) (R56a), wherein R56a and R56a 'are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated group having at least a nitrogen atom, or a C-? 6 alkyl group, which may be substituted with a substituent selected from the following Group f: [Group f] f1. An amino group, f2. A monoalkyl (C? -6) amino group, f3. A group d¡alqu¡l (d.6) amíno, f4. A carboxy group, f5. An alkoxy (d-6) carbonyl group, f6. A hydroxyl group, y, f7. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, having at least one nitrogen atom, F'10. -N (R56b) (R56b) where R56b and R56b are identical to each other or different from each other and i aU.- ii represent a hydrogen atom, a C-? 6 alkyl group, which may be substituted with an imino group, an aralkyl group, which may be substituted with one or more identical or different substituents, selected from a group imino and a halogen atom, an arylsulfonyl group, which may be substituted with a C6_6 alkyl group, a (C6_6) alkylsulfonyl group, an acyl group, a carbamoyl group, a monoalkyl group (C6_6) carbamoyl or a dialkyl (C -? - 6) carbamoyl group, F'11. -N = CR57 (-N (R58) (R58 ')), where R57 is a hydrogen atom or an alkyl group CM, R58 and R58 are identical to each other or different from each other and represent a hydrogen atom or a alkyl group CM, F'12. A heteroaromatic group, monocyclic, of 5 or 6 members, and, F'13. A methylenedioxy group or an ethylenedioxy group. 14. The pharmaceutical composition for treating or preventing diabetes according to any of claims 2 to 7, further characterized in that R5 is a C6-6 alkyl group substituted with a heteroaromatic, monocyclic, 5- or 6-membered group and the The heteroaromatic group may be substituted with one or more substituents selected from the following Group G ': [Group G'] G'1. A C? .6 alkyl group, which may be substituted with a substituent selected from Group g ', presented below: [Group g'] g'1. A halogen atom, g'2. An amino group, g'3. A monoalkyl (C? ^) Amino group, g'4. A dialkyl (C 6) amino group, g 5. An alkoxy (d-6) carbonyl group, and, g'6. A hydroxyimino group, G'2. A halogen atom, G'3. An alkoxy group d-6 > which may be substituted with a halogen atom, G'4. An aryloxy group, G'5. A group -L.1.U Í, .ll cyano, G'6. -N (R59a) (R59a), where R59a and R59a 'are identical to each other or different from one another and represent a hydrogen atom or an alkyl group d. 6 and R59a and 593 ^ together with the adjacent nitrogen atom, can form a 5- or 6-membered heterocyclic, saturated monocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group (C? -6) amino or a dialkyl (d.6) amino group, G7. -CO-N (R59b) (R59b ') wherein R59b and R59b' are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic group, monocyclic, 5- or 6-membered, saturated, or an alkyl d-β group, which may be substituted with the heterocyclic group, G'8. An aryl group, and, G'9. A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group. 15. The pharmaceutical composition for treating or preventing diabetes according to any of claims 2 to 6, further characterized in that R5 and R4, together with the adjacent nitrogen atom, form a heterocyclic, monocyclic, 5- or 6-membered group , saturated, where a portion of the saturated heterocyclic group may have a double bond, and the saturated heterocyclic group may be fused to a benzene ring, to form a fused ring, or the saturated heterocyclic group, which may be fused to a ring benzene to form a fused ring, may be substituted with a halogen atom, an alkyl group Ci ^, a group alkoxy C? .6, a carboxy group or a (C-? 6) alkoxycarbonyl group. tiyiÜA. 16. - The pharmaceutical composition for treating or preventing diabetes according to claim 2, further characterized in that the pyrazole compound is a pyrazole compound represented by the following general formula (IV): where R "is as described in claim 2; R? 1, R? ' and R jX3 are identical to each other or different from each other and represent a hydrogen atom or a substituent selected from the following Group F "; and m is 0 or an integer between 1 and 2, [Group F "] F" 1. A C1-6 alkyl group, F "2. A halogen atom, F" 3. A cyano group, F "4. A hydroxy group, F" 5. A C-M alkoxy group, which may be substituted with a carboxy group or a (C? ^) Carbonyl alkoxy group, F "6. A halo-C-? 6 alkyl group, F" 7. A carboxy group, F "8. An alkoxy (d.6) carbonyl group, F" 9. -CO-N (R56a) (R56a ') wherein R56a and R56a are identical to each other or different from one another and represent a hydrogen atom, a saturated, monocyclic, 5- or 6-membered heterocyclic group having at least one nitrogen atom, or a d6 alkyl group, which may be substituted with a substituent selected from Group f ", presented below: [Group f] f'1 An amino group, f'2 A monoalkyl group (C ?. 6) amino, f'3 A dialkyl (C? ^) Amino group, f'4 A carboxy group, f'5 An alkoxy group (C? 6) carbonyl, f '6. A hydroxyl group, and , f'7. The saturated, saturated monocyclic, 5- or 6-membered heterocyclic group having at least one nitrogen atom, F "10 -N (R56b) (R56b ') wherein R56b and R56b' are identical to each other or different from one of the others and represent a hydrogen atom, a C-α-6 alkyl group, which may be substituted with a lower group, an aralkyl group, which may be substituted with one or more identical or different substituents, selected from an imino group and a halogen atom, an arylsulfonyl group which may be substituted by a C? -6 alkyl group, an alk (d_6) sulfonyl group, an acyl group, a carbamoyl group, a monoalkyl (C?) carbamoyl group or a dialkyl (C 6) carbamoyl group, F "11. -N = CR57 (-N (R58) (R58 ')), wherein R57 is a hydrogen atom or an alkyl group d.6; R58 and R58 are identical to each other or different from one another and represent a hydrogen atom or an alkyl group d. 6, F "12. A heteroaromatic group, monocyclic, of 5 or 6 members, and, F" 13. A methylenedioxy group or an ethylenedioxy group. 17. The pharmaceutical composition for treating or preventing diabetes according to claim 2, further characterized in that the pyrazole compound is a pyrazole compound represented by the following: .or ,. ki. where R 4 is as defined in claim 2, the Het ring represents a heteroaromatic group of a 5 or 6 membered monocyclic ring; RY1, RY2 and RY3 are identical to each other or different from one another and represent a hydrogen atom or a substituent selected from the following Group G '; and m 'is 0 or an integer between 1 and 2, [Group G'j G'1. A C-? 6 alkyl group, which may be substituted with a substituent selected from Group g 'presented below: [Group g'] g'1. A halogen atom, g'2. An amino group, g'3. A monoalkyl group (C? -6) amn, g'4. A dialkyl (C? ^) Amine group, g'5. An alkoxy group (C? .6) carbonylamino, and, g'6. A hydroxyimino group, G'2. A halogen atom, G'3. A C1.6 alkoxy group, which may be substituted with a halogen atom, G'4. An aryloxy group, G'5. A cyano group, G'6. -N (R59a) (R59a), wherein R59a and R59a 'are identical to each other or different from each other and represent a hydrogen atom or a d-6 alkyl group; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic, heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group (C ? .6) amino or a dialkyl (d.6) amino group, G7. -CO-N (R59b) (R59b) wherein R59b and R59b 'are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated, or an alkyl group C1-6, which may be substituted with the heterocyclic group, G'8. An aryl group, and, G'9. A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group. 18. The pharmaceutical composition for treating or preventing diabetes according to claim 17, further characterized in that the Het ring is a pyridine ring, a triazole ring or an oxazole ring. 19. The pharmaceutical composition for treating or preventing diabetes according to claim 18, further characterized in that the pyrazole compound is a pyrazole compound represented by the following: where R4, RY1, RY2, RY3 and m 'are as described above. 20. The pharmaceutical composition for treating or preventing diabetes according to claim 2, further characterized in that the pyrazole compound or a pharmacologically acceptable salt thereof is selected from the following group: (pyridin-3-ylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-prazol-3-carboxylic acid, 5- (2-chloro-4,5-) pyridin-3-ylmethyl-amide-dihydrochloride difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (pyridin-3-ylmethyl) -amide-hydrochloride carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (4-methyl-oxazol-5-ylmethyl) -amide (4-Methyl-oxazole) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-chloro-4,5-ylmethyl) -amide, (4-Methyl-oxazol-5-ylmethyl) -amide-p-toluenesulfonate 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (4-Methyl-oxazol-5-ylmethyl) -amide - L - (+) - tartrate -(2- Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (2,4-Dimethyl-oxazol-5-ylmethyl) -amide p- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -3,5-dimethoxy-benzylamide -1 H-pyrazole-3-carboxylic acid, 3,4-dimethoxy-benzylamide of 5- (2-chloro-4,5-d-fluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 2, 3-Difluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,4-Difluoro-benzylamide of 5- (2-chloro-4,5-acid) -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,5-Difluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2 , 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid, 6-difluoro-benzylamide, 5- (2-chloro-4-difluoro-benzylamide) , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3,5-Difluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-lsopropoxy-pyridin-3-methylmethyl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (2-phenoxy-pyridin-3-ylmethyl) -amide, (3,5-Difluoro-pyridin-2) -methyl) -amino 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid amide, 2- (2-chloro-4-trifluoromethyl-benzylamide) , 5-difluoro-benzoylamino) -1H-pyrazol-3-carboxylic acid, 3-trifluoromethyl-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid trifluoromethyl-benzylamide, 5- (2-chloro-4, 4-tert-butyl-benzylamide) 5-difluoro-benzolamlam) -1H-pyrrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (6-lsopropoxy-pyridin-3-ylmethyl) -amide. ) -1 H-pyrazole-3-carboxylic acid, [2- (2,2,2-Trifluoro-ethoxy) - iult * ~ or pyridin-3-ylmethyl] -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H- '| pyrazole-3-carboxylic acid 4- (2-dimethylamino-ethylcarbamoyl) -benzylamide of acid (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-Ethyl-benzyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylic acid, 4- (5-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5-chloro-6-fluoro-benzylamide acid - (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-) 6-ethoxy-pyridin-3-ylmethyl) -? - dihydrochloride 4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid5- (2-Chloro-4,5-difluoro- [benzoylamino) -1 H -pyrazole-3-carboxylic acid (thiazol-4-ylmethyl) -amide, [6- (2,2,2-Trifluoro- 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-I-pyrazole-3-carboxylic acid, 2,6-dimethyl-benzylamide ethoxy) -pyridin-3'-ylmethyl] -amide dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [2- (pyridin-3-yl) -thiazol-4-ylmethyl] -amide-dihydrochloride of 5 - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-hydroquinone) - (1H-Benzoimidazol-2-ylmethyl) -amide-dihydrochloride difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Methyl ester [4- ( { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] - amino.}. -methyl) -benzoylamino-acetic acid, Methyl ester of 3- [4- ( { [5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carbonyl] -amino.}. -methyl) -benzoylamino] -propionic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) 2- (2-methyl-thiazol-4-ylmethyl) -amide-dihydrochloride) -1 H-pyrazole-3 -carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,5-dimethyl-isoxazol-4-ylmethyl) -amide, 4- [2 -Bis- (2-acetoxyethyl) -amino-ethylcarbamoyl] -benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-Hydroxy-ethylcarbamoyl) ) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid benzylamide, 4-. { 2 - [(2-Acetoxyethyl) - (2-hydroxyethyl) -amino] -ethylcarbamoyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, (1-Methyl-1H-benzoimidazol-2-ylmethyl) -amide-5-hydrochloride (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (thiazol-2-ylmethyl) -amide-dihydrochloride ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (Benzothiazol-2-ylmethyl) -amide-dihydrochloride, ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2,5-dimethyl-thiazol-4-ylmethyl) -amide dihydrochloride, [2- (Morpholin-4 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1, 3,5-) -thiazole-4-ylmethyl] -amide-dichlorhydrate. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid trimethyl-1H-pyrazol-4-ylmethyl) -amide, (2-Chloro-6-methyl-pyridine- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-, 3-carboxylic acid, 3-ylmethyl-amide dihydrochloride, 2-Dimethylamino-thiazole-4-yl 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid methyl ester (1-methyl-1 H-pyrrol-2-ylmethyl) - ammonium dichloride. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3! carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,4-dimethoxy-pyridin-2-ylmethyl) -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-I-pyrazole-3-carboxylic acid-3-butyl-thiazole-2- (methyl) -amide-dichlorhydrate, (5-Methyl) -2-phenyl-2H- [1, 2,3] triazol-4-ylmethyl) -amide of acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [4- (tert-butoxycarbonyl-amino) -met-1-pyridin-2-ylmethyl] -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [4-Methyl-2- (morpholin-4-yl) -thiazol-5-ylmethyl] -amide-dihydrochloride of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-prazol-3-carboxylic acid, (pyridin-3-methylmethyl) amide 3/2-hydrochloride-hemihydrate, of acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) - 2-Amino-benzylamide 1 H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-methoxy-benzylamide of 5-methoxy-benzylamide - (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-chloro-4,5-difluoro-benzoylamino) -1- H-pyroxy-4-methoxy-benzylamide pyrazole-3-carboxylic acid, 4- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-methyl-benzylamide, 4-fluoro-benzylamide of acid or 5- (2-chloro-4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-chloro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) - 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzolamino) -1H-pyrazole-3-carboxylic acid 4-ethoxycarbonyl-benzylamide, 4-carboxy-benzylamide - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazol-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoxylamino) -1 H-pyrazole- dibenzylamide 3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexylmethyl-amide of 5- (2- Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1- (2-hydroxy-ethyl) -phenyl-amide H-pyrazole-3-carboxylic acid, Cyclohexyl-methyl-amide of 5- (2-chloro-4,5-d-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Cyclohexylamide of 5- (2-) acid chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, cyclohexyl-ethyl-amide of 5- (2-chloro) o-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-allyl-cyclohexyl-amide carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl- (pyridin-2-methyl) -amide, methyl- (1-methyl-piperidin- 4- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, [(3,4-methylenedioxyphenyl) -methyl] -amide-hydrochloride acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-benzyl-butyl-amide -pyrazol-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzyl- (4-hydroxy-butyl) -amide-hydrochloride, Butyl 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl, 5- (2-chloro-4,5-difluoro) cyclohexyl-propyl-amide -benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl-cyclohexyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pir azole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl- (2-methoxy-ethyl) -amide, Cyclohexyl- (pyridine-3 -ylmethyl) -amido of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, [2- (Morpholin-4-yl) -phenyl) ] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H acid dibutyl amide -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid bis- (2-methoxy-ethyl) -amide, (2- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methoxy-ethyl) -propyl-amide, B-butyl- (tetrahydro-pyran-4-yl) -amide of acid 5- (2-chloro- I I l l 4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, (2-methoxy-ethyl) - (tetrahydro-pyran-4-yl) -amide of 5- (2-chloro-4 , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Cyclopentyl- (2-methoxy-ethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole -3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid cyclohexyl- (3-methoxy-propyl) -amide, Cyclohexyl- (2-ethoxy-ethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Cyclohexyl- (2-isopropoxy-ethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-cyclohexyl- (2-propoxy-ethyl) -amide) -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - (1-Ethyl-propyl) - (2-methoxy-ethyl) -amide - 1H-pyrazole-3-carboxylic acid, butyl- (1-tert-butoxycarbonyl-piperidin-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 -amide carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (tetrahydro-thiopyran-4-yl) -amide) (2-methoxy-ethyl) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-Chloro-4,5) butyl- (pyridin-3-ylmethyl) -amide -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-benzyl- (2-methoxy-ethyl) -amide. -carboxylic , Butyl- (piperidin-4-yl-5-yl acid amide (2-chloro-4,5-difluoro-benzolamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro) (1-acetyl-piperidin-4-yl) -butyl-amide -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl- (1-methanesulfonyl-piperidin-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) ) -1 H-pyrazole-3-carboxylic acid, butyl- (1-ethoxalyl-piperidin-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 -amide -carboxylic, ,.,. and 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (1-oxalo-piperidin-4-yl) -amide, butyl- (1-, 1-) dioxo-hexahydro-1? 6-thiopyr-4-yl) -amido of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid, butyl- (1-oxo- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid hexahydro-1? 4-thiopyran-4-yl) -amide (6-methoxy-pyrid) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid n-3-methyl-propyl- (3-methyl) -propyl-amide of propyl- (pyridin-3-ylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -4-Diethylcarbamoyl-benzylamide -pyrazol-3-carboxylic acid, 3- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-ethylcarbamoyl-benzylamide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-Ethylcarbamoyl-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-carbamoyl-benzylamide, (1-Oxalo-piperidin-4-yl) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1-carboxy-ethyl-piperidin-4-yl) -propyl-amide acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [1- (2-carboxypropyl) -piperidin-4-yl] -propyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, cyclopropyl- (6-methoxy-pyridin-3-ylmethyl) -amide of 5- (2-chloro-4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -cyclohexyl- (6-methoxy-pyridin-3-ylmethyl) -amide -1 H-pyrazole-3-carboxylic acid, cyclopropylmethyl- (6-methoxy-pyridin-3-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro- and benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3 (6-dimethylamino-pyridin-3-ylmethyl) -amide. -carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-dimethylamino-pyridin-3-ylmethyl) -propyl-amide, Benzyl- (2- carboxy-ethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Benzyl- (2-ethoxycarbonyl-ethyl) -amide of 5- (2-carboxylic acid) -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro) (6-chloro-pyridin-3-ylmethyl) -propyl-amide -benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,6-dichloro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (3, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 5-dichloro-pyridin-4-methylmethanolamide, (3,5-Dichloro-pyridine) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-ylmethyl) -propyl-amide, [6- (1 H-Pyrazol-1-yl) -pyridin -3-ylmethyl] - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide-dihydrochloride, [6- (4-Hydroxy-piperidin-1-yl) -pyridin-3- 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-pyridin-2-yl-ethyl) -amide acid ammethyl] -amide-dichloride. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (2-pyridin-3-yl-ethyl) -amido of 5- (2-chloro-4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (2-pyridin-4-yl-ethyl) -amide -pyrazol-3-carboxylic acid (4- [1,2,3] thiadiazol-4-yl-benzyl) -amide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-Methyl-pyrazin-2-ylmethyl) -amide, pyrazin-2-ylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid quinolin-5-ylamide, quinolin-8-ylamide; 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) lsoquinolin-5-ylamide -1 H-pyrazole-3-carboxylic acid, [3-ethoxy-5- (1-ethoxycarbonyl-1-methyl-ethyl) -pyridin-2-yl) -amide of 5- (2-chloro-4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [3-Ethoxy-5- (1-ethoxycarbonyl-1-hydroxy-ethyl) -pyridin-2-yl] -amide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [5- (1-Carboxy-1-methyl-ethyl) -3-ethoxy-pyridin-2-yl] -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [5- (1-Carboxy-1-hydroxy-ethyl) -3-ethoxy-pyridin-2-yl] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, 5- (2-chloro-4,5-acid) (5-chloro-4,5-pyrazin-2-ylmethyl) -amide -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamine [6- (thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide. ) -1 H-pyrazole-3-carboxylic acid, [6- (1, 1-Dioxo-1? 6-thiomorpholin-4-yl) -pyridin-3-ylme Useful] 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4,5-Dibromo-thiophen-2-ylmethyl) -amide acid 5- (2-chloro- I i) 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (5-chloro-thiophen-2-ylmethyl) - | 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, i (4-Ethyl-2-methyl-oxazol-5-ylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid, 5- (2-ethyl-4-methyl-oxazol-5-ylmethyl) -amide-dihydrochloride 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5- ([2,2 '] Bithiophenyl-5-ylmethyl) -amide difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (3-methoxy-thiophen-2-ylmethyl) -amide ü M 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-3-dichloro-thiophen-2-ylmethyl) -amide chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, (2,5-D-methyl-oxazol-4-ylmethyl) -amide of 5- (2-chloro-4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) (2-hexyl-4-methyl-oxazol-5-ylmethyl) -amide) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxy-thiophen-3-ylmethyl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-Methyl-2-phenyl-oxazol-5-ylmethyl) -amide, (2-Methyl-4-) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid phenyl-oxazol-5-ylmethyl) -amide, (4-hexyl-2-methyl-oxazole-5-) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ylmethyl) -amide dihydrochloride, 5- (2-chloro-4,5-difluoro-benzoylamino) -1- (6-chloro-pyridin-3-ylmethyl) -amide. 2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carbo xyl, 5- (2-chloro-4,5-difluoro-benzolamino) -1H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-ylmethyl) -amide-dihydrochloride, (4H- [ 1, 2,4] Triazol-3-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, (4H- [1, 2,4 ] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid triazol-3-ylmethyl) -amide-dihydrochloride, (5-Fluoro-4H-quinazolin-3-yl) ) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, (5-Fluoro-4H-quinazolin-3-yl) -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2- (4,6-Dimethyl-pyridin-3-ylmethyl) -amide acid chloro-4,5-difluoro-benzoylamino) -1 H-prazol-3-carboxylic acid, 5- (2- (2-6-methyl-pyridin-3-ylmethyl) -amide-dichlorhydrate) chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole- Ui iti 3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-6-methyl-pyridin-3-ylmethyl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxy-6-methyl-pyridin-3-ylmethyl) -amide, (4-methoxy-6) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-methyl-pyridin-3-ylmethyl] -amide-d-hydrochloride carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-4,6-dimethyl-pyridin-3-ylmethyl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-methoxy-4,6-dimethyl-pyridin-3-ylmethyl) -amide dihydrochloride (3 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl (pyridin-2-ylmethyl) -amide, (5-Methyl-pyridin-3-ylmethyl) ) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-methyl-pyridin-3-ylmethyl) -amide 2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, (6-Methyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide-dihydrochloride 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro- (6-fluoropyridin-3-ylmethyl) -amide-dihydrochloride) 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole (3-Carboxy-phenyl) -methyl-amide -3-carboxylic acid, 3-methanesulfonylamino-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-methanesulfonylamino-benzylamide of 5- (2-chloro) acid -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3- 'i Acetylamino-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 -carboxylic acid 5- (2-chloro-4,5-) acetylamino-benzylamide IÍÜJL difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole (2-phenyl-thiazol-4-ylmethyl) -amide -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrrazol-3-carboxylic acid ((R) -1- phenylethyl) -amide, ((S 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-1-phenyl-ethyl) -amide, (6-Phenoxy-pyridin-3-ylmethyl) -amide- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole- 3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid phenylamide, 5- (2-chloro-4,5-) methyl-phenyl-amide difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (Piperidin-1-yl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (4-ethoxycarbonyl-piperidin-1-yl) -amide (4-Methyl-piperazin-1-) il) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2-chloro-4-carboxy-piperidin-1-yl) -amide -chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid phenethylamide, Methyl 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid phenethyl-5- (2-c) acid ethyl phenyl-amide par-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, (1, 2,3,4-tetrahydroisoquinolin-2-yl) -amide of 5- (2-chloro-4,5- difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- ((S) -a-methoxycarbonyl-benzyl) -amide- 3-Carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ((R) -a-methoxycarbonyl-benzyl) -amide (1,2,3) , 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-tetrahydroquinolin-1-yl) -amide, 5- (2-) chloro-4,5-difluoro-benzoylamino) -1 H-pyrazol-3-carboxylic acid, butyl-phenyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole- 3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid phenyl-phenyl-amide, M a) Benzhydril-acid amide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (Pyridin-2-ylmethyl) -amide-5-hydrochloride (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (5- (2-chloro-4,5-difluoro-benzoylamino) - (Pyridin-4-ylmethyl) -amide-hydrochloride] ) -1 H-pyrazole-3-carboxylic acid, ((R) -2-Hydroxy-1-phenyl-ethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ((S) -2-hydroxy-1-phenyl-ethyl) -amide. , 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (Dimethyl-benzylamide), 5- (2-chloro) -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole, (Tiofen-2-ylmethyl) -amide -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamine) -1H-pyrazole-3-carboxylic acid (2-methoxy-phenyl) -amide, (2-methoxy-phenyl) -methyl- acid amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-chloro-4,5-difluoro-benzoylamino) -4-dimethylamino-benzylamide-hydrochloride H-pyrazole-3-carboxylic acid, 3-Amino-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-Amino-benzylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1 H-2-Methyl-benzylamide -pyrazol-3-carboxylic acid, 3- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3-methyl-benzylamide, 3-dimethylamino-benzylamide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5- (2-chloro-pyridin-3-ylmethyl) -amide) 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-chloro-benzylamide, 3 5- (2-Chloro-4-chloro-benzyl amide), 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-methoxycarbonyl-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid carboxy-benzylamide, 5- (2-trifluoromethyl-pyridin-3-ylmethyl) -amide chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (2- (3-ethoxy-pyridin-3-ylmethyl) -amide) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-dimethylamine-ethyl) -amide, Ethyl- (2- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dimethylamino-ethyl) -amide-dihydrochloride, 5- Cyclohexyl- (2-dimethylamino-ethyl) -amide (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro) (4-methoxy-pyridin-2-ylmethyl) -amide -benzoylamino) -1H-pyrazole-3-carboxylic acid, (2,6-dimethoxy-pyridin-3-ylmethyl) -amide of 5- (2-cl) gold-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-methoxycarbonylmethoxy-benzylamide carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-methoxy-pyridin-3-ylmethyl) -amido acid - (4,5-Difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid (5- (2,4-Dichloro-) (6-methoxy-pyridin-3-ylmethyl) -amide) benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- (3,5-dimethoxy-pyridin-4-ylmethyl) -amide. 3-carboxylic acid 5- (4,5-Difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-oxazol-5-ylmethyl) -amide, (2,4- Dimethyl-oxazole-5- , 5- (2,4-dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-methoxycarbonyl-phenyl) -methyl-amide methyl- (5- ( 2-Chloro-4,5-difluorobenzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1- H- (4-Carboxyphenyl) -methyl-amide pyrazole-3-carboxylic acid, 4- {[5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] -methyl-amino} -benzoate monosodium Isopropyl 5- (2-Chloro-4,5-difluoro-benzoylamino) -! H -pyrazole-3-carboxylic acid phenyl-amide, 5- (2-chloro-) acid (ethoxycarbonyl-methyl) -phenyl-amide 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- (Carboxymethyl) -phenyl-amide 3-carboxylic acid, 5- (2-chloro-4-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2,4-Dichloro-benzoylamino) -1H-pyrazole- 3-carboxylic acid, 5- (2-chloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, Benzyl-fe 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (1-methyl-1-phenyl-ethyl) -amide of 5 ( 2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid [2-Oxo-2- (piperidn-1-yl) -ethyl] -phenyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (5-Fluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Chloro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (4-Methoxy-2-methyl-benzoylamino) -1H-pyrazole-3-benzylamide carboxylic acid, 5- (4-Chloro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Fluoro-2-methoxy-benzoylamino) -1H-pyrazole- 3-carboxylic, 5- (5-Chloro-2-methoxy-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-4,5-) 2- (2-ethoxy-ethyl) -phenyl-amide difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Fluoro-5-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Chloro-2-) acid benzylamide fluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (3-Chloro-2,6-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro) acid benzylamide -3-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ethylcarbamoylmethyl-phenyl-amide, Isobutyl 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid phenyl-amide, 5- (2-chloro) acid (2-methoxycarbonyl-ethyl) -phenyl-amide -4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (3-ethoxycarbonyl-propyl) -phenyl-amide -pyrazol-3-carboxylic acid, (2-carboxy-ethyl) -phenyl-amide of 5- (2-c) acid par-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (3-Carboxy-propyl) -phenyl-amide -pyrazole-3-carboxylic acid, 5- (2-Hydroxy-4-methoxy-benzoxylamino) -1H-pyrazol-3-carboxylic acid benzylamide, 5- (2-Hydroxy-5-methoxy-benzoylamino) acid benzylamide ) -1H-pyrazole-3-carboxylic acid, 5- (5-Fluoro-2-hydroxy-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (4-Fluoro-2-trifluoromethyl) acid benzylamide -benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (5-Fluoro-2-trifluoromethyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, (2-methoxy-ethyl) -phenyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5- (2,5-Dimethyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide , Benzylamide of 5- (2-chloro-5-methyl-benzoylamino) -1 H -pyrazole- iU 3-carboxylic acid, 5- (2-chloro-pyridine-3-carbonylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (4-Chloro-pyridine-2-carbonylamino) -1H-pyrazole acid benzylamide -3-carboxylic acid, 5- (2,6-dichloro-pyridine-3-carbonyl-amino) -1 H-prazol-3-carboxylic acid benzylamide, 5- (3-ethoxycarbonyl-phenyl) -amide (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) butyl- (4-carboxy-phenyl) -amide) -1 H-pyrazole-3-carboxylic acid, 5- (2-Methyl-pyridine-3-carbonylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-Chloro-6-methyl-pyridin-3-carbonylamino) -1 H -pyrazole-3-carboxylic acid benzylamide, 5- (3-Chloro-pyridine-4-carbonylamino) -benzylamide 1 H-pyrazole-3-carboxylic acid, butyl- (4-ethoxycarbonylmethyl-phenyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Butyl- (4 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (carboxymethyl-phenyl) -amide (4-methoxycarbonyl-phenyl) - (2-methoxy-ethyl) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, (4-Carboxy-phenyl) - (2-methoxy-ethyl) -amide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-) 6-methoxy-pyridin-3-ylmethyl) -amide-dihydrochloride difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-Methyl-4,5-difluoro-benzoylamino) (6-methoxy-pyridin-3-ylmethyl) -amide-dichlorhydrate -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 Hp (thiazol-4-ylmethyl) -amide-dihydrochloride Indole-3-carboxylic acid, 4- [2- (Morpholin-4-yl) -ethylcarbamoyl] -benzylamide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3- acid carboxylic acid 4- (Morpholin-4-ylcarbamoyl) -benzylamide-dihydrochloride of 5- (2-chloro-4,5- difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, sodium salt of [4- ( { [5- (2-chloro-4,5-difluoro-benzoylamino) -1 Hp -razol-3-carbon] L] -amino.}. -methyl) -benzoylamino-acetic acid, sodium salt of 3- [4- ( { [5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole -3-carbonyl] -amino.}. -methyl) -benzoylamino] -propionic acid. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,5-Dimethyl-isoxazole-4-methylmethoxy) -amide hydrochloride, (1, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3,5-trimethyl-l-pyrazol-4-ylmethyl) -amide-dichloride (3,5 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dimethyl-3-ylmethyl) -amide-sulfonate, 3- [2- (Molin-4- il) -ethylcarbamoyl] -benzylamide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3- (Molin-4-ylcarbamoyl) -benzylamide-dihydrochloride of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid,. { 2- [2- (Molin-4-yl) -ethylcarbamoyl] -pyridin-4-ylmethyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide trichlorohydrate, [2- (Molin-4-ylcarbamoyl) -pyridin-4-ylmethyl] - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide trichlorohydrate, 5- (2-methoxy-pyridin-3-ylmethyl) -amide methanesulfonate -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-) (6-methoxy-pyridin-3-ylmethyl) -amide-hemiside. benzoylamino) -1 H p -razol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (3,5-dimethoxy-pyridin-4-ylmethyl) -amide-dihydrochloride pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-Aminomethyl-pyridin-2-ylmethyl) -amide-trichlorhydrate. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-ylmethyl) -amide methanesulfonate, (6-chloro-pyridin) -3-ylmethyl) 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3- acid dimethanesulfonate carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-pyridin-3-ylmethyl) -amide-hydrochloride, (Pyridin- 3- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (3-methoxy-pyridin-3-ylmethyl) -amide hydrochloride. ) -propyl amide-5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid dihydrochloride, [6- (Piperidin-1-yl) -pyridin-3-ylmethyl ] - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide dihydrochloride, [6- (Molin-4-yl) -pyridin-3-ylmethyl] -amide-acid dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid, (3,5-Dichloro-pyridin-4-ylmethyl) -amide-5- (2-hydrochloride -chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro) (6-dimethylamino-pyridin-3-ylmethyl) -amide-dihydrochloride -benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (6-dimethylamino-pyridin-3-ylmethyl) -propyl-amide-dihydrochloride -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (6-diethylamino-pyridin-3-ylmethyl) -amide-dichlorhydrate. -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 (6-chloro-2-dimethylamino-pyridin-3-ylmethyl) -amide-dihydrochloride -carboxylic, 4- (1, 2,3) thiadiazol-4-yl-benzyl) -amide-5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- acid hydrochloride carboxylic acid, 5- (2-chloro-4,5-) 4- (methyl-thiazol-5-ylmethyl) -amide-hydrochloride | I ik v.lI difluoro-benzoylamino) -1 H -prazole-3-carboxylic acid (5- (2-chloro-4,5-2,4-dimethyl-thiazol-5-ylmethyl) -amide-hydrochloride] -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [6- (4-hydroxy-piperidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride of acid, 5- (2 -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -5-Methyl-pyrazin-2-ylamide-dihydrochloride -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid quinoline-5-ylamide-dihydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid quinoline-8-ilamide-dihydrochloride, 5- (2-chloro) acid lsoquinolin-5-ylamide-dichloride. -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [5- (4-Methylpiperazin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride of 5- (2-chloro) -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [6- (4-Dimethylamino-p1peridin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [6- (pyrrolidin-1-yl) -pyridin-3-ylmethyl] -amide-acid dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro), (pyrazin-2-ylmethyl) -amide-dihydrochloride -benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5) -6- (2-chloro-4,5-dihydrochloride [6- (thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride] -difluoro-benzoylamino) -1 H-pyrrazol-3-carboxylic acid, [6- (1,1-Dioxo-1 l6-thomorpholin-4-yl) -pyridin-3-ylmethyl] -amide- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid dihydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) -carbamoylmethyl-amide H-pyrazole-3-carboxylic acid, (4-carbamoyl-phenyl) -methyl-amide, 5- (2,4-dichloro-5-fluoro-benzoylamino) - U 1 H -pyrazole-3-carboxylic acid, 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid methyl- (4-methylcarbamoyl-phenyl) -amide, (4- Dimethylcarbamoyl-phenyl) -methyl-amide of 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (4-methanesulfonylaminocarbonyl-phenyl) -methyl-5-methyl acid amide (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, Sodium salt of 5- (2-chloro-4,5) (4-methanesulfonylaminocarbonyl-phenyl) -methyl-amide acid -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 (4-cyano-phenyl) -methyl-amide -carboxylic acid, methyl- [4- (4H- [1, 2,4] triazol-3-yl) -phenyl] -amide-5- (2-chloro-4,5-difluoro-benzoylamino) -hydrochloride -1H-pyrazole-3-carboxylic acid, 5- (4-azido-2-chloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-cyano-phenyl) -methyl-amide, methyl - 5- (4-Azido-2-chloro-5-fluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid [4- (1 H-tetrazol-5-yl) -phenyl] -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid [4- (N-hydroxycarbamimidoyl) -phenyl] -methyl-amide, Methyl- [4- (5 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-5-dihydro- [1, 2,4] oxadiazol-3-yl) -phenyl] -amide. 3-carboxylic,. { 4 - [(2,2-Dimethyl-propionyloxy) -methoxycarbonyl] -phenyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid methylamide, 4- [N- (methoxy-thiocarbonyloxy) -carbamimidoyl] -methyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Methyl- [4- (5-thioxo-4,5-dihydro- [1,2,4] oxadiazole] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, -3- (5-oxo-4,5-methyl) -3-yl) -phenyl] -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid [1, 2,4] thiadiazol-3-yl) -phenyl) -amide ,. { 4- [1 - (Ccyclohexyloxycarbonyloxy) -ethoxycarbonyl] -phenyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-ethoxycarbonyl-thiazol-2-yl) -etyl-amide acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-methanesulfonylamino-benzylamide -pyrazol-3-carboxylic acid, 2-acetylamino-benzylamide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (dimethylamino-methyleneamino) -benzylamide- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid hydrochloride, 3- (2-chloro-4-dimethylamino-methyleneamino) -benzylamide-hydrochloride 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- 4- (dimethylamino-methyleneamino) -benzylamide-hydrochloride 3-carboxylic acid 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2- (1- (dimethylamino) ethylidenamino] -benzylamide-dihydrochloride, 3- [1 - (Dimethylamino) ethylidenamino] -benzylamide-dichloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid hydrate, 4- [1- (Dimethylamino) -ethyldylamino] -benzylamide-dihydrochloride of 5- (2-Acid) -chloro-4,5-difluoro-benzoylamine) -1 H-pyrrazol-3-carboxylic acid 2- (2-chloro-4,5-diethylamino-methyleneamino) -benzylamide-dihydrochloride difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3- (diethylamino-methyleneamino) -benzylamide-dihydrochloride 4- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) acid, 2-acetylimidoamino-benzylamide-dihydrochloride (2-chloro-4,5-difluoro-benzoylamino) -1 H- L. pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3-acetimidoylamino-benzylamide-dihydrochloride, 4- acetimidoylamino-benzylamide-dihydrochloride acid - (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-cyano-benzylamide acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylic acid, 3- (2-fluoro-benzimidoyl) -amino] -benzylamide-hydroxy acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid , 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4- (3-fluoro-benzoimidoyl) -amino] -benzylamide-hydroiodide 3-Dimethyl-ureido) -benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (3,3-dimethyl-ureido) -benzylamide of acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro) 2- (Toluene-4-sulfonylamino) -benzyl-amide -benzoylamino) -1 H-pyrazole-3-carboxylic acid, 2-Amino-6-fluoro-benzylamide-cl 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid orhydrate, 2- (2-chloro) 2-Amino-4,5-difluoro-benzylamide-5-chlorohydrate -4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole (lndan-l-yl) -amide -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (lHndan-2-yl) -amide, (4H-Quinazolin-3-yl) - acid amide 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, (4H-quinazolin-3-yl) -piperidine-dihydrochloride 5- (2-chloro- 4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) 7-Fluoro-4H-quinazolin-3-yl) -amide-dihydrochloride ) -1 H p -razol-3-carboxylic, (6-Fluoro-4H- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid khachnyl-3-yl) -amide-hydrochloride (2-Ethoxy-2-methyl-1,4) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-dihydro-2H-quinazolin-3-yl) -amide, (2-Cyano-pyridin-4-yl); lmethyl) 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, [2- (N-Hydroxycarbamimidoyl) -pyridin-4-ylmethyl] -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, [2- (5-Oxo-4,5-dihydro- [1,4,4] oxadiazole- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3-yl) -pyridin-4-ylmethyl-amide, sodium salt of 4- acid. { [5- (4,5-difluoro-2-methyl-benzoylamino) -1 H-pyrazole-3-carbonyl] -methyl-amino} -benzoic Methyl- [4- (1 H-tetrazol-5-yl) -phenyl] 5- (4,5-Difluoro-2-methyl-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2,4-Dichloro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide, 5- (2,4-Dichloro) -amide (5- (2,4-Dichloro) -5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2,6-Dichloro-5-fluoro-pyridine-3-carbonylamino) -1- H-pyridin-3-ylmethyl-amide pyrazole-3-carboxylic acid, 5 - [(3-Chloro-benzo [b] thiophen-2-carbonyl) -amino] -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide, (Pyridin) -3-ylmethyl) -amide 5 - [(3-Chloro-thiophen-2-carbonyl) -amino] -1 H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -am¡da acid 5 -Benzoylamino-1 H-pyrazole-3-carboxylic acid, 5-phenylacetylamine-1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide, 5-phenylacetylamine-1-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide-dihydrochloride - (2-Methyl-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Amino-4,5-difluoro-ben) (pyridin-3-methyl) -amide zoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (4,5-difluoro-2-pyridin-3-ylmethyl) -amide l iü ji methanesulphonylamino-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-acetylamino-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3 (pyridin-3-ylmethyl) -amide. -carboxylic acid, 5 - [(3,4,5-trichloro-thiophene-2-carbonyl) -amino] -1H-pyrazole-3-carboxylic acid (2-cyano-, pyridin-3-ylmethyl) -amide. pyridin-4-ylmethyl) -amide 5- (4,5-difluoro-2-methyl-benzoylamino) -1 H-pyrazole-3-carboxylic acid [2- (1 H-tetrazol-5-yl) -p 5- (4,5-difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid ridin-4-ylmethyl] -amide.and 5 - [(2,4-dichloro-phenyl) -amide] -1H-Pyrazole-3,5-dicarboxylic acid 3-benzylamide. 21. A medicament comprising a combination of a pharmaceutical composition for treating or preventing diabetes, according to any of claims 1 to 20, and another therapeutic or prophylactic agent for combating diabetes. 22. The medicament according to claim 21, further characterized in that the other therapeutic or prophylactic agent for the control of diabetes is a preparation (injection) of insulin, an oral insulin agent, of low molecular weight, a receptor agonist of sulfonylurea (SU agent), an insulinotropic agent without sulfonylurea, a potassium-dependent ATP channel opening agent (KATP), an α-glucosidase inhibitor, an α-amylase inhibitor, an α-amylase inhibitor, insulin sensitivity, a low molecular weight tGLP receptor agonist, a peptide analogue tGLP-1, an inhibitor of dipeptidyl peptidase IV (DPP-IV), a glucagon receptor antagonist, a receptor antagonist of glucocorticoids, a biguanide, a SGLUT inhibitor, a fructose-1, 6- bisphosphatase inhibitor (FBPase), an inhibitor of glycogen synthase kinase 3 (GSK-3, glycogen synthase kinase 3), a Phosphoenolpyruvate carboxy kinase inhibitor (PEPCK, phosphoenolpyruvate carboxikinase), an inhibitor of protein tyrosine 1B phosphatase (PTPaselB, protein tyrosine phosphatase 1B), an inhibitor of the SH2 domain containing inositol phosphatase (SHIP2, SH2 domain containing inositol phosphatase) , a glycogen phosphorylase inhibitor (GP, glycogen phosphorylase), a glucokinase activator, a GPR40 receptor agonist, a pyruvate dehydrogenase kinase (PDHK) inhibitor, a glutamine inhibitor: fructose- 6-phosphate aminotransferase (GFAT), an antioxidant; a nitric oxide sequestrant, an inhibitor of carnitine O-palmitoyltransferase 1 (CPT-1), a growth hormone releasing factor (GHRF), a triacylglycerol lipase inhibitor (hormone-sensitive lapase) ), a PPARα receptor agonist, a PPARα receptor antagonist, a PPARα receptor agonist a / ?, an activator of the AMP activation protein kinase (AMPK, AMP activation protein kinase), a adiponectin receptor agonist or a β3-adrenoceptor agonist. 23. The medicine according to claim 21 or 22, further characterized in that the other therapeutic or prophylactic agent for diabetes is insulin, toibutamide, gluclopyramide, acetohexamide, chlorpropamide, glibuzol, glibenclamide, gliclazide, glimepiride, mitiglinide, repaglinide, nateglinide , voglibose, acarbose, miglitol, maleate M? . Rosiglitazone, metformin hydrochloride, Poglitazone hydrochloride or buformin hydrochloride. 24. A medicament comprising a combination of a pharmaceutical composition for treating or preventing diabetes, according to any of claims 1 to 20, and another therapeutic or prophylactic agent to combat diabetic complications. 25. The drug according to claim 24, further characterized in that the other therapeutic or prophylactic agent to combat diabetic complications is an inhibitor of the protein kinase β (PKC β), an antagonist of the angiotensin II receptor, an inhibitor of aldose reductase, an inhibitor of angiotensin-converting enzyme (ACE), an inhibitor of advanced glycation end-product production (AGE), a therapeutic agent against neuropathy or a therapeutic agent against diabetic nephropathy. 26. The drug according to claim 24 or 25, further characterized in that the other therapeutic or prophylactic agent for combating diabetic complications is epalrestat, mexiletine hydrochloride or imidapril hydrochloride. 27. A medicine comprising a combination of a pharmaceutical composition for treating or preventing diabetes, according to any of claims 1 to 20, and another therapeutic or prophylactic agent to combat hyperlipidemia. lill L, tl 28. The medicament according to claim 27, further characterized in that the other therapeutic or prophylactic agent for combating hyperlipidemia is a fibrate (PPARα receptor agonist), a PPARα receptor agonist, an inhibitor of the protein transfer protein microsomal triglycerides (MTP), an inhibitor of cholesteryl ester transfer protein (CETP), a statin (HMG-CoA reductase inhibitor), an anion exchanger, probucol, a nicotinic drug, a plant sterol, an inducer of apolipoprotein-A1 (Apo-A1), a lipoprotein lipase activator (LPL), an inhibitor of endodermis lipase, ezetimibu, an inhibitor of IBAT, an inhibitor of the enzyme of squalene synthesis, an ACAT inhibitor, an LXR receptor agonist, an FXR receptor agonist, an FXR receptor antagonist or an adenos agonist ina A1. 29. The medicament according to claim 27 or 28, characterized in that the other therapeutic or prophylactic agent to combat hyperlipidemia is clofibrate, bezafibrate, fenofibrate, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin, cerivastatin. , cholestyramine, nicotinate tocopherol, nicomol, niceritrol, soisterol or gamma oryzanol. 30. A medicine comprising a combination of a pharmaceutical composition for treating or preventing diabetes, in accordance with MkA ??? with any of claims 1 to 20, and another therapeutic or prophylactic agent to combat obesity. 31. The medicine according to claim 30, further characterized in that the other therapeutic or prophylactic agent to combat obesity is a preparation of leptin, a pancreatic lipase inhibitor, a noradrenaline-serotonin reuptake inhibitor, a cannabinoid receptor antagonist, a monoamine reuptake inhibitor, an inhibitor of diacylglycerol acyltransferase (DGAT), a glucose dependent insulin-dependent polypeptide receptor (GIP) antagonist, an agonist of the leptin receptor, an agonist of subtype 3 of bombesin receptors (BRS-3, bombesin receptor subtype 3), an inhibitor of perilipine, an inhibitor of acetyl-CoA carboxylase 1 (ACC1), an inhibitor of acetyl-CoA carboxylase 2 (ACC2), an inhibitor of fatty acid synthase, an inhibitor of sn-1-acyl-glycerol-3-phosphate-acyltransferase (AGPAT), an inhibitor of phospholipase A2 of the pancreas (pPLA2, pancreas phospholipase A2), a receptor agonist of melanocortin (MC), a neuropeptide receptor antagonist Y5 (NPY5), an inducer or activator of the uncoupling protein (UCP), an activator of carnitine O-palmitoyltransferase 1 (CPT-1), an agonist of CCK1 (CCKA), a ciliary neurotrophic factor (CNTF, ciliary neurotrophic factor), a CRF2 agonist, a neuropeptide Y2 receptor antagonist (NPY2), a neuropeptide Y4 receptor antagonist (NPY4), a beta-receptor agonist of the iv) thyroid hormone, a growth hormone, an ATP citrate lyase inhibitor, a 5-HT6 antagonist, or a 5-HT2C agonist. 32. The drug according to claim 30 or 31, further characterized in that the other therapeutic or prophylactic agent to combat obesity is leptin, oriistat, sibutramine, rimonabant or mazindol. 33. A medicine comprising a combination of a pharmaceutical composition for treating or preventing diabetes, according to any of claims 1 to 20, with another therapeutic or prophylactic agent against hypertension. 34. The medication according to claim 33, further characterized in that the other therapeutic or prophylactic agent against hypertension is a thiazide diuretic, a thiazide diuretic similar, a loop diuretic, a K-retention diuretic, a β a blocker, a a, b blocker, a blocker, a central sympathetic nervous system depressant, a peripheral sympathetic nervous system depressant (rauwolfia preparation), a Ca (benzothiazepine) antagonist, a Ca (dihydropyridine) antagonist, a vasodilator, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, a nitric acid preparation, an endothelin receptor antagonist ETA, an inhibitor of the enzyme converting enzyme, endothelin; an inhibitor of neprilysin, a prostaglandin; a prostanoid FP agonist, a renin inhibitor, an expression enhancer of ?, U ..., I | NOS3; an analogue of prostacyclin, an inhibitor of phosphodiesterase V (PDE5A), an analogue of prostacyclin or an aldosterone antagonist. The medication according to claim 33 or 34, further characterized in that the other therapeutic or prophylactic agent to combat hypertension is hydrochlorothiazide, trichlormethiazide, benzylchlororthiazide, meticrane, indapamide, tripamide, chlorthalidone, mefruside, furosemide, spironolactone, triamterene, atenolol, bisoprolol fumarate, betaxolol hydrochloride, bevantolol hydrochloride, metoprolol tartrate, acebutolol hydrochloride, celiprolol hydrochloride, nipradilol, tilisolol hydrochloride, nadolol, propranolol hydrochloride, indenolol hydrochloride, carteolol hydrochloride, pindolol, Sustained release of pindolol, bunitrolol hydrochloride, penbutolol sulfate, bopindolol malonate, amosulalol hydrochloride, arotinolol hydrochloride, carvedilol, labetalol hydrochloride, urapidil, terazosin hydrochloride, doxazosin mesylate, bunazosin hydrochloride, prazosin hydrochloride, mesylate of phentolamine, clo rhidrato clonidine de_guanfacina hydrochloride, guanabenz acetate, methyldopa, reserpine, rescinnamine, amlodipine besilate, aranidipine, hydrochloride efonidipine, cilnidipine, nicardipine hydrochloride, nisoldipine, nitrendipine, nifedipine, nifedipine sustained release, nilvadipine, hydrochloride barnidipine, felodipine, benidipine hydrochloride, manidipine hydrochloride, azelnidipine, diltiazem hydrochloride, hydrazine monohydrochloride, allralazine hydrochloride, budralazine, cadralazine, captopril, enalapril maleate, alacepril, delapril hydrochloride, |; I.I. cilazapril, lisinopril, benazepril hydrochloride, imidapril hydrochloride, tamocapril hydrochloride, quinapril hydrochloride, trandolapril, perindopril erbumine, candesartan cilexetil, valsartan, telmisartan, olmesartan medoxomil, sodium nitroprusside or nitroglycerin. 36.- A pyrazole compound or a pharmacologically acceptable salt thereof, represented by the following general formula (I): wherein, the Q ring represents an aryl group or a heteroaromatic group; R1 represents a hydrogen atom, a halogen atom, a d6 alkyl group or a C1-6 alkoxy group; R 2 represents a halogen atom, a d 6 alkyl group, a d 6 alkoxy group or an azido group; R3 represents a halogen atom, a hydroxyl group, a C? 6 alkyl group, a haloalkyl group d_6, an alkoxy group Ci-e, an azido group, an amino group, an acylamino group or an alkyl group (C? _6) sulfonyllamino; and R4 and R5 are identical to each other or different from one another, and represent: (1) a hydrogen atom; (2) a C? _6 alkyl group, which may be substituted with a substituent selected from Group A presented below: [Group A] A1. A hydroxyl group, A2. An alkoxy group d.6l A3. -N (R41) (R41 ') wherein R41 and R41' are identical to each other or different from each other and represent a hydrogen atom or an alkyl group d.6; and R41 and R41, together with the adjacent nitrogen atom, can form a saturated, monocyclic 5 or 6 membered heterocyclic ring, A4. An aryl group, A5. A heteroaromatic group, A6. -CO-N (R411) (R411 ') where p4n and p4ir are jj? Tjcos to each other or different from each other and represent a hydrogen atom or an alkyl group d.6; and R411 and R411, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic heterocyclic ring, A7. A carboxy group, and, A8. An alkoxy (d-6) carbonyl group, (3) a C2.6 alkenyl group; (4) a C2.6 alkynyl group; (5) a C3.8 cycloalkyl group; wherein the cycloalkyl group may be substituted with a hydroxy group, a carboxy group or an alkoxy (d6) carbonyl group, or it may be fused with a pyridine ring, (6) a (C3.8) alkyl cycloalkyl group d- H.H; where the cycloalkyl group of the cycloalkyl (C3. 8) alkyl group C 1 can be substituted with a hydroxyl group, a carboxy group or an alkoxy (d 6) carbonyl group, or it can be fused with a pyridine ring, (7) a saturated, monocyclic, 5- or 6-membered heterocyclic group which may be substituted with a substituent selected from Group C presented below: [Group C] C1. An alkyl group C -? - 6, C2. A group acílo, C3. An alkyl (d-6) sulfonyl group, C4. A carboxy group, C5. An alkoxy group (C? .6) carbonyl, and, C6. -CO- (Alk) n-COOR52, wherein R52 is a hydrogen atom or a C-i-β alkyl group; Alk is an alkylene C-M group; and n is 0 or an integer comprised between 1 and 3, (8) an aryl group which may be substituted with one or more substituents selected from Group D presented below: [Group D] D1. A hydroxy group, D2. An alkoxy group d.6, D3. A cyano group, D4. A d-β alkyl group, where the d-β-alkyl group ,? may be substituted with a substituent selected from the group consisting of a hydroxyl group, a carboxy group and a (C6-6) alkoxycarbonyl group, D5. -N (R53) (R53 '), where R53 and R53' are identical to each other or different from one another and represent a hydrogen atom, an alkyl group d.6 or an alkyl group (d.6) sulfon What, D6. -CO-N (R531) (R531) wherein R531 and R531 are identical to each other or different from each other and represent a hydrogen atom, a C? .6 alkyl group or an alkyl group (C? ) sulfonyl, D7. -COOR54, where R54 is a hydrogen atom, a C6_6 alkyl group, a (C-? 6) alkylcarbonyloxy-d6 alkyl group or a cycloalkyloxy (C3.8) carbonyloxy-alkyl group; .6, D8. -C (NH (OH)) = N-R55, where R55 is a hydrogen atom or an alkyl (d.6) sulfonyl group, D9. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, and, D10. A heteroaromatic group, monocyclic, 5- or 6-membered, which may be substituted with an oxo or thioxo group, (9) a heteroaromatic group fused with a benzene ring or a 5- or 6-membered monocyclic ring, which may be substituted a substituent selected from the group consisting of a carboxy group and a (C6-6) alkoxycarbonyl group; (10) an aralkyl group C7_? 4; where the alkyl part of the aralkyl group C7_-? may be substituted with one or two substituents, selected from Group E, presented below, and the aryl portion may be substituted with one or more substituents selected from Group F, presented below: [Group E] E1. A C? _6 alkyl group, which may be substituted with a hydroxyl group, E2. A cyano group, E3. A carboxy group, E4. An alkoxy group (C? .6) carbonyl, and, E5. mli i A phenyl group, [Group F] F1. A C? 6) F2 alkyl group. A halogen atom, F3. A cyano group, F4. A hydroxyl group, F5. An alkoxy group d. 6, which may be substituted with a substituent selected from a carboxy group and a (C-α-6) alkoxycarbonyl group, F6. A haloalkyl group d.6, F7. A carboxy group, F8. An alkoxy group (C? ^) Carbonyl, F9. -CO-N (R56a) (R56a), wherein R56a and R56a are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated group, having at least one a nitrogen atom, or a C? 6 alkyl group, which may be substituted with a substituent selected from Group f presented below: [Group f] f1. An amino group, f2. A monoalkyl group (C -? _ 6) amino, f3. A dialkyl (C-? 6) amino group, f4. A carboxy group, f5. An alkoxy group (C? ^) Carbonyl, f6. A hydroxyl group, y, f7. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, having at least one nitrogen atom, F10. -N (R56b) (R56b) wherein R56b and R56b 'are identical to each other or different from each other and represent a hydrogen atom, a C- | 6 alkyl group, which may be substituted with a lower group, a aralkyl group, which may be substituted with one or more identical or different substituents selected from an imino group and a halogen atom, an arylsulfonyl group which may be substituted with an alkyl group d-6, an alkyl group (C-? 6) ) sulfonyl, an acyl group, a carbamoyl group, a monoalkyl (C6-6) carbamoyl group or a dialkyl (C6-6) carbamoyl group, F11. -N = CR57 (-N (R58) (R58), where R57 is a hydrogen atom or a C? 6 alkyl group) R58 and R58 are identical to each other or different tiikkyi ?? one of the others and represent a hydrogen atom or an alkyl group d. 6, F12. A heteroaromatic group, monocyclic, of 5 or 6 members, and, F13. A methylenedioxy group or an ethylendioxy group, or, (11) a d6 alkyl group substituted with a heteroaromatic, monocyclic, 5- or 6-membered group, or a heteroaromatic group obtained by condensation of the heteroaromatic group with a benzene ring; wherein the heteroaromatic group may be substituted with one or more substituents selected from Group G, presented below: [Group G] G1. A C -? - 6 alkyl group, which may be substituted with a substituent selected from Group g, presented below: [Group g] g1. A halogen atom, g2. An amino group, g3. A monoalkyl (d-6) amino group, g4. A dialkyl (C? .6) amino group, g5. An alkoxy group (C? -6) carbonylamino, and, g6. A hydroxyamide group, G2. A halogen atom, G3. An alkoxy group d.6 which may be substituted with a halogen atom, G4. An aryloxy group, G5. A cyano group, G6. -N (R59a) (R59a), where R59a and R59a 'are identical to each other or different from each other and represent a hydrogen atom or a C1-6 alkyl group; and R59a and R59a, together with the adjacent nitrogen atom, can form a 5 or 6 membered heterocyclic, monocyclic, saturated ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group (d) -6) amino or a dialkyl (C? -6) amino group, G7. -CO-N (R59b) (R59b) wherein R59b and R59b 'are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated, or an alkyl group d-6, which can ..It be substituted with the heterocyclic group, G8. An aryl group, and, G9. A heteroaromatic, monocyclic group of 5 or 6 members, which may be substituted with an oxo or thioxo group, R4 and R5, together with the adjacent nitrogen atom, may form a saturated, 5- or 6-membered heterocyclic ring, where a part of the saturated heterocyclic ring may have a double bond, and the saturated heterocyclic ring may be fused to a benzene ring to form a fused ring, or the saturated heterocyclic ring which may be fused to a benzene ring to form a fused ring it may be substituted with a halogen atom, a d-β alkyl group, a d-6 alkoxy group, a carboxy group or a C 1 6 alkoxycarbonyl group. 37. The pyrazole compound according to claim 36, represented by the following general formula (I) or a pharmacologically acceptable salt thereof: wherein the Q ring represents an aryl group or a heteroaromatic group; R1 represents a hydrogen atom, a halogen atom, a C1.6 alkyl group or a d6 alkoxy group; R 2 represents a halogen atom, a C 6 alkyl group, a C 6 alkoxy group or an azido group; R3 represents a halogen atom, a hydroxyl group, a C1-4 alkyl group, a haloalkyl group d-6, a C6-6 alkoxy group, an azido group, an amino group, an acylamino group or a ix, the alkyl (C -? - 6) sulfonylamino group; R represents (1) a hydrogen atom; (2) a C? _6 alkyl group, which may be substituted with a substituent selected from Group A presented below: [Group A] A1. A hydroxyl group, A2. An alkoxy group d.6l A3. -N (R41) (R41 '), where R41 and R41' are identical to each other or different from each other and represent a hydrogen atom or a C1-6 alkyl group, and R41 and R41, together with the nitrogen atom adjacent, can form a heterocyclic ring, monocyclic 5 or 6 members, saturated, A4. An aryl group, A5. A heteroaromatic group, A6. -CO-N (R411) (R411), wherein R411 and R411 'are identical to each other or different from each other and represent a hydrogen atom or a C1-6 alkyl group; and R411 and R411, together with the adjacent nitrogen atom, can form a 5 or 6 membered monocyclic, saturated, heterocyclic ring, A7. A carboxy group, and, A8. An alkoxy (C? ^) Carbonyl group, (3) a C2-β alkenyl group; (4) a C2 ^ alkynyl group; (5) a C3.8 cycloalkyl; (6) a cycloalkyl (C3.8) alkyl group Ci ^; or, (7) an aryl group; and R5 represents (1) a C1-6 alkyl group, which may be substituted with a substituent selected from group B presented below: [Group B] B1. A hydroxyl group, B2. An alkoxy group C-i-β, B3. -N (R51) (R5r), where R51 and R51 'are identical to each other or different from each other and represent a hydrogen atom or an alkyl group and R51 and R51, together with the adjacent nitrogen atom, can form a heterocyclic ring, monocyclic 5 or 6 membered, saturated, and, B4. -CO-N (R511) (R511 '), wherein R511 and R511' are identical to each other or different from each other and represent a hydrogen atom or a C1.6 alkyl group, and R511 and R511, together with the atom of adjacent nitrogen, can form a heterocyclic, saturated 5 or 6 membered monocyclic ring, (2) a C3.8 cycloalkyl; wherein the cycloalkyl group may be substituted with a hydroxyl group, a carboxy group or a (C6-6) alkoxycarbonyl group or may be fused with a pyridine ring, (3) a (C3.8) cycloalkyl group, C- alkyl-? 6; wherein the cycloalkyl group of the (C3.8) cycloalkyl group, C 1-6 alkyl, may be substituted with a hydroxyl group, a carboxy group or an alkoxy group (d., .beta.carbonyl, or may be fused with a pyridine ring, (4) a 5- or 6-membered heterocyclic, monocyclic, saturated group which may be substituted with a substituent selected from Group C presented below: [Group C] C1: An alkyl group d-6, C2 An acyl group, C3 A group alkyl (C6) sulfonyl, C4 A carboxy group, C5 An alkoxy (d6) carbonyl group, and, C6.-CO- (Alk) n-COOR52, where R52 is a hydrogen atom or a alkyl group d-β; Alk is an alkylene C-M group; and n is 0 or an integer comprised between 1 and 3, (5) an aryl group which may be substituted with one or more substituents selected from Group D, presented below: [Group D] D1. A hydroxyl group, D2. An alkoxy d-β, D3 group. A cyano group, D4. A C? _6 alkyl group, wherein the C? .6 alkyl group may be substituted with a substituent selected from the group consisting of a hydroxyl group, a carboxy group and a (C? -6) carbonyl, D5 alkoxy group. -N (R53) (R53 '), where R53 and R53' are identical to each other or different from each other and represent a hydrogen atom, an alkyl group d-β or an alkyl (C6.6) sulfonyl group; what, D6. -CO-N (R531) (R531 '), where R531 and R531' are identical They are mutually different from each other and represent a hydrogen atom, a C? .6 alkyl group or an alkyl (C -? - 6) sulfonyl group, D7. -COOR54, where R54 is a hydrogen atom, a C1-6 alkyl group, an alkyl (d_6) carbonylloxy-alkyl d-β or a cycloalkyloxy group (C3.8) carbonyloxy-C1_6 alkyl , D8. -C (NH (OH)) = N-R55, where R55 is a hydrogen atom or an alkyl (C6) sulfonyl group, D9. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, and, D10. A heteroaromatic group, monocyclic, 5- or 6-membered, which may be substituted with an oxo or thioxo group, (6) a heteroaromatic group fused with a benzene ring or a 5- or 6-membered monocyclic ring, which may be substituted with a substituent selected from the group consisting of a carboxy group and a (C? 6) alkoxycarbonyl group; (7) a C-14 aralkyl group wherein the alkyl part of the C7-4 aralkyl group may be substituted with one or two substituents selected from Group E presented below, and the aryl part may be substituted with one or more substituents selected from Group F, presented below: [Group E] E1. An alkyl group d-6, which may be substituted with a hydroxyl group, E2. A cyano group, E3. A carboxy group, E4. An alkoxy group (C? ^) Carbonyl, and, E5. A phenyl group, [Group F] F1. An alkyl group d_6, F2. A halogen atom, F3. A cyano group, F4. A hydroxyl group, F5. An alkoxy d-6 group, which may be substituted with a substituent selected from the group consisting of a carboxy group and an alkoxy group (C-? 6) carbonyl, F6. A haloalkyl group F7. A carboxy group, F8. An alkoxy (d-6) carbonyl group, F9. -CO-N (R56a) (R56a), where R56a kUd and R56a are identical to each other or different from each other and represent a hydrogen atom, a 5- or 6-membered monocyclic heterocyclic group, saturated II, having at least one nitrogen atom, or a C? -6, which may be substituted with a substituent selected from Group f presented below: [Group f] f 1. An amino group, f2. A monoalkyl group (C? -6) amn, f3. A dialkyl group (C? _6) amino, f4. A carboxy group, f5. An alkoxy group (C? _6) carbonyl, f6. A hydroxyl group, y, f7. A heterocyclic group, monocyclic, 5- or 6-membered, saturated, having at least one nitrogen atom, F10. -N (R56b) (R56b '), wherein R56b and R56b' are identical to each other or different from one another and represent a hydrogen atom, a d6 alkyl group, which may be substituted with an imino group, an aralkyl group, which may be substituted with one or more identical or different substituents selected from an imino group and a halogen atom, an arylsulfonyl group which may be substituted by a C? -6 alkyl group, a (C? -6) sulfonyl alkyl group, an acyl group, a carbamoyl group, a monoalkyl (C? -6) carbamoyl group or a dialkJKC ^ carbamoyl group, F11. -N = CR57 (-N (R58) (R58 ')), where R57 is a hydrogen atom or a C? -6 alkyl group, R58 and R58 are identical to each other or different from each other and represent an hydrogen or a C alquilo6 alkyl group, F12. A heteroaromatic group, monocyclic, of 5 or 6 members, and, F13. A methylenedioxy group or an ethylenedioxy group, or, (8) a d-6 alkyl group substituted with a heteroaromatic, monocyclic, 5- or 6-membered group or a heteroaromatic group obtained by the condensation of the heteroaromatic group with HÜrilril a benzene ring; wherein the heteroaromatic group may be substituted with one or more substituents selected from Group G, presented below: [Group G] G1. A C? .6 alkyl group, which may be substituted with a substituent selected from Group g, presented below: [Group g] g1. A halogen atom, g2. An amino group, g3. A monoalkyl group (C? -6) amine, g4. A dyalkyl (d.6) amino group, g5. An alkoxy group (C -? _ 6) carbonyl, and, g6. A hydroxyimino group, G2. A halogen atom, G3. A C1-6 alkoxy group which may be substituted with a halogen atom, G4. An aryloxy group, G5. A cyano group, G6. -N (R59a) (R59a), where R59a and R59a are identical to each other or different from each other and represent a hydrogen atom or a d-β-alkyl group; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, saturated 5 or 6 membered heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group, and (C- | .6) amino or a dialkyl (d_6) amino group, G7. -CO-N (R59b) (R59b ') wherein R59b and R59b' are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated, or a group alkyl d-6, which may be substituted with the heterocyclic group, G8. An aryl group, and, G9. A heteroaromatic, monocyclic group of 5 or 6 members, which may be substituted with an oxo or thioxo group, R4 and R5, together with the adjacent nitrogen atom, may form a saturated, 5- or 6-membered heterocyclic ring, where a part of the saturated heterocyclic ring may have a double bond, and the saturated heterocyclic ring may be fused to a benzene ring to form a fused ring, or the saturated heterocyclic ring which may be fused to a benzene ring to form a fused ring it may be substituted with a halogen atom, an alkyl group, a C6-C6 alkoxy group, a carboxy group or an alkoxy (d6-C) carbonyl group. 38.- The pyrazole compound according to claim 36, represented by the following general formula (II ') or a pharmacologically acceptable salt thereof: wherein R1, R2, R3, R4 and R5 are as defined in claim 36. 39. The pyrazole compound according to claim 36, represented by the following general formula (II) or a pharmacologically acceptable salt of the same: wherein R4 and R5 are such as defined in claim 36; R1a represents a halogen atom or a hydrogen atom; R2a, a halogen atom; and R3a, a halogen atom or a C? 6 alkyl group. 40.- The pyrazole compound according to claim 39, further characterized in that R1a is a hydrogen or fluorine atom; R2a, a fluorine or chlorine atom; and R3a is a chloro atom or a d6 alkyl group, or a pharmacologically acceptable salt thereof. 41. The pyrazole compound according to claim 40, further characterized in that the pyrazole compound is a pyrazole compound represented by the following general formula (III) or a pharmacologically acceptable salt thereof: wherein R4 and R5 are as defined in claim 37. 42. The pyrazole compound according to any of claims 37 to 41, further characterized in that R4 is a group selected from the following group: (1) an atom of hydrogen; (2) an alkyl group d-6, which may be substituted with a substituent selected from Group A ', presented below or a pharmacologically acceptable salt thereof: [Group A] A'1. A hydroxyl group, A'2. A C1-4 alkoxy group, A'3. -N (R41) (R41), where R41 and R41 are identical to each other or different from one of the! others and represent a hydrogen atom or a C-M alkyl group, and R41 and R41, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered heterocyclic ring, A'4. A phenyl group, A'5. A heteroaromatic group, monocyclic, of 5 or 6 members, A'6. -CO-N (R411) (R411), wherein R411 and R411 are identical to each other or different from one another and represent a hydrogen atom or a C-M alkyl group; and R4 1 and R411, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic heterocyclic ring, A7. A carboxy group, and, A'8. A (C 4) alkoxycarbonyl group, (3) a C 2-6 alkenyl group (4) a C 2-6 alkynyl group; (5) a C3.8 cycloalkyl; and, (6) a (C3-8) alkylcycloalkyl group. 4- 43. The pyrazole compound or a pharmacologically acceptable salt thereof, according to any of claims 37 to 42, further characterized in that R5 is a d6 alkyl group, or a pharmacologically acceptable salt thereof. 44. The pyrazole compound or a pharmacologically acceptable salt thereof, according to any of claims 37 to 42, further characterized in that R5 is a C3.8 cycloalkyl, which may be substituted with a hydroxyl group, a carboxy group, or an alkoxy group (C? -6) carbonyl. 45.- The pyrazole compound or a pharmacologically acceptable salt thereof, according to any of the claims i Imláj i 37 a 42, characterized in that R 5 is a cycloalkyl (C3_8) alkyl group 46. - The pyrazole compound or a pharmacologically acceptable salt thereof, according to any of claims 37 to 42, further characterized in that R5 is a saturated, monocyclic, 5- or 6-membered heterocyclic group, which may be substituted with a substituent selected from an acyl group and -CO- (Alk) n-COOR52, wherein R52 is a hydrogen atom or a d-6 alkyl group, Alk is an alkylene group C, and n is 0 or an integer comprised between 1 and 3. The pyrazole compound or a pharmacologically acceptable salt thereof according to any of claims 37 to 42, further characterized in that R5 is a phenyl group, which may be substituted with one or more substituents selected from the following Group D ': [Group D'] D'1. An alkyl group d-4, which may be substituted with a carboxy group, D'2. -CO-N (R53) (R53), where R53 and R53 'are identical to each other or different from one another and represent a hydrogen atom, a C-M alkyl group or a C-M-sulfonyl alkyl group, D'3. -COOR54, where R54 is a hydrogen atom, an alkyl group an alkyl (C? -4) carbonyloxy-C-M alkyl group or a cycloalkyloxy group (C3.8) carbonyloxy-C-M alkyl, and, D'4. A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group. 48. The pyrazole compound or a pharmacologically acceptable salt thereof, according to any of claims 37 to 42, further characterized in that R5 is a C7.14 aralkyl group and the aryl part of the C7.14 aralkyl group can be be substituted with one or more substituents selected from the following Group F ': [Group F'] F'1. An alkyl group d-6, F'2. A halogen atom, F'3. A cyano group, F'4. A hydroxyl group, F'5. A C6_6 alkoxy group, which may be substituted with a carboxy group or a (C2_) alkoxycarbonyl group, F'6. A haloalkyl group d-6, F7. A carboxy group, F'8. An alkoxy (d-6) carbonyl group, F'9. -CO-N (R56a) (R56a) wherein R56a and R56a are identical to each other or different from each other and represent a hydrogen atom, a saturated, monocyclic, 5- or 6-membered heterocyclic group having at least one atom of nitrogen, or an alkyl group d_6, which may be substituted with a substituent selected from Group f, presented below: [Group f] f1. An amino group, f2. A monoalkyl group (C? -6) amine, f3. A dialkyl (C -? - 6) amino group, f4. A carboxy group, f5. An alkoxy (d_6) carbonyl group, f6. A hydroxy group, y, f7. A heterocyclic, monocyclic, 5- or 6-membered, saturated group having at least one nitrogen atom, F'10. -N (R56b) (R56b), wherein R56b and R56b 'are identical to each other or different from each other and represent a hydrogen atom, a C1-6 alkyl group, which may be substituted with an imino group, an aralkyl group , which may be substituted with one or more identical or different substituents selected from an imino group and a halogen atom, an arylsulfonyl group which may be substituted with a C? _6 alkyl group, an alkyl (d-6) sulfonyl group , an acyl group, a carbamoyl group, a monoalkyl (d.6) carbamoyl group or a dialkyl (C? 6) carbamoyl, F'11. -N = CR57 (-N (R58) (R58 ')), where R57 is a hydrogen atom or an alkyl group CM, R58 and R58 are identical to each other or different from each other and represent a hydrogen atom or a alkyl group d. 4, F'12. A heteroaromatic group, monocyclic, of 5 or 6 members, and, F'13. A methylenedioxy group or an ethylenedioxy group. 49.- The pyrazole compound or a pharmacologically acceptable salt thereof, according to any of claims 37 to 42, further characterized in that R5 is a d-6 alkyl group substituted with a heteroaromatic, monocyclic group of 5 or 6 members, and the heteroaromatic group may be substituted with one or more substituents selected from the following Group G ': [Group G'] G'1. A C6_6 alkyl group, which may be substituted with a substituent selected from Group g ', presented below: [Group g') g'1. A halogen atom, g'2. An amino group, g'3. A monoalkyl group (C? -6) amino, g'4. A dialkyl (d.6) amino group, g'5. An alkoxy (d-6) carbonylamino group, and, g'6. A hydroxyimino group, G'2. A halogen atom, G'3. An alkoxy d_6 group, which may be substituted with a halogen atom, G'4. An aryloxy group, G'5. A cyano group, G'6. -N (R59a) (R59a '), where R59a and R59a' are identical to each other or different from each other and represent a hydrogen atom or an alkyl group d. H.H; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic, heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group (C ? 6) amino or a dialkyl (C -? - 6) amino group, G'7. - l? lil CO-N (R59b) (R59b) wherein R59b and R59b 'are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated or a C1-alkyl group -6, which may be substituted with the heterocyclic group, G'8. An aryl group, and, G'9. A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group. 50.- The pyrazole compound or a pharmacologically acceptable salt thereof, according to any of claims 37 to 41, further characterized in that R5 and R4, together with the adjacent nitrogen atom, form a heterocyclic, monocyclic ring of 5. or 6 members, saturated, and the saturated heterocyclic group may have a double bond in one part, and may be fused to a benzene ring to form a fused ring, or the saturated heterocyclic group, which may be fused to a benzene ring to form a fused ring, it may be substituted with a halogen atom, a C 1-6 alkyl group, a d-6 alkoxy group, a carboxy group or an alkoxy (d-6) carbonyl group. 51.- The pyrazole compound or a pharmacologically acceptable salt thereof, according to claim 37, further characterized in that the pyrazole compound is a pyrazole compound represented by the following general formula (IV): wherein R4 is as described in claim 37; RX1, RX2 and RX3 are identical to each other or different from one another and represent a hydrogen atom or a substituent selected from the following Group F "; and m is 0 or an integer between 1 and 2, [Group F"] F "1. An alkyl group C? -6, F" 2. A halogen atom, F "3. A cyano group, F" 4. A hydroxyl group, F "5. An alkoxy group which may be substituted by a carboxy group or a alkoxy (d-4) carbonyl group, F" 6. A haloalkyl group d_6, F "7. A carboxy group, F" 8. An alkoxy (d-6) carbonyl group, F "9. -CO-N (R56a) (R56a) wherein R56a and R56a are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic group , 5 or 6 membered, saturated having at least one nitrogen atom, or a C? .6 alkyl group, which may be substituted with a substituent selected from Group f "presented below: [Group f] f'1. An amino group, f'2. A monoalkyl group (C? .6) amn, f'3. A dialkyl (C -? 6) amino group, f'4. A carboxy group, f'5. An alkoxy (d-6) carbonyl group, f'6. A hydroxyl group, y, f 7. A saturated, saturated, monocyclic, 5- or 6-membered heterocyclic group having at least one nitrogen atom, F "10 -N (R56b) (R56b *), wherein R56b and R56b ' They are .I and II identical to each other or different from each other and represent a hydrogen atom, an alkyl group d.6, which may be substituted with an imino group, an aralkyl group, which may be substituted with one or more identical substituents or different, selected from an imino group and a halogen atom, an arylsulfonyl group which may be substituted by a C? -6 alkyl group, a (C? -6) sulfonyl alkyl group, an acyl group, a carbamoyl group, a group monoalkyl (d.6) carbamoyl or a dialkyl (d .6) carbamoyl group, F "11. -N = CR57 (-N (R58) (R58 ')), where R57 is a hydrogen atom or a C 1-6 alkyl group, R58 and R58 are identical to each other or different from each other and represent a hydrogen atom or a d6 alkyl group, F "12. A heteroaromatic group, monocyclic, 5- or 6-membered, and, F "13. A methylenedioxy group or an ethylenedioxy group 52. The pyrazole compound or a pharmacologically acceptable salt thereof, according to claim 37, characterized also because the pyrazole compound is a pyrazole compound represented by the appropriate general formula (V): where R4 is as defined above, the Het ring represents a heteroaromatic, monocyclic group, of 5 or 6 members; RY1, RY2 and R? 3 are identical to each other or different from each other and represent an atom of Má hydrogen or a substituent selected from the following Group G '; and m 'is 0 or an integer between 1 and 2, [Group G'] G'1. A C? -6 alkyl group, which may be substituted with a substituent selected from Group g ', presented below: [Group g'] g'1. A halogen atom, g'2. An amino group, g'3. A monoalkyl (d_6) amino group, g'4. A dialkyl (C-? 6) amino group, g'5. An alkoxy group (C? .6) carbonylamino, and, g'6. A hydroxyimino group, G'2. A halogen atom, G'3. An alkoxy d_6 group which may be substituted with a halogen atom, G'4. An aryloxy group, G'5. A cyano group, G'6. -N (R59a) (R59a '), where R59a and R59a' are identical to each other or different from each other and represent a hydrogen atom or an alkyl group Ci. 6; and R59a and R59a, together with the adjacent nitrogen atom, can form a saturated, 5- or 6-membered monocyclic, heterocyclic ring, and the saturated heterocyclic ring can be substituted with a hydroxyl group, an amino group, a monoalkyl group (C .6) amino or a dialkyl (d.6) amino group, G7. -CO-N (R59b) (R59b ') wherein R59b and R59b' are identical to each other or different from each other and represent a hydrogen atom, a heterocyclic, monocyclic, 5- or 6-membered, saturated or an alkyl group C? .6, which may be substituted with the heterocyclic group, G'8. An aryl group, and, G'9. A heteroaromatic, monocyclic, 5- or 6-membered group, which may be substituted with an oxo or thioxo group. 53. The pyrazole compound or a pharmacologically acceptable salt thereof, according to claim 52, characterized JjH also because the Het ring is a pyridine ring, a triazole ring or an oxazole ring. 54.- The pyrazole compound or a pharmacologically acceptable salt thereof, according to claim 53, further characterized in that the pyrazole compound is a pyrazole compound, represented by the following general formula (VI), where R4, RY1, RY2, RY3 and m 'are as defined above. The pyrazole compound or a pharmacologically acceptable salt thereof, according to claim 37, further characterized in that the pyrazole compound or a pharmacologically acceptable salt thereof is selected from the following group: (pyridin-3-ylmethyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-prazol-3-carboxylic acid amide, 5- (2-chloro-4-pyridin-3-ylmethyl) -amide-dihydrochloride , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (pyridin-3-ylmethyl) -amide-hydrochloride pyrazol-3-carboxyl, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-Methyl-oxazol-5-ylmethyl) -amide, (4-Methyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (4-methyl-oxazole-5-oxazol-5-ylmethyl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (4-Methyl-oxazol-5-ylmethyl) amidate; L - (+) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid tartrate, (2,4-Dimethyl-oxazol-5-ylmethyl) -amide p 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid toluenesulfonate, 5- (2-dimethyl-oxazol-5-ylmethyl) -amide -chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5- (2,4-dimethyl-pyridin-3-ylmethyl) -amide of acid difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid diethylamide, Ethyl- (pyridin-4-ylmethyl) ) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid amide, 5- (2-chloro-) 2-methoxy-ethyl) -methyl-amide 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Ethyl- (2-methoxy-ethyl) -amide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylic or, 2- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazol-3-carboxylic acid 2-fluoro-benzylamide, 5- (2-chloro-4-acid, 3-fluoro-benzylamide), 5-difluoro-benzoylamino) -1H-pyrazol-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2-dimethylamino-benzyl amide, (4-ethoxycarbonyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (cyclohexyl) -propyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-methoxy-pyridin-3-ylmethyl) -amide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,3-dimethoxy-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2,4-dimethoxy-benzylamide, 2,6-dimethoxy-benzylamide acid - (2-chloro-4,5-difluoro-benzoilamíno) -1 H-pirazol-3- The carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 3,5-dimethoxy-benzylamide, 5- (2) -3-dimethoxy-benzylamide -chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,3-difluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,4-difluoro-benzylamide, 5- 5-difluoro-benzylamide (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2,6-Difluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazol-3-carboxylic acid, 3,4-difluoro-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid, 3,5-difluoro-benzylamide of acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-2- (2-lsopropoxy-pyridin-3-ylmethyl) -amide) -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (2-phenoxy-pyridin-3-ylmethyl) -amide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro) (3,5-difluoro-pyridin-2-ylmethyl) -amide -benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-trifluoromethyl-benzylamide, 3-trifluoromethyl-benzylamide 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -3-trifluoromethyl-benzylamide -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-tert-butyl-benzylamide, (6-lsopropoxy-pyridin-3) 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 2- (2,2,2-trifluoro-ethoxy) -pyridin -3-ylmethyl] -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- kiiáé ^ pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid 4- (2-dimethylamino-ethylcarbamoyl) -benzyl-amide, 4-Ethyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-4,5-difluoro-benzoylamino) -4-isopropyl-benzylamide -1 H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2-chloro-6-fluoro-benzylamide, (6-Ethoxy- 5- (2-chloro-4-pyridin-3-ylmethyl) -amide-dihydrochloride), 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 (thiazol-4-ylmethyl) -amide. -carboxylic, [6- (2,2,2-Trifluoro-ethoxy) -pyridin-3-ylmethyl-amide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole- 3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 2- (2-pyridin-3-yl) -thiazole-2,6-dimethyl-benzylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-4-ylmethyl] -amide-dihydrochloride, (1 H-Benzoimidazol-2-ylmethyl) -amide- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dihydrochloride, [4- ( { [5- (2-chloro-4,5- difluoro-benzoylamino) -1H-pyrazole-3-carbonyl] -amino.}. -methyl) -benzoylamino] -acetic acid, Methyl ester of 3- [4- ( { [5- (2-chloro-4,5 -difluoro-benzoylamino) -1 H-pyrazole-3-carbonyl] -amino.}. -methyl) -benzoylamino] -propionic acid, 5- (2-methyl-thiazol-4-ylmethyl) -amide-dihydrochloride. -clo ro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro- (3,5-dimethyl-isoxazol-4-ylmethyl) -amide) benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-Bism- (2-acetoxyethyl) -amino-ethylcarbamoyl] -benzyl-amide of 5- (2-chloro-4,5-difluoro- benzoylamino) -1H-pyrazole-3-carboxylic acid, 4- (2-Hydroxy-ethylcarbamoyl) - IÍÍ? .I? 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 4-. { 2 - [(2-Acetoxyethyl) - (2-hydroxyethyl) -amino] -ethylcarbamoyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, (1-Methyl-1H-benzoimidazol-2-ylmethyl) -amide-hydrochloride acid - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro- (thiazol-2-ylmethyl) -amide-dihydrochloride) benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (Benzothiazol-2-ylmethyl) -amide-dihydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,5-dimethyl-thiazol-4-ylmethyl) -amide-dihydrochloride, [2- (Morpholine- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (1, 3,5-Trimethyl) -thiazol-4-ylmethyl] -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (H-pyrazol-4-ylmethyl) -amide, (2-Chloro-6-methyl-pyridin-3) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (2-dimethylamino-thiazol-4-yl) -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid methyl) -amide-dihydrochloride, (1-Methyl-1 H-pyrrole-2-methyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, 5- (3,4-dimethoxy-pyridin-2-ylmethyl) -amide-dihydrochloride of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4, 5- (tert-butyl-thiazol-2-ylmethyl) -amide-dihydrochloride) 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro) - (5-Methyl-2-phenyl-2H- [1,2] triazol-4-ylmethyl) -amide. -4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4) (4- (tert-butoxycarbonyl-amino) -methyl-pyridin-2-ylmethyl] -amide. , 5- difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro), [4-Methyl-2- (morpholin-4-yl) -thiazol-5-ylmethyl] -amide-dihydrochloride] -4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, (pyridin-3-ylmethyl) -amide 3/2-hydrochloride hemihydrate, of 5- (2-chloro-4,5-acid -difluoro-benzoylamino) -1 H-pira zol-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid 2-Amino-benzylamide, 5- (2- (2- (2-methoxy-benzylamide chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 3-methoxy-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid , 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-methoxy-benzylamide, 5- (2-chloro-4,5-methyl) -benzylamide -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-fluoro-benzylamide, 4-chloro 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-prazol-3-carboxylic acid benzyl amide, 4- (2-chloro-4,5-difluoro) 4-ethoxycarbonyl-benzylamide -benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-carboxy-benzylamide, 5-dibenzylamide (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, (Cyan 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid o-phenyl-methyl) -amide of 5- (2-Chloro-4,5-acid) -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 (2-hydroxy-ethyl) -phenyl-amide -carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl-methyl-amide, 5- (2-chloro-4,5-difluoro acid) cyclohexyl-amide -benzoylamino) -1 H-pyrazole-3- carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl-ethyl-amide, 5- (2-chloro-4-allyl-cyclohexyl) -amide , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole cyclohexyl- (pyridin-2-ylmethyl) -amide -3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl- (1-methyl-piperidin-4-yl) -amide, [(3 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) acid, 4-methylenedioxyphenyl) -methyl] -amide-hydrochloride (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-benzyl- (4-hydroxy-butyl) -amide-chlorohydrate) -difluoro-benzoylamine) -1 H-pyrazole-3-carboxylic acid, butyl-ethyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl-propyl-amide, 5- (2-chloro-4,5-) -butyl-cyclohexyl-amide difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Ciclohexyl- (2-methoxy-ethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3 -amide carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl- (pyridin-3-ylmethyl) l- [2- (Morpholin-4-) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid yl) -phenyl] -amide, 5- (2-chloro-4,5-difluoro- benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid bis- (2-methoxy-ethyl) -amide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (2-methoxy-ethyl) -propyl-amide, B-butyl- (tetrahydro-pyran-4-yl) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, (2-methoxy-ethyl) - (tetrahydro- hiiii 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid pyran-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, cyclopentyl- (2-methoxy-ethyl) -amide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) cyclohexyl- (3-methoxy-propyl) -amide) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyclohexyl- (2-ethoxy-ethyl) -amide, Cyclohexyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (2-isopropoxy-ethyl) -amide, Ciclohexyl- (2-propoxy-ethyl) -amido acid - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-) (1-Ethyl-propyl) - (2-methoxy-ethyl) -amide 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl- (1-tert-butoxycarbonyl-piperidin-4-yl) -amide of 5- (2-chloro-4,5-difluoro- benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl- (tetrahydro-thiopyran-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid or, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-ethyl) -amide, butyl- (pyridin-3-ylmethyl) -amide of acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Benzyl- (2-methoxy-ethyl) -amide of 5- (2-chloro-4,5-dif-luoro) -benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl- (piperidin-4-yl-5-yl acid amide (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-chloro-4,5-acetyl-piperidin-4-yl) -butyl-amide -difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl- (1-methanesulfonyl-piperidin-4-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) - 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (1-ethoxalyl-piperidin-4-yl) -amide. , Butyl- (1-oxalo-piperidin-4-yl) -amide of 5- (2-chloro-4,5-difluoro- i. ij j, ii benzoylamino) -1 H -pyrazole-3-carboxylic acid, butyl- (1,1-dioxo-hexahydro-1,6-thiopyran-4-yl) -amide of 5- (2-chloro-4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, butyl- (1-oxo-hexahydro-1? 4-thiopyran-4-yl) -amide of 5- (2-chloro-4,5- difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (6-methoxy-pyridin-3-ylmethyl) -propyl-amide pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid propyl- (pyridin-3-ylmethyl) -amide, 4-diethylcarbamoyl-benzylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3- Diethylcarbamoyl-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-ethylcarbamoyl-benzylamide, 5- (2-chloro-benzoylamino) -3-ethylcarbamoyl-benzylamide Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 4-Carbamoyl-benzylamide of 5- (2-chloro) -4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (1-oxalo-piperidin-4-yl) -propyl-amide ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) z1H = pyrazole: 3-carboxylic acid (1-carboxy-acetyl-piperidin-4-yl) -propyl-amide5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [1- (2-carboxypropionyl) -piperidin-4-yl] -propyl-amide, cyclopropyl- ( 6-methoxy-pyridin-3-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, C-cyclobutyl- (6-methoxy-pyridin-3-) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amyl ester, Cyclopropylmethyl- (6-methoxy-pyridin-3-ylmethyl) -amide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, (6-Dimethylamino-pyridin-3-ylmethyl) -amide ? 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro) (6-dimethylamino-pyridin-3-ylmethyl) -propyl-amide -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -amido- (2-carboxy-ethyl) -amide. pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzyl- (2-ethoxycarbonyl-ethyl) -amide, (6-chloro-pyridine) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid-3-ylmethyl) -propyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) acid, 2,6-dichloro-benzylamide of 5- (2- Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro- (3,5-dichloro-pyridin-4-ylmethyl) -amide) benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole (3,5-Dichloro-pyridin-4-methylmethyl) -propyl-amide -3-carboxylic acid, [6- (1 H-pyrazol-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carbo xyl, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole- [6- (4-hydroxy-piperidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride 3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-pyridin-2-yl-ethyl) -amide (2-pyridin-3) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-pyridin-4-yl-ethyl) -amide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4- [1,2,3] thiadiazol-4-yl-benzyl) -amide of acid, 5- (2 -chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (5-Methyl-pyrazin-2-ylmethyl) -amide. ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid pyrazin-2-ylamide, quinolin-5-ylamide of acid 5- (2-chloro- 4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid quinolin-8-ylamide , 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid lsoquinolin-5-ylamide, [3-ethoxy-5- (1-ethoxycarbonyl-1-methyl-ethyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, -3-ethoxy-5- (1-ethoxycarbonyl-1) -pyridin-2-yl] -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid-hydroxy-pyridin-2-yl] -amide, [5- (1-Carboxy-1) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl-3-ethoxy-pyridin-2-yl] -amide, [5- (1 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxycarboxy-1-hydroxyethyl) -3-ethoxy-pyridin-2-yl] -amide -carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (pyrazin-2-ylmethyl) -amide, [6- (thiomorpholin-4-yl) - pyridin-3-ylmethyl] -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazol-3-carboxylic acid, [6- (1, 1-Dioxo-1? 6-thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide of 5- (2-chloro- 4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (4,5-Dibromo-thiophen-2-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H p -razol-3-carboxylic acid (5-chloro-thiophen-2-ylmethyl) -amide. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-ethyl-2-methyl-oxazol-5-ylmethyl) -amide, (2-Ethyl-4) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid methyl-oxazol-5-ylmethyl) -amide-dihydrochloride, ([2,2 '] Bithiophenyl-5 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-methoxy-thiophen-2-ylmethyl) -amide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (4,5- ? ki t 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid dichloro-thiophen-2-methylmethyl (2,5-dimethyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid oxazol-4-ylmethyl) -amide, (2-hexyl-4-methyl-oxazol-5-ylmethyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, 5- (2-chloro) acid (4-methoxy-thiophen-3-ylmethyl) -amide -4, 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (4-Methyl-2-phenyl-oxazol-5-ylmethyl) -amide -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-methyl (2-methyl-4-phenyl-oxazol-5-ylmethyl) -amide. -carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-hexyl-2-methyl-oxazol-5-ylmethyl) -amide-dihydrochloride ( 6-Chloro-pyridin-3-ylmethyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, (6-Chloro-pyridin-3-) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid ylmethyl) -amide dihydrochloride (4H- [1,2,4] Triazol-3-ylmethyl) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, (4H- [1,2,4] Triazol-3-ylmethyl) -amide-dihydrochloride acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4-5-fluoro-4H-quinazolin-3-yl) -amide , 5-difluoro-benzoylamino) -1 H -pyrrazole-3-carbo xyl, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (5-Fluoro-4H-quinazolin-3-yl) -amide-dihydrochloride, (4,6 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-dimethyl-pyridin-3-ylmethyl) -amide, (4,6-Dimethyl-pyridin-3-ylmethyl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid dichloride, (2-Methoxy-6-methyl-pyridin-3-ylmethyl) - 5- (2-chloro-4,5-) acid amide liliUÚ ujl difluoro-b enzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro- (4-methoxy-6-methyl-pyridin-3-methylmethyl) -amide) benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (4-methoxy-6-methyl-pyridin-3-ylmethyl) -amide-dihydrochloride -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamine) -1 H-pyrazole-3 (2-methoxy-4,6-dimethyl-pyridin-3-ylmethyl) -amide. -carboxylic, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-4,6-dimethyl-pyridin-3-ylmethyl) -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (3-Methyl-pyridin-2-ylmethyl) -amide, (5-Methyl-pyridin- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3-ylmethyl) -amide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1-pyrazole-3-carboxylic acid (6-methyl-pyridin-3-ylmethyl) -amide (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro) (6-Methyl-pyridin-2-ylmethyl) -amide. -benzoylamino) -1H-pira zol-3-carboxylic acid 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide dihydrochloride (6-Fluoro-pyridine) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-3-ylmethyl-amide dihydrochloride (3-Carboxy-phenyl) -methyl-acid amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-methanesulfonylamino-benzylamide of 5- (2-chloro-4,5-difluoro-benzoylamino) - 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4-methanesulfonylamino-benzylamide, 3-Acetylamino-benzylamide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole, 4-Acetylamino-benzylamide -3-carboxylic, (2-Phenyl-thiazol-4-ylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro- 4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) - ((S) -1-Phenylethyl) -amide) - 1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-phenoxy-pyridin-3-ylmethyl) -amide-dihydrochloride 5- (2-Methyl-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-ylmethyl) -amide-dihydrochloride, (2-Chloro-pyridine) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid 3-ylmethyl-amide-dichloride (S-6-chloro-pyridin-3-ylmethyl) - 5- (2-methyl-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid amide, 5- (3-pyridin-3-yl) -ethyl] -amide-dihydrochloride 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4-chloro-pyridin-3-methylmethyl) -amide-dihydrochloride , 5-difluoro-benzoi lamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole- (2-Methyl-pyridin-3-ylmethyl) -amide-dihydrochloride 3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (Biphenyl-3-ylmethyl) -amide ((1 R, 2S) -2- Hydroxy-indan-1-yl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, ((1S, 2R) -2-Hydroxy-indan- 1-yl) -amino acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-phenyl-pyridin-3-ylmethyl) -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro) (6-Methyl-2-pyridon-3-ylmethyl) -amide-hydrochloride -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Benzyl-methyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, iilii 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H- phenylamide pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methylphenyl-amide, (piperidin-1-yl) -amide of acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-ethoxycarbonyl-piperidin-1-yl) -amide of 5- (2-chloro-4), 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H (4-Methyl-piperazin-1-yl) -amide. -pyrazol-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4-carboxy-piperidin-1-yl) -amide, acid phenethylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-methylphenethyl-amide -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid (1, 2,3,4-tetrahydroisoquinoline- 2- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, ((S) -a-methoxycarbonyl-benzyl) -amide of 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, ((R) -a-methoxycarbonyl-benzyl) -amide of 5- (2-chloro-4,5-difluoro) -benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H (1,2,3,4-tetrahydroquinolin-1-yl) -amide -pyrazole-3 carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid phenyl-propyl-amide, 5- (2-chloro-4-butyl-phenyl) -amide 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid phenyl-phenyl-amide, Benzhydril- acid amide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, (pyridin-2-ylmethyl) -amide-hydrochloride of 5- (2-chloro-4) acid , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole, (Pyridin-4-ylmethyl) -amide-hydrochloride -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ((R) -2-hydroxy-1-phenyl-ethyl) -amide, ( (S) -2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-hydroxy-1-phenyl-ethyl) -amide, 4-dimethylamino-benzylamide of acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-di) (5- (2-chloro-4,5-di-furan-2-ylmethyl) -amide) fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (Tiofen-2-ylmethyl) -amide, ( 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxy-phenyl) -methyl-amide acid 5- (2-methoxy-phenyl) -amide. 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 4-Dimethylamino-benzylamide-5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole hydrochloride -3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-amino-benzylamide, 5- (2-chloro) acid -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2-methyl-benzylamide, 3 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl-benzylamide, 5- (2-chloro-4,5-difluoro) -3-dimethylamino-benzylamide -benzoylamino) -1 H-pyrazole-3-carboxylic acid (2-methoxy-pyridin-3-methylmethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1 H-2-chloro-benzylamide -pyrazol-3-carboxylic acid, 3-chloro-benzylamide i ii. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3- (2-chloro-4,5-difluoro-benzoylamino) -3-methoxycarbonyl-benzylamide H-pyrazole-3-carboxylic acid, 3- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-carboxy-benzylamide, (6-trifluoromethyl-pyridin-3-ylmethyl) )-amide carboxylic, methyl- (5- (2-chloro-4,5-difluorobenzoylamino) -1 H -pyrazole-3-carboxylic acid (4-methoxycarbonyl-phenyl) -methyl-amide, (4-carboxy-phenyl) -methyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 4- { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -amino-3-carbonyl] -methyl-amino} -benzoate 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid (5- (2-chloro-4,5-difluoro-benzoylamino) acid (5- (2-chloro-4,5-difluoro-benzoylamino) acid (carboxymethyl) -phenyl-amide of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, Benzylamide of 5- (2,4-Dichloro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Chloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, Benzyl- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid phenyl-amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1-methyl-1-phenyl-ethyl) -amide, [2-Oxo-2- (piperidin 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (5-Fluoro-2-yl) -ethyl] -phenyl-amide. -methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (5-Chloro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (4-Methoxy) -benzylamide 2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (4-Chloro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Fluoro acid) benzylamide -2-methoxy-benzoylamino) -1 H -pyrrazole-3-carboxylic acid, 5- (5-Chloro-2-methoxy-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, (2-Ethoxy-ethyl) 5- (2-chloro-4,5-difluoro-) phenyl-amide Bencholylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-Fluoro-5-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (5-Chloro-2-) -benzylamide fluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (3-Chloro-2,6-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid benzylamide, 5- (2- chloro-3-fluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid ethylcarbamoylmethyl-phenyl-amide, 5- (2-chloro-4, 5-) -isobutyl-phenyl-amide dif luorobenzoylamino) -! H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-methoxycarbonyl-ethyl) -phenyl-amide, (3-ethoxycarbonyl) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2-carboxy-ethyl) -phenyl-amide 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (3-carboxy-propyl) -phenyl-amide) -1 H-pyrazole-3-carboxylic acid, 5- (2-Hydroxy-4-methoxy-benzoylamino) -1 H -pyrrazole-3-carboxylic acid benzylamide, 5- (2-Hydroxy-5-methoxy) acid benzylamide benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (5-Fluoro-2-hydroxybenzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (4-Fluoro-2-) acid benzylamide trifluoromethyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (5-Fluoro-2-trifluoromethyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, (2-Methoxy-ethyl) - 5- (2-Chloro-4,5-difluoro-benzoylamino) -1-phenyl-amide H-pyrazole-3-carboxylic acid, 5- (2,5-Dimethyl-benzoylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2-chloro-5-methyl-benzoylamino) -1 H acid benzylamide -pyrazole-3-carboxylic acid, 5- (2-chloro-pyridine-3-carbonylamino) -1- H-benzylamide pyrazole-3-carboxylic acid, 5- (4-chloro-pyridine-2-carbonylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (2,6-dichloro-pi-din-3-! carbonylamino) -1H-pyrazole-3-carboxylic acid, Butyl- (4-ethoxycarbonyl-phenyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Butyl- (4-carboxy-phenyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-Methyl-pyridine-3-carbonylamino) -1 H- acid benzylamide | i pyrazole-3-carboxylic acid, 5- (2-chloro-6-methyl-pyridin-3-carbonylamino) -1H-pyrazole-3-carboxylic acid benzylamide, 5- (3-chloro-pyridine) acid benzylamide -4-carbonylamino) -1 H-pyrazol-3-carboxylic acid, butyl- (4-ethoxycarbonylmethyl- 'i phenyl) -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole- 3- Carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid butyl- (4-carboxymethyl-phenyl) -amide (4-methoxycarbonyl-phenyl) - (2-methoxy-ethyl) - I- 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide; (4-Carboxy-phenyl) - 5- (2-chloro-4,5-difluoro-β-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-methoxy) - (2-methoxy-ethyl) -amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3'-carboxylic acid-6-methoxy-pyridin-3-ylmethyl acid pyridin-3-ylmethyl) -amide. ) 5- (2-Methyl-> 4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (thiazol-4-ylmethyl) -amide-dichlorhydrate 5- (5-methyl) acid dichloride. 2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 4- [2- (Morpholin-4-yl) -ethylcarbamoyl] -benzylamide-dihydrochloride of 5- (2-chloro) acid -4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 4- (Morpholin-4-ylcarbamoyl) -benzylamide-dihydrochloride of 5- (2-chloro-4,5-I j difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, Sodium salt of acid [4- (. { [5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carbonyl] -amino] -methyl) -benzoylamino] -acetic acid, sodium salt of 3- [4] acid - ( { [5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carbonyl] -amino.} - methyl) -benzoylamino] -propionic acid. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (3,5-dimethyl-isoxazol-4-ylmethyl) -amide hydrochloride, (1, 3.5 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (3,5-Dimethyl) -trimethyl-1 H -pyrazol-4-methylmethyl-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-3-ylmethyl) -amide-sulfonate, 3- [2- (Morpholin-4-yl) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-ethylcarbamoyl] -benzylamide-dihydrochloride, 3- (Morpholin-4-ylcarbamoyl) -benzylamide-dihydrochloride - (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid,. { 2- [2- (Morpholin-4-yl) -ethylcarbamoyl] -pyridin-4-ylmethyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide trichlorohydrate [2- (Morpholin-4-ylcarbamoyl) -pyridin-4-) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (6-methoxy-pyridin-3-ylmethyl) -amide methanesulfonate acid ylmethyl] -amide trichlorhydrate. 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4, (6-methoxy-pyridin-3-ylmethyl) -amide hemisulfate), 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (3,5-dimethoxy-pyridin-4-ylmethyl) -amide-dihydrochloride ) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole (4-Aminomethyl-pyridin-2-ylmethyl) -amide-trichlorohydrate -3-carboxylic acid 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-ylmethyl) -amide methanesulfonate (6-Chloro) 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carbo-pyridin-3-ylmethyl) -amide dimethanesulfonate xylic, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (2,4-dimethyl-pyridin-3-ylmethyl) -amide-hydrochloride, (Pyridin- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (3-ylmethyl) -amide-hydrochloride (6-methoxy-pyridin-3-ylmethyl) -propyl-amide 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dihydrochloride, [6- (Piperidin-1-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, [6- (Morpholin-4-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro) -chloride (3,5-Dichloro-pyridin-4-ylmethyl) -amide-hydrochloride -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (6-Dimethylamino-pyridin-3-ylmethyl) -amide-dihydrochloride) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) (6-Dimethyl-pyridin-3-ylmethyl) -propyl-amide-d-hydrochloride -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (6-diethylamino-pyridin-3-ylmethyl) -amide-dihydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (6-chloro-2-dimethylamino-pyridin-3-ylmethyl) -amide-dihydrochloride5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid (4- [1,2,3] thiadiazol-4-yl-benzyl) -amide-hydrochloride, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrrazole-3-carboxylic acid (4-Methyl-thiazol-5-ylmethyl) -amide-hydrochloride, (2,4-Dimethyl) thiazol-5-ylmethyl) - 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide hydrochloride, [6- (4-Hydroxy] -piperidin-1- il) -pyridin-3-ylmethyl] -amide-acid dihydrochloride, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5-Methyl-pyrazin-2-ylamide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid dihydrochloride, 5- (2-Chloro-4,5-difluoro) quinoline-5-ylamide-dihydrochloride -benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid quinoline-8-ylamide-dihydrochloride, lsoquinolin-5- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid ilamide-dihydrochloride [6- (4-Methylpiperazin-1-yl) ) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid-pyridin-3-ylmethyl] -amide-dihydrochloride, [6- (4-Dimethylamino-piperidin-1) 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid pyridin-3-ylmethyl] -amide-dihydrochloride, [6- (Pyrrolidin-1 -yl) -pyridin-3-ylmethyl] -amide-acid dihydrochloride 5- (2-Chloro-4,5-d-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-chloro-4,5-dihydrochloride, (pyrazin-2-ylmethyl) -amide-dihydrochloride) -difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5- [2- (thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide-dihydrochloride] -difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, [6- (1, 1-Dioxo-1 l6-thiomorpholin-4-yl) -pyridin-3-ylmethyl] -amide-dichlorohydrate of 5- ( 2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Carbamoylmethyl-amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid , (4-Carbamoyl-phenyl) -methyl-acid amide, 5- (2,4-Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Methyl- (4-methylcarbamoyl-phenyl) - acid amide 5- (2,4- i Íú? á, i .... Ú Dichloro-5-fluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, (4-Dimethylcarbamoyl-phenyl) -methyl-amide of 5- (2,4-Dichloro) -5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole (4-methanesulfonylaminocarbonyl-phenyl) -methyl-amide -3-carboxylic acid, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid (4-methanesulfonylaminocarbonyl-phenyl) -methyl-amide salt (4- 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid cyano-phenyl) -methyl-amide, [4- (4H- [1, 2,4]] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid triazol-3-yl) -phenyl] -amide-hydrochloride, (4-Cyano-phenyl) -methyl- 5- (4-Azido-2-chloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, methyl- [4- (1 H -tetrazol-5-yl) -phenyl] -amide 5- (4-Azido-2-chloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-hydroxycarbamimidoyl) -phenyl] -methyl-amide -clo ro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, Methyl- [4- (5-oxo-2,5-dihydro- [1, 2,4] oxadiazol-3-yl) - phenyl] -amide of 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid,. { 4 - [(2,2-Dimethyl-propionyloxy) -methoxycarbonyl] -phenyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid methyl-4- (N- (methoxy-thiocarbonyloxy) -carbamimidoyl] -methyl-acid amide 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, Methyl- [4- (5-t-oxo-4,5-dihydro- [1,2,4] 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid oxadiazol-3-yl) -phenyl] -amide, [4- (5-oxo-4, 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 5-dihydro- [1,4-thiazol-3-yl) -phenyl] -amide. ,. { 4- [1 - (Cyclohexyloxycarbonyloxy) -ethoxycarbonyl] -phenyl} 5- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl-amide, 5- (3-ethoxycarbonyl-thiazol-2-yl) -ethyl-amide (2-Chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-difluoro-benzoylamino) -1 H-pyrazole 2-methanesulfonylamino-benzylamide -3-carboxylic acid, 2-Acetylamino-benzylamide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 2- (Dimethylamino-methyleneamino) -benzylamide-hydrochloride 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 3- (Dimethylamino-methyleneamino) -benzylamide-5- (2-chloro-4,5-) -hydrochloride difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3- (dimethylamino-methyleneamino) -benzylamide-hydrochloride carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 2- [1- (dimethylamino) ethylideneamino] -benzylamide-dihydrochloride, 3- [1- (dimethylamino) ethylidene] -benzylamide-di 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid hydrochloride, 4- [1- (Dimethylamino) ethylidenamine) -benzylamide-dihydrochloride of 5- (2-chloro) acid -4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H- 2- (Diethylamino-methyleneamino) -benzylamide-dihydrochloride 3- (2-Chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid 4- (diethylamino-methyleneamino) -benzylamide-dihydrochloride of 5- (2-chloro-4,5-difluoro-benzoylamino) acid 5- (2-Chloro-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid methylenamino) -benzylamide-dihydrochloride, 5- (2-chloro-4-dichlorohydrate) 2-Acetymidylamino-benzylamide-dihydrochloride , 5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3-acetimidoylamino-benzylamide-dichlorohydrate Iiíáj, "i (2-chloro-4,5-difluoro-benzoilamíno) -1 H-pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) 4- acetimidoylamino-benzylamido-dihydrochloride ) -1 H-pyrazole-3-carboxylic acid, 4-cyano-benzylamide, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 3 - [(2- Fluoro- benzoylamino) -1 H-pyrazole-3-carboxylic acid, 2- (2-chloro-4,5-) 2- (2-ethoxy-2-methyl-1,4-dihydro-2H-quinazolin-3-yl) -amido acid difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1 H- (2-cyano-pyridin-4-ylmethyl) -amide. pyrazole-3-carboxylic acid, 5- (2-chloro-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid [2- (N-hydroxycarbamimidoyl) -pyridin-4-ylmethyl] -amide, [ 2- (2-Chloro-4,5- 5- (5-Oxo-4,5-dihydro- [1,4] oxadiazol-3-yl) -pyridin-4-ylmethyl] -amide difluoro-benzoylamino) -1 H-pyrazole-3-carboxylic acid, Sodium salt of 4- acid. { [5- (4,5-difluoro-2-methyl-benzoylamino) -1 H-pyrazole-3-carbonyl] -methyl-amino} -benzoic acid, 5- (4,5-Difluoro-2-methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid methyl- [4- (1 H-tetrazol-5-yl) -phenyl] -amide, 5- (2,4-Dichloro-benzoylamino) -1H-pyrazol-3-carboxylic acid (pyridin-3-ylmethyl) -amide of 5- (2,4-dichloro-benzoylamino) -1- Dichloro-5-fluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid, 5- (2,6-Dichloro-5-fluoro-pyridine-3-carbonylamino) -1 H (pyridin-3-ylmethyl) -amide. -pyrazole-3-carboxylic acid, 5 - [(3-Chloro-benzo [b] thiophen-2-carbonyl) -amino] -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide, ( Pyridin-3-ylmethyl) -amide of 5-r [(3-Chloro-thiophene-2-carbonyl) -amino] -1H-pyrazole-3-carboxylic acid, (Pyridin-3-ylmethyl) -amide of 5-Benzoylamino acid -1 H-pyrazole-3-carboxylic acid, 5-phenylacetylamino-1 H -pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide, (pyridin-3-ylmethyl) -amide-dihydrochloride 5- (2-Methyl-4,5-difluoro-benzoylamino) -1 H -pyrazole-3-carboxylic acid, 5- (2-Amino-4,5-difluoro-) pyridin-3-ylmethyl) -amide benz oleylamino) -1H-pyrazole-3-carboxylic acid, 5- (4,5-Difluoro-2-methanesulfonylamino-benzoylamino) -1H-pyrazole-3-carboxylic acid (pyridin-3-ylmethyl) -amide, (Pyridin -3-ylmethyl) - 5- (2-acetylamino-4,5-difluoro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide, 5 - [(3, 4,5-trichloro-thiophene-2-carbonyl) -amino] -1 H-pyrazole-3-carboxylic acid, 5- (4,5-difluoro-2-cyano-pyridin-4-ylmethyl) -amide -methyl-benzoylamino) -1 H-pyrazole-3-carboxylic acid, 5- (4,5-difluoro-2- (1 H-Tetrazol-5-yl) -pyridin-4-ylmethyl] -amide methyl-benzoylamino) -1H-pyrazole-3-carboxylic acid, and 3-Benzylamide of 5 - [(2,4-dichloro-phenyl) -amide] -1H-Pyrazole-3,5-dicarboxylic acid. 56.- A therapeutic or prophylactic agent to fight insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataract, glycemia, hypercholesterolemia, hypertension, hyperinsulinism, hyperlipidemia, atherosclerosis, tissue ischemia, myocardial ischemia, obesity, bacterial infection , fungal, parasitic or viral, comprising a pyrazole compound according to any of claims 36 to 55, or a pharmacologically acceptable salt thereof, as an active ingredient. 57.- A medicine comprising a combination of a therapeutic or prophylactic agent, according to claim 56, and another drug.